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Summary
Fc receptors (FcRs) provide a critical link between the humoral and cellular 
arms of the immune system through the targeting of antigen-antibody 
complexes to effector cells and modulation of an immune response. B cells 
express a low affinity IgG Fc receptor, FcYRIIb, which negatively regulates 
antigen receptor-mediated proliferative signalling through the binding of IgG- 
containing immune complexes. Co-ligation of the B cell antigen receptor (BCR) 
complex with FcyRllb promotes the induction of B cell growth arrest in the Gi 
phase of the cell cycle and this ultimately results in commitment to apoptosis. 
Furthermore, FcyRllb co-ligation also acts as an important negative feedback 
mechanism to switch off ongoing B cell responses once the pathogen has been 
cleared. Thus, on resting B cells, FcyRllb acts to prevent aberrant B cell 
activation by immune complexes and suppresses the potential induction of 
autoimmunity.
It was therefore the aim of this study to identify and characterise the key 
signalling pathways responsible for FcyRIlb-mediated negative regulation of 
BCR-mediated proliferation. During the course of this study, it emerged that in 
normal splenic B cells, FcyRllb signalling appears to act by modulating the BCR 
signalling threshold, via the rapid recruitment and phosphorylation of a variety of 
phosphatases that ultimately result in the uncoupling of the BCR from 
MAPKinase activation. We have corroborated these published findings that the 
tyrosine kinases SHP-1 and SHP-2 and the inositol 5’-phosphatase, SHIP-1, 
are recruited during FcyRllb signalling and we have extended these studies in 
that we have generated novel data regarding their mechanism of action. We 
now also show that FcyRllb co-ligation, in addition to preventing the initiation of 
MAPKinase signalling, induces the rapid recruitment and activation of the 
MAPKinase phosphatase, Pac-1, resulting in the abrogation of ongoing 
ErkMAPK signalling. Furthermore, we show for the first time that FcyRllb co­
ligation results in the activation of the inositol 3’-phosphatase, PTEN, with 
kinetics which suggest that recruitment of this tumour suppressor element 
antagonises BCR-coupling to the PI-3-K/Akt pathway and hence abrogates pro­
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survival mechanisms in B cells. Taken together, this dual pronged mechanism 
of FcyRllb-mediated abrogation of the ErkMAPKinase and Akt pathways 
provides a molecular rationale for the biological consequences of BCR-FcyRllb 
co-ligation, namely commitment to growth arrest and apoptosis. Finally, analysis 
of potential downstream molecular targets of ErkMAPKinase and Akt revealed 
that FcyRI lb-signalling not only inhibits the phosphorylation and activation of the 
tumour suppressor protein, retinoblastoma (Rb), but also induces the 
phosphorylation and activation of the pro-apoptotic tumour suppressor protein, 
p53 and disruption of mitochondrial potential. Inhibition of Rb activation and 
consequent induction of genes required for the transition to S phase, is 
consistent with the observed FcyRI lb-mediated arrest in the Gi phase of the cell 
cycle. Similarly induction of p53 and collapse of mitochondrial integrity provide 
insight into the effector mechanisms underlying FcyRI lb-driven commitment to B 
cell apoptosis.
To maintain homeostasis and tolerance to self-antigens, B cells require a 
balance of signals via activatory and inhibitory co-receptors. Thus, aberrant 
signalling through FcyRllb during B cell development could lead to the induction 
of autoimmunity and/or promote the progression of certain autoimmune 
diseases. Consistent with this, recently published studies in FcyRI lb-deficient 
mice suggested that this lesion could result in collagen-induced arthritis (CIA) 
in normally resistant strains of mice. Similarly, FcyRllb-deficient mice have been 
reported to display lupus-like symptoms of autoimmune disease suggesting that 
dysfunction of FcyRI lb-mediated negative regulation of B cell activation plays a 
causative role in onset and/or progression of these diseases. We have 
investigated this role of FcyRllb in regulating the development of autoimmunity 
by analysing the functionality of FcyRllb signalling during onset and progression 
of CIA in susceptible (DBA/1, H-2^) strains and also in the spontaneous murine 
systemic lupus erythematosus model, MRL-/pr//pr In contrast to the knockout 
studies, we have demonstrated that FcyRllb-mediated B cell inhibition appears 
to be intact throughout development of CIA in naturally susceptible strains of 
mice, suggesting that this regulatory pathway is not important in the induction or 
progression of this disease in FI-2  ^ susceptible strains of mice. Clearly,
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although, dysfunctional FcyRllb signalling could play a role in predisposing mice 
of different genetic backgrounds to CIA, these findings make it unlikely that this 
molecular lesion will provide a uniform risk factor for this disease. In contrast, 
FcyRllb-mediated B cell inhibition was found to be dysregulated in the later 
stages of lupus-like disease in MRL-/pr//pr mice. Suggesting that FcyRllb may 
be a susceptibility factor, contributing to the genetic and environmental 
background that is required for the emergence of lupus-like disease in mice.
To determine whether the differential findings regarding dysfunctional FcyRllb 
signalling, as a susceptibility factor in murine models of arthritis and systemic 
lupus erythematosus (SLE), reflected the molecular mechanisms underlying 
onset and progression of human disease, the functionality of FcyRllb signalling 
in peripheral blood cells from autoimmune patients was investigated. B cells 
encode two isoforms of FcyRllb, FcyRllbl and FcyRllb2. While both isoforms of 
FcyRllb are able to mediate negative regulation of B cell activation, FcyRI I b2 
can also internalise IgG-containing immune complexes. A sequence Insertion in 
the cytoplasmic tail of FcyRllbl disrupts its ability to modulate receptor 
endocytosis. Therefore, it is possible that differences in the relative expression 
levels of the two isoforms of FcyRllb may influence the regulation of B cell 
responses by immune-complexes and may be related to, or indicative of, 
disease susceptibility and progression. An investigation of the mRNA message 
levels of FcyRllb in peripheral blood cells from autoimmune patients, revealed 
that FcyRllbl expression levels were lower in rheumatoid arthritis patients 
compared to normal controls. In contrast to the murine lupus-like model, 
message levels of the two isoforms in patients with systemic lupus 
erythematosus were similar. These preliminary results indicate that progression 
of rheumatoid arthritis in humans may be perpetuated by a down-regulation of 
the inhibitory receptor, thus resulting in a dysregulation in the balance of normal 
B cell signalling.
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Chapter 1 -  General Introduction
Chapter 1 - General Introduction
1.1 The Immune Response
The immune response is the defence mechanism initiated by the host following 
an encounter with a foreign substance or pathogen. The cells and molecules 
that make up the immune response collaborate through a finely balanced 
network of interactions. This network enables the host to detect the invasive 
agent, recruit and co-ordinate an attack and finally, once the agent has been 
successfully eliminated, suppress any further response. Host immunity can be 
broadly divided into two functionally distinct but interacting systems, the innate 
and the adaptive immune responses.
Both the innate and adaptive immune responses depend upon the activities of 
white blood cells derived from common pluripotent haematopoieitc stem cells in 
the bone marrow. These stems cells divide to produce specialised myeloid and 
lymphoid progenitors cells. The myeloid precursor cell gives rise to erythrocytes 
(red blood cells that transport oxygen), platelets (important in blood clotting), 
monocytes and granulocytes. The granulocytes are further comprised of 
eosinophils, neutrophils and basophils. Mast cells, which are similar to 
basophils, are also derived from the myeloid precursor cell but complete their 
maturation in the tissues. The lymphoid progenitor gives rise to two major types 
of lymphocytes, B lymphocytes (B cells) and T lymphocytes (T cells). These 
cells are involved in the adaptive immune response and will be discussed in 
more detail in later sections. Other cells derived from the common lymphoid 
progenitor include natural killer (NK) cells and dendritic cells (DCs), however 
some DCs are myeloid derived. NK cells are large granular lymphocytes that 
release lytic granules upon stimulation and play an important role in innate 
immunity and clearance of viral infection. Dendritic cells are able to trap antigen 
on their cell surface and present it to other cells of the immune system. These 
antigen-presenting cells (APGs) are also able to deliver cell activating signals 
and therefore play a central role in both innate and adaptive immunity.
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The innate immune system is non-specific and functions regardless of the 
antigenic nature of the foreign substance or pathogen. Yet the innate response 
is an integrated effort by the host to combat microbial invasion, decrease tissue 
injury and cell death, promote recovery of the host and reduce the likelihood of 
secondary or opportunistic infections (Fearon and Locksley, 1996). The innate 
response relies primarily on cell surface receptors and secreted proteins of 
myeloid cells to recognise conserved pathogen structures such as 
carbohydrate, lipid, protein and DNA components associated with infection. 
These cellular structures can trigger phagocytic cells such as macrophages 
(derived from monocytes) and neutrophils to engulf foreign particles and destroy 
the ingested material by the release of potent intracellular enzymes and 
chemicals. Further members of the myeloid family are induced to release pro- 
inflammatory substances (cytokines) that promote an immune response and aid 
clearance of the pathogen. However, the innate system is only effective in 
eliminating infectious agents with common surface molecules that can be 
recognised by the neutrophils, macrophages and dendritic cells. Moreover, 
many infectious agents have evolved mechanisms to avoid detection by the 
innate immune cells. Thus, the adaptive immune system evolved to provide an 
improved recognition mechanism and a more versatile means of defence. In 
addition, the adaptive system possesses the ability to fine-tune its response 
with successive antigenic encounters and generate immunological memory to 
prevent against subsequent re-infection by the same pathogen.
The adaptive immune system relies upon lymphocytes to recognise antigens 
and react in a highly specific and selective manner. B cells are associated with 
the production and secretion of antigen-specific antibodies (immunoglobulin, Ig). 
Antibodies circulate in the bloodstream and permeate other body fluids, where 
they bind and react specifically to an antigen. Once bound to the antigen, 
antibodies can protect the host from the antigen-bearing pathogen by processes 
of neutralisation, opsonisation and complement activation. For example, 
formation of antigen-antibody immune complexes can prevent antigen binding 
to certain target host receptors thus neutralising its effects. Moreover, the 
antibody coating can also enable the antigen to be recognised as foreign by
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phagocytic cells, a process known as opsonisation, and thus promote its 
destruction. Immune complexes also provide a receptor for a system of plasma 
proteins, known as complement. Activation of this cascade of proteins 
enhances opsonisation of the antigen and can directly lyse some bacteria.
T cells can be divided into CD8^, cytotoxic (Tc) cells and CD4'", helper (Th) 
cells. Tc cells direct the destruction of host cells that have become infected by 
viruses or other pathogens whilst Th cells can modulate the activities of other 
cells, such as B cells, macrophages and Tc. Following an antigenic encounter, 
Th cells can differentiate into either Th1 or Th2 effector T cells. The overall 
balance of cytokines present early in the immune response determines the 
class of effector cell produced. Thus, for example, by producing different 
repertoires of cytokines effector T cells can bias the adaptive immune response 
towards a cellular or a humoral (antibody) response. This choice can determine 
whether the pathogen survives or is eliminated and is therefore one of the most 
important events in the initiation of an adaptive immune response. Recently, a 
small subpopulation (~10%) of CD4^ Tn cells have been shown to express the 
CD25 marker and are associated with the suppression of harmful 
immunopathological responses to self or foreign antigens (reviewed by Maloy 
and Powrie, 2001). These naturally occurring suppressor T cells, now regarded 
as regulatory T cells (T r), possess the ability to inhibit the proliferation of other 
T cell populations both in vitro and in vivo. Further investigations into the 
functional role of these cells could have widespread implications in the field of 
autoimmunity and maintenance of self-tolerance.
As the innate system only represents the first line of defence there is 
considerable interplay between it and the adaptive response. Communication 
between the two systems produces a diverse repertoire of immunological 
responses. Antigen-presenting cells of the innate system, such as dendritic cells 
and macrophages, appear to play a central role in this aspect. These potent 
cells can present antigen in a form recognisable by T cells thus resulting in a 
specific cell-mediated response. Whilst the opsonisation process, described
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above, is a classic example of how antibodies produced by B cells can aid the 
innate system in the recognition of potential pathogens.
The cells responsible for mediating the humoral and cellular responses have 
become major targets of biomedical research. In the case of B and T cells there 
is growing recognition that inappropriate stimulation and activation of these cells 
can result in a variety of chronic inflammatory processes, including autoimmune 
disease. Much of this research has concentrated on the co-operation between T 
and B cells in mediating a normal adaptive immune response. In particular, 
investigating how communication between these cells can lead to a 
dysfunctional immune response. Therefore studies into the molecular and 
biochemical mechanisms underlying lymphocyte responses are important in an 
attempt to understand how these diseases arise and to aid in the decision of the 
best course of therapy.
1.2 The role of B cells In the adaptive immune response
1.2.1 Generation and selection of B cells
B cells are the principal cellular mediators of the specific humoral response to 
infection by bacteria, viruses and parasites. The developmental processes prior 
to antigen recognition need to be tightly regulated to ensure a continual 
production of B cells bearing antigen receptors of distinct specificity. However, 
whilst the system must produce antibodies that are able to identify any 
encountered antigen, at the same time it must avoid the generation of 
autoreactive B cells that recognise ‘self antigens. The complex process 
requires the integration of signals at each stage, not only from antigen but also 
from a structured microenvironment made up of a vast array of extracellular, 
soluble mediators and accessory cells. The following section will discuss the 
different stages of B cell development and the generation and selection of the 
diverse B cell receptor repertoire. This developmental process is summarised in 
Figure 1.1.
In mammals the earliest B cells (pro-B cells) develop from pluripotential 
hematopoietic stem cells (HSC) in the foetal liver. Commitment of HSCs to the
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B cell lineage occurs early on in the developmental process and is shown to be 
dependent on the expression of Pax5, a paired box transcription factor (Cory, 
1999). Pax5 acts to promote the expression of B lineage genes whilst 
suppressing those genes concerned with T cell, erythroid or myeloid cell 
development. In later embryonic stages, the site of B cell production moves to 
the bone marrow where it continues during adult life (Alt, et a i, 1997). Once 
committed, the precursor B cells pass through a number of developmental 
stages marked by a series of changes in location and in the expression of 
genes, intracellular proteins, and surface markers. Once the immature B cell 
stage is reached the B cells emerge into the periphery and migrate to the 
secondary lymphoid organs, such as the spleen and lymph nodes. Here, in 
association with specialised antigen-presenting cells and stromal cells, B cell 
recognition of antigen can lead to one of several developmental pathways: (1) 
cellular anergy (unresponsiveness) and/or programmed cell death, (2) 
activation, proliferation and differentiation into high rate antibody secreting 
plasma cells, or (3) differentiation into memory B cells (Tarlinton, 1994).
The different B cell developmental events can be broadly divided into two main 
stages; antigen independent and antigen dependent (reviewed by Relink and 
Melchers, 1991). The antigen independent stage occurs in the bone marrow 
and is concerned with producing a repertoire of immature B cells with a 
functional antigen receptor (B cell receptor, BCR). Importantly, in accordance 
with Burnet's Clonal Selection Theory, each B cell that is produced by this 
process should express a receptor that is specific for a single antigen (Burnet, 
1959). Thus, the mature antigen receptors are clonally distributed. The 
processes involved in the formation of BCR complexes have been studied in 
detail in mouse models and have been shown to be essential in directing the 
development and survival of the immature cell.
The production of a BCR relies on a complex pattern of immunoglobulin gene 
rearrangements to produce one functional heavy chain, followed by one 
functional light chain (Coleclough e ta l., 1981). This rearrangement is 
dependent on the expression of recombination-activating genes, RAG-1 and
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RAG-2, at the pro- and pre-B cell stages of differentiation (Spanopoulou, 1994). 
Rearrangement of the D (diversity), J (joining) and V (variable) heavy chain 
locus genes begins in the early pro-B stage with the joining of Dh to Jh. Cells are 
allowed to progress to the next stage if a productive rearrangement has been 
achieved. Progression to the late pro-B cell stage is accompanied by the joining 
of a Vh gene to the pre-formed DJh complex. Although no functional 
immunoglobulin is expressed in late pro-B cells, recent studies have shown the 
expression of BCR accessory lg-a/lg-(3heterodimers on the surface in 
association with calnexin (Nagata et al., 1997) (Figure 1.2). These accessory 
molecules, in particular Ig-p, have been shown to be essential for the continuing 
development of the pro-B cells to the pre-B cell stage (Gong and Nussenzweig, 
1996, Nagata et al., 1997). Indeed, these studies have shown that mice 
deficient in Ig-P exhibit a complete block in B cell development before Vh to 
DhJh rearrangement. It has therefore been suggested that signalling through 
the Ig-a/lg-p-calnexin receptor on pro-B cells may be required for successful 
initiation of Vh to DhJh gene rearrangement (Nagata et a!., 1997).
A successful first rearrangement means that intact | l i  heavy chains are produced 
and expressed in an immunoglobulin-like “pre-BCR” complex with surrogate 
light chains, 15 and VpreB (Karasuyama et a!., 1994). 15 bears close similarity 
to the known constant (C) 1 light-chain domains (see below), whilst VpreB 
resembles a variable (V) domain but bears an extra N-terminal protein 
sequence. If this first rearrangement is unsuccessful, a second rearrangement 
is undertaken. Pro-B cells in which both rearrangements are unsuccessful are 
unable to produce a pre-B cell receptor. Surface expression of a pre-BCR is 
known to be important for instructing the cell to stop further Vh gene 
rearrangements (Neuberger, 1997) by inhibiting recombination at the heavy 
chain locus, a process described as allelic exclusion (reviewed by Benschop 
and Cambier, 1999). Pre-B cell receptor expression also drives the transition to 
the large pre-B cell stage and induces proliferation whilst signalling to the cell 
that gene rearrangements to the immunoglobulin light chain should begin. Thus, 
a lack of pre-B cell receptor expression results in a block in B cell development 
at the pre-B cell stage.
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Once a light chain gene (k  or X) has been rearranged successfully a BCR 
consisting of fxheavy chain, conventional light chains and accessory Ig-a/lg-p 
molecules is expressed by the immature B cells. This intact surface IgM is the 
first BCR to exhibit antigen specificity (Reth, 1992) and thus the B cell enters 
the antigen-dependent stage of development. It has been estimated that about 
10® B lineage precursors are generated every day in the murine bone marrow, 
which in turn give rise to about 2 x 10  ^ sIgM-expressing immature B cells 
(Osmond, 1986). Thus, it is clear that the majority of B cells (80%) maturing in 
the bone marrow undergo a process of negative selection. Indeed, ligation of 
the antigen receptors on the vast majority of immature B cells leads ultimately to 
anergy (Goodnow et al., 1988) or deletion via apoptosis (programmed cell 
death) (Nemazee and Burki, 1989; Hasbold and Klaus, 1990; Hartley eta!.,
1991).
The deletion or silencing of self-reactive B cell clones is important for the 
maintenance of self-tolerance by the immune system. Immature B cells which 
are capable of recognising self-antigens are eliminated or inactivated, 
preventing them from developing further and secreting antibodies that bind to 
self-cells or tissues. Self-reactive immature B cells may also be rescued from 
deletion by undergoing receptor editing, where the autoreactive receptor is 
replaced with the product of a further rearrangement event (Radie et al., 1993). 
This editing process is aided by the reactivation of the RAG gene system, which 
is believed to allow further light-chain rearrangements (Hertz and Nemazee,
1998). However, most of the immature B cells do not make new 
rearrangements and are subsequently deleted.
By maintaining high level expression of mIgM, transitional-immature (T1) B cells 
entering the periphery remain sensitive to antigen deletion for a number of days 
(Allman et al., 1993). This is especially important for the development of 
tolerance, since not all self-antigens are expressed within the bone marrow 
(Sandel and Monroe, 1999; Monroe, 2000). To promote their survival and 
migration to the spleen, these cells require T cell-dependent help. Typically, of 
the 2x10^ sIgM B cells that develop daily in murine bone marrow only 10% will
Chapter 1 -  General Introduction
reach the spleen and only 1-3% will survive and develop to the next stage of 
maturation (Allman et ai, 1993). The development into a transitional (T2) B cell 
is accompanied by the surface expression of IgD and requires constant BCR- 
derived signals for progression (Carsetti et ai, 1995; Neuberger, 1997; Sandel 
and Monroe, 1999). In addition, stimulation via cytokines or co-receptor ligation 
helps to shape the BCR repertoire and signalling thresholds (Craxton et al.,
1999). As the B cells migrate into the primary follicles of the spleen they are 
finally regarded as “mature” IgM'®'" IgO*^ '^ *^  B cells.
In contrast to the immature cell, the mature B cell responds positively to 
antigen-receptor ligation. In the presence of T cell-derived cytokines and cell­
cell contact, the activated B cell can develop into an IgM antibody-secreting 
plasma cell or undergo isotype switching and V region somatic mutation to 
become a memory B cell (reviewed in Cushley and Harnett, 1993; Liu et ai,
1992). Following re-exposure to the same antigen and affinity maturation, the 
memory B cell can evolve into an IgG secreting plasma cell. The formation of 
memory is critical for mounting a rapid, specific secondary immune response 
and the ability of the immune system to generate these memory B cells forms 
the basis of effective vaccination.
The generation of memory B cells in the germinal centres (GCs) of secondary 
lymphoid organs has been actively researched for many years (Loder et a i,
1999) and is briefly outlined in Figure 1.3. T-cell dependent antigen-activated B 
cells enter the primary lymphoid follicles where they are driven to proliferate and 
form germinal centres. In the primary immune response, GCs first appear 
around 4-5 days after antigenic encounter. The proliferating B cells 
(lymphoblasts) enter the dark zone of the germinal centre where they continue 
to proliferate. The rapidly dividing centroblasts lose expression of sIg and 
undergo somatic mutation of the immunoglobulin variable-domain genes. 
Centroblasts give rise to small, non-dividing centrocytes, which express the 
mutated antigen-receptors. Centrocytes with high affinity antigen-receptors are 
selected for survival in the light zone of the germinal centre. The follicles consist 
of follicular dendritic cells (FDCs) that are able to fix unprocessed antigen on
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their cell surface through the expression of complement receptors and receptors 
for the Fc portion of immunoglobulin. Since centrocytes are programmed to die 
unless actively rescued, high levels of apoptosis accompany their migration into 
the light zone. In vitro studies have shown that two signals enable centrocyte 
survival. The first is generated by FDC-displayed antigen resulting in ligation of 
the high-affinity surface immunoglobulin, the second involves ligation of CD40 
on the surface of centrocytes, suggesting a role for helper T-cell interactions in 
promoting centrocyte rescue (Craxton etal., 1999). This process results in the 
rescue and selection of high affinity B cell clones, as redundant and low affinity 
spécificités are selected against. The positively selected centrocytes then go on 
to establish the memory B cell pool in the apical light zone, providing the 
precursors for plasma cell generation.
The developmental stages described in this section give rise to a population of 
“conventional” B cells. However a second population of B cells exists that 
appear to arise from distinct stem cells early on in development (reviewed by 
Hayakawa and Hardy, 2000). These latter cells are known as B-1 B cells, to 
distinguish them from the conventional B-2 B cells described above. This subset 
of B cells was first distinguished from conventional B cells by the surface 
expression of CDS. Stem cells arising from the foetal liver give rise to B cell 
progenitors that have little or no terminal deoxynucleotidyl transferase (TdT), 
which in turn give rise to B-1 cells. A lack of TdT activity in these B-1 cells 
results in limited immunoglobulin heavy chain rearrangements and the 
expression of low-affinity antigen receptors for multivalent self-antigens. The 
restricted diversity of B-1 cell antigen-receptors includes broad specificities in 
antigen recognition, particularly to common bacterial polysaccharides such as 
lipopolysaccharide (LPS) and phosphorylcholine (PC). Thus B-1 B cells are 
particularly important in newborns, as they are presumed to be responsible for 
natural immunity prior to the production of conventional B-2 B cells in adult life.
Predominantly located in the peritoneal cavity, the self-renewing population of 
mature B-1 cells express sIgM with little or no surface expression of IgD. Little is 
known about the function of B-1 cells. However, the propensity of B-1 cells to
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produce low-affinity autoreactive antibodies implicates a role for these cells in 
autoimmune disease. Indeed, B-1 B cell populations that produce 
autoantibodies are expanded in autoimmune disease models such as SHP-1 
(motheaten) and Lyn deficient, mice (Hayakawa and Hardy, 2000). Whilst 
elevated levels of B-1 a (CD5^) cells have been found in a proportion of patients 
with rheumatoid arthritis and systemic lupus erythematosus (Porakishvili etal., 
2001).
1.2.2 B Cell Receptor (BCR) structure
From the above description of B cell generation and development, it can be 
seen that components of the B cell receptor (BCR) for antigen recognition play 
important roles in determining the fate of B cells even before they encounter 
antigen. The mature BCR is functionally divided into two main units; the 
membrane-bound, ligand binding, immunoglobulin (Ig) molecule and the 
accessory, signal transducing molecules, Ig-a (CD79a) and Ig-p (CD79b) 
(reviewed in Reth, 1992, 1994; Pao et al., 1997) (Figure 1.4). In contrast to the 
T cell receptor for antigen, which only recognises processed antigen in 
association with MHC molecules, the BCR recognises antigens in solution or on 
cell surfaces in a native conformation. B cell activation by antigen leads to 
antigen uptake by the BCR, processing and presentation to T cells.
Antibodies of all heavy-chain isotypes namely, IgM, IgD, IgG, IgA and IgE, can 
be produced either in secreted or membrane-bound receptor form. However, 
only IgM and IgD are expressed on the surface of mature naive B cells. The 
ligand-binding unit consists of a tetrameric complex of Ig heavy chain 
homodimers; each linked by disulphide bonds to an Ig light chain. A 
transmembrane region of 25 amino acids anchors it to the cell surface. The sig 
subunit lacks any intrinsic enzymatic activity within its cytoplasmic domains; 
thus it associates with accessory signal transducing molecules. Encoded by the 
mb1 and b29 genes respectively (Reth, 1995), Ig-a (34 kDa) and Ig-p (38 kDa) 
possess single, immunoglobulin extracellular domains and exist as disulphide 
linked heterodimers.
10
Chapter 1 -  General Introduction
Cellular signalling is mediated by a common mechanism in many 
immunoreceptors. In the case of the BCR, the associated accessory molecules 
possess consensus sequence motifs responsible for the initiation of signal 
transduction. This motif originally designated as TAM, ARAM or RETH, is now 
termed the immunoreceptor tyrosine-based activation motif (ITAM) (Cambier et 
ai, 1995; Cambier, 1995). This motif, spaced over 18 amino acids, is composed 
of a twice-repeated YxxL sequence flanking seven variable residues (Table 
1.1). Antigen-ligation of the BCR promotes the phosphorylation of the two 
tyrosine residues within each ITAM (four tandem motifs per BCR) by non- 
receptor protein tyrosine kinases (PTKs) (Figure 1.4). Phosphorylation of the 
tyrosine residues is essential to the function of the motif and is deemed as 
being necessary and sufficient to initiate signal transduction (Cambier, 1995).
Other ITAM containing membrane proteins include the CD3 and ^-chains of the 
T cell receptor (TCR) and several receptors for the Fc domain of 
immunoglobulin (FcRs). The discovery of this critical motif and the subsequent 
studies into the initiation of ITAM mediated signal transduction has 
revolutionised immunoreceptor biology.
1.2.3 BCR Signalling
The downstream signalling pathways that couple sig ligation to B cell activation 
and differentiation, have become a major area of research in the field of 
immunology, in the quest to understand and ultimately ‘control’ the immune 
response. The current model of sig mediated B cell activation demonstrates that 
the earliest event detected following BCR ligation is the activation of protein 
tyrosine phosphorylation (reviewed in Kurosaki, 1997, 1999; Campbell, 1999). 
Recruitment and activation of three distinct types of non-receptor protein 
tyrosine kinases (PTKs) are known, these include the Src- (including Lyn, BIk 
and Fyn), Syk- and Tec- (Bruton’s tyrosine kinase; Btk) PTKs (Cambier, 1995; 
Kurosaki, 1999) (Figure 1.4) The domain structures of these PTKs are shown 
in Figure 1.5A. In resting B cells a small amount of the Src-family PTKs are 
associated with the BCR as folded, inactive molecules via hinged N-terminal 
regions. Following BCR ligation, the Src-family PTKs become activated, unfold.
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and phosphorylate the tyrosines within the BCR accessory molecules (Figure 
1.5B). The phosphorylated ITAMs create new binding sites for the tandem SH2 
domains of Syk. Once bound, Syk becomes tyrosine phosphorylated, increasing 
its activity by at least 10-fold. Btk is proposed to be activated in a similar Src- 
PTK dependent manner (Takata and Kurosaki, 1996). Together these activated 
kinases phosphorylate downstream targets in the signalling cascade. This 
simple model, however, does not explain recent findings suggesting that both 
Lyn' '^ and Syk' '^ B cells can still signal through their BCR (Craxton et al., 1999). 
This suggests that the BCR can activate both Lyn- and Syk-independent 
pathways and that differential activation of these PTKs could play a role in 
directing BCR-mediated signalling cascades down distinct paths, producing 
different physiological outcomes.
Indeed, Lyn has been shown to be involved in the tyrosine phosphorylation of 
the B cell inhibitory co-receptors, FcyRllb (section 1.4) and CD22 (reviewed by 
Doody et al., 1995; DeFranco et al., 1998; Tsubata, 1999). Following activation 
by Lyn, both receptors recruit and activate a SH2-domain containing protein 
tyrosine phosphatase (SHP-1) which is thought to inhibit the association of Syk 
and Src-family PTKs with the BCR ITAMs by dephosphorylating Ig-p. Inhibition 
of Src-family PTK activity may also be achieved by the phosphorylation of the 
inhibitory site within the PTK, by C-terminal Src kinase (Csk). Csk acts to keep 
the PTKs in a folded, inactive conformation until déphosphorylation of the site 
by the transmembrane protein tyrosine phosphatase CD45 (reviewed by 
Thomas, 1999). Since in resting cells both CD45 and Csk are constitutively 
active enzymes, this suggests that their opposing activities keep the Src-family 
PTKs in a net dephosphorylated state. The role of co-receptors in modulating 
BCR signal is discussed further in section 1.2.5.
In addition to the initiation of signal transduction events, the BCR serves to 
target bound antigen for processing and presentation by MHC class II 
molecules. Recent advances in the understanding of BCR functions have 
suggested a role for sphingolipid- and cholesterol-rich plasma membrane lipid 
micro-domains, termed lipid rafts, in the initiation of both signalling and antigen
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targeting functions of the BCR (Cheng, etal., 1999). Upon antigen binding, the 
BCR complex is rapidly recruited into these lipid rafts bringing the BCR into 
close contact with downstream signalling molecules and adaptor proteins. 
Subsequently, BCR bound antigen is targeted to the endocytic MHC class II 
peptide-loading compartments. Importantly, these rafts were shown to contain 
the Src-family kinase Lyn, but were deficient in the membrane phosphatase, 
CD45 (Cheng, et al., 1999). Thus, these lipid rafts have been proposed to 
function as platforms for both receptor signalling and antigen internalisation.
The early BCR-mediated signalling events result in the aggregation and 
activation of a number of important downstream enzymes and adapter proteins 
that in turn result in the initiation of three independent, yet potentially interactive, 
signalling pathways (Figure 1.6) (reviewed by Cushley and Harnett, 1993). The 
first pathway involves the hydrolysis of phosphatidylinositol 4,5 bisphosphate 
(Ptdlns(4,5)P2) to diacylglycero! (DAG) and inositol 1,4,5-triphosphate 
(lns(1,4,5)P3) by poly-phosphoinositide-specific phospholipase C-y (PLC-y). 
The second results in the generation of phosphatidylinositol 3,4,5 triphosphate 
(Ptdlns(3,4,5)Ps) by phosphatidylinositol 3-kinase (PI-3-kinase) and finally the 
classical Ras/MAPKinase cascade can be activated. These pathways all 
converge at the nucleus where they regulate transcription factors and ultimately 
dictate the fate of the cell.
1.2.3.1 Activation of PLC-y
The PLC-y pathway was one of the first downstream pathways shown to be 
activated by the BCR (DeFranco, 1997). The generation of second messengers, 
DAG and lns(1,4,5)P3, has been shown to be important for the activation of 
protein kinase C (PKC) isoforms, the release of intracellular calcium stores and 
the nuclear translocation of NF-kB (Berridge and Irvine, 1989; Berridge, 1993; 
Lee and Rhee, 1995). DAG activates certain serine/threonine protein kinase C 
(PKC) isoforms at the plasma membrane (reviewed by Parekh et al., 2000) 
whilst lns(1,4,5)Pa binds to receptors (InsPsR) in the endoplasmic reticulum. 
InsPsR activation leads to a process of capacitative calcium entry, by which the
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depletion of intracellular stores activates calcium influx across the plasma 
membrane (Parekh and Penner, 1997).
PKC isoforms are divided into three groups depending on their structure and 
cofactor regulation (Dekker and Parker, 1994). Conventional PKCs (a, p i,(32 
and y) require both calcium and DAG for activation, novel (Ô, e, q, |x and 0) are 
calcium independent but require DAG whilst, atypical PKCs (^, l/ i)  require 
neither. Several studies have highlighted the role for PKCs in modulating the 
BCR-mediated response in a maturation stage-dependent manner. Studies in 
knockout or depletion models of PKC isoforms have demonstrated that a lack of 
DAG-responsive PKC isoform activation, in particular PKCp, may be 
responsible for BCR-induced apoptosis in immature B cells (Leitges etal., 1996, 
King et ai, 1999). Thus, apoptosis can be overcome by stimulating immature B 
cells with phorbol esters (e.g. PMA), which bypass the BCR and activate the 
conventional and novel PKC isoenzymes directly (Nishizuka, 1992; King et ai,
1999).
The PLC family contain three homologous groups of enzymes (PLC-p, y and 6) 
all of which contain pleckstrin homology (PH) domains. In tyrosine kinase 
dependent signalling, including most immune receptors, one or both of the two 
isoforms of PLC-y, PLC-yl and PLC-y2, are activated. In addition to the PH 
domain, PLC-y isoforms also contain two SH2 domains and an SH3 domain 
(Lee and Rhee, 1995). The SH2 domain aids the recruitment and 
phosphorylation of PLC-y by the PTKs Btk and Syk, whilst the PH domain 
permits docking to the inner plasma membrane via a Ptdlns(3,4,5)Ps dependent 
mechanism (Campbell, 1999). The translocation of PLC-y to the cell membrane 
and its subsequent PTK-mediated tyrosine phosphorylation is essential for its 
activation. Indeed, a deficiency in either Btk or Syk results in ablation of PLC-y 
activation and lns(1,4,5)Ps production. Ptdlns(3,4,5)P3 can bind or activate Btk 
which, in turn, phosphorylates and activates PLC-y. In addition, Ptdlns(3,4,5)Ps 
may directly activate PLC-y via PH domain binding interactions. Although the 
SH2 domain of PLC-y can bind to Syk in vitro, reconstitution experiments 
indicated that additional factors were required to initiate a BCR-mediated
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calcium response (Kelly and Chan, 2000). More recently, the B cell specific 
adapter protein, BLNK (B cell linker protein), also termed SLP-65, has been 
shown to be required for coupling Btk and Syk activation to the activation of 
PLC-y (Fu etal., 1998; Ishiai et a!., 1999). Indeed, studies using the chicken 
DT40 cell line have shown that BLNK gene disruption abolishes PLC-y 
phosphorylation (Ishiai eta l., 1999). BLNK also has an involvement in the 
recruitment and activation of Vav, Grb2 and Nek, serving to focus these 
signalling effectors at the plasma membrane for phosphorylation by Syk.
PLC-yl deficient mice are embryonic lethal and fail to mobilise calcium (Ji et al.,
1997). Whilst PLC-y2 insufficiency is not lethal (Wang etal., 2000), PLC-y2 
deficient B cells have signalling defects similar to that seen in Btk knockouts 
(Khan et al., 1995) or the naturally occurring xld immunodeficient mice 
(Rawlings et al., 1993) both of which possess a mutation in the PH domain of 
Btk.
1.2.3.2 Activation of PI-3-K
Phosphatidylinositol 3-kinase (PI-3-Kinase) catalyses the phosphorylation of the 
inositol phospholipids Ptdlns, Ptdlns(4)P and Ptdlns(4,5)P2 on the 3’ position of 
the inositol ring to produce Ptdlns(3)P, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3, 
respectively (Fry, 1994) (Figure 1.7). The three classes of PI-3-K are 
determined by their in vitro substrate specificities. Class I PI-3-kinases 
phosphorylate all three forms of inositol phospholipid and can be further 
subdivided into Class lA and Class IB. Class lA comprise a p i 10 catalytic 
subunit (a, p or 6) and a regulatory SH2/SH3-domain containing p85 family 
adapter subunit. The Class lA isoforms are normally activated by PTK coupled 
receptors. Class IB isoforms consist of a pIlOy catalytic subunit and are 
activated following signalling via G-protein coupled receptors. Class II isoforms 
phosphorylate PI and Ptdlns(4)P whilst Class III phosphorylates PI only.
PI-3-Kinase activity and the generation of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3, 
are known to be important for BCR-mediated B cell proliferation, differentiation 
(Aagaard-Tiliery and Jelinek, 1996) and survival (Campbell, 1999). Such that
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inhibition of PI-3-Kinase activity in actively cycling B cells results in apoptosis 
(Craxton et al., 1999). However, a negative role for PI-3-Kinase has been 
shown in a human RL B cell line where BCR-induced growth-arrest can be 
blocked by inhibiting PI-3-Kinase activity (Craxton et al., 1999). The interaction 
of Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3 with SH2 and PH domain containing 
proteins, such as PLC-y, Btk, Vav, PDK1/2 and Akt/PKB permits their 
recruitment to the plasma membrane (Aagaard-Tiliery and Jelinek, 1996; Alessi 
et al., 1997; Falasca et al., 1998; Franke et al., 1997). PI-3-Kinase activation 
following BCR ligation was thought to be solely dependent on PTK activity. 
However, studies have demonstrated the essential requirement for upstream 
activation of the GTPase Ras (Kodak! et al., 1994) which then binds the pi 10 
catalytic sub-unit of the p85-dependent PI-3-Kinase (Genot and Cantrell, 2000). 
This mechanism establishes a link between the PI-3-Kinase pathway and the 
pathways driven by GTP binding proteins, such as the Ras MAPK pathway. Pl- 
3-Kinase activation may also result from recruitment and phosphorylation by 
CD19 following BCR ligation. (Aagaard-Tiliery and Jelinek, 1996; Kurosaki, 
1999; DeFranco, 1997). Upon BCR-ligation, the cytoplasmic tail of CD19 
becomes tyrosine-phosphorylated by the Src-family PTK Lyn and provides 
binding sites for PI-3-Kinase, the GEF Vav, She and the Src-family PTKs. The 
binding of PI-3-Kinase to CD19 following BCR-ligation serves to localise PI-3- 
Kinase to the plasma membrane where its phosphoinositide substrates are 
located.
1.2.3.3 Activation of the Ras/MAPKinase pathway
The mitogen-activated protein (MAP) kinases are a family of serine-threonine 
protein kinases. They are activated by a wide range of extracellular stimuli and 
are able to mediate a wide range of cellular functions from proliferation and 
activation to growth arrest and cell death (Figure 1.8). The MAPKinase family is 
further classified into three sub-groups; the classical extracellular signal- 
regulated kinases (ErkMAPKinase), the c-Jun N-terminal kinases, also known 
as the stress activated protein kinases (JNK/SAPK) and the p38 MAPKinases 
(Dhanasekaran and Premkumar-Reddy, 1998; Elion, 1998). Activation of each 
sub-group is determined by distinct upstream MAPKinase kinases (MEKs).
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MAPKs are activated by dual phosphorylation on tyrosine and threonine 
residues, located in a T-x-Y motif. Each sub-group of MAPKinase is 
independently activated and regulated by a specific MEKK (MAPKinase kinase 
kinase) and MEK following cell stimulation. However, significant pathway cross 
talk exists. Following MAPKinase activation, independent activation of 
downstream transcription factors occurs thus, ErkMAPKinase activates Elk-1 
and c-myc, JNK activates c-Jun and ATF-2 and p38 MAPKinase activates ATF- 
2 and MAX. The phosphorylation of these transcriptional regulators enables the 
MAPKinase families to dictate gene expression and hence, cellular responses.
In B cells, coupling of the BCR to the MAPKinase pathway relies on the 
formation of adapter protein scaffolds, which are recruited by activated protein 
tyrosine kinases. These complexes then facilitate the recruitment of 
downstream guanine nucleotide exchange factors (GEFs) and kinase cassettes 
of the MAPKinase pathway. Following BCR ligation, the adapter protein She 
binds to the phosphorylated BCR ITAMs and is in turn phosphorylated by the 
PTK Syk. Activated She then recruits Grb2-SoS complexes to the 
phosphorylated ITAMs (Li etal., 1993; Harmer and DeFranco, 1997). In 
conjunction with a GTPase activating protein (RasGAP), the GEF SoS (son of 
sevenless) regulates the activities of the guanine nucleotide binding protein 
Ras.
Small GTPases, such as Ras, cycle between inactive GDP-bound and active 
GTP-bound states and thus function as signal relays linking membrane 
receptors to signal transduction pathways. GEFs promote the exchange of GDP 
for GTP resulting in the production of an active GTPase to turn on downstream 
signalling effectors, whilst GAPs accelerate the normally slow intrinsic GTPase 
activity, thereby inactivating it (Henning and Cantrell, 1998). Thus, following 
BCR ligation Grb2-SoS complexes acts to displace GDP from the GTPase Ras 
to generate an active GTP-bound form (Figure 1.9). Ras is then able to 
regulate a wide range of downstream cellular processes, from cytoskeletal 
reorganisation through to modulation of transcription (reviewed by Vojtek and 
Der, 1998). In particular, active Ras can bind and derepress Raf, a
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serine/threonine kinase, resulting in the activation of MAPKinase kinases (MEK) 
and the subsequent downstream activation of the ErkMAPKinases (ErkMAPK) 
(Kolch, 2000) (Figure 1.8). Active Ras also promotes cell survival by direct 
interactions with PI-3-Kinase, resulting in the production of the second 
messengers, Ptdlns(3,4)P2 and Ptdlns(3,4,5)P3.
It is important to note that Ras activation can also occur through an alternative 
route due to the utilisation of the linker protein BLNK (Kelly and Chan, 2000). 
Whilst already implicated as an intermediate adapter in the membrane 
recruitment and activation of PLC-y by Syk, BLNK is known to associate with 
Grb2 and SoS to form a BLNK/Grb2/SoS complex. Thus, bypassing the 
requirement for the adapter protein. She, in Ras activation. In addition, co­
recruitment of the GEF Vav by BLNK (Fu et al., 1998) can in turn activate the 
Rho-family of GTPases (Rac, RhoA and Cdc42) (Crespo et al., 1997). These 
GTPases provide a critical linkage for the activation of the other MAPKs, 
JNK/SAPK and p38 MAPK, by specific MEKKs (MEKK1-4). (Figure 1.9). Rho- 
GTPases are also able to activate PI-5-Kinase, leading to the activation of PLC- 
y and the generation of lns(3,4,5)P3 and calcium mobilisation (Campbell, 1999). 
Alternative pathways following GEF activation may also occur due to the 
structural similarities between the effector binding domains of the GTPases Ras 
and Rap-1. The Rap-1 GEF, C3G, interacts with Crk, a Grb2 like adapter 
molecule, to form a C3G-Crk complex that associates with phosphorylated 
receptor tyrosine kinases. Activation of Rap-1 by C3G may lead to the 
sequestering of the downstream effector Raf, the down-regulation of 
MAPKinase activation and modulation of the cellular response (Figure 1.9) 
However, in some cases, Rap-1 activation may actually occur in a Crk/C3G 
independent manner. Studies by York et. al., 1998 have shown that formation 
of a stable complex between Rap-1 and p-Raf promotes the activation of ERK- 
MAPKinase in nerve growth factor treated PCI2 cells, suggesting that Rap-1 
activity can positively regulate receptor-mediated responses. Indeed, transient 
Ras-dependent MAPKinase activation in PCI2 cells results in proliferation, 
whilst sustained Rap-1-dependent MAPKinase activation induces differentiation 
(York eta l., 1998). Utilisation of this alternative pathway process may be
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facilitated by the differential cellular localisation of these two GTPases; Ras Is 
predominantly membrane bound whilst Rap-1 is located in endocytic and 
lysosomal vesicles.
MAPKinase pathways are able to regulate cell cycle machinery thus controlling 
the fate of a cell and dictating whether it progress through to rounds of 
proliferation or enters into growth arrest or apoptosis. In B cells, the 
ErkMAPKinase pathway has been shown to promote proliferation by inducing 
the expression of cyclin D1 (Lavoie et al., 1996) (section 1.2.4). The cyclins are 
pivotal in controlling successful passage of cells through the cell cycle. 
Phosphorylation of certain Ribosomal 86 Kinase isoforms (p90RSK1-3) by 
ErkMAPKinase has also been postulated to be important for the regulation of 
translation. In contrast, activation of the JNK/SAPK and p38 MAPKinases 
induces growth arrest and apoptosis in a human immature B cell line following 
BCR-ligation (Graves etal., 1996).
To understand how these signalling pathways influence cellular responses, the 
regulation of the cell cycle and the induction of programmed cell death, or 
apoptosis, will be discussed.
1.2.4 Cell cycle and apoptosis
Signalling via the BCR has been shown to play a pivotal role in the activation of 
B cells that can lead to various distinct cellular responses, including 
proliferation, differentiation, anergy and cell death. Despite numerous 
investigations, it is still not clear how the biochemical signalling events can be 
translated into these responses. What is clear is that any cellular response is 
regulated by a number of enforced checkpoints. Checkpoints serve a critical 
role in the control of cell cycle progression and the damage response system, 
as they provide the cell with an opportunity to assess the appropriateness of 
response. Thus a cellular response is the integration of biochemical signals that 
promote and inhibit the progression of the cell cycle.
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The cell cycle is the period of time from one cell division to the next. This 
complex process relies on the assembly of nuclear proteins that integrate 
signals and programme cell cycle progression (Figure 1.10) (O’Connor ef a/.,
2000). There are fours main stages of the cycle, during which a cell must 
duplicate its contents and divide. In Gi (gap 1) the cell increases in size, 
separates its centrioles and prepares to copy its DNA. DNA duplication occurs 
in the S phase (synthesis). After chromosome replication a second gap period, 
G2 , allows the cell to monitor DNA integrity and cell growth prior to M (mitosis) 
when the cell finally divides. The daughter cell products immediately enter Gi 
and may go through the full cycle again or alternatively stop cycling temporarily 
and enter the Go phase (reviewed in Planas-Silva and Weinberg, 1997). Cell 
cycle progression is driven by two essential components, cyclins and cyclin 
dependent kinases (Cdks). The kinases include Cdk4 and Cdk6 which 
associate with the cyclins D1, D2 and D3 whilst, Cdk2 associates with cyclin E 
(Pavletich, 1999). At the Gi checkpoint cells have to decide whether to commit 
to DNA synthesis. Here, D-type cyclins bind to Cdks 4 or 6 and the resulting 
complex promotes Gi/S transition by releasing the braking effect of 
retinoblastoma protein, pRb^ °®. Hypophosphorylated Rb actively blocks cycling 
by sequestering the transcription factor, E2F, thus blocking expression of 
necessary S-phase genes (Dyson, 1998). Once phosphorylated by the cyclin- 
Cdk complexes, E2-F is released and S phase genes are transcribed (Figure 
1.10).
In response to cellular stress or damage, various external signals and inhibitory 
proteins can restrain the cycle progression at the Gi/S boundary and promote 
growth-arrest and/or apoptosis (see below). Extracellular regulators include the 
transforming growth factor-p (TGF-p) and interferon-a (IFN-a) (Sangfelt etal.,
2000). These pleiotropic factors act in part to suppress Rb phosphorylation, 
through the inhibition of Cdks and the recruitment of Cdk inhibitors (Figure 
1.10) (reviewed in Sherr and Roberts, 1999). The INK4 (p i5, p16, pi 8 and p i9) 
and the WAF1 (p21, p27 and p57) families of Cdk inhibitors act to block Cdk 
activity at various stages of the cell cycle. p15, pie'^^"^^ and p27^ '"^  ^have all 
been demonstrated to inhibit the Cyclin D-Cdk 4/6 complex, whilst pi 9^ *^^  and
20
Chapter 1 -  General Introduction
p2 ^wAFi thought to induce cell cycle arrest through interactions with the 
tumour suppressor gene, p53.
Activation of the tumour suppressor gene, p53, in response to DNA damage 
from both endogenous and exogenous sources results in cell cycle arrest in the 
Gi phase. This is presumably to allow an opportunity for DNA repair to occur 
before replication or mitosis (Hartwell and Kastan, 1994). However, in some cell 
types including immature B cells, p53 activation results in apoptosis (Wu et a/.,
1998). The final outcome of p53 activation thus depends on the action of a 
variety of downstream effector genes transactivated by p53. The protective role 
of p53 is highlighted by the fact that around 50% of all cancers have lost, or 
possess an inactive form of p53. Indeed, the inactivation of various cell cycle 
proteins including Rb °^®, pi6'NK4A p is  has been implicated in the 
progression of human cancers. The net effect of their loss being deregulation of 
the cell cycle and, in turn, survival and excessive proliferation of the cell.
The growth and proliferation of cells must be tightly regulated to prevent the 
production of excessive cell numbers. Programmed cell death, or apoptosis, 
provides a mechanism for the disposal of “unwanted” cells in a co-ordinated 
manner (reviewed by Hengartner, 2000). This mechanism also protects the 
system by enabling the destruction of damaged or potentially harmful cells. The 
classical morphological features of apoptosis include the condensation of 
chromatin, protein and DNA fragmentation and the formation of apoptotic 
bodies. Thus, biologically activated apoptosis is quite distinct from necrosis, 
where cellular death arises due to chemical or physical injury. Most of the 
observed changes associated with apoptosis (i.e. DNA/protein cleavage, 
nuclear shrinking, loss of cell shape) are implemented by a set of cysteine 
proteases, caspases, which are specifically activated in apoptotic cells 
(reviewed by Thornberry and Lazebnik, 1998).
The caspases are a family of proteases that possess an active-site cysteine and 
cleave substrates after aspartic residues. The four residues amino-terminal to 
the cleavage site determines the distinct substrate specificity of different
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caspases (Thornberry et al., 1997). Proteolytic cleavage by caspases can lead 
to diverse results depending on the nature of the substrate and the exact 
cleavage site position. Thus, caspases are able to mediate both activation and 
inactivation of downstream target proteins. Most caspases are activated by 
proteolytic cleavage of an inactive pro-caspase form (Figure 1.11). Each pro- 
caspase contains in its prodomain a protein-protein interaction module, which 
allows it to bind and associate with upstream regulators. Initiator caspases-8 
and -10 contain a death-effector domain (DED), permitting interaction with 
CD95 and the adapter molecule FADD, whilst the effector caspases-2 and -9 
contain a caspase activation and recruitment domain (CARD). Activation can 
occur simply by exposure to another previously activated caspase, resulting in a 
‘caspase cascade’ of activation.
Many of the functions of the cascade appear to converge on mitochondria, 
where the induction of apoptosis has been shown to result in a rapid loss of 
mitochondrial membrane potential and organelle swelling. However, a cells fate 
is often decided through the activation of the Bcl-2 family of apoptosis regulator 
proteins (Figure 1.12) (Jacobson, 1997). Homo- or heterodimers of pro- and 
anti-apoptotic Bcl-2 members, act at the surface of the mitochondria and 
compete to regulate cytochrome c release which, in association with the 
adapter Apaf-1, has been implicated in the activation of caspase-9 in the 
cytosol. This complex results in the activation of the effector caspase-3 and can 
be antagonised by the expression of inhibitors-of-apoptosis (lAPs). However, 
the Smac/DIABLO protein, also released from the mitochondria, negatively 
regulates lAP family members ensuring that they do not Inhibit caspase 
activation once a cell is committed to apoptosis.
Cleavage of the pro-apoptotic Bcl-2 family member. Bid, by caspase-8 releases 
an active, truncated form (tBid) which translocates to the mitochondria and 
promotes the release of cytochrome c (Porter, 1999) (Figure 1.13) In addition, 
interaction of the pro-apoptotic regulator Bad with anti-apoptotic regulators Bcl-2 
or B c I-X l at the mitochondrial surface promotes apoptosis. In contrast, 
phosphorylation of Bad by the survival protein Akt promotes the association of
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Bad with the phospho-serine binding protein, 14-3-3 and its removal from the 
mitochondria. The blocking of the interaction of Bad with other Bcl-2 family 
members thus promotes cell survival (Franke and Cantley, 1997).
Thus, the regulation of the cell cycle and the apoptotic pathways exemplify the 
high degree of crosstalk and integration between cell signalling pathways that 
are involved in deciding cell fate.
1.2.5 B cell co-receptors and signalling
A hallmark of the immune response is the maintenance of equilibrium between 
antigen reactivity and cellular quiescence. Tight regulation and control over a 
potentially inappropriate response is critical. On the cellular level, many aspects 
of positive signalling in the generation of a controlled immune response have 
been investigated. In contrast, detailed knowledge of counteracting inhibitory 
pathways has been quite limited. Recent studies into inhibitory cell surface 
receptors have highlighted the requirement for the balance of activatory and 
inhibitory pathways to maintain this control. Indeed, loss of suitable inhibitory 
signalling is frequently associated with the development of inflammatory 
responses and, in some cases, autoimmunity.
This balance of control is exemplified by the fine-tuning of B cell responses to 
antigen, resulting in differential biological responses. Extracellular mediators 
which can alter BCR mediated signalling, include; the concentration of the 
antigen, the avidity with which it Is bound, the timing and duration of antigen 
encounter and co-stimulation by other cells, receptors or antigenic sources, 
(reviewed by Healy and Goodnow, 1998). Similarly, the differential expression 
of signalling molecules at different B cell maturation stages or the use of 
alternative signalling pathways by the recruitment of different adapter molecules 
leads to the generation of a full repertoire of responses.
The involvement of B cell co-receptors and their modulation of the cellular 
response have been widely studied (reviewed by Tsubata, 1999). Molecules
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such as CD19, CD22, CD72 and the Fey receptor, FcyRllb, appear to alter the 
signalling threshold of the BCR either by facilitating positive signalling or by 
downmodulating BCR function.
1.2.5.1 CD19
CD19 is a cell surface glycoprotein that forms a non-covalent complex with 
CD21 (complement receptor type 2, CR2), CD81 (TAPA-1) and Leu-13 on B 
cells. Co-ligation of this complex on B cells results in a reduction of the 
signalling threshold required for B cell activation, such that CD19-deficient mice 
are hyporesponsive to stimulation via the BCR (Engel et al., 1995). CD19-BCR 
co-ligation results in an increase in the release of intracellular calcium, DNA 
synthesis, ErkMAPK activation and antibody production (Tedder etal., 1997). 
CD19 is uniformly expressed throughout B cell development, with an increase in 
expression shown by mature B cells. Alteration in the levels of CD19 expression 
has little effect on B cell development until maturity, where an overexpression of 
CD19 by immature B cells results in a significant reduction of conventional B 
cells in the periphery (Engel et al., 1995). This reduction is presumably as a 
result of a hyper-responsive antigen receptor leading to enhanced negative 
selection in the bone marrow.
In some cases, CD19-overexpression can lead to hyper-gammaglobulinema 
and autoimmune disease, which is believed to be due to CD19-mediated 
lowering of the threshold for BCR-mediated signalling. Thus, overexpression of 
CD19 may permit autoreactive B cells to overcome their anergic state. CD19- 
deficient mature B cells have also been reported to have lowered responses to 
T-cell dependent antigens and subsequent lack of germinal centre formation 
and decreased affinity maturation of serum antibodies (Fujimoto et al., 1999). 
This suggests that CD19-signalling is important for T-cell dependent B cell 
responses.
Following BCR-ligation the PTK Lyn phosphorylates the cytoplasmic tail of 
CD19 and subsequently leads to the creation of SH2 binding sites and the 
recruitment and activation of various downstream signal-transducing molecules
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(Fujimoto et a/., 1999). Src-famiiy PTKs, PLC-y, PI-3-Kinase, the GEF Vav and 
the adapter molecule, She, have all been associated with direct binding to 
activated GDI9 (Tuveson et al., 1993; Weng et al., 1994). Studies into these 
complex associations have lead to the belief that GDI 9 may be responsible for 
many of the initial early signalling events following BCR co-ligation, as CD19- 
deficiency leads to a reduction in the tyrosine phosphorylation of multiple 
effector molecules downstream of BCR activation (Fujimoto et al., 1999). The 
association of adapter molecules with GDI9 has also helped to explain the 
ability of GDI 9 to promote events normally associated with positive BCR 
signalling. Thus, GDI9 can regulate BCR coupling to PLC-y and sustained 
calcium influx via amplification of the Src-famiiy PTK signal. The 
phosphorylation of GDI9 by Lyn initiates additional rounds of PTK activation 
including the activation of Syk and Btk, leading to the recruitment of the 
BLNK/PLC-y/calcium pathway.
However, calcium influx in GDI 9-deficient B cells is sustained at later time 
points when it normally decreases in wild-type B cells. This may be due to a 
reduction in the tyrosine phosphorylation of multiple effector molecules 
downstream of the BCR following BCR-ligation in GDI 9-deficient cells. This 
leads to decreased levels of PLC-y or the decreased phosphorylation of the 
SH2 domain containing inositol phosphatase, SHIP. SHIP negatively regulates 
calcium mobilisation by decreasing the availability of the major PLC-y substrate, 
Ptdlns(3,4,5)P3 and is an important mediator in the negative regulation of B cell 
activation by FcyRllb (see section 1.3). Additional studies have also accounted 
for the ability of GDI 9 to augment BCR-mediated ErkMAPK activation by the 
synergistic enhancement of MEK1 activity, in a Ras- and PKC-independent 
manner (Li and Carter, 1998).
1.2.6.2 CD22
GDI9 can also interact with other regulators of BCR signalling such as CD22, 
which is a B cell specific protein that appears to be both a negative and a 
positive regulator of B cell activation (Sato et al., 1996). In contrast to GDI 9, co­
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ligation of CD22 with the BCR results in the specific suppression of ErkMAPK 
and the modulation of JNK activity. Thus, CD22-deficient mice show enhanced 
B cell responses, including augmented intracellular calcium mobilisation. 
Following BCR ligation, CD22 is tyrosine phosphorylation via the PTK Lyn and 
recruits the tyrosine phosphatase SHP-1 to its cytoplasmic ITIM. SHP-1 is a 
strong candidate for mediating the negative effects of CD22, as there are 
increased levels of SHP-1 recruited by CD22 following BCR ligation. Indeed, 
recent data suggests that CD22 may function as a molecular "scaffold" that 
specifically coordinates the docking of multiple effector molecules, in addition to 
SHP-1, in a context necessary for BCR-dependent JNK stimulation. (Poe et a l ,
2000).
A role for CD22 in the induction of autoimmunity has also been suggested since 
the gene for CD22 maps within a region associated with the development of 
autoimmune disease in certain strains of mice. The CD22 protein expressed in 
these autoimmune mice is markedly underphosphorylated and binds very little 
SHP-1 (Cornall eta l., 1998). However, the disease phenotype displayed is 
milder than that of SHP-1 deficient mice, confirming that SHP-1 may also 
regulate B cell signalling by affecting other signalling molecules. The 
transmembrane protein tyrosine phosphatase CD45 has also been implicated in 
the regulation of CD22, since CD45 deficient mice display increased resting 
CD22 phosphorylation. Consistent with this, cross-linking of CD45 leads to a 
decrease in tyrosine phosphorylation of CD22 and subsequent SHP-1 
recruitment (Greer and Justement, 1999).
1.2.5.3 CD72
CD72, a type II membrane protein, is also thought to negatively regulate B cell 
activation via the recruitment of SHP-1 (reviewed by Parnes and Pan, 2000). 
However, the Interaction of SHP-1 with CD72 is thought to have a different 
function than that displayed by other SHP-1 dependent inhibitory receptors. The 
tyrosine phosphorylation of CD72 in response to BCR ligation correlates 
strongly with BCR-induced growth arrest and/or apoptosis in B cell lines and 
primary B cells. Thus, CD72 acts to send a signal resulting in cell death by
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decreasing the activation threshold level of the BCR in immature B cells. 
However, if CD72 is pre-ligated its tyrosine phosphorylation levels are 
decreased and B cell tolerance levels are increased preventing BCR mediated 
apoptosis. Thus, SHP-1 acts to keep CD72 dephosphorylated and prevent BCR 
signalling from causing cell death.
1.3 Fc Receptors
Produced by B cells, antibodies (immunoglobulins, Ig) are constructed from 
heavy and light polypeptide chains. Two heavy (H) chains and two light (L) 
chains are joined by disulphide bridges and a flexible hinge region to construct 
a Y-shaped molecule (Figure 1.14). Proteases have been used to dissect the 
structure of antibody molecules and to determine which parts of the molecule 
are responsible for its various functions. The P(ab’)2  fragment has exactly the 
same binding characteristics as the original antibody but is unable to interact 
with any effector molecules or receptors. This is exemplified by the fact that 
intact antibodies that experimentally ligate the BCR are poor polyclonal B cell 
activators, in comparison to P(ab’)2  fragments, because the Fc portion is able to 
interact with an inhibitory Fc receptor (FcyRllb) expressed by the B cells.
By binding the Fc domain (Fc) of antibodies, Fc receptors (FcRs) provide a 
critical link between the humoral and cellular arms of the immune system 
through the targeting of antigen-antibody complexes to effector cells and 
priming of an immune response. Despite being members of the same family, 
FcRs exhibit rich structural and functional diversity. Indeed, there exists a 
separate FcR for every class of Ig; IgA (FcaR), IgD (FcÔR), IgE (FceR), IgG 
(FcyR) and IgM (FcpR) (Ravetch and Kinet, 1991; Raghavan and Bjorkman, 
1996). With the exception of the FcR for IgE (CD23) and the 
polyimmunoglobulin transporters for IgM/lgA (pIgR) and neonatal gut IgG 
(FcRn) (Raghavan and Bjorkman, 1996) most human and murine FcR are 
members of the immunoglobulin domain super family (IgSF) (Ravetch and 
Kinet, 1991; Daeron, 1997a; Daeron, 1997b). This group includes the high 
affinity receptors for IgE (FceRI), IgA (FcaRI) and all the IgG receptors (FcyR),
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Recent studies have also reported the identification of a new family member, 
Fca/pR, that binds to both IgM and IgA (Shibuya et al., 2000). Fca/pR is the first 
IgM receptor to be characterised on a molecular level in lymphocytes and 
macrophages and may play an essential role in both innate and adaptive 
immunity.
With the exception of some classes of FcyRII (section 1.3.5), which possess an 
integral cytoplasmic signalling motif, the majority of these receptors exist as 
multisubunit receptor complexes (Figure 1.15). These complexes comprise a 
ligand binding chain and an associated signalling chain, such as the y-chain. 
The ligand binding chains of these receptors are all type I membrane 
glycoproteins. The highly conserved extracellular regions contain two or three 
immunoglobulin (V-class) domains formed by disulphide loops of varying length. 
The transmembrane and cytoplasmic regions are less conserved. However, 
FcyRlllb (section 1.3.6) lacks a transmembrane region and is tethered to the 
membrane via a glycosylphosphatidyl linkage (GPI), preventing is association 
with a signalling chain.
1.3.1 Fey receptors
The Fey receptors (FcyRs) are specific for the Fc domain of immunoglobulin G 
(IgG). They comprise a multimembered family of structurally homologous but 
distinct receptors and are expressed on the vast majority of leukocytes, 
(reviewed by Daeron, 1997a) (Figure 1.15). Three main classes of FcyR exist, 
FcyRI, FcyRII and FcyRII I (Ravetch and Kinet, 1991; Hulett and Hogarth, 1994). 
In the mouse, single genes encode each of the classes whereas in humans 
multiple genes have been described for each class, encoding several forms of 
these receptors. With the exception of the murine FcyRI gene on chromosome 
3, the FcyR genes are located on chromosome 1 in both humans and mice. As 
products of alternative transcript splicing or receptor proteolysis, FcyRs are able 
to exist as both membrane receptors and as soluble molecules.
Soluble immunoglobulin binding factors (IBFs) specific for each immunoglobulin 
isotype have also been described (Fridman et al., 1992). Most FcyR expressing
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cells can produce binding factors in response to various cytokines and the 
interaction with immunoglobulin. Factors that influence the expression of the 
membrane forms of FcyR correlate with the production of soluble FcyRs. 
Soluble FcyRs arise by different mechanisms; via stop codons in the 
extracellular domains (FcyRlbl and FcyRIc), via alternative splicing events 
(FcyRIIa2) or via proteolytic cleavage (FcyRllla and FcyRlllb). Proteolytic 
cleavage of the murine membrane bound FcyRllb2, between the 
transmembrane and first cytoplasmic domains, creates a soluble form of 
FcyRIIb3. (Sautes et al., 1992). Interestingly, the shedding of FcRs by human B 
cells directly correlates with the upregulation of trypsin like serine-proteases 
within activated B cells (Sarmay etal., 1991).
Although the biological relevance of soluble FcyRs or soluble IgG-binding 
factors is unclear, the immunomodulatory potential of these receptors has 
generated substantial interest. Binding factors have been shown to modulate 
the in vitro synthesis of immunoglobulins and to regulate antibody production in 
an isotype-specific manner. Human serum contains high levels of soluble 
FcyRlllb, released by serine protease activity on neutrophils. Increased levels of 
sFcyRlllb have been shown to be associated with significantly lower risk of 
infection, which may be accounted for by the ability of sFcyRlllb to induced 
cytolysis in certain cell types (Hoover et al., 1995). Moreover, sFcyRII has been 
shown to suppress antibody production in cell culture (Varin et al., 1989).
1.3.2 FcyRs display different binding affinities for IgG
The three distinct classes of FcyR, FcyRI, FcyRII and FcyRIII, are defined by 
their cellular distribution, structure and affinity for the IgG subclasses (Figure 
1.15 and Table 1.2) (Hulett and Hogarth, 1994). There are four known 
subclasses of IgG, IgGI, lgG2, lgG3 and lgG4, differing only slightly in their 
amino acid sequence. Each subclass varies in its size, carbohydrate content, 
half life and binding affinity to the Individual FcyRs. Humans possess all four 
subclasses whilst the murine system lacks lgG4 and produces lgG2 variants 
(IgGI, lgG2a, lgG2b and lgG3). The high affinity FcyRI (CD64) receptor, is the 
only class of FcyR capable of recognising and binding monomeric IgG at
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physiological concentrations (section 1.3.4) (Allen and Seed, 1989). In humans, 
FcyRI binds IgGI with higher affinity than IgGS or lgG4 but is unable to bind 
lgG2. In contrast, FcyRII (CD32) (section 1.3.5) and FcyRIII (GDI6) (section 
1.3.6) are low affinity receptors which can only recognise IgG in the form of an 
immune complex (Van de Winkel and Capel, 1993; Raghavan and Bjorkman, 
1996; Hulett and Hogarth, 1994). Interestingly, whilst human FcyRI la and 
FcyRllb display high homology in their extracellular domains they differ in their 
IgG subclass binding affinities; FcyRI la is unable to bind lgG4 whilst FcyRllb is 
unable to bind lgG2 (Van de Winkel and Capel, 1993). Thus, IgG subclass 
plays an important role in the regulation of the immune response as it dictates 
which FcyRs are ligated and therefore determines the effector mechanism 
elicited. In particular, a variation in subclass type may affect the rate of immune 
complex clearance from the system, which has implications for immune 
complex-mediated diseases (see Chapter 4).
IgG subclass can also affect the activation of complement by immunoglobulin. 
The term complement constitutes a complex group of serum proteins that 
mediate inflammatory reactions and are essential for innate immunity against 
bacterial pathogens. In particular, complement is thought to aid host defence by 
directly opsonising and lysing bacteria and by activating other immune cells. 
IgGI and lgG3 mediate many of the effector mechanisms involved in this 
cascade, whilst lgG2 is less effective and lgG4 displays no binding affinity for 
the functional proteins within the complement system. Thus, IgG subclass will 
directly influence whether a host is susceptible to infection by its ability to recruit 
complement or FcyR bearing effector cells.
1.3.3 FcyR biological responses
The diversity of biological responses elicited by FcyR classes is presumably 
accounted for by the divergence in cytoplasmic tail domains of these receptors, 
as the extracellular domains are structurally related. However, when expressed 
in different types of cells, FcyR tend to trigger a cell type specific response, 
suggesting that the response triggered by FcyR depends on the cell type more 
so than on the receptor (Daeron, 1997a). Ligand occupation and subsequent
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aggregation of FcyR can result in ligand internalisation, by a process of 
endocytosis or phagocytosis, and/or cell activation. FcyR-mediated cell 
activation can lead to cytokine release, antibody directed cellular cytotoxicity 
(ADCC), degranulation and induction of cytokine gene transcription.
Despite being structurally and functionally different, the initiation of cell 
activation by the FcyRs is similar to that of other immunoreceptors. The 
signalling pathways recruited by several FcyRs depend upon the conserved 
immunoreceptor tyrosine based activation motif (ITAM) (Reth, 1989), previously 
discussed in the context of the BCR signalling accessory molecules Ig-a/lg-p. 
The ITAM motif is present in the cytoplasmic tails of certain FcyRs or in their 
associated signalling molecules, such as the y-chain (Figure 1.15). An atypical 
ITAM is found in the tails of FcyRI la and FcyRllc, where 12 variable residues, 
instead of 7, separate the conserved Yxx(l/L) sequences (Van den Herik-Oudijk 
et al., 1995). Phosphorylation of the tyrosine residues in these ITAM motifs is 
necessary and sufficient to initiate signals transduction by these FcyRs 
(Cambier, 1995). The phosphorylated ITAMs then recruit and activate further 
downstream effector molecules, in a manner similar to that of the BCR.
As studies into ITAM-containing immune receptors and their associated 
signalling pathways continued, it was discovered that an additional group of 
FcyRs were capable of producing inhibitory signals. Studies on FcyRllb, a 
known inhibitor of B cell activation, led to the discovery of the alternative 
immunoreceptor tyrosine-based inhibition motif (ITIM) (Amigorena etal., 1992a 
and 1992b; Muta etal., 1994). Subsequent studies found an identical motif 
within the cytoplasmic domains of other ‘inhibitory' receptors, including the NK 
cell inhibitory receptors (KIRs), the B cell co-receptor, CD22, and the T cell 
negative regulator CTLA-4 (Daeron, 1997b; Fong and Cambier, 1999). The 
consensus sequence of the ITIM is reminiscent of the ITAM, with a leucine 
residue at position Y+3 following the critical tyrosine residue (Table 1.1), 
although the characteristic double YxxL motif of the ITAM is replaced by a 
single YxxL motif. Further analysis of the sequences flanking the inhibitory motif 
resulted in the observation of a conserved valine or an isoleucine residue at
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position Y -2. Thus, the consensus motif V/lxYxxL constitutes the minimal 
structural requirement for the ITIM, such that mutation of the tyrosine is 
sufficient to abrogate the inhibitory properties.
When activated by immune complexes, ITIM containing FcyRs are involved in 
capping, endocytosis, and phagocytosis. However, inhibitory FcyRs are more 
commonly associated with negative regulation of other ITAM containing 
receptors. For example, FcyRllb inhibition of the BCR on B cells and FceRI and 
FcyRIII on murine mast cells (Ono et al., 1996; Ujike et al., 1999). Thus, FcyRs 
can positively or negatively regulate cell activation depending upon the 
cytoplasmic consensus motif that they employ for mediating signal transduction 
(Figure 1.16). A third group of FcyRs neither trigger nor inhibit cell activation. 
These include the polyimmunoglobulin transporters, involved in the transcytosis 
of immunoglobulins and FcyRlllb, which lacks any intrinsic signalling capability 
but contributes to cell signalling via its association with other FcR (Raghavan 
and Bjorkman, 1996).
The main focus of this thesis centres on the expression and signalling aspects 
of FcyRllb. However, the structural and signalling similarities to other members 
of the FcyR will also be discussed.
1.3.4 FcyRI
FcyRI (CD64) is a 70 kDa, type I membrane glycoprotein. It is constitutively 
expressed on the surface of macrophages, monocytes and can be induced on 
IFN-y stimulated neutrophils and eosinophils (Van de Winkel and Capel, 1993; 
Hulett and Hogarth, 1994). FcyRI is a high affinity receptor and the only FcyR to 
bind monomeric IgG at physiological concentrations (Allen and Seed, 1989). 
IgG binding by FcyRI can result in ligand internalisation, ADCC or degranulation 
depending on the cell type. Three human FcyRI genes have been identified and 
mapped to chromosome 1q21.1 (Van de Winkel and Capel, 1993; Hulett and 
Hogarth, 1994). The receptor structure is comprised of three extracellular IgSF, 
V-like domains, a single transmembrane domain and a short cytoplasmic
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domain with no known signalling motifs. The third extracellular domain is 
distinct, whereas the first two are homologous to the extracellular domains of 
FcyRII and FcyRIII, suggesting that the unique IgG binding characteristics of 
FcyRI are conferred by third domain (Allen and Seed, 1989).
Signal transduction occurs through the non-covalent association of FcyRI with y- 
chain homodimers or FcyRlla, both of which possess ITAMs necessary for 
activation of soluble tyrosine kinases. In the monocytic cell line, U937, the 
recruitment of FcyRII or the y-chain depends on the differentiation state of the 
cell. In the monocytic-like cells, FcyRI mediates signal transduction via the y- 
chain whilst the macrophage-like cells require FcyRlla (Cameron et al., 2001). 
The signal transduction unit employed has been shown to determine the 
signalling pathway and thus the cellular response elicited.
1.3.5 FcyRII
In contrast to FcyRI, the FcyRII (CD32) receptors display low affinity for IgG (K a 
<1 X 10  ^ M'^). With the exception of FcyRlla, which can signal by association 
with FcyRI, FcyRII isoforms are only activated through aggregation. This occurs 
in vivo when IgG is presented as an immune complex (Raghavan and 
Bjorkman, 1996; Van de Winkel and Capel, 1993; Hulett and Hogarth, 1994). In 
humans three distinct genes FcyRI I A, MB and IIC, mapped to q23-24 on 
chromosome 1, encode a total of six transcripts. Separate exons encode the 
transmembrane and cytoplasmic domains; thus alternative splicing of mRNA 
transcripts can create several isoforms (Brooks et al., 1989). All isoforms, with 
the exception of FcyRlla2 (see below), are type 1 integral membrane 
glycoproteins comprising two extracellular IgSF domains, a transmembrane 
domain and a cytoplasmic domain of varying length. Due to the homologous 
nature (>95%) of the extracellular domains, divergence between the receptors 
is contained within the cytoplasmic domain signalling motifs (sections 1.3.2 and 
1.3.3). Together, FcyRII receptors are an interesting example of how different 
cellular responses can be initiated by structural similar proteins. Thus, placing 
significant importance on the signalling pathways that they recruit.
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uman FcyRI IA encodes three transcripts, two of which encode identical 
membrane receptors (FcyRllal, known as FcyRlla) whilst the third encodes a 
putative soluble product (FcyRIIa2). Primarily expressed by cells of the myeloid 
lineage, including monocytes, macrophages and neutrophils, the ITAM- 
containing FcyRlla isoforms are able to mediate phagocytosis and endocytosis 
upon receptor ligation.
Human FcyRI IB encodes three transcripts, FcyRI lb 1, FcyRllb2 and FcyRllbS, 
which arise by alternative splicing mechanisms. The mature forms of FcyRIIb1 
and FcyRllbS are identical but they differ in their peptide leader sequences 
(Brooks e ta l., 1989). FcyRllbS lacks the information required for surface 
expression, encoded on the S2 exon, and is thus not expressed. FcyRllb2 is 
capable of mediating rapid IgG endocytosis by means of clathrin-coated 
vesicles. However, an insertion of 19 amino acids in the cytoplasmic tail of 
FcyRllbl disrupts the cytoskeletal attachment domain responsible for 
modulating receptor internalisation (Figure 1.17) (Daeron, 1997a). FcyRllb 
isoforms are widely expressed by cells of haematopoetic origin, with preferential 
expression of FcyRllbl on B cells and FcyRIIb2 on myeloid cells. All isoforms of 
FcyRllb possess an inhibitory ITIM motif in their cytoplasmic domains and in 
vitro and in vivo studies have shown that FcyRllb acts as a negative regulator of 
immune complex-triggered activation (section 1.4) (Ono etal., 1996; Ujike etal., 
1999).
Human FcyRIIC encodes only a single transcript, which predicts a receptor 
comprising of the extracellular domains of FcyRllb bearing an ITAM containing 
cytoplasmic domain, similar to that of FcyRlla (Van de Winkel and Capel, 1993). 
Four known splice variants of FcyRllc exist (FcyRIId-4) although their biological 
importance is unknown. Expression of FcyRllc, in association with FcyRllla 
(section 1.3.6), has recently been reported in NK cells (Metes etal., 1994).
In contrast to humans, a single gene encodes FcyRII in mice, which maps to the 
Ly-17 locus on chromosome 1. Three integral membrane glycoproteins have
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been isolated FcyRllbl, FcyRllb2 and FcyRllbT. No ITAM bearing FcyRII 
receptor isoforms exist in mouse. Similar to the human FcyRllb isoforms, murine 
FcyRllbl and FcyR 11 b2 are identical except for a 47 amino acid insertion in the 
first cytoplasmic exon of FcyRllbl, which inhibits its endocytic capacity. An 
additional murine isoform exists as a result of a cryptic splice donor site in the 
first cytoplasmic exon, creating a murine homologue of human FcyRllbl (named 
FcyRllbT).
1.3.6 FcyRIII
FcyRIII (CD16) is a low affinity IgG receptor that exists as a multimeric signalling 
complex (Daeron, 1997b; Van de Winkel and Capel 1993; Hulett and Hogarth, 
1994). Two isoforms, with differential cell expression, exist in humans. FcyRllla 
is expressed mainly on NK cells and macrophages, whilst FcyRlllb is present 
almost exclusively on neutrophils. FcyRIII are structurally similar to FyRII 
however they exhibit unique forms of membrane anchoring (Ravetch and 
Perussia, 1989). Whilst FcyRllla is an integral membrane glycoprotein, FcyRlllb 
exists as a glycosylphosphatidylinositol (GPI)-linked receptor lacking any 
transmembrane or cytoplasmic domains. Signalling by FcyRllla is mediated by 
ITAM containing accessory molecules, recruiting y-chain homodimers in 
macrophages and y-chain or Ç-chain homo- or heterodimers in NK cells. No 
other Fc subunits or ITAM containing accessory molecules are known to 
associate with FcyRlllb, but it is thought to signal in co-operation with FcyRlla 
and complement receptors. The murine FcyRIII exists as a single, 
transmembrane bound isoform, with no FcyRlllb equivalent. Signalling and cell- 
surface expression is mediated via its co-association with y-chain subunits only.
1.4 Mechanisms of FcTRIIb-medlated negative regulation
Negative regulation of BCR-mediated activation was first recognised when 
passively administered antigen-specific IgG antibodies were shown to inhibit in 
vivo primary responses to that antigen (Chan and Sinclair, 1971). A molecular 
basis for this inhibition was revealed following the cloning of the genes for 
murine low-affinity IgG receptors, Fcyllb and FcyRIII (Ravetch etal., 1986).
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Inhibition by IgG-containing immune complexes required the co-ligation of the 
BCR with the Fc receptor, FcyRllb (reviewed by Chan and Sinclair, 1971; Van 
de Winkel and Capel, 1993). Further studies demonstrated that FcyRllb 
inhibited BCR-mediated activation when the two receptors were co-ag g regated 
by antigen-IgG antibody complexes and/or anti-idiotypic antibodies (reviewed by 
Sinclair and Panoskaltsis, 1987). Similarly, on mast cells, co-aggregation of 
FcyRllb with FceRI (the high affinity receptor for IgE) or FcyRIII was shown to 
inhibit mast cell degranulation and the release of inflammatory mediators (Ono 
et al., 1996; Fong et al., 1996). Co-ligation with FceRI is via lgE:antigen 
complexes, for which FcyRllb has demonstrated low affinity (Choi et ai, 1996) 
and inhibition is dependent on the recruitment of SHIP by FcyRllb (Ono et ai, 
1996, Ujike et ai, 1999). Although the mechanisms underlying the negative 
regulation of BCR signalling are poorly understood, several of the well 
characterised cellular responses of BCR stimulation; phosphoinositide 
hydrolysis, influx of extracellular calcium, cellular proliferation and 
immunoglobulin secretion are all inhibited following co-engagement of FcyRllb.
Following the discovery of the ITIM motif within the cytoplasmic domain of 
FcyRllb and other inhibitory receptors, distinct pathways of inhibition have been 
described (Scharenberg and Kinet, 1998; Gupta et ai, 1997). The signalling 
pathways involve the tyrosine phosphorylation of the ITIM by protein tyrosine 
kinases and the recruitment of Src-homology domain 2 (SH2) containing 
proteins to the phosphorylated ITIM. The protein tyrosine phosphatases, SHP-1 
and SHP-2 (Long et ai, 1997; Burshtyn and Long, 1999) and the inositol 5’ 
phosphatase, SHIP (Ono et ai, 1996) have been shown to be the major 
proteins recruited by ITIM containing inhibitory receptors such as FcyRllb, CD22 
and CD72 in B cells, CTLA-4 in T cells and the family of Leukocyte Inhibitory 
Receptors (LIRs) (Daeron, 1997a/b; Unkeless and Jin, 1997; Vely et ai, 1997). 
These SH2-domain containing phosphatases act to dephosphorylate key 
signalling components downstream of the inhibiting receptors, thereby inhibiting 
normal cellular responses.
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Early in vitro studies on FcyRllb indicated that recruitment of the tyrosine 
phosphatases, SHP-1 and SHP-2, mediated the inhibitory effect of this receptor 
in B cells (D’Ambrosio et al., 1995). SHP-2 has a broad expression profile and 
has been shown to mediate both positive and negative regulatory effects. Its 
association with the platelet-derived growth factor p (PDGF-P) receptor, leads to 
the recruitment of the Grb-2-SoS complex and MAPKinase activation (Bennett 
et al., 1994). However, in human B cells, SHP-2 is thought to mediate FcyRllb 
inhibition of the Ras/MAPKinase and PI-3-Kinase pathways by 
dephosphorylating its potential substrates SHIP and She (Koncz et al., 1999).
In contrast, expression of SHP-1 appears to be limited to cells of the 
haematopoetic lineage. SHP-1 is widely accepted as a negative regulator of 
many immunoreceptors, including the B cell receptor, CD22, CD72, and the 
natural killer cell inhibitory receptor (KIR) (Daeron, 1997a/b; Vely et al., 1997). 
The ligation of KIR on NK cells, by major histocompatibility (MHC) class I 
complexes, inhibits NK mediated cell lysis of target cells and cytotoxic T cell 
function (Burshtyn and Long, 1997; Long et al., 1997; Vely et al., 1997). This 
inhibitory effect requires the phosphotyrosine-dependent association of SHP-1; 
indeed the inhibitory function is prevented by expression of a dominant negative 
SHP-1 mutant. SHP-1 dephosphorylates the SH2 domain-containing leukocyte 
protein-76 (SLP-76), which is normally required for optimal activation of 
cytotoxic lymphocytes (Binstadt etal., 1998). A newly identified ITIM bearing 
receptor, gp49B, is also expressed by NK and mast cells. Studies show that like 
KIR, gp49B signalling involves SHP-1 and this association is dependent on 
tyrosine phosphorylation of the ITIM motif (Wang etal., 1999). The significance 
of this finding is, as yet, undetermined.
The negative regulatory role of SHP-1 was highlighted in SHP-1 deficient 
motheaten {me) and motheaten viable {me') mice. These mice, which are SHP- 
1 null or express a catalytically inactive form of SHP-1, respectively (Tsui and 
Tsui, 1994) display a phenotype of widespread autoimmunity as a result of 
multiple haematopoetic cell defects (Shultz et al., 1997). In particular, B cells 
from me and me'' mice are hyper-responsive to stimulation via the BCR. Indeed, 
studies of these mice with transgenic sig specific for hen egg lysozyme (HEL),
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showed that B cell deletion could be induced using levels of antigen that would 
normally only result in anergy (Cyster and Goodnow, 1995). This suggests that 
by removing SHP-1, the threshold of activation of B cells is substantially 
lowered. Hence, SHP-1 deficient mice possess a reduced number of bone 
marrow B220* progenitor B cells and a decreased resting B cell population. A 
high percentage of the residual peripheral B cells are also spontaneously 
activated with a skewing towards the B-1 subset. As B-1 B cells are associated 
with autoantibody production and are often expanded under conditions of 
autoimmunity (Hayakawa and Hardy, 2000), it would explain the observation 
that these mice exhibit many autoreactive features such as hyper­
gammaglobulinemia, increased autoantibody titres and immune complex 
deposition. Moreover, a recent study by Dustin etal., 1999 showed that 
expression of catalytically inactive SHP-1 increased BCR-mediated calcium 
mobilisation and ErkMAPK activation suggesting that SHP-1 regulates both 
early and late events in B cell activation.
However, studies in these mice and chimeric receptor experiments in murine 
(A20) and chicken (DT40) B cell lines demonstrated that FcyRI lb-mediated 
inhibition was still functional. Thus, in vivo, FcyRllb does not necessarily recruit 
SHP-1 or SHP-2 but rather recruits the inositol 5' phosphatase, SHIP (Chacko 
etal., 1996; Ono etal., 1997; Liu etal., 1998). Thus, SHP-1 was shown to be 
dispensable for FcyRI lb-mediated inhibition of B cell antigen receptor activation 
(Nadler et al., 1997). Conversely, the KIR cytoplasmic domain was shown to 
only associate with SHP-1. Interestingly, the binding of SHP-1 to the 
phosphorylated ITIM of FcyRllb seems to be correlated with the amount of 
receptor aggregation (Sato and Ochi, 1998; Lesourne et al., 2001). Thus, in 
conditions of low receptor aggregation SHIP appears to be preferentially 
utilised. However, when there are high levels of immune complexes and 
superclustering of receptors both SHIP and SHP-1 are recruited to FcyRllb. 
Thus, FcyRI lb-associated SHP-1 activity may be involved in downregulating 
BCR signalling for example, by deactivating the Src-famiiy PTK, Lyn. It is 
possible, therefore, that the conditions of BCR-FcyRllb co-ligation determine the
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selectivity of these phosphatases and that SHP-1 may act to enhance the 
downstream inhibitory effects of SHIP.
Studies with dominant negative SHIP mutants and knockout models have 
confirmed the inhibitory role of SHIP in mediating the FcyRllb negative signal 
(Gupta ef al., 1997, Liu et al., 1998, Huber et al., 1998). SHIP is a 145 kDa, 
SH2-domain containing, 5'-inositol-polyphosphate phosphatase. It was initially 
cloned by its association with the adapter protein She in response to multiple 
cytokines (Ware et al., 1996, Damen et al., 1996). The catalytic domain bears 
homology to several 5'-inositol phosphatases, whilst the c-terminal region 
contains several PTB (phospho-tyrosine binding) domains and a proline rich 
region. In vitro, SHIP preferentially targets substrates that are phosphorylated 
on the D3 position of the inositol ring thus converting phosphatidylinositol 3,4,5 
phosphate (Ptdlns(3,4,5)P3) to phosphatidylinositol 3,4 phosphate 
(Ptdlns(3,4)Pz) and inositol 1,3,4,5-tetrakisphosphate (lns(1,3,4,5)P4) to inositol 
1,3,4-trisphosphate (Ins(1,3,4)p3). Post-translational C-terminal truncated forms 
of SHIP, 135-, 125- and 110-kDa in size, have recently been identified (Damen 
et al., 1998). The 110 kDa form possesses the same inositol 5' phosphatase 
activity as the 145 kDa form. It is therefore possible that different forms of SHIP 
are generated in vivo and perform distinct functions within haematopoetic cells. 
Similarly to SHIP-1, SHIP-2 has been shown to associate with FcyRllb following 
ligation in A20 B cells and displays She binding activity (Muraille et al., 2000). 
Moreover, its discovery in activated B cells may provide an alternative inhibitory 
mechanism for FcyRllb on memory and plasma cells compared to resting B 
cells (Bruhns et al., 2000).
Recruitment of SHIP to the tyrosine-phosphorylated ITIM of FcyRllb, following 
co-ligation with the BCR, leads to a drastic reduction in levels of 
phosphoinositide hydrolysis, influx of extracellular calcium, cellular proliferation 
and immunoglobulin secretion. FcyRllb abrogation of BCR activation by the 
hydrolysis of Ptdlns(3,4,5)p3 (Ono et al., 1996) was thought to occur by the 
direct conversion of Ptdlns(3,4,5)P3 to Ptdlns(3,4)Pz by SHIP or by inactivation 
of PI-3-Kinase (Damen, et al., 1996). It was subsequently demonstrated that
39
Chapter 1 -  General introduction
SHIP-mediated hydrolysis of Ptdlns(3,4,5)P3 disrupts PH domain 
phosphoinositol lipid interactions and prevents the association of Btk and PLC-y 
with the plasma membrane (Bolland et al., 1998). The deletion of SHIP 
increases Ptdlns(3,4,5)P3 levels, resulting in increased Btk membrane 
association and hyper-responsive BCR signalling. The negative effects of SHIP 
on Btk recruitment can also be overcome by the expression of Btk as a 
membrane-associated chimera. Thus, SHIP-1 acts to inhibit the pathways 
leading to calcium mobilisation by interrupting PLC-y recruitment to the 
membrane.
The ability of FcyRllb to modulate calcium levels was supported by the 
observation that SH IP-deficient B cells display enhanced calcium mobilisation in 
response to BCR ligation (Okada etal., 1998). FcyRllb and BCR co-aggregation 
does not affect the initial mobilisation of calcium from B cell intracellular stores, 
probably because of direct G-protein mediated BCR-PLC-y coupling to calcium 
release. However, FcyRllb ligation affects the subsequent influx of calcium. 
SHIP has also been shown to convert lns(1,3,4,5)P4 to lns(1,3,4)P3 (Bolland et 
al., 1998, Scharenberg, et al., 1998). lns(1,3,4,5)P4 is thought to regulate 
capacitive calcium entry though a membrane channel and hence 
dephosphorylation of lns(1,3,4,5)P4 by SHIP would prevent extracellular calcium 
flux (Luckhoff and Clapham, 1992). Furthermore, BCR-mediated production of 
lns(1,3,5)P3 induces the release of calcium from intracellular stores (Berridge, 
1993). However, SH IP-mediated hydrolysis of lns(1,3,4,5)P4 produces an 
alternative form of lnsP3 (lns(1,3,4)P3) that is unable to bind InsPsR in the 
endoplasmic reticulum (Bolland, etal., 1998, Scharenberg, et al., 1998) (Figure 
1.18). FcyRllb may also attenuate these activation signals by interfering with the 
G-protein regulation of BCR-PLC-y coupling, resulting in a reduction of the 
calcium influx (Bijsterbosch and Klaus, 1985; Bijsterbosch etal., 1986).
Through its catalytic phosphatase domain, SHIP-1 also results in the partial 
inhibition of the survival factor Akt/PKB by hydrolysis of Ptdlns(3,4,5)p3 (Jacob 
etal., 1999; Aman et al., 1998) (Figure 1.19). However, the hydrolysis product, 
Ptdlns(3,4)p2 has also been shown to be involved in the positive regulation of
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Akt activity (Downward, 1998). Thus, the inhibition of Akt may be as a result of 
upstream deregulation by the alternative inositol phosphatase, PTEN (reviewed 
by Cantley and Neel, 1999), which is able to dephosphorylate the 3’ position of 
its inositol substrates (Maehama and Dixon, 1998). Indeed, a study by 
Stambolic etal., 1998 confirmed that PTEN can negatively regulate Akt/PKB by 
dephosphorylating Ptdlns(3,4,5)P3. Furthermore, PTEN has also been shown to 
dephosphorylate Ptdlns(3,4)P2 suggesting that PTEN may directly counteract 
PI-3-kinase activation of Akt/PKB (Haas-Kogan et al., 1998).
FcyRllb ligation also inhibits BCR-mediated activation of the RasMAPK 
pathway. However, there is a lack of consensus as to the mechanism 
underlying this downstream effect. There are currently three proposed models; 
the first concerns the GTPase exchange factors (GEFs), SOS and Vav. SOS 
and Vav interact with Ptdlns(3,4,5)P3 at the plasma membrane via PH domain 
interactions. As discussed above, by hydrolysing Ptdlns(3,4,5)p3, SHIP-1 may 
prevent Ras activation by preventing the translocation of exchange factors to 
the plasma membrane.
The second and most popular of the models involves the ability of SHIP-1 to 
also act as an adapter protein and engage in PTB binding domain interactions. 
Phosphorylated SHIP-1 can recruit the adapter molecules She (p52/46) and 
Grb-2 and the association of SHIP-1 with She is enhanced upon BCR-FcyRllb 
coligation (Chacko et al., 1996). Thus, SHIP may indirectly inhibit RasMAPK 
activation by competing with S0S/Grb2 complexes for She binding 
(Tridandapani etal . ,  1997 and 1998). However, this interaction is not 
considered sufficient to mediate the inhibitory action of SHlP-1 on the 
RasMAPK pathway as multiple stimuli, including BCR aggregation and cytokine 
activation, can induce the association between SHIP and She, possibly via PTB 
binding domain interactions (Lamkin etal., 1997).
Thirdly, a Ras GTPase activating protein (RasGAP) has been shown to be 
recruited by the adapter protein, p62Dok, in a SHIP-dependent manner 
following FcyRllb co-ligation with the BCR (Tamir et al., 2000a). By activating
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RasGAP via p62Dok, FcyRllb may enhance the conversion of active Ras-GTP 
to inactive Ras-GDP, thus preventing activation of the ErkMAPK pathway.
Overall, the recruitment and activation of SHIP by FcyRllb results in the 
inhibition of multiple B cell signalling pathways and the modulation of both BCR- 
induced B cell activation and antigen internalisation (Figure 1.20). In addition, 
ligation of FcyRllb alone on B cells has been found to be capable of generating 
an apoptotic signal (Ashman et al., 1996; Ono et al., 1997). Studies in the B cell 
line, DT40, demonstrated that this response was independent of SHIP 
recruitment, suggesting that FcyRllb may directly couple to an apoptotic 
pathway in the absence of BCR-ligation. Additional work by Pearse et al., 1999 
demonstrated that failure to recruit SHIP, either by deletion of SHIP or mutation 
of FcyRllb, resulted in enhanced FcyRI lb-triggered apoptosis. Further studies 
demonstrated that this SHIP-independent pathway lead to the Btk-dependent 
activation of JNK (Figure 1.20) Overall, these studies suggest that aggregation 
of FcyRllb in B cells results in a stress response that leads to apoptosis and that 
SHIP recruitment following co-ligation with the BCR ‘rescues’ the cells from 
apoptosis. Interestingly, SHIP-1 may mediate this effect by recruiting the p85 
subunit of PI-3-Kinase upon BCR-ligation and could act to regulate downstream 
events such as B cell activation-induced apoptosis. (Gupta et al., 1999).
Pearse et al., 1999 postulate that this mechanism, which is unique to B cells, 
may be of importance in the germinal centre, where FcyRllb may be an active 
determinant in the negative selection of B cells. B cells that have undergone 
somatic hypermutation of their antigen-receptors are selected on the ability of 
their mutated receptors to bind antigen presented within the germinal centre. 
This process discriminates between B cells that display high-affinity cognate 
antigen binding and those with low-affinity, potentially cross-reactive 
specificities. Antigen that interacts with FcyRllb alone will result in B cell 
apoptosis whilst antigen co-engagement of FcyRllb with the BCR will promote 
survival. Thus, selection of B cells may represent the sum of opposing signals 
generated by the interaction of immunocomplexes with the BCR and FcyRllb 
through pathways modulated by SHIP.
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In addition, co-ligation of FcyRllbl with the BCR blocks the processing and 
presentation of BCR-bound antigen and thus can indirectly inhibit antigen 
dependent T-cell stimulation (Minskoff, et al., 1998). In contrast, co-ligation of 
the endocytosis competent isoform, FcyRllb2, does not inhibit these BCR- 
mediated functions. A potential model was recently proposed by Aman, et al., 
2001 to explain this negative inhibition of BCR endocytosis. It was believed that 
FcyRllbl might be excluded from the lipid rafts in resting B cells and that co­
ligation resulted in the destabilisation of raft-dependent BCR signalling. 
However, a fraction of FcyRllbl was shown to be constitutively localised in the 
rafts which increased upon BCR-FcyRllbl co-ligation. Furthermore, SHIP was 
shown to be actively recruited to the lipid rafts following receptor co-ligation.
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1.5 Aims and objectives of this study
To maintain homeostasis and tolerance to self-antigens, B cells require a 
balance of signals via activatory and inhibitory co-receptors. Indeed, animal 
models have demonstrated that a loss of suitable inhibitory signalling is 
frequently associated with the development of inflammatory responses and, in 
some cases, autoimmunity. By binding the Fc domain (Fc) of antibodies, Fc 
receptors (FcRs) provide a critical link between the humoral and cellular arms of 
the immune system through the targeting of antigen-antibody complexes to 
effector cells and priming of an immune response. Interestingly, B cells express 
only one form of Fc receptor for IgG, the low affinity IgG receptor, FcyRllb. In 
contrast to the priming situation described above, ligation of FcyRllb, by means 
of IgG-containing antigen-antibody complexes, negatively regulates the BCR 
response to antigen.
Moreover, in vitro and in vivo studies have shown that FcyRllb displays 
differential inhibitory activities in B cells dependent on the nature of receptor- 
aggregation (Figure 1.20). Homo-aggregation of FcyRllb, via non-cognate 
antigen-antibody complexes, generates a pro-apoptotic signal. In contrast, co­
ligation of FcyRllb with the BCR, by cognate antigen-antibody complexes, 
promotes B cell survival. However, co-ligation also results in the inhibition of 
BCR-mediated phosphoinositide hydrolysis, influx of extracellular calcium, 
cellular proliferation and immunoglobulin secretion. Furthermore, co-ligation 
acts as a negative feedback mechanism to switch off ongoing B cell responses 
once the pathogen has been cleared.
Experimentally the BCR can be mitogenically stimulated with F(ab’) 2  fragments 
of anti-lg antibodies alone. In contrast, intact anti-lg antibodies result in the co­
ligation of the BCR with FcyRllb, resulting in the induction of anergy and 
commitment to apoptosis. Stimulation of B cells with a combination of both 
F(ab' )2  fragments and intact anti-lg antibodies produces an alternative co­
ligation event which leads to the abortive activation of BCR-mediated 
proliferation and mimics the negative feedback regulation of ongoing B cell
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responses. The primary aim of this study was to investigate the differential 
signalling mechanisms following the two methods of FcyRllb co-ligation in 
primary B cells and to define how FcyRllb co-ligation modulates:
• BCR-mediated proliferation and survival signalling pathways, in particular 
the mitogen-activated protein kinase (MARK) and PI-3-Kinase/Akt pathways.
• BCR-mediated regulation of cell cycle machinery and the recruitment of 
nuclear transcription components required for proliferation and the induction 
of immunomodulatory genes.
Having examined FcyRllb signalling mechanisms in B cells from normal mice, 
the secondary aim of this study was to investigate FcyRllb expression and 
function in B cells from established murine models of autoimmune disease. In 
particular, to investigate whether aberrant FcyRI lb-mediated negative regulation 
of B cell activation becomes defective during onset and progression of disease 
in the collagen-induced arthritis (CIA) and murine systemic lupus erythematosus 
(MRL-/pr//prj models.
B cells encode two isoforms of FcyRllb, FcyRllbl and FcyRllb2. While both 
isoforms of FcyRllb are able to mediate negative regulation of B cell activation, 
FcyRllb2 can also internalise IgG containing immune complexes. A sequence 
insertion in the cytoplasmic tail of FcyRllbl disrupts its ability to modulate 
receptor endocytosis. Therefore, it is possible that differences in the relative 
expression levels of the two isoforms of FcyRllb may influence the regulation of 
B cell responses by immune-complexes and the overall susceptibility of an 
individual to developing autoimmune disease.
Thus, the final objective of this study was to investigate the expression levels of 
the specific FcyRllb isoforms in peripheral blood cells from autoimmune 
patients. To determine whether differential FcyRllb isoform expression is related 
to, or indicative of, disease susceptibility and progression.
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Figure 1.1 Summary of the developmental stages of conventional B 
cells.
The stages of B cell development are marked by a series of changes in location 
and in the expression of immunoglobulin heavy and light genes, intracellular 
proteins, and surface markers. B cell development starts in the bone marrow (or 
foetal liver) with the commitment of haematopoetic stem cells (HSCs) to the B 
cell lineage, in an antigen-independent manner. Rearrangement of the heavy 
chain locus genes begins in the early pro-B stage. Cells are allowed to progress 
to the next stage if a productive rearrangement has been achieved. Although no 
functional immunoglobulin is expressed in late pro-B cells expression of 
accessory lg-a/lg-|3heterodimers on the surface in association with calnexin 
has been demonstrated (Gong and Nussenzweig, 1996; Nagata et al., 1997). 
The antigen-independent stage continues within the bone marrow, where pre-B 
cells express a pre-BCR consisting of cytoplasmic p chain in combination with a 
surrogate light chain, Vpres and X5. Successful light-chain gene rearrangements 
result in the surface expression of a complete IgM molecule. The immature B 
cells then enter the antigen-dependent stage of B cell development where 
recognition of self-antigen can lead to clonal deletion, receptor editing or clonal 
inactivation (anergy). Once in the periphery, the mature B cells migrate to the 
lymphoid follicles and following further selection stages, enter the mature B cell 
pool until they encounter antigen. Upon interacting with their specific antigen in 
conjunction with co-stimulatory signals from Th cells, the B cell is activated. 
Depending on the nature of the signals, the mature B cell gives rise to antibody 
generating plasma cells or long-lived memory cells which contribute to lasting 
protective immunity (Adapted from Alt et a!., 1997).
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Figure 1.2 The developmental stages of the B cell receptor (BCR) for 
antigen.
The progression of B cells from the pro-B cell stage to the mature B cell, is 
accompanied by changes in surface expression of the BCR accessory 
molecules, Ig-a/lg-p, and associated molecules such as the chaperone 
molecule, calnexin, and the immunoglobulin heavy chain, j.im. Progression 
through the developmental stages is driven by incremental signalling through 
these Ig-a/lg-p-containing receptors, thus these molecules must be expressed 
as receptor complexes for normal B cell development. Successful B cell 
development is dictated by (1) expression of Ig-a/lg-p in association with 
calnexin at the late pro-B cell stage. (2) Intact p heavy chains expressed in an 
immunoglobulin-like “pre-BCR” complex with surrogate light chains, X6 and 
VpreB at the pre-B cell stage. (3) A mature BCR consisting of p heavy chain, 
conventional light chains and accessory Ig-a/lg-P molecules from the immature 
B cell stage onwards.
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Figure 1.3 Schematic representation of B cell activation and selection 
within a germinal centre.
Following T cell dependent activation (1) B cells migrate into the primary 
lymphoid follicles and form germinal centres. Here the proliferating B cells (2) 
differentiate into centroblasts (3) where they form the dark zone of the germinal 
centre. The rapidly dividing centroblasts undergo somatic hypermutation of their 
immunoglobulin variable-domain genes before differentiating into centrocytes
(4). Within the light zone of the germinal centre, the small, non-dividing 
centrocytes are programmed to die unless they interact with follicular dendritic 
cells (FDC) that display complexed antigen on their cell surface. Positive 
selection of centrocytes is dependent on the affinity of their mutated antigen 
receptors. Centrocytes with low affinity or autoreactive antigen receptors 
undergo spontaneous apoptosis. The positively selected centrocytes move to 
the outer edge of the light zone and interact with CD40 ligand expressing T cells
(5). Here the centrocytes may undergo CD40-mediated isotype switching, 
become protected from Fas-induced apoptosis and finally differentiate into 
either memory B cells (6) or plasma cells (7).
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Figure 1.4 The mature B cell receptor (BCR) for antigen.
The mature B cell receptor for antigen (BCR) is functionally divided into the 
ligand binding, immunoglobulin molecule (slg) and the signal transducing 
heterodimers, Ig-a (CD79a) and Ig-p (CD79b). Conserved immunoreceptor 
tyrosine-based activation motifs (ITAMs), present in the cytoplasmic domains of 
the accessory molecules, are essential for the signal transducing capacity of the 
receptor. The ITAMs aid the recruitment and activation of three distinct types of 
non-receptor protein tyrosine kinases (PTKs).
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Table 1.1 immunoreceptor ITAM and ITIM sequence motifs.
Consensus and key receptor sequences for the immunoreceptor tyrosine-based 
activation motif (ITAM) and the immunoreceptor tyrosine-based inhibition motif 
(ITIM). Conserved residues are displayed in red.
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Consensus ITAM D/EXXYXXLX(7-11 )YXXL/I 7-11
BCR Ig-a 
chain
ITAM ENLYEGLNLDDCSMYEDI 7
BCR Ig-p 
chain
ITAM DHTYEGLDIDQTATYEDI 7
Consensus ITIM XXXIA/XYXXLXXXXX n/a
Human
FcyRllb
ITIM ENTITYSLLMHPDA n/a
Murine
FcyRllb
ITIM ENTITYSLLKHPEA n/a
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Figure 1.5 The domain-structure and activation of the BCR-associated 
non-receptor protein tyrosine kinases.
(A) Three distinct types of non-receptor protein tyrosine kinases (PTKs) are 
known to be recruited and activated by the BCR ITAMs following BCR-ligation. 
These include the Src-PTKs (including Lyn, BIk and Fyn), Syk and the Tec- 
family kinase, Bruton’s tyrosine kinase (Btk). Src-homology 2 (SH2) domains 
are modules that bind to phospho-tyrosine containing proteins, whilst Src- 
homology 3 (SH3) domains preferentially bind proline-rich proteins. Pleckstrin- 
homology (PH) domains permit association of the protein with 
phosphoinositides.
(B) In resting B cells, phosphorylation of the inhibitory site within Src-family 
PTKs, by C-terminal Src kinase (Csk), keeps the kinase domain in a 
catalytically inactive conformation. Following BCR ligation, the Inhibitory site is 
thought to be dephosphorylated by the transmembrane protein tyrosine 
phosphatase CD45. Release of inhibition and phosphorylation at the auto- 
phosphorylation site results in the activation and unfolding of the Src-family 
PTKs and phosphorylation of key tyrosine residues within the kinases. Activated 
PTKs are then able to phosphorylate the tyrosines within the BCR accessory 
molecules. A cascade of PTK activation then occurs, leading to the 
phosphorylation and activation of key downstream targets in the BCR- 
associated signal transduction pathways.
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Figure 1.6 B cell receptor (BCR) signal transduction pathways.
A schematic representation of the parallel cascades initiated following ligation of 
the B cell receptor (BCR) on mature B cells. The tyrosine phosphorylation of 
conserved ITAMs, present in the cytoplasmic domains of the slg accessory 
molecules Ig-a and Ig-p, results in the recruitment of slg associated PTKs. 
These include the Src-PTK family (BIk, Fyn, Lck, and Lyn), Syk, and Btk. 
Following activation of these kinases three parallel, but potentially cross- 
regulatory, pathways are recruited to the activated BCR complex. The 
phospholipase C-y (PLC-y) pathway results in the hydrolysis of 
phosphatidylinositol 4,5 bisphosphate (Ptdlns(4,5)P2), to produce diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (InsPs). The phosphatidylinositol 3-kinase 
(Pl-3-Kinase) pathway generates phosphatidylinositol 3,4,5 triphosphate 
(Ptdlns(3,4,5)P3) whilst the classical Ras/MAPKinase cascade leads to the 
activation of ErkMAPK. These pathways converge on the nucleus and initiate 
activation-state dependent effector responses.
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Figure 1.7 Schematic diagram of phosphoinositide signalling.
Phosphatidylinositol 3-kinase (PI-3-Kinase) catalyses the phosphorylation of the 
inositol phospholipids Ptdlns, Ptdlns(4)P and Ptdlns(4 ,5 )p2 on the 3' position of 
the inositol ring to produce Ptdlns(3)P, Ptdlns(3,4)Pz and Ptdlns(3 ,4 ,5 )P3 , 
respectively. Ptdlns(3 ,4 )P2 and Ptdlns(3 ,4 ,5 )P3 are important regulators of 
membrane localisation signals. Several PH domain containing proteins 
selectively bind and are regulated by these phosphoinositides, including PLC-y 
isoforms, small G-protein exchange factors (e.g. Vav), Tec family tyrosine 
kinases (e.g. Btk) and the serine/ threonine kinase, PDK1/2 and Akt/PKB. 
Ptdlns(3 ,4 )p2 and Ptdlns(3 ,4 ,5 )P3 are also substrates for the inositol 3’ 
phosphatase, PTEN, which selectively dephosphorylate the 3' positions of the 
inositol ring. The inositol 5’ phosphatase, SHIP can also dephosphorylate the 5’ 
position of Ptdlns(3,4,5)Ps. Thus, these two phosphatases act to antagonise the 
actions of PI-3-Kinase.
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Figure 1.8 The mitogen-activated protein kinase (MAPKinase) signalling 
pathways.
The mitogen-activated protein kinases (MAPKinase) are a family of serine- 
threonine protein kinases. They are activated by a wide range of extracellular 
stimuli and are able to mediate a wide range of cellular functions from 
proliferation and activation to growth arrest and cell death. The MAPKinase 
family is further classified into three sub-groups; the classical extracellular 
signal-regulated kinases (ErkMAPKinase), the c-Jun N-terminal kinases, also 
known as the stress activated protein kinases (JNK/SAPK) and the p38 
MAPKinases. Activation of each sub-group is determined by distinct upstream 
MAPKinase kinases (MEKs), which are themselves activated by specific 
MAPKinase kinase kinases (MEKK). MAPKs are activated by dual 
phosphorylation on tyrosine and threonine residues, located in a T-x-Y motif. 
Each sub-group of MAPKinase is independently activated and regulated by a 
specific MEKK and MEK following cell stimulation but extensive cross-talk 
mechanisms exist. Following MAPKinase activation there occurs independent 
activation of downstream transcription factors thus, ErkMAPKinase has been 
shown to activate Elk-1 and c-myc, JNK activates c-Jun and ATF-2 and p38 
MAPKinase activates ATF-2 and MAX.
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Figure 1.9 Regulation of GTPase activity by guanine nucleotide exchange 
factors (GEFs) and GTPase-activating proteins (GAPs).
Small GTPases, such as Ras, Rac-1 and Rap-1, cycle between inactive GDP- 
bound and active GTP-bound states and thus function as signal relays linking 
membrane receptors to signal transduction pathways. GEFs (guanine 
nucleotide exchange factors) 8 0 S, Vav and C3G, promote the exchange of 
GDP for GTP resulting in the production of an active GTPase to turn on 
downstream signalling effectors. GAPs (GTPase activating proteins) RasGAP, 
RacGAP and RapGAP, accelerate the normally slow intrinsic GTPase activity, 
thereby inactivating their target GTPases.
Following BCR ligation Shc-Grb-2-SOS complexes acts to displace GDP from 
the GTPase Ras to generate an active GTP-bound form. Ras is then able to 
regulate a wide range of downstream cellular processes, from cytoskeletal 
reorganisation through to modulation of transcription. In particular, active Ras 
can bind and derepress Raf-1, a serine/threonine kinase, resulting in the 
activation of MAPKinase kinases (MEK). Co-recruitment of the GEF Vav and 
PLC-y by BLNK and Syk can also result in the activation of the Rho-family 
GTPases (Rac, RhoA and Cdc42) providing a critical link for the activation of 
the stress-activated MAPKs, JNK and p38. Activation of the alternative GTPase 
Rap-1 by the GEF C3G may lead to the sequestering of the downstream 
effector Raf-1, due to the structural similarities between the effector binding 
domains of Ras and Rap-1. This may lead to the down-regulation of 
MAPKinase activation, as shown for the induction of T cell anergy.
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Figure 1.10 important cell cycle stages.
The cell cycle comprises four main stages, during which a cell must duplicate its 
contents and check the integrity of duplication prior to division. In Gi (gap 1) the 
cell increases in size, separates its centrioles and prepares to copy its DNA. 
DNA duplication occurs in the S phase (synthesis). After chromosome 
replication a second gap period, G2 , allows the cell to monitor DNA integrity and 
cell growth prior to M (mitosis) when the cell finally divides. The daughter cell 
products immediately enter Gi and may go through the full cycle again or 
alternatively stop cycling temporarily and enter the Go phase. Cyclins and their 
activation of cyclin-dependent kinases (Cdks) are essential for the regulation of 
the cell cycle. At the Gi checkpoint cells have to decide whether to commit to 
DNA synthesis. Here, D-type cyclins bind to Cdks 4 or 6 and the resulting 
complex promotes Gi/S transition by releasing the braking effect of 
retinoblastoma protein, pRb^° .^ Hypophosphorylated Rb actively blocks cycling 
by sequestering the transcription factor, E2F, thus blocking expression of 
necessary S-phase genes. Once phosphorylated by the cyclin-Cdk complexes, 
E2~F is released and S phase genes are transcribed. Cdk inhibitory proteins of 
the INK4 (p15, p i6, p i8 and p i9) and the WAF1 (p21, p27 and p57) families 
act to block the activity of Cdks at various stages of the cell cycle. Their 
inhibitory actions can restrain the cycle progression at the Gi/S boundary by 
promoting gro\A4h-arrest and/ or commitment to apoptosis.
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Figure 1.11 The cascade pathway of caspase activation.
The caspases are a family of cysteine proteases that are activated specifically 
in apoptotic cells. Most caspases are activated by proteolytic cleavage of an 
enzymatically inactive pro-caspase form. Each pro-caspase contains in its 
prodomain a protein-protein interaction module, which allows it to bind and 
associate with upstream regulators. Initiator caspases-8 and -10 contain a 
death-effector domain (DED), permitting interaction with death receptors such 
as CD95 (Apo-1/Fas) and the adapter molecule FADD (Fas-associated death 
domain protein). The effector caspases-2 and -9 contain a similar domain, a 
caspase activation and recruitment domain (CARD). Activation can occur simply 
by pre-exposure to another previously activated caspase, resulting in a 
‘caspase cascade’ of activation. Upon ligand binding, CD95 aggregates and 
forms membrane bound signalling complexes. These complexes recruit, via the 
adapter molecule FADD the pro-caspase-8 molecule, resulting in caspase-8 
activation through induced proximity. Following activation of the initiator 
caspases (8 and 10) a cascade of activation occurs. Caspase-8 activation also 
induces cytochrome c release from the mitochondria (Figure 1.13) and thus 
initiates a second apoptotic pathway. These two pathways converge in the 
activation of effector caspases-3, -6 and -7, which finally cleave various death 
substrates. Caspase-8 can also be activated by caspase-6 following cleavage 
by caspase-9, thereby amplifying the apoptotic signal.
57
TNF-a
CD95
Fas
FADD
P ro -C a s p a s e -8 ,ld J H  Pro-Caspase-9I
Pro-Caspase-3I
•K
Pro-Caspase-6 Pro-Caspase-7I
I
• K
I
Apoptotic substrates 
& Cell Death
Chapter 1 -  General Introduction
Figure 1.12 The Bcl-2 family of apoptotic regulators.
The Bcl-2 family of apoptotic regulators is comprised of over a dozen proteins, 
which have been classified into three functional groups. All family members are 
structurally distinct due to conserved Bcl-2 homology (BH) domains. Group I 
members all possess anti-apoptotic activity, and protect cells from death 
whereas members of group II and III promote cell death. Many family members 
can homodimerise, but more importantly, pro- and anti-apoptotic members can 
form heterodimers. For example, pro-apoptotic Bax can heterodimerise with the 
anti-apoptotic protein, Bcl-2. This interaction blocks the anti-apoptotic 
capabilities of the Bcl-2 protein and induces a pro-apoptotic response.
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Figure 1.13 Role of mitochondria in the apoptotic response pathway.
Many of the signals leading to cell death appear to converge on the 
mitochondria, which plays a pivotal role in the decision of a cell's fate. For 
many, but not all of these apoptotic signals, activation of apoptosis regulator 
proteins, the Bcl-2 family is central to the mechanism. The Bcl-2 family proteins 
form homo- or heterodimers and integrate competing pro- and anti-apoptotic 
signals at the surface of the mitochondria and other sites within the cell. The 
pro-apoptotic members of the Bcl-2 family have been proposed to act by 
inactivating dimers of anti-apoptotic Bcl-2 family members, which act to 
preserve mitochondrial integrity. For example, following apoptotic signals, the 
pro-apoptotic regulator Bax, is believed to heterodimerise with the anti-apoptotic 
regulator Bcl-2. This interaction blocks the anti-apoptotic capabilities of the Bcl- 
2-like proteins. Similarly, the pro-apoptotic regulator Bad is believed to interact 
with Bcl-2 or Bc I-X l, thus promoting apoptosis. Phosphorylation of Bad by the 
survival factor Akt promotes the association of Bad with the phospho-serine 
binding protein, 14-3-3 and its removal from the mitochondria. The blocking of 
the interaction of Bad with its other family members thus promotes cell survival. 
Pro-apoptotic signals also result in the cleavage of Bid by caspase-8 which 
releases an active, truncated form (tBid). tBid then translocates to the 
mitochondria, where it is involved in promoting the release of cytochrome c. The 
released cytochrome c associates with the adapter Apaf-1 and together activate 
caspase-9 in the cytosol. The death and mitochondrial pathways converge at 
the level of caspase-3 activation. Caspase 3 activation and activity is 
antagonised by the expression of inhlbitors-of-apoptosis (lAPs) which in turn are 
inhibited by Smac/DIABLO proteins, also released from the mitochondria. The 
induction of apoptosis exemplifies the high degree of cross talk and integration 
between cell signalling pathways that are involved in the decision of a cells fate.
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Figure 1.14 Schematic diagram of the domain structure of IgG.
Immunoglobulin G (IgG) is comprised of two heavy chains (H) linked to two light 
chains (L) by interchain disulphide bonds (red lines). The variable (V) and 
constant (C) domains are as indicated. Green circles represent N-linked 
carbohydrate groups, which vary between the isoforms of IgG. Each rectangular 
unit represents a complete immunoglobulin super-family (IgSF) domain. The Cy 
domains are unique to IgG and, though very similar to each other, small 
structural differences confer specialised functions.
Proteases, such as pepsin and papain, have been used to dissect the structure 
of antibody molecules and to determine which parts of the molecule are 
responsible for its various functions. The variable Fab fragments (Fragment 
antigen binding) contain the antigen-binding activity of the antibody. In contrast, 
the Fc fragment (Fragment crystallisable) contains no antigen-binding ability but 
is able to interact with effector molecules of the complement cascade and Fc 
receptor (FcR) expressing cells. The F(ab’)2  fragment has exactly the same 
binding characteristics as the original antibody but is unable to interact with any 
effector molecules or receptors.
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Figure 1.15 Structure of Fc receptors and their associated signalling 
chains.
Most human and murine Fc receptors are members of the immunoglobulin 
domain super family (IgSF). This group includes the high affinity receptors for 
IgE (FceRI), IgA (FcaRI) and all the IgG receptors (FcyR). The Fey receptors 
(FcyRs) are specific for the Fc domain of immunoglobulin G (IgG). They 
comprise a multi-membered family of structurally homologous but distinct 
receptors and are expressed on the vast, majority of leukocytes. Three classes 
of FcyR exist, FcyRI, FcyRII and FcyRIII. As products of alternative transcript 
splicing or receptor proteolysis, FcyRs are able to exist as both membrane 
receptors and as soluble molecules.
Activation (ITAM) and or inhibition (ITIM) signalling motifs are located within the 
cytoplasmic domains of the Fc receptors or their associated signalling 
molecules, as indicated. With the exception of some classes of FcyRII, which 
possess an integral cytoplasmic signalling motif, the majority of these receptors 
exist as multi-subunit receptor complexes. These complexes comprise a ligand 
binding chain and an associated signalling chain, such as the y-chain, as 
shown. FceRI expresses an additional g-chain, whilst FcyRllla is also capable of 
associating with the Ç-chain. The ligand binding chains of these receptors are all 
type I membrane glycoproteins. The highly conserved extracellular regions 
contain two or three immunoglobulin (V-class) domains formed by disulphide 
loops of varying length. The transmembrane and cytoplasmic regions are less 
conserved. FcyRlllb lacks a transmembrane region and is tethered to the 
membrane via a glycosylphosphatidyl linkage (GPI), preventing is association 
with a signalling chain.
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Table 1.2 Fey receptor binding affinities and cellular distribution.
Fc receptors are defined by their cellular distribution, structure and affinity for 
their specific immunoglobulin isotypes. Three classes of FcyR exist, that have 
varying affinities for the four known subclasses of IgG (lgG1, lgG2, lgG3 and 
lgG4). The high affinity FcyRI (CD64) receptor, is the only class of FcyR capable 
of recognising and binding monomeric IgG at physiological concentrations. In 
humans, FcyRI binds lgG1 with higher affinity than lgG3 or lgG4 but is unable to 
bind lgG2. In contrast, FcyRII (CD32) and FcyRIII (CD16) are low affinity 
receptors which can only recognise IgG in the form of an immune complex. 
Interestingly, whilst human FcyRlla and FcyRllb display high homology in their 
extracellular domains they differ in their IgG subclass binding affinities; FcyRlla 
is unable to bind lgG4 whilst FcyRllb is unable to bind lgG2. Thus, IgG subclass 
plays an important role in the regulation of the immune response as it dictates 
which FcyRs are ligated and therefore determines the effector mechanism 
elicited. For the low affinity receptors, FcyRII and FcyRIII, the binding affinities 
refer to immune complexes and not monomeric immunoglobulin.
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Figure 1.16 Activatery versus inhibitory Fey Receptors.
The diversity of biological responses between FcyRs is accounted for by the 
divergence in cytoplasmic tail domains of these receptors, as the ligand-binding 
domains are structurally related. Two general classes of FcyR exist that can 
either positively or negatively regulate cell activation. The activation FcyR 
possess a cytoplasmic ITAM consensus motif whilst the inhibitory FcyR employ 
an ITIM motif for mediating signal transduction (Adapted from Ravetch and 
Bolland, 2001)
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Figure 1.17 FcyRllb genes and isoforms.
Separate exons encode the transmembrane and cytoplasmic domains of 
FcyRllb; thus several isoforms can be created by alternative splicing of mRNA 
transcripts. Widely expressed by cells of haematopoetic origin, all isoforms of 
FcyRllb possess an ITIM in their cytoplasmic domains and are therefore able to 
mediate inhibitory signalling mechanisms. In vitro and in vivo studies have 
shown that FcyRllb acts as a negative regulator of immune complex-triggered 
activation, with preferential expression of FcyRllbl on B cells and FcyRllb2 on 
myeloid cells.
Human FcyRllb encodes three transcripts, FcyRllbl, FcyRI I b2 and FcyRllbS, 
which arise by alternative splicing mechanisms. The mature forms of hFcyRllbl 
and hFcyRllbS are identical but differences in their peptide leader sequences 
prevent the expression of hFcyRllbS. Upon IgG binding, hFcyRllb2 is capable of 
mediating rapid endocytosis by means of clathrin-coated vesicles. However, an 
insertion of 19 amino acids in the cytoplasmic tail of hFcyRllbl disrupts the 
cytoskeletal attachment domain responsible for modulating receptor 
internalisation.
In contrast to humans, a single gene encodes FcyRII in mice and three integral 
membrane glycoproteins have been isolated, FcyRllbl, FcyRIIb2 and FcyRllbT. 
Similar to the human FcyRllb isoforms, murine FcyRllbl and FcyRllb2 are 
identical except for a 47 amino acid insertion in the first cytoplasmic exon of 
FcyRllbl, which inhibits its endocytic capacity. An additional murine isoform 
exists as a result of a cryptic splice donor site in the first cytoplasmic exon, 
creating a murine homologue of human FcyRllbl (named FcyRllbT).
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Figure 1.18 SHIP-mediated inhibition of B cell activation.
Co-ligation of the BCR and FcyRllb by immune complexes leads to tyrosine 
phosphorylation of the ITIM, the recruitment of SHIP and the inhibition of BCR- 
mediated calcium mobilisation and cellular proliferation. SHIP is able to inhibit 
calcium mobilisation by hydrolysing the membrane inositol phosphate, 
Ptdlns(3,4,5)p3. In the absence of Ptdlns(3,4,5)P3, PH domain binding proteins, 
Btk and PLC-y, are released from the membrane and a sustained calcium signal 
is blocked as the influx of extracellular calcium is prevented. FcyRllb recruited 
SHIP is also able to abrogate BCR-mediated proliferation by the downregulation 
of the MARK pathway and inactivation of the survival factor Akt/PKB (Adapted 
from Ravetch and Lanier, 2000).
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Figure 1.19 Regulation of the survival-promoting factor Akt/PKB.
The generation of Ptdlns(3,4,5)P3 by Pi-3-kinase can activate the survival- 
promoting factor Akt/PKB via the recruitment of the protein-serine/threonine 
kinases, PDK1 and PDK2, to the plasma membrane. PDK1 and PDK2 activate 
Akt via phosphorylation of Thr^ °® and Ser"^ ^^ ’ respectively, within its activation 
loop. Akt then promotes cell survival by phosphorylating and compromising 
multiple targets of the cell-death pathway, including the pro-apoptotic Bcl-2 
family member BAD and the cell-death pathway enzyme caspase-9. In addition 
to promoting cell survival, Akt may regulate cell proliferation by phosphorylation 
of the pro-apoptotic serine/threonine kinase, glycogen synthase kinase-3 (GSK- 
3). GSK-3 promotes cyclin D proteolysis, thus by phosphorylating and inhibiting 
GSK-3, Akt contributes to cyclin D accumulation and cell cycle entry. The 
inositol 5’-phosphatase, SHIP-1, partially inhibits Akt/PKB activation by 
converting Ptdlns(3,4,5)P3 to Ptdlns(3,4)Pz whilst the inositol 3'-phosphatase, 
PTEN, converts Ptdlns(3,4,5)P3 to Ptdlns(4,5)P2. Since Ptdlns(3,4)P2 is also 
capable of activating Akt/PKB, the sequential activation of SHIP and PTEN 
potentially counteracts PI-3-kinase activity and terminate downstream 
signalling.
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Figure 1.20 Antigen-antibody recognition by FcyRllb can determine B cell 
fate.
FcyRllb displays three separate inhibitory activities dependent on the nature of 
antigen-ligation. Co-ligation of the BCR and FcyRllb by cognate antigen- 
antibody complexes leads to tyrosine phosphorylation of the ITIM by the Src- 
family kinase Lyn, recruitment of SHIP and the inhibition of BCR-triggered 
calcium mobilisation and arrest of cellular proliferation. Aggregation of FcyRllb 
alone, via non-cognate antigen-antibody complexes, generates a pro-apoptotic 
signal that is mediated via Btk. Rather surprisingly, this pro-apoptotic signal is 
blocked by the recruitment of SHIP to FcyRllb following BCR co-ligation. This 
novel FcyRI lb-mediated mechanism has been proposed to act as a means of 
maintaining B cell peripheral tolerance in the germinal centre, by promoting 
apoptosis of B cells with low-affinity, potentially cross-reactive antigen- 
receptors. Antigen that interacts with FcyRllb alone will result in B cell apoptosis 
whilst antigen co-engagement of FcyRllb with the BCR will promote survival. 
Thus, selection of B cells may represent the sum of opposing signals generated 
by the interaction of immunocomplexes with the BCR and FcyRllb through 
pathways modulated by SHIP (Adapted from Ravetch and Lanier, 2000).
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Chapter 2 - Materials and Methods
2.1 Cell culture reagents and antibodies
All cell culture reagents were purchased from Gibco-BRL. All other reagents 
were obtained from Slgma-Aldrich, unless otherwise indicated, and were of the 
highest grade available. See Tables 2.6 and 2.7.
2.2 Animals
2.2.1 Balb/c
Male Balb/c mice, at least 8 weeks of age, were used unless otherwise stated. 
These mice were maintained at the animal facility of the Department of 
Immunology, University of Strathclyde, Glasgow or the Central Research 
Facility (CRF), University of Glasgow. Mice, arriving from Flarlan UK Ltd, were 
quarantined for 7 days prior to commencing any experiment.
2.2.2 IVIRL/Mp-/pr//pr
Male MRLMp-lpr/Ola/Hsd, (H-2’^ ) mice (Harlan UK Ltd), aged 14-26 weeks, 
were maintained at the Central Research Facility (CRF), University of Glasgow. 
The strain was developed by E D. Murphy (Jackson Laboratory, Bay Harbor, 
USA) by backcrossing the congenic mutant gene Ipr {lymphoproliferation) by 5- 
cycles of cross-intercross matings from substrain MRL/1 to substrain MRL/n 
(now designated MRL/Mp^'^). A gradual onset of disease was observed from 18 
weeks and animals were monitored for a further 8 weeks for the development of 
disease characteristics, such as enlarged lymph nodes. Timepoints for ex vivo 
analysis were selected on the basis of disease progression. Spleens were 
removed at the times indicated and purified B cells were cultured as described 
(see Chapter 4). Mice were quarantined for 7 days prior to commencing the 
study.
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2.2.3 Collagen-induced arthritis (CIA) model
Male DBA/1 mice (Harlan UK Ltd), aged 6-8 weeks, were maintained at the 
Joint Animal Facility (JAF), University of Glasgow, in accordance with the UK 
Home Office animal care guidelines. Dr. Bernard Leung (Department of 
Immunology, University of Glasgow) performed all procedures. Mice were 
quarantined for 7 days prior to commencing the study.
CIA was induced as described previously (Ruchatz, et al., 1998). Bovine type II 
collagen (Sigma-Aldrich) was solubilised in 0.01 M acetic acid (4 mg/ml) 
overnight at 4°C. The resultant suspension was emulsified in an equal volume 
of freshly prepared Freund’s complete adjuvant (Difco) supplemented with 5 
mg/ml of heat killed Mycobacterium tuberculosis, H37RA (Difco).
Mice were immunised intradermally at the tail base with a total of 100 pi of the 
prepared emulsion (Cll, 200 pg) or CFA alone. An intraperitoneal Cll challenge 
(CII, 200 pg in PBS) was carried out on day 21. A gradual onset of arthritis was 
observed 7-10 days after the intraperitoneal challenge and animals were 
observed for up to 5 weeks for the development of arthritis (Figure 2.1).
2.2.4 ES-62/CIA prophylactic model
CIA was induced in male DBA/1 mice as previously described (see section 
2.2.3). Dr. Bernard Leung (Department of Immunology, University of Glasgow) 
undertook all procedures, clinical measurements and histological assessments. 
ES-62, a glycoprotein that is a major ES product of the rodent filarial parasite 
Acanthocheilonema viteae, was prepared as previously described (Houston, et 
a!., 1997) and kindly supplied by Dr. William Harnett (Department of 
Immunology, University of Strathclyde, UK). Mice were immunised sub- 
cutaneously (2 pg/animal) with ES-62 at d-2, dO and d21 or PBS as control. 
Extra treatments of ES-62 were administered to a third group (ES-62 multi) on 
d22-24, plus an additional treatment once every three days until the end of the 
study. Animals were observed for up to 4 weeks for the development of arthritis. 
Spleens were removed at the time indicated and purified B cells cultured as 
described (see Chapter 4).
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2.2.5 In vivo ES-62 release model
To mimic the in vivo release of the filarial nematode excretory-secretory 
product, ES-62, ALZET osmotic mini-pump model 2002 (Charles River UK Ltd.) 
was used as directed by the manufacturer (Theeuwes and Yum, 1976). All 
procedures were performed by Dr. Maureen Deehan (Department of 
Immunology, University of Glasgow, UK) or Emma Wilson (Department of 
Immunology, University of Strathclyde, UK). Pumps were loaded with 200 pi of 
100 or 400 pg ES-62 or PBS, pH 7.4 and left overnight at room temperature in 
sterile 0.9 % saline solution. Male Balb/c mice, aged 6-8 weeks and weighing at 
least 20 g, were anaesthetised with Halothane-RM (Aventis Pasteur MSD). The 
pumps were inserted into a mid-scapular incision made in the back of the neck, 
the wounds sutured and the animal observed until consciousness was regained. 
Animals were sacrificed on day 14. Spleens and lymph nodes were removed 
and cultured as described.
2.3 Purification of murine B cells
Primary B cells were prepared from murine spleens or lymph nodes using the 
CD43-magnetic bead negative-selection method of Miltenyi Biotec. All 
procedures were performed at 4°C. A single cell suspension was prepared by 
mashing the spleens or nodes through a wire mesh (Sigma-Aldrich), in RPMI- 
1640 media. The resultant suspension was centrifuged (400 x g, 7 min, 4°C) 
and the pellet resuspended in 9 mis of red blood cell removal buffer (0.168 M 
NH4CI, pH 7.2). The suspension was carefully layered over 1 ml heat- 
inactivated foetal calf serum (PCS) and incubated on ice for 7 min to permit red 
blood cell lysis and lipid precipitation. The supernatant was removed, carefully 
layered over 1 ml PCS in a fresh tube and centrifuged again (400 x g, 7 min, 
4°C).
The cell pellet was resuspended in 9 ml dead cell removal buffer (HEPES- 
buffered, mouse tonicity, balanced salt solution (BSS) supplemented with 0.12 
M Sorbitol, 20 mM Glucose) (Shortman et a!., 1972; Von Boehmer and 
Shortman, 1973). The suspension was immediately filtered through two 
prepared dead cell removal columns (absorbent cotton wool plugged, short-
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form, glass pipettes, wetted with 0.5 ml BSS/2% PCS). Cells were recovered 
from the column into a 15 ml tube on ice containing 1 ml BSS/2% PCS. The 
cells were centrifuged (400 x g, 7 min, 4°C) and resuspended in 50 ml ice-cold 
MAGS buffer (phosphate buffered saline (PBS), 0.5% BSA, 2 mM EDTA) 
counted by Trypan blue exclusion, and pelleted by centrifugation (400 x g, 7 
min, 4°C).
The cells were resuspended in ice-cold MACS buffer (2x10® cells/ml) and 
passed through gauze, to produce a single cell suspension for labelling. Cells 
were incubated for 25 min at 4°C with anti-CD43 (Ly-48) beads (100 pi CD43+ 
beads/2 x 10® cells). Labelled cells were passed through gauze again and 
applied to a CS-type negative selection magnetic column (Miltenyi Biotec) in a 
strong magnetic field. Purified mature B cells (CD43-) were eluted from the 
column by washing with 50 mis ice-cold MACS buffer. The cells were 
centrifuged (400 x g, 7 min, 4°C), resuspended in RPMI-1640 medium 
supplemented with 5% PCS, 100 U/ml penicillin, 100 pg/ml streptomycin, and 2 
mM glutamine, counted and assessed for purity by FACS analysis. Typically, B 
cells were obtained with a purity >98 % B220 positivity (as assessed by flow 
cytometry).
High density “resting” and low-density “activated” B cells were separated by 
Percoll density gradient centrifugation. Percoll (100%) was prepared by the 
addition of 2 ml 10 x PBS to 18 ml Percoll and dilutions (85%, 65% and 50%) 
were prepared by the addition of 1 x PBS. Percoll dilutions were layered (2.5 ml 
aliquots) into 13 ml centrifuge tubes to form a discontinuous gradient onto which 
the prepared B cells were loaded (approximately 6 x 1 0 ^  cells/tube in 2 ml 
RPMI-1640) and the tubes centrifuged (1230 x g, 20 min, room temperature). 
High density “resting” B cells were harvested from the 85%-65% interface and 
low-density “activated” B cells from the 65%-50% interface. The cells were 
washed twice by centrifugation (400 x g, 7 min, 4°C), resuspended in RPMI- 
1640 medium supplemented with 5% PCS, 100 U/ml penicillin, 100 jig/ml 
streptomycin, and 2 mM glutamine, counted and assessed for purity and 
activation status (size and granularity) by FACS analysis.
71
Chapter 2 -  Materials and Methods
2.4 Isolation of human peripheral blood mononuclear cells
Peripheral blood samples were obtained from rheumatoid arthritis (RA) patients 
attending the Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 
Glasgow, who satisfied the 1987 American College of Rheumatology diagnostic 
criteria, (Arnett et al., 1988). Total RNA from peripheral blood mononuclear cells 
of systemic lupus erythematosus (SLE) patients and controls was kindly 
provided by Dr. H. Slew (Dept, of Rheumatology, Allergy and Immunology, Tan 
Took Seng Hospital, Singapore).
Blood samples (7-14 ml) were collected in heparinised vials and mononuclear 
cell fractions were obtained by density gradient centrifugation through 
Lymphoprep (Nycomed). Briefly, blood samples were diluted 1:1 with warm 
RPMI-1640 and layered over Lymphoprep cushions (6 ml diluted blood per 6ml 
cushion). Following centrifugation (400 x g, 30 min, 20°C) cells at the interface 
(‘fluffy’ mononuclear layer) were removed to a clean 15 ml tube and washed 
with warm RPMI-1640 (400 x g, 10 min, 20°C). Mononuclear cells were 
counted by Trypan blue exclusion and total RNA isolated.
2.5 Ethical considerations
Peripheral blood samples were surplus to clinical requirements following routine 
therapeutic or diagnostic procedures and would otherwise have been discarded. 
These samples were collected by Dr. lain Mclnnes (Centre for Rheumatic 
Diseases, Glasgow Royal Infirmary, Glasgow) only when clinically indicated and 
informed consent was obtained from patients prior to research use of samples 
obtained.
All animal and disease model experiments was performed under project 
procedure licence 60/2217, provided following UK Home Office review and were 
used only to address questions not amenable to in vitro study of human tissue.
2.6 [^H]-Thynriidlne DNA synthesis assay
Proliferation of primary cells was assessed by a DNA synthesis assay. Briefly, 
purified cells (2x10® cells/well) were cultured in triplicate in round bottomed
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microtitre plates in RPMI-1640 medium supplemented with 5% PCS, 100 U/ml 
penicillin, 100 p,g/ml streptomycin, 2 mM glutamine, 1% (v/v) non-essential 
amino acids, 1 mM sodium pyruvate and 50 |iM 2-Mercaptoethanol (2-Me). 
Cells were stimulated in the presence of the appropriate agonists in a final well 
volume of 200 \i\. Cells were cultured for 48 hours at 37°C in a 5% (v/v) CO2 
atmosphere at 95% humidity.
Proliferation was assessed by pulsing with 0.5 pC i/we 1 [6-^H]-thymidine 
(Amersham Pharmacia Biotech) for the last four hours of culture, to allow 
incorporation into cellular DNA. Cells were harvested onto glass fibre filter mats 
(Wallac) using a Betaplate 96-well harvester (Amersham Pharmacia Biotech). 
Incorporated label was assessed by liquid scintillation counting and results are 
expressed as counts per minute (c.p.m) incorporated ± SD.
2.7 Cell stimulation and preparation of cell lysates
Splenic B cells (10^) were stimulated for the times indicated at 37°C. Control 
stimulations were carried out in the presence of medium alone (RPMI-1640 
medium supplemented with 5% PCS, 100 U/ml penicillin, 100 |ig/ml 
streptomycin, and 2 mM glutamine). Pollowing incubation, cells were lysed by 
the addition of ice-cold, modified RIPA buffer (50 mM Tris, pH 7.4, 150 mM 
sodium chloride, 2% (v/v) NP-40, 0.25% (w/v) sodium deoxycholate, 1 mM 
EGTA, 10 mM sodium orthovanadate plus 0.5 mM phenylmethylsulfonyl 
fluoride, 10 |ig/ml CLAP [chymostatin, leupeptin, antipain and pepstatin]). 
Whole cell lysates were incubated on ice for 30 min to permit protein extraction. 
Cellular debris was removed by centrifugation (20000 x g, 30 min, 4°C) and the 
supernatants transferred to fresh tubes, either for immediate use or stored at - 
20°C until required.
2.8 Preparation of nuclear protein extracts
Nuclear extracts were prepared using a modified protocol, as described 
previously (Dignam, et al., 1983; Lee et al., 1988). Stimulated B cells (10-30 x 
10®) were washed twice with ice-cold TBS and then resuspended in 400 jxl of 
ice-cold buffer A (10 mM HEPES buffer, pH 7.9, containing 10 mM KCI, 0.1 mM
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EDTA, 0.1 mM EGTA, 1 mM DTT, 0.15 mM spermine, 0.75 mM spermidine, 0.5 
mM PMSF and 100 p.M sodium orthovanadate). Cells were allowed to swell on 
ice for 15 min, after which 25 p,l of a 10% (v/v) IGEPAL solution was added and 
the cells vortexed for 15 seconds. Following centrifugation (13,000 x g, 30 s, 
4°C) the nuclear pellet was resuspended in 100 \x\ ice-cold buffer C (20 mM 
FIEPES buffer, pH 7.9, containing 0.4 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1 
mM DTT, 1 mM PMSF and 100 jxM sodium orthovanadate) and samples were 
incubated on ice for 15 min with vigorous agitation. The nuclear extract was 
harvested by centrifugation (13,000 x g, 5 min, 4°C) and the supernatant 
collected and frozen in aliquots at -70°C until required.
2.9 Immunoprécipitation
A BCA Protein Assay kit (Bio-Rad Laboratories Ltd) was used to assess the 
protein concentration of the whole cell lysates. Samples were normalised to 1 
jxg/|xl with 2 x  modified RIPA buffer and then pre-cleared with 10 |llI o f a 50% 
protein-G-sepharose:RlPA slurry for 30 min at 4°C with constant rotation. 
Following centrifugation (13,000 x g, 15 min, 4°C), the pre-cleared supernatant 
was transferred to a fresh tube and incubated with the appropriate 
immunoprecipitating antibody (1-2 pg/sample) overnight at 4°C with constant 
rotation.
The protein-antibody complex was pulled down with 10 jiil of protein G- 
sepharose for 2 hours at 4°C with constant rotation. Protein-agarose 
complexes were harvested by centrifugation (13,000 x g, 30 min, 4°C) and 
washed three times in ice-cold modified RIPA buffer. The samples were then 
used immediately and assayed for phosphatase activity or dissociated from the 
sepharose beads by boiling in 50 |il of 2 x sample loading buffer (100 mM Tris 
pH 6.8, 4% (v/v) bromophenol blue, 0.2% SDS and 20% v/v glycerol) containing 
5% 2-Me for 10 min at 100°C. Samples were pulse centrifuged, and resolved by 
SDS-PAGE, or stored at -20°C until required.
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2.10 SDS-Polyacrylamide Gel Electrophoresis
Standard gel electrophoresis apparatus and glass plates were cleaned with a 
deproteinating detergent and 70% ethanol prior to assembling according to the 
manufacturers instructions. Cell lysates or immunoprecipitates were resolved by 
Tris-glycine, SDS-PAGE (Laemlli, 1970).
A resolving gel of an appropriate percentage for protein resolution was poured 
into the prepared gel apparatus (Table 2.1) and overlaid with 70% ethanol 
solution to promote setting. The gel was allowed to set for at least 30 min. The 
ethanol layer was discarded and the gel interface washed with distilled water. 
Prior to pouring of the stacking gel, a well comb was inserted. The stacking gel 
was allowed to set for 30 min. The comb was carefully removed and the 
resultant wells were washed with electrophoresis buffer (25 mM Tris, 250 mM 
glycine and 0.1% SDS (w/v)).
Equal protein loadings of cell lysates or immunoprecipitates were resuspended 
in an equivalent volume of 2 x sample buffer containing 5% 2-Me and denatured 
by heating for 10 min at 100°C. Samples were loaded into the individual wells. 
Prestained wide-range molecular weight rainbow markers (Sigma-Aldrich) were 
used to elucidate the molecular weights of the unknowns. The samples were 
then eiectrophoresed into the stacking gel at 100V and then run at 200V 
through the resolving gel.
2.11 Western Blotting
Protein equivalent samples were resolved on a 7.5-12% polyacrylamide gel 
under reducing conditions and transferred to PVDF nitro-cellulose membrane 
(Millipore) using a transblot system (Bio-Rad Laboratories Ltd), cooled by the 
presence of an ice-block. Ponceau Red staining determined even protein 
loading and sample recovery of gels. The PVDF membranes were then 
incubated in modified TBS buffer I (TBS, pH 7.4, containing 10% non-fat milk 
and 0.1% Tween-20) for at least 1 hour at 4°C to block non-specific protein 
binding. Primary antibodies were diluted, at concentrations as recommended 
by the manufacturer, in TBS buffer II (TBS, pH 7.4, containing 5% non-fat milk
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and 0.1% Tween-20) and incubated with the membranes for 1 hour at room 
temperature, or overnight at 4°C. Membranes were washed four times in TBS 
buffer (TBS, pH 7.4, and 0.1% Tween-20) before incubating with the 
appropriate HRP-conjugated secondary antibody in modified TBS buffer II for 1 
hour at room temperature. The membranes were then washed thoroughly in 
TBS buffer and the immuno-reactive protein bands visualised using the 
Enhanced ChemiLuminescence (ECL) Western Blotting Detection System 
(Amersham Pharmacia Biotech) and exposed to X-OMAT film (Kodak).
2.12 Purification of anti-FcYRii/MI antibody
Equal volumes of saturated ammonium sulphate solution and tissue culture 
supernatant (2.4G2) were mixed and the immunoglobulin fraction allowed to 
precipitate overnight at 4°G. The immunoglobulin precipitate was harvested by 
centrifugation and then dialysed exhaustively in PBS. A column, consisting of a 
glass wool-stoppered syringe containing 1 ml of Protein G-sepharose (capacity: 
35 mg/ml)) was prepared, and this was connected to a reservoir made from a 
50 ml syringe. The column was washed with 20 ml of PBS, prior to the antibody 
supernatant, and the flow-through retained. The column was washed with PBS 
until the level of eluted protein (as measured at A280) had reached a steady 
state.
The bound antibody was eluted using 1 ml aliquots of 0.2 M acetic acid, into 
vials containing 100 |il of 1 M Tris buffer, pH 8.8. The elution profile was 
followed and the amount of protein estimated by measuring A280 (OD of 1.4 = 1 
mg/ml of protein). The appropriate fractions were then pooled and dialysed in 
PBS overnight, filter sterilised and stored in 0.5 ml aliquots at4°C or -20°C.
2.13 Flow cytometric analysis
2.13.1 Cell surface markers
Cells (0.5-1.0 X 10®) were washed twice in a 96-well round bottom plate with 
200 pi cold FACS buffer (PBS, 2% PCS, 2 mM EDTA) at 400 x g for 5 min, 4°C. 
Cells were resuspended in 15 pi of an anti-Fc receptor blocking solution (2.4G2 
supernatant) or 15 pi of FACS buffer for 10 min on ice. Cells were incubated
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with 30 pi of an appropriate concentration of primary antibody (or 15 pi of 2 x 
concentration, if Fc receptor block was used) and incubated for 20 min on ice. 
Cells were washed with 2 x 100 pi FACS buffer (400 x g, 5 min, 4°C) and then 
resuspended in 300 pi FACS buffer. For non-fluorescence conjugated primary 
antibodies, the staining procedure was repeated with the addition of the 
secondary antibody. Cellular fluorescence data was acquired using a Becton 
Dickinson FACSCalibar™ flow cy to meter and analysed using Cell Quest 
software.
2.13.2 Cell cycle analysis
To determine what percentage of cells were at a particular stage of the cell 
cycle, propidium iodide (PI) staining of cells was undertaken. Cells (0.5 xIO®) 
were washed twice in ice-cold FACS buffer and stained for appropriate cell 
surface markers as previously described, see section 2.13.1. Following washing 
in FACS buffer, cells were fixed with 100 pi ice-cold 70% ethanol for 15 min at 
4°C. The cells were washed in FACS buffer and then incubated with propidium 
iodide (250 pg/ml) for 35 min at room temperature. The PI fluorescence of the 
stained cells was measured at an excitation wavelength of 488 nm. Cellular 
fluorescence data was acquired using a Becton Dickinson FACSCalibar™ flow 
cytometer and analysed using Cell Quest software.
To determine what percentage of cells were apoptotic, in Gq/Gi arrest, in S 
phase or in G2 /M of the cell cycle, linear FL-3 voltage settings were used 
(Figure 2.2) The Gi peak (2N DNA) was set at 400 fluorescence units on the x- 
axis and a marker was set at either side of the peak. The upper and lower 2N 
DNA peak values were then doubled to produce the upper and lower 4N DNA 
peak values and markers set. Sub-diploid DNA or apoptotic cells were 
determined by setting markers below the 2N peak, whilst cells in the S phase 
were taken as those between the 2N and 4N peaks.
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2.13.3 Cell division by CFSE dye analysis
Cells (1.25 X 10^/ml) were washed in sterile PBS/0.1% BSA and incubated with
2.5 mM CFSE (3.5 x 10  ^cells/ml) in PBS/0.1% BSA for 10 min at 37°C in the 
dark. Cells were then washed twice in PBS/0.1% BSA, resuspended in RPMI- 
1640 medium supplemented with 5% PCS, 100 U/ml penicillin, 100 pg/ml 
streptomycin, 2 mM glutamine and stimulated as required. A cell sample of 10"^  
cells was taken to determine the initial dye intensity loading at timepoint zero. 
After stimulation, cells were washed twice in FACS buffer and resuspended at
3.5 X 10  ^ cells/ml. Cellular fluorescence data was acquired using a Becton 
Dickinson FACSCalibar™ flow cytometer and analysed using Cell Quest 
software.
For each stimulation cell division number was determined as a percentage of 
total dye uptake relative to timepoint zero. Briefly, total dye intensity at 
timepoint zero was plotted on a histogram and division markers were set so that 
each marker range was half of the previous marker setting (e.g. 8000, 4000, 
2000, 1000 etc.). The markers represented each cell division resulting in 
daughter cells with half the dye intensity. The percentage of cells within each 
marker range was then determined.
2.13.4 Mitochondrial membrane potential
Incorporation of the cationic lipophilic dye DiOC6(3) into the mitochondria is 
proportional to the mitochondrial transmembrane potential, A\|/m (Zamzami et 
al., 1995). Cells were stained for surface markers, as previously described, and 
then washed with FACS buffer. Cells were then incubated with 2.5 pM DiOC6(3) 
for 30 min at room temperature, washed with FACS buffer and resuspended in 
PBS/2 mM EDTA. Fluorescence data was acquired using a Becton Dickinson 
FACSCalibar™ flow cytometer and results were analysed using Cell Quest 
software (Figure 2.3)
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2.14 Inositol phosphate hydrolysis
2.14.1 Preparation and characterisation of Dowex-formate
For use in the assessment of inositol phosphate hydrolysis, Dowex-chloride was 
formate exchanged and the inositol phosphate elution profile characterised. 
Briefly, 100 g of Dowex-chloride (1x8-400, Sigma-Aldrich) was washed twice 
with 500 ml of distilled water in a glass beaker to remove any broken beads. 
The slurry was subsequently washed with 2 I of 2 M sodium hydroxide, 1 I of 
distilled water, and 500 ml of 1 M formic acid. The exchanged Dowex was 
washed repeatedly with distilled water (approximately 5 I) until the phi remained 
constant (phi 5.5). Exchanged Dowex was kept covered with distilled water at 
4°C to prevent drying prior to use.
For characterisation, glass wool-plugged Pasteur pipettes were filled with 0.5 ml 
of a 1:1 Dowex-formate:water slurry. Standards of [®FI]-lns(1,3,4,5) P4 and [®H]- 
lns(1,3,4)Ps were made up in 5 mM sodium tetraborate/0.5 mM EDTA, pFI 6.7 
(3 pi of [®H]/ml). 1 ml of the standard was passed through the column and the 
eluted load collected in a scintillation vial. The columns were subsequently 
washed with 3 x 1 ml aliquots of distilled water followed by 5 mM sodium 
tetraborate/0.5 mM EDTA, pH 6.7. For elution of the bound InsP forms the 
columns were washed with increasing concentrations of ammonium formate/0 .1  
M Formic acid ( 10x1 ml, 0.4-2M ammonium formate). High salt scintillation 
fluid (Uniscint BD, National Diagnostics) was added to each eluted fraction and 
to an equivalent amount of each standard used and assessed for [®H] 
incorporation by liquid scintillation counting. The individual InsP forms were 
typically eluted in the following concentrations of ammonium formate/0.1 M 
Formic acid; 0.4 M for IP1/IP2 , 0.65 M for IP3 and 1 M for IP4 (Figure 2.4).
2.14.2 Dialysis of Caif-Serum for Inositol Labelling
To permit better ®H-inositol labelling of cells, heat inactivated foetal calf-serum 
was dialysed to remove endogenous inositol. Briefly, 50 ml of FCS was placed 
in prepared dialysis tubing (pre-boiled in 10 mM EDTA and stored in 20% 
Ethanol) and dialysed exhaustively against Earle’s salts (0.12 M NaCI, 1 mM
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KCI, 1 mM MgSO4.7H20, 1 mM NaH2P0 4 , 8 mM Glucose) at 4°C for 2 days. 
Dialysed FCS was filter sterilised, aliquoted and stored at -20°C prior to use.
2.14.3 Assessment of inositol tetra-phosphate hydrolysis
Flydrolysis of ®FI-Iabelled inositol 1,3,4,5-tetrakisphosphate ([®FI]-lns (1,3,4,5) 
P4), by whole cell lysates, anti-SHIP or anti-PTEN immunoprecipitates derived 
from splenic B cells was assessed by measurement of released ([®H]-lns 
(1,3,4) P3). Cell lysates were prepared from stimulated splenic B cells (10^), as 
previously described, and aliquoted for triplicate immunoprecipitates. To each 
sample 2 pg of anti-SFIIP or anti-PTEN antibody was added and samples 
incubated overnight at 4°C with constant rotation. Protein-agarose complexes 
were pelleted by centrifugation (13,000 x g, 30 min, 4°C) and washed three 
times with ice-cold lysis buffer and once with assay buffer (50 mM Tris, pH 7.5, 
10 mM MgCy. Agarose-complexes were resuspended in lOpI of assay buffer.
Reaction mixtures (25 pi) containing whole cells, immunoprecipitate or assay 
buffer plus 16 pM Ins (1,3,4,5) P4 and 0.5 pi [®H]-lns (1,3,4,5) P4 (5000 cpm/pl) 
were incubated for 10 min at 37°C with constant agitation. The reactions were 
terminated by the successive addition of 0.22 N HCI and 300 pi chloroform: 
methanol (1:2, v/v). To separate the phases, 100 pi chloroform and 100 pi water 
was added and the samples were allowed to extract for 10 min at 4°C. Aliquots 
of the upper phase were diluted with water and applied to a 0.5 ml 1 x 8-400 
Dowex-formate column equilibrated with water and 50 mM ammonium 
formate/0.1 M formic acid. To elute the [®H]-lns(1,3,4)p3 product, columns were 
washed with 0.6 M ammonium formate/0.1 M formic acid. The non-hydrolysed 
substrate (lnsP4) was eluted with 1.0 M ammonium formate/0.1 M formic acid. 
For assessment of total inositol phosphates, products were eluted with 1.5 M 
ammonium formate/0.1 M formic acid only. Eluting fractions of 2 ml were 
collected and assayed for radioactivity by liquid scintillation counting.
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2.15 In vitro Phosphatase assay (peptide assay)
Phosphatase activity was measured using a malachite green detection system, 
as previously described (Harder et ai, 1994). Measurement of phosphatase 
activity was performed using a commercial tyrosine phosphatase assay kit 
(Upstate Biotechnology) specific for SHP-1 activity. Cell lysates were prepared 
from stimulated splenic B cells (15 x 10®) as previously described (section 2.7) 
and immunoprecipitated with the appropriate antibody. Protein-agarose 
complexes were pelleted by centrifugation and washed four times with 10 mM 
Tris-HCI buffer, pH 7.4, to remove all traces of contaminating phosphates. 
Samples were resuspended in 75 |liI of the same buffer and aliquoted (3 x 25 |il) 
for triplicate measurements.
SHP-1 specific phosphopeptide (R-R-L-l-E-D-A-E-pY-A-A-R-G; 350 jiM) and 
100 jil of a malachite green solution was added to each well and the plate 
incubated at room temperature for 30 min. The Aeso was measured for each 
sample and the phosphate concentration determined from a standard reference 
curve. Pac-1, PP2A and anti-ErkMAPK associated phosphatase activity was 
also assessed using the Upstate Biotechnology kit by the hydrolysis of pNPP 
(para-nitrophenylphosphate) by the appropriate immunoprecipitate. All results 
are obtained from triplicate assay readings and presented as the mean ± S.D.
2.16 Measurement of Ras activity
A Ras activation assay kit (Upstate Biotechnology) was used to determine the 
Ras activity in stimulated cell samples. The protocol was followed according to 
the manufacturer's instructions. Briefly, splenic B cells (10^) were stimulated, 
harvested by centrifugation and lysed with 200 pi of 5 x Mg^  ^ lysis buffer. The 
protein content of the whole cell lysates was determined and the samples 
normalised to 1 mg/ml with lysis buffer. Samples were precleared with 10 pi of 
50% glutathione-agarose:lysis buffer slurry, for 30 min at 4°C with constant 
rotation.
Samples were then centrifuged (13,000 x g, 10 min, 4°C) and the supernatants 
were transferred to fresh tubes. Samples were incubated with 5 pi of Raf-1-Ras
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binding domain (RBD)-agarose conjugate for 30 min at 4°C with constant 
rotation. Following centrifugation (13,000 x g, 10 min, 4°C) the protein-agarose 
complexes were washed 3 times in lysis buffer and denatured by resuspending 
in 50 pi 3 X sample buffer (187.5 mM Tris-HCI, pH 6.8, 6% w/v SDS, 30% 
glycerol, 150 mM DTT, 0.03% w/v bromophenol blue) and boiled for 10 min at 
100°C. The agarose beads were collected by pulse centrifugation and the 
supernatants resolved by SDS-PAGE. Proteins were transferred to PVDF 
membranes and were subjected to Western blotting with 1 pg/ml anti-Ras 
antibody. Immuno-reactive proteins were visualised using the ECL system and 
exposure to X-OMAT film.
2.17Measurement of Rap-1 activity
Rap activity in stimulated B cells was determined using a similar protocol 
undertaken for the measurement of Ras activity, see section 2.16. Briefly, 
splenic B cells (10^) were stimulated, harvested by centrifugation and lysed with 
200 pi of 5 X Mg^  ^ lysis buffer (Upstate Biotechnology). Lysates were pre­
cleared with glutathione-agarose and incubated for 30 min at 4°C with 5 pg of 
Ral-Ras binding domain (RBD)-agarose conjugate. The conjugate was 
prepared in our lab from a Ral-RBD construct, kindly provided by Dr. J. L. Bos 
(Utrecht University, The Netherlands). Protein-agarose complexes were 
harvested by centrifugation (13,000 x g, 10 min, 4°C) and washed three times in 
lysis buffer. The complexes were harvested by centrifugation, resuspended in 3 
X sample buffer (187.5 mM Tris-HCI, pH 6.8, 6% w/v SDS, 30% glycerol, 150 
mM DTT, 0.03% w/v bromophenol blue), resolved by SDS-PAGE and subjected 
to Western blotting with 1 pg/ml anti-Rap-1 antibody. Immuno-reactive proteins 
were visualised using the ECL system and exposure to X-OMAT film.
2.18 Measurement of SAPK activity
Stimulated splenic B cells (10^) were pelleted by pulse centrifugation and 
resuspended in 100 pi of modified RIPA lysis buffer (20 mM Tris pH7.4, 150 mM 
NaCI, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 
ImM p-glycerophosphate, ImM Sodium Orthovanadate, 1mM PMSF, 10 mg/ml
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chymostatin, leupeptin, antipain and pepstatin A). Whole cell lysates were 
incubated on ice for 20 min. Following centrifugation (13,000 x g, 30 min, 4°C), 
the supernatants were split into 2 fresh Eppendorfs and 2 pg of c-Jun fusion 
protein was added to one and 2 pg of ATF-2 fusion protein to the other. 
Samples were incubated overnight at 4°C with continuous rotation.
10 pi protein G sepharose:RIPA buffer slurry was added to each sample and 
incubated for 2 hours at 4°C, with continuous rotation. Samples were pelleted 
by centrifugation (13,000 x g, 5 min, 4°C) and were washed twice in RIPA lysis 
buffer and twice in kinase buffer (25 mM Tris ph7.5, 5 mM p-glycerophosphate, 
2 mM DTT, 0.1 mM sodium orthovanadate, 10 mM MgCy. The pellet was 
resuspended in 50 pi kinase buffer containing 100 mM ATP.
Samples were incubated for 30 min at 30°C and the reactions terminated by the 
addition of 25 pi 3x sample buffer (187.5 mM Tris-FICI, pFI 6.8, 6% w/v SDS, 
30% glycerol, 150 mM DTT, 0.03% w/v bromophenol blue). Samples were 
boiled for 5 min and resolved by SDS-PAGE, transferred to PVDF membrane 
and Western blotted for phospho-p38 or phospho-JNK.
2.19 Measurement of MEK activity
A modified experimental protocol supplied with a MEK Activation Assay Kit 
(Upstate Biotechnology) was used to determine the MEK activity in splenic B 
cells. Stimulated B cells (10^) were pelleted by pulse centrifugation and 
resuspended in 100 pi of modified RIPA lysis buffer (20 mM Tris pFI7.4, 150 mM 
NaCI, 1 mM EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 
mM P-glycerophosphate, 1 mM sodium orthovanadate, 1 mM PMSF, 10 mg/ml 
chymostatin, leupeptin, antipain and pepstatin A) and incubated on ice for 20 
min. Following centrifugation (13,000 x g, 30 min, 4°C), supernatants were 
adjusted to 1 mg/ml and incubated with 2 pg of MEK1/2 antibody overnight at 
4°C with continuous rotation.
10 pi of protein G sepharose:RIPA buffer slurry was added to each sample and 
incubated for 3 hours at 4°C, with continuous rotation. Samples were pelleted
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by centrifugation (13,000 x g, 5 min, 4°C) and were washed twice in RIPA lysis 
buffer and twice in assay dilution buffer (ADB -  20 mM MOPS, pH 7.2, 25 mM 
P-glycerophosphate, 5 mM EGTA, 1 mM sodium orthovanadate, and 1 mM 
DTT). The pellet was resuspended in 20 pi of ADB supplemented with 10 pi of a 
magnesium/ATP cocktail (ADB, 75 mM MgCb, 500 pM ATP). The positive 
control contained 0.5 Units of activated human MEK1. Samples were then 
incubated for 30 min at 30°C with 1 pg of inactive murine GST-p42 MAPKinase. 
Reactions were terminated by the addition of 25 pi 3 x sample buffer (187.5 mM 
Tris-HCI, pH 6.8, 6% w/v SDS, 30% glycerol, 150 mM DTT, 0.03% w/v 
bromophenol blue) and boiled for 5 min. Following centrifugation (13,000 x g, 2 
min, 4°C), supernatants were resolved by SDS-PAGE, transferred to PVDF 
membrane and Western blotted for phospho-ErkMAPK.
2.20 Measurement of AKT activity
An Akt Kinase Assay Kit (Cell Signalling Technology, Lake Placid, NY) was 
used to determine the activity of Akt in splenic B cells. Stimulated cells (3 x 10^ ) 
were washed with PBS, pH 7.4 and pelleted by pulse centrifugation. Cell pellets 
were resuspended in 200 pi of modified RIPA lysis buffer (20 mM Tris pH7.4, 
150 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM [3-glycerophosphate, 1 mM sodium orthovanadate, 1 mM 
PMSF, 1 pg/ml leupeptin) and incubated on ice for 10 min. Following 
centrifugation (13,000 x g, 30 min, 4°C), the supernatants were transferred to 
fresh tubes and incubated for 3 hours at 4°C with 20 pi of agarose-conjugated 
Akt antibody (Akt 1G1).
Antibody-agarose complexes were harvested by centrifugation (13,000 x g, 5 
min, 4°C) and washed twice in lysis buffer and twice in kinase buffer (25 mM 
Tris pH 7.5, 5 mM p-glycerophosphate, 2 mM DTT, 0.1 mM sodium 
orthovanadate, 10 mM MgCL). Sample pellets were resuspended in 40 pi 
kinase buffer and incubated for 30 min at 30°C in the presence of 200 pM ATP 
and 1 pg of a GSK-3 fusion protein. Reactions were terminated by the addition 
of 20 pi of 3 X sample buffer (187.5 mM Tris-HCI, pH 6.8, 6% w/v SDS, 30% 
glycerol, 150 mM DTT, 0.03% w/v bromophenol blue). Samples were vortexed.
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boiled for 5 min and then harvested by centrifugation. Supernatants were 
resolved by SDS-PAGE, transferred to PVDF membrane and Western blotted 
for phospho-GSK-3-a/p.
2.21 Total cellular RNA preparation
Total RNA was extracted using RNAzoF"'^ B (Biogenesis) as described 
(Chomczynski and Sacchi, 1987). Briefly, cells (5 x 10®) were washed twice 
with ice-cold PBS (2000 x g, 5 min at 4°C) and the cellular pellet was 
resuspended in RNAzol™ B (0.2 ml/10® cells). Samples were extracted for 5 
min on ice and the suspension was transferred to a fresh tube. Chloroform was 
added (0.1 ml /I ml of RNAzol™) and the solution mixed by vigorous shaking 
for 15 seconds. The samples were incubated on ice for a further 5 min.
Following centrifugation (13,000 x g, 15 min, 4°C) the colourless upper phase 
was removed to a fresh tube (approximately 50% of the initial RNAzol"^ volume) 
and an equal volume of isopropanol was added. RNA was precipitated by 
incubation on ice for 30 min and separated by centrifugation (13,000 x g, 15 
min, 4°C). The RNA pellet was washed with ice-cold 75% ethanol (1 ml/ 1 ml 
RNAzol™ volume), briefly dried for 10 min at room temperature and finally 
resuspended in 20-50|xl of sterile, distilled water. RNA samples were incubated 
at 68°C for 5 min prior to concentration assessment by UV spectroscopy. 
Absorbance readings of diluted samples (1:50) were taken at A260/280 and the 
concentration of RNA calculated (40 |xg/ml RNA = A260 of 1).
2.22RT-PCR
Total cellular RNA (5 \ig), prepared as previously described, was pre-incubated 
with 5 iiM Oligo(dT)16 (Roche) at 70°C for 10 min and then reverse transcribed 
in the presence of 50 mM Tris-FICI pFI, 8.3, 75 mM KCI, 3 mM MgCb, 5 mM 
DTT, 0.5 mM dNTPs (Gibco-BRL) and 100 U Superscript II RT (Gibco-BRL) at 
25°C for 10 min, followed by 42°C for 50 min and 70°C for 10 min. This protocol 
allowed annealing of the Oligo(dT) and conversion of RNA, via reverse 
transcription, into cDNA.
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PCR amplifications were performed in a total volume of 50 |il, containing 1 \i\ 
cDNA sample (250 ng), 20 mM Tris-HCI pH 8.4, 50 mM KCI, 1.5 mM MgCF, 0.2 
mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dUTP, 0.5 pM each primer 
(Table 2.2) and 2.5 U Tag DNA polymerase (5 U/pl; Promega). Each 
amplification was performed under optimised conditions, on a Techne 
Cyclogene PCR Cycler typically: 5 min at 94°C, followed by a total of 30 three- 
temperature cycles (30 s at 94°C, 1 min at 55°C and 1 min at 72°C) and a 
single cycle of 5 min at 72°C. Samples were then stored at -20°C until use.
2.22.1 Agarose gel electrophoresis of nucleic acid
PCR products were routinely analysed by agarose gel electrophoresis. Briefly, 
an agarose gel, of an appropriate percentage for efficient DNA separation (1- 
2% w/v) containing 0.5 jig/ml ethidium bromide (Sigma-Aldrich), was poured 
into the prepared gel apparatus, in the presence of a well comb. The gel was 
allowed to set for at least 30 min and the comb was carefully removed.
Approximately 10 jiil of PCR product with 2 \i\ of DNA loading buffer was loaded 
into the individual wells. A prestained, 1 Kb DNA ladder (Promega) was used to 
elucidate the length of the unknown linear DNA. The samples were 
eiectrophoresed into the gel at 60 V, in TAE buffer (40 mM Tris, 20 mM Acetic 
acid, 1 mM EDTA), until the bands were sufficiently resolved. Gels were 
analysed under UV light and a photographic image recorded.
2.23TaqMan®
TaqMan® real-time PCR (Gibson et al., 1996) was performed according to the 
manufacturers instructions (PE Biosystems) as previously described 
(Overbergh etal., 1999). See Figure 2.5.
Primers and fluorogenic probes were designed using the PrimerExpress™ vl.O 
programme purchased from PE Biosystems (Figure 2.7) The fluorogenic 
probes contained a reporter dye (FAM or VIC^ "' )^ covalently attached at the 5’ 
end and a quencher dye (TAMRA) covalently attached at the 3’ end, and were
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HPLC purified. Extension from the 3' end was blocked by attachment of a 3' 
phosphate group See Tables 2.3 and 2.4
cDNA samples were prepared by reverse transcription of total cellular RNA, as 
previously described. PCR reactions were performed in the ABI-prism 7700 
Sequence Detector, which contains a Gene-Amp PCR System 9600 (PE 
Biosystems). PCR amplifications were performed in a total volume of 25 |xl, 
containing 0.5 |xl cDNA sample (125 ng), 50 mM KCI, 10 mM Tris-HCI pH 8.3, 
10 mM EDTA, 200 \iM dATP, dCTP, dGTP and 400 |iM dUTP, 5 mM MgCb, 
300 nM each primer, 0.625 U AmpliTaqGold™ (PE Biosystems) and 0.25 U 
AmpErase Uracil N-Glycosylase (PE Biosystems). Each reaction also contained 
200 nM detection probe. Each amplification was performed in triplicate wells, 
using the following conditions: 2 min at 50°C and 10 min at 94°C, followed by a 
total of 45 two-temperature cycles (15 s at 94°C and 1 min at 60°C).
Data was analysed using the Sequence Detection software (PE Biosystems) 
which calculates the threshold cycle; Ct. This value represents the PCR cycle 
number in which an increase in fluorescence, over and above threshold, can 
first be detected. This threshold cycle is determined during the exponential 
phase of amplification to ensure 100% efficiency. Samples were normalised 
with respect to a reference reporter gene (HPRT) through the subtraction of 
respective Ct values to produce a ACt value (Figure 2.6).
To obtain an absolute value for fold increase, relative to HPRT levels, the 
formula 2-ACt was used. Multiplication of the absolute value by 100 gives the 
expression of the gene of interest as a percentage of HPRT. The positive error 
is the standard deviation of the difference, s = V(s1  ^+ s2^), where si and s2 are 
the standard deviation of the Cts of HPRT and the gene of interest.
2.24 Synthetic oligonucleotide DNA labelling
Synthetic oligonucleotide probes were supplied freeze-dried from Sigma- 
Genosys. Dried probes were reconstituted by the addition of 500 \x\ of distilled 
water and the concentration determined A260, against a water blank. For single
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stranded DNA, an absorbance of 1 = approximately 33 |Lig/ml. Molarity was 
calculated on the assumption that the average weight of 1 DNA base is equal to 
324 Da using the formula;
(1/Total oligo Mr in Da) x oligo concentration in pg/jil x 10"® = moles oligo/|il
40 nmoles (90 |al) of each single strand oligo were incubated together with 20 ql 
of a high salt buffer (H buffer: Gibco BRL) and boiled at 100°C for 10 min. The 
probes were allowed to cool slowly for up to 4 hours to permit the annealing 
reaction.
The resultant double stranded oligonucleotide probes were labelled with [a-®^P]- 
dATP (Amersham-Pharmacia) using a commercially available random priming 
kit (Gibco-BRL). 2 \i\ of DNA was incubated together with 2 |il each of 0.5 mM 
(dCTP, dGTP, dTTP), 5 |o,l of 10 x H buffer, 2 |il (2 nCi) of [a-^^P]-dATP and 1 |il 
Klenow DNA polymerase (Exonuclease-free, 2 units/jiil, Boehringer-lngelheim) 
made up to a total volume of 50 \i\ with distilled water. The reaction was 
incubated at 37°C for 2 hours and the probes were purified on an 8% non­
denaturing polyacrylamide gel, using 0.5 x TBE (90 mM Tris, 90 mM Boric acid, 
2 mM EDTA) as the running buffer. Gels were exposed to X-RAY film (Kodak) 
to detect labelled probes and excised gel pieces were incubated in TE buffer 
(10 mM Tris, pH 8, 1 mM EDTA) overnight at 37°C.
2.25 Electrophoretic Mobility Shift Assay (EMSA)
5-10 |xg of nuclear extract protein was pre-incubated with 200 ng double- 
stranded poly (dl-dC).(dl-dC) (Amersham-Pharmacia Biotech) in reaction buffer 
(20 mM HEPES buffer, pH 7.9, containing 40 mM KCI, 1 mM MgClz, 0.1 mM 
EGTA, 0.5 mM DTT, 10% glycerol and 0.1% NP-40) in a total volume of 30 ii\ 
for 30 min on ice (Wu et al., 1994). [a-®^P]-dATP labelled oligonucleotide probe 
(0.5 ng) was then added (Table 2.5), and the mixture incubated on ice for a 
further 20 minutes.
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DNA-protein complexes were resolved on a non-denaturing 6% PAGE in 0.5 x 
TBE buffer and the gels were fixed (20% methanol, 10% acetic acid, 10% 
glycerol) for 20 min at room temperature. Following fixing, gels were vacuum- 
dried and exposed to film for 5 days at -70°C.
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2.26 Suppliers Addresses
Alexis Corporation (UK) Ltd
3 Moorbridge Court 
Moorbridge Road East 
Bingham
Nottingham NG13 8QG
Amersham Pharmacia Biotech
Amersham Place 
Little Chalfont 
Buckinghamshire HP7 9NA
Anachem Ltd
20 Charles Street 
Luton
Bedfordshire LU2 OEB
Aventis Pasteur A/ISD
Bridge Avenue 
Maidenhead 
Berks SL6 1QP
Beckton Dickinson (BD) UK Ltd
21 Between Towns Road 
Cowley
Oxford 0X4 3LY
Bio/Gene Limited
6 The Business Centre 
Harvard Way 
Kimbolton
Cambridgeshire PE18 ONJ
Biogenesis
Technology Road 
Poole BH17 7DA
Binding Site Ltd
P.O. Box 4073 
Birmingham B29 6AT
Bio-Rad Laboratories Ltd
Bio-Rad House 
Maylands Avenue 
Hemel Hempstead 
Hertfordshire HP2 7TD
BioSource UK Ltd
Rue de l'industrie, 8,
B-1400 Nivelles 
Belgium
Boehringer-lngelheim Ltd
Ellesford Avenue 
Bracknell
Berkshire RG12 8YS 
Caltag
c/o TCS Biologicals Ltd
Botolph Claydon 
Buckingham MK18 2LR
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Charles River UK Ltd
Manston Road 
Margate 
Kent CT9 4LT
DAKO
Angel Drove 
Ely
Cambridgeshire CB7 4ET 
Difco
c/o Beckton Dickinson (BD) UK 
Ltd
Harlan UK Ltd
Shaw’s Farm
Blackthorne
Bicester
Oxon 0X25 1TP
Invitrogen (Gibco-BRL/ Life 
Technologies)
3 Fountain Drive 
Inchinnan Business Park 
Paisley PA4 9RF
Jackson ImmunoResearch
Laboratories
c/o Stratech Scientific
61-63 Dudley Street 
Luton
Bedfordshire LU2 ONP
Kodak Ltd
Kodak House 
Station Road 
Hemel Hempstead 
Hertfordshire HP1 1JU
Millipore
The Boulevard 
Blackmoor Lane 
Watford
Hertfordshire WD1 8YN
Miltenyi Biotech
Almac House 
Church Lane 
Bisley
Surrey GU24 9DR
Molecular Probes
c/o Cambridge Bioscience
24-25 Signet Court 
Newmarket Road 
Cambridge CB5 8LA
National Diagnostics
Unit 4
Fleet Business Park 
Itlings Lane 
Hessle
HUIIHU13 9LX
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NEN Life Science Products (UK) 
Ltd
BRU/BRU/40349 
P.O Box 66 
Hounslow TW5 9RT
New England Biolabs
73 Knowl Piece 
Wilbury Way 
Hitch in
Hertfordshire SG4 OTY
Nycomed
Oslo, Norway
Oncogene (Calbiochem- 
Novabiochem (UK) Ltd) 
c/o CN Biosciences
Boulevard Industrial Park
Padge Road
Beeston
Nottingham NG9 2JR
PE Applied Biosystems 
(Applera UK)
Kelvin Close
Birchwood Science Park North
Warrington
Cheshire WA3 7PB
Pharmingen/T ransduction 
Laboratories
c/o Insight Biotechnology Ltd
P.O Box 520 
Wembley
Middlesex HA9 7YN
Pierce and Warnier (UK) Ltd
44 Upper Northgate Street 
Chester CH1 4EF
Promega/Roche Diagnostics Ltd
Bell Lane 
Lewes
East Sussex BN7 1 LG
R&D Systems Europe Ltd
4-10 The Quadrant 
Barton Lane 
Abingdon 0X14 3YS
Santa Cruz
c/o Insight Biotechnology Ltd
P.O Box 520 
Wembley
Middlesex HA9 7YN
SAPU (Diagnostics Scotland)
Law Hospital 
Carluke ML8 5ES
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Sigma-Aldrich Company Ltd
Fancy Road 
Poole
Dorset BH12 4QH
Sigma-Genosys
London Road 
Pampisford 
Cambridge CB2 4EF
Serotec Ltd
22 Bankside 
Station Approach 
Kidlington 
Oxford
Upstate Biotechnology 
c/o TCS Biologicals Ltd
Botolph Claydon 
Buckingham MK18 2LR
Wallac
c/o PE Life Sciences 
(Applera UK)
Zymed Laboratories Inc. 
c/o Cambridge Bioscience
24-25 Signet Court 
Newmarket Road 
Cambridge CB5 8LT
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Table 2.1 SDS-Polyacrylamide Gel Solutions (Laemmli, 1970)
Solution Components Component volumes (ml) per gel 
mould volume of 40 mis
Resolving Gel 
7.5% 10% 12%
Stacking
Gel
5%
distilled water 21.5 15.9 13.2 27.2
30% bis-acrylamide mix 10.2 13.3 16 6.8
1.5 M Tris (pH 8.8) 7.5 10 10 -
1.0 Wl Tris (pH 6.8) - - - 5
10% SDS 0.4 0.4 0.4 0.4
10% Ammonium persulphate 0.4 0.4 0.4 0.4
TEMED 0.028 0.016 0.016 0.04
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Table 2.2 RT-PCR Primer Sequences
Primer Species Primer Sequence d5^(-)3’
FcyRilBI-For
FcyRIIBI-Rev
Murine
Murine
GGGAAACCATCACGCTAAGG
CAGTTTTGGCAGCTTCTTCC
FcyRIIB1-Splic-For
FayRIIBI-Spiic-Rev
Murine
Murine
ACAGGGAAATGGGAGAAACC
GCTTGTTGGCTCCAGTCC
FcyRIIB1-For
FcyRIIBI-Rev
Fiuman
Human
CACTGCACAGGAAAGATAGGC
CAAGACAATGGAGACTAAATAC
GG
FcyRllB1-Splic-For
FcyRllB1-Splic-Rev
Human
Human
CCCAGGATACCCTGAGTGC
GCTGGTTTCTCAGGGAGGG
P-Actin-For
p-Actin~Rev
Murine
Murine
GGGCTATGCTCTCCCTCACGC
CATCCTGCG
TTGGCATAGAGGTCTTTACGGA
TGTGAACG
P-Actin-For
P-Actin-Rev
Human
Human
GGGGTATGCCCTCCCCCATGC
CATCCTGCG
TTGGCGTACAGGTCTTTGCGGA
TGTCCACG
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Table 2.3 TaqMan® Primer Sequences
Primer Species Primer Sequence d6’(-)3’
FcyRllBI-For
FcyRIIB1-Rev
Human
Human
GGC CTT GAT CTA CTG CAG GAA 
GGG AGG GTC TCT CCC ATT TC
FcyRIIB2“For
FcyRIIB2-Rev
Human
Human
TGC TGC TGT AGT GGC CTT GA 
CCC CAA CTT TGT CAG CCT CAT
FcyRllB1-For
FcyRIIB1“Rev
Murine
Murine
CAT TGT TAT TAT CCT AGT ATC CTT GGT 
CTATC
GTT TCT CCC ATT TCC CTG TGA TC
FcyRIIB2-For
FcyRIIB2-Rev
Murine
Murine
AAA AAG CAG GTT CCA GAC AAT CC 
GAG GAG TGA GTA GGT GAT CGT GTT C
PAC-For 
PAC “Rev
Human
Human
TGG AGA TCT TGC CCT ACC TGT T 
ACG TTG AGG ACG GCT GTG AT
HPRT-For
HPRT-Rev
Human
Human
Supplied by PE-Biosystems. 
GenBank Accession Number; M31642
HPRT-For
HPRT-Rev
Murine
Murine
GCA GTA CAG CCC CAA AAT GG 
AAC AAA GTC TGG CCT GTA TCC AA
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Table 2.4 TaqMan Detection Probe Sequences
Probe Species Probe Sequence d5’(-)3’
FcyRIIBI
FcyRIIB2
Human
Human
FAM - CGG ATT TCA GCT CTC CCA GGA 
TAC CCT - TAMRA
FAM -AGG AAA AaG CGG ATT TCA GCA ATC 
CCA CTA - TAMRA
FcyRIIBI
FcyRIIB2
Murine
Murine
FAM -CAA GAA AAA GCA GGT TCC AGC TCT 
CCC AG - TAMRA
FAM-
TGGAAGAAGCTCCCAAAACTGAGGCTG-
TAMRA
PAC Human FAM -AGC TGC AGT CAC TCG TCA GAC CTG 
CAG - TAMRA
HPRT
HPRT
Murine
Human
FAM -TAA GGT TGC AAG CTT GCT GGT GAA 
AAG GA - TAMRA
VIC-Supplied by PE-Biosystems. GenBank 
Accession Number: M31642-TAMRA
5’ FAM (6-carboxy-fluoresein) labelled 
5’ VIC™ labelled
3' TAMRA (6-carboxy-tetramethylrhoadmine: quencher) labelled
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Table 2.5 EMSA Probe Sequences
Probe Probe Sequence dS’(-)3’
NF-kB from iNOS 
promoter
CCC AAC TGG GGA CTO ICC GIT TGG
E2-F from 
Adenovirus E2A 
promoter
GOG GIT TIG GGG GIT AAA ITT  GAG AAA 
GGG GGG G
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Table 2.6 Antibodies
Protein Conjugate Host^ Clone Use^ Source
Akt R W,IP NEB
pAkt R W,IP NEB
anti-mouse IgG + G,R,D s Stratech
IgM F(ab ’) 2
anti-mouse IgG + G,R,D s Stratech
IgM Intact
anti-mouse IgM (p G s Stratech
chain) F(ab ’) 2
anti-IgG Goat, HRP V w SAPU
Mouse, Rabbit
anti-IgG Goat, HRP V w Sigma-
Mouse, Rabbit, Rat Aldrich
anti-Rat IgG FITC R F Pharmingen
ATF-2 fusion protein 9224S PD NEB
B220 APC RA3-6B2 F Pharmingen
B220 FITC RA3-6B2 F In house
BLNK M 2B11 W Santa Cruz
CD11b PE M1/70 F Pharmingen
GD19 FITC F Se rote c
GD19 1D3 F Pharmingen
CD3 FITC KT3 F In house
CD4 FITC GK1.5 F In house
CD43 1B11 F Pharmingen
cdc42 M B-8 W Santa Cruz
Cdk4 M C-22 W Santa Cruz
C3G R C-19 W Santa Cruz
Dok-1 R M-276 W Santa Cruz
p44/42 ErkMAPK R 9102 W,IP NEB
phospho-p44/42 M 9106 W,IP NEB
ErkMAPK
phospho-p44/42 R 9101S W,IP NEB
ErkMAPK
F cyR II/III FITC Ra 2.4G2 W,F In house
Fyn M 15 W,IP Santa Cruz
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Protein Conjugate Host^ Clone Use^ Source
GAP R LI W,IP Transduction
Grb2 M C-7 W,1P Santa Cruz
c-Jun R 9162 W,IP NEB
phospho-c-Jun R 9162 W,IP NEB
c-Jun fusion protein R 60938 W,IP NEB
JNK R 9252 WJP NEB
pJNK(T183/Y185) R 9251L W.IP NEB
Lyn R 44 W.IP Santa Cruz
Lyn M L05620 W.IP Transduction
mdm2 M SMP14 W,IP Santa Cruz
phospho-p38 M 9219 W,IP NEB
p38 R 9212 WJP NEB
p53 R FL-393 w Santa Cruz
p53 M Pab 240 w Santa Cruz
p53 M O P03 w Oncogene
p53 S w SAPU
phospho-p53 R w NEB
(Ser15)
PAC-1 G C-20, N- 
19
WJP Santa Cruz
PD-1 Biotin Ra J43 W,F Gift
pERK R 91018 w NEB
phospho -Tyrosine Ra 4G10 w UBI
phospho “Tyrosine M 9411 WJP NEB
phospho -Threonine M 13-9200 WJP Zymed
phospho - Serine R 61-8100 WJP Zymed
PI-3K R Z-8 WJP Santa Cruz
PP2A G C-20 WJP Santa Cruz
PTEN R 06-894 WJP UBI
Rac R C-14 WJP Santa Cruz
Raf-1 R C-12 WJP Santa Cruz
Raf-I(RBD) IP W. Bos
Ral M w
Rap“1 (Krev-1) R 121 WJP Santa Cruz
Rap-1 M R22020 WJP Transduction
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Protein Conjugate Host^ Clone Usé^ Source
Rap-1/GAP W
Ras R W Santa Cruz
Rb M G3-245 W,IP Pharmingen
Rb G C-15-G W,IP Santa Cruz
RKIP R w W. Kolch
SHC M S68020 W,IP Transduction
SHC R S14630 W,IP Transduction
SHIP R N-1 W,IP Santa Cruz
SHIP G M-14 W,IP Santa Cruz
SHIP G V-19 W,IP Santa Cruz
SHIP Agarose G V-19 W,IP Santa Cruz
SH-PTP-1 G C-19-G W,IP Santa Cruz
SH-PTP-1 R C-19 W,IP Santa Cruz
SH-PTP-2 R C-18 W,IP Santa Cruz
SLP76 G C-20 W,IP Santa Cruz
SLP76 M S60720 W,IP Transduction
SOS M S I 5520 W,IP Transduction
Syk M 4D10 w Santa Cruz
VAV R C-14 w Santa Cruz
CD43 Magnetic
beads
Ra Pure Miitenyi
Biotech
Fas (CD95) M L0B3 F Serotoc
Antibodies were originally raised against the murine form of the protein, unless 
otherwise indicated.
^Host: R = Rabbit, G = Goat, D = Donkey, Ra = Rat, M = Mouse, V = Various. 
^Use; WB = Western Blotting, IP = Immunoprécipitation, F = FACS, S = 
Stimulation {in vitro), PD = Pull Down, Pure = Purification
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Table 2.7 Other Reagents
Description Common Name
3.3’-dihexyloxacarbocyanine iodide DiOCe (3) Mol. Probes
5-/6-Garboxyfiuorescindiacetate, CFSE Calbiochem
succinimidyl ester
Acrylamide/Bis Solution, 29:1 Acrylamide Bio-Rad
AmpllTaq Gold DNA Polymerase Taq PE Biosystems
Bovine type II collagen Collagen Sigma-Aldrich
Carboxy-fluorescein diacetate CFSE Mol. Probes
succinimidyl ester
Dowex-1-Chloride (1 x 8-400) Dowex Sigma-Aldrich
Enhanced ChemiLuminescence Kit ECL Amersham
Freund’s complete adjuvant CFA Difco
Foetal Calf Serum FCS Gibco-BRL
Glutamine Glutamine Gibco-BRL
MEM Non-essential amino acids Amino acids Gibco-BRL
MicroBCA or Coomassie Protein Assay Protein Assay Pierce
Oligo-d(T)16 Oligo-d(T) Roche
Penicillin/Streptomycin Pen/Strep Gibco-BRL
Propidium Iodide PI Calbiochem
RPMI-1640 culture media RPMI-1640 Gibco-BRL
Sodium Pyruvate Sodium Pyruvate Gibco-BRL
SP-Sepharose Fast Flow Sepharose Amersham
Superscript Preamplification System Superscriptll Gibco-BRL
[6-^H]-thymidine (5 Ci/mmol) [3H]- thymidine Amersham
[^H]-lnositol-1,3,4-phosphate [3H]-IP3 MEN
[^H]-lnositol-1,3,4,5,-tetrakisphosphate [^H]-IP4 NEN
[inositol-1-3H(N)]
D-myo-lnositol-1,3,4,5 IP4 Alexis
tetrakisphosphate.octapotassium
Uniscint BD (High Salt) Scintillation fluid National
Diagnostics
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Figure 2.1 Protocol for induction of Collagen-induced Arthritis (CIA) in 
DBA/1 mice.
Î  = Induction of CIA. Male DBA/1 mice (3 per group) were immunised 
intradermally at the tail base with bovine type II collagen (Oil, 200 jig) emulsified 
in CFA (lOOjil) or CFA alone on day 0. An intraperitoneal collagen challenge 
(CM, 200 jig in PBS) was carried out on day 21. A gradual onset of arthritis was 
observed 7-10 days after the intraperitoneal challenge and animals were 
observed for up to 5 weeks for the development of arthritis. Dr. Bernard Leung 
undertook all clinical measurements and histological assessments of the 
collagen-induced arthritis model. Data of individual measurements from the 
groups were collected from the time of the intraperitoneal Cl I challenge on day 
21 until the termination of the study on day 47. Graphs are representative of the 
mean articular index and disease incidence rates of the C FA/C 11 group only. 
Data are expressed as the mean ± S.E.M from a single experiment, 
representative of at least three other independent experiments.
103
CFA or PBS or
Collagen Collagen in PBS
in CFA 
(i d.)
0)>
0 )(/)
0)
0 )(0
0 )(/)
Q
Time o 5 10 15 20 25 30 35 40 45 50 55 60 65 70
(d) Pre-Disease Acute Chronic Remission 
Onset
fe 6 -  
.1 5-
<  4-
ro 3-Q>
S  2 -
80-
(D 40-"O
20-
21 23 25 27 29 31 33 35 37 39 41
Tim e (d) 
Collagen/CFA
Chapter 2 -  Materials and Methods
Figure 2.2 FACS histogram of DNA content analysis of murine splenic B 
cells.
A histogram plot of splenic B cells from Baib/c mice (1 x 10®) stained with 
propidium iodide (250 pg/ml) for DNA content analysis. Histogram markers 
determine what percentage of cells are in each stage of the cell cycle. The Gi 
peak (2N DNA) is set at 400 fluorescence units on the FL-3 x-axis and the G2/M 
(4N DNA) calculated accordingly. Sub-diploid DNA or apoptotic cells are 
marked as those below the 2N peak. Whilst cells in the S phase are determined 
as those between the 2N and 4N peaks.
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Figure 2.3 FACS histogram of the mitochondria! membrane potential of 
murine splenic B cells.
A histogram plot of splenic B cells from Balb/c mice (1 x 10®) stained with 
DiOC6(3) (2.5 p.M) for analysis of mitochondrial membrane potential. Histogram 
markers determine what proportion of cells are represented by low and high 
DiOC6(3) fluorescence on the FL-1 x-axis. Cells with low DiOC6(3) fluorescence 
are thought to represent the apoptotic population with increased membrane 
potential and permeability.
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Figure 2.4 Characterisation of Dowex-formate 1x 8-400.
Elution profiles of pH]-IP4 and pHJ-IPa standards run through Dowex-formate 1 
X 8-400 columns. Loaded [^H]-standards are eluted in 1 ml fractions of 
increasing concentrations of Ammonium formate/0.1 M formic acid. Eluted loads 
are assessed for [^H]-incorporation by liquid scintillation counting.
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Figure 2.5 TaqMan real-time RT-PCR.
The TaqMan® oligonucleotide probe contains a 5’ reporter dye (R) and a 3’ 
quencher (Q). Whilst the probe is intact, the reporter fluorescence is 
suppressed by the close proximity of the quencher. As the PCR reaction 
proceeds, the 5’-3’ nuclease activity of the polymerase enzyme cleaves the 
probe. The reporter and quencher become separated, resulting in reporter 
fluorescence. The 3’ end of the probe is blocked to prevent extension of the 
probe during PCR.
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Figure 2.6 TaqMan® amplification plot
The TaqMan® amplification plot depicts how the fluorescence emission 
(normalised Reporter, Rn) varies with PCR cycle (0-45). During the first rounds 
of PCR amplification, the fluorescence emission is below the limit of detection. 
Detection occurs as the signal increases in direct proportion to the amount of 
specific amplified product. As the reaction continues the ratio of polymerase 
enzyme to PCR product decreases and hence the amount of PCR product 
ceases to increase exponentially. Eventually the Rn reaches a plateau. The Ct 
(threshold cycle) is determined during the exponential phase of amplification (Ct 
indicated by the black line). A typical triplicate sample (F4-F6) is shown with a 
Ct value of 0.013.
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Figure 2.7 TaqMan amplification of the FcyRllb isoforms
To amplify the FcyRllbl isoform (A) the probe and primer set were designed to 
amplify a FcyRllbl insert specific sequence of 82 base pairs. To amplify the 
FcYRilb2  isoform (B) the forward FcyRllb2 primer was designed to have four 
base pairs overlapping the FcyRllbl specific insert junction to prevent the 
primers from amplifying if the probe bound the wrong isotype sequence. It is 
essential for TaqMan® PCR amplification that the 3' sequence is a perfect 
match, so four incorrect base pair matches will prevent spurious amplification.
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Chapter 3 - Molecular mechanisms of FcyRllb signalling
3.1 Introduction
B cell regulation of the immune response to antigen requires the maintenance 
of appropriate levels of signalling through the B cell antigen receptor (sIg/BCR). 
To maintain this control, B cells employ a variety of positive and negative co­
receptors such as CD19, CD22, CD72 and FcyRllb that modulate the signal that 
is transduced by the BCR (section 1.2.5). Signals generated by these molecules 
appear to alter the signalling threshold of the BCR either by facilitating the 
positive signalling or by downmodulating its function (Doody et ai, 1995; Sato et 
ai, 1996; Cornall et ai, 1998). The essential requirement for a balance of 
activatory and inhibitory pathways has been highlighted by observations that a 
loss of suitable inhibitory signalling can lead to inappropriate stimulation and 
activation of B cells (O’Keefe et ai, 1996; Clynes et ai, 1999; Dijstelbloem et 
ai, 2001). Indeed, aberrant B cell activation can result in a variety of chronic 
inflammatory processes, including autoimmune disease.
By binding the Fc domain (Fc) of antibodies, Fc receptors (FcRs) provide a 
critical link between the humoral and cellular arms of the immune system by the 
targeting of antigen-antibody complexes to effector cells and priming of an 
immune response (section 1.3) B cells express only one class of Fc receptor, 
the low affinity IgG receptor, FcyRllb (Daeron, 1997a). Co-ligation of the BCR 
with FcyRllb, by means of IgG-containing antigen-antibody complexes, 
negatively regulates the BCR response to antigen (section 1.4). Although the 
mechanisms underlying the negative regulation of BCR by FcyRllb are poorly 
understood, several of the well characterised cellular responses of BCR 
stimulation: protein tyrosine phosphorylation, phosphoinositide hydrolysis, 
calcium influx, cellular proliferation and immunoglobulin secretion are all 
inhibited following co-engagement. By the induction of growth arrest and/or 
apoptosis, aggregation of FcyRllb provides a valuable physiological negative 
feedback mechanism for the inhibition of B cell activation, indeed, this feedback 
mechanism may be an active determinant in the selection of B cells by signals 
generated by the interaction of immune complexes. Moreover, FcyRllb
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signalling may be of importance for preventing the entry of autoreactive B cells 
into the periphery, in addition to the negative selection of immature B cells, by 
promoting the deletion of low-affinity, self-reactive B cells in the germinal 
centres and by the induction of IgG-mediated peripheral B cell tolerance.
In common with many inhibitory immunoreceptors, coupling of FcyRllb to 
downstream signalling pathways is dependent upon the clustering of a 
cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) (Muta et al., 
1994, Amigorena et al., 1992a). This unique thirteen amino acid motif 
possesses a consensus sequence lA/xYxxLA/ that constitutes the minimal 
structural requirement for the ITIM. In an analogous fashion to that observed 
with the Ig-a/lg-p ITAMs, aggregation of FcyRllb by immune complexes results 
in the phosphorylation of an essential tyrosine residue within the ITIM by Src- 
family kinases. Phosphorylation of the ITIM provides a docking site for the 
recruitment of Src-homology domain 2 (SH2 ) containing phosphatases that act 
to dephosphorylate key signalling components downstream of the BCR, thereby 
inhibiting normal B cell responses.
3.1.1 FcyRllb modulation of BCR activated signalling pathways
FcyRllb appears to inhibit B cell activation by modulating key BCR-activated 
signalling pathways involving the hydrolysis of phosphatidylinositol 4,5 
bisphosphate (Ptdlns-(4 ,5 )P2) by phospholipase C-y (PLC-y), the generation of 
phospha tidy Iinos ito  1-3,4,5-trisphosphate  (P td ln s -(3 ,4 ,5 )P 3 ) by
phosphatidylinositol 3-kinase (PI-3-Kinase) and the activation of the 
Ras/MAPKinase pathway. Signals emanating from these pathways all converge 
at the level of nuclear signalling where they regulate transcription factors and 
ultimately dictate the fate of the B cell. In order to determine the mechanisms of 
FcyRIlb-induced growth arrest and/or apoptosis in B cells, it is necessary to re­
examine the components of these BCR signalling pathways and how they 
regulate B cell growth and survival.
Activated by a range of extracellular stimuli, the mitogen-activated protein 
(MAP) kinases are able to mediate a wide range of cellular functions from
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proliferation and activation to growth arrest and cell death (Figure 1.8). MARK 
signalling cascades, consisting of an upstream serine/threonine kinase 
(MAPKKK), a middle dual-specificity kinase (MAPKK) and a downstream 
serine/threonine kinase (MARK) (Dhanasekaran and Premkumar-Reddy, 1998) 
are common to many cell types. Activation of the extracellular signal-regulated 
kinase (Erk) MARK pathway has been shown to act on a wide range of 
downstream molecules and transcription factors controlling growth and 
differentiation. In B cells, initiation of this signalling cascade requires recruitment 
of the adaptor molecule She to the phosphorylated cytoplasmic tail of the 
activated receptor. The phosphorylation of She promotes its interaction with the 
adaptor molecule, Grb2, which is already complexed to the Ras guanine 
nucleotide exchange factor (GEF), SOS , in an SH2-domain dependent manner. 
SOS then promotes conversion of Ras from its GDP-bound inactive form into its 
active GTP-bound form (Li et al., 1993; Henning and Cantrell, 1996). Active Ras 
then recruits the serine/threonine kinase Raf-1 (ErkMAPKKK) to the plasma 
membrane. Phosphorylated Raf-1 is then able to activate the dual-specificity 
kinases MEK1 (MAPKinase Kinase 1) and MEK2 (MAPKinase Kinase 2) 
through the phosphorylation of serine residues 217/218 and 221, respectively. 
MEK1 and MEK2 then activate Erki (p44) and Erk2 (p42) MARK by 
phosphorylating specific threonine (202) and tyrosine (204) residues within a 
characteristic TRY motif. Activated Erk1/2 MARK then phosphorylates and 
activates a number of cytoplasmic effectors, such as cytosolic phospholipase A2 
(CPLA2 ) and/or translocates to the nucleus where it phosphorylates a variety of 
transcription factors regulating gene expression, such as Elk-1 and Stat3. The 
90 kDa Ribosomal S6  Kinase (p90RSK) is also phosphorylated by active 
ErkMAPK and regulates gene expression through the phosphorylation of the 
Creb and c-fos transcription factors.
The elevation of cytosolic calcium levels is a major downstream event of B cell 
activation via the BCR. Intracellular levels can be increased both by the release 
of calcium from intracellular stores and by calcium influx. The generation of the 
second messenger, lns(1 ,4 ,5 )P3 , by PLC-y has been shown to be essential for 
the release of calcium by binding to InsPs receptors on intracellular store
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membranes (Parekh and Penner, 1997). This, in turn, induces calcium influx 
through cytoplasmic membrane calcium channels, termed I c r a c  (calcium 
release activated current). In co-operation with the second PLC-y product, 
diacylglycerol (DAG), calcium regulates several key B cell signalling events 
including protein kinase C (PKC) activation and the nuclear localisation and 
activity of the transcription factor NF-kB (Berridge, 1993). The activation of PKC 
isoforms is one of the earliest events in the cascade leading to a variety of 
cellular responses such as gene expression and proliferation (Nishizuka, 1992; 
Dekker and Parker, 1994). Whilst both PKC activation and calcium mobilisation 
seem to be required for the induction of genes such as c-fos, induction of egr-1 
and c-m yc appear to require only PKC activation. In contrast, Ets~1 
phosphorylation requires calcium but is independent of PKC activation. PKC 
activation is also thought to play a role in the regulation of the MAPK pathways, 
by exerting regulatory control on the activation of ErkMAPK at multiple levels 
(Schonwesser et ai, 1998).
PI-3-Kinase activity and the generation of Ptdlns(3 ,4 )p2 and Ptdlns(3 ,4 ,5 )P3 , 
are known to be important for BCR-mediated B cell proliferation, differentiation 
and survival (Campbell, 1999). Recent studies have identified that the 
generation of Ptdlns(3 ,4 ,5 )P3 by PI-3-Kinase can activate the survival- 
promoting factor Akt/PKB via the recruitment of the protein-serine/threonine 
kinases, PDK1 and PDK2, to the plasma membrane. PDK1 and PDK2 activate 
Akt via phosphorylation of Thr^ °® and Ser"*^ '^ respectively, within its activation 
loop. Further phosphorylation at its C-terminal facilitates the activation of Akt. 
Akt then promotes cell survival by phosphorylating and compromising multiple 
targets of the cell-death pathway. These include the pro-apoptotic Bcl-2 family 
member BAD (del Peso et ai, 1997) and the cell-death pathway enzyme 
caspase-9 (Cardone et ai, 1998) (Figure 1.19). In addition to promoting cell 
survival, Akt may regulate cell proliferation by phosphorylation of other target 
molecules. For example, Akt phosphorylation of the pro-apoptotic 
serine/threonine kinase, glycogen synthase kinase-3 (GSK-3), results in GSK-3 
inhibition and promotes cell survival. Recent studies indicating that GSK-3 
promotes Cyclin D proteolysis provide a mechanism for such survival signalling
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as by inhibiting GSK-3 Akt signalling contributes to Cyclin D accumulation and 
cell cycle entry. Furthermore, GSK-3 has also been proposed to regulate sub- 
cellular localisation of the calcium dependent transcription factor. NF-ATc (Gold 
et a/., 1999; Cross et a/., 1995). By inhibiting GSK-3, Akt prevents the export of 
NF-ATc from the nucleus in response to calcium thus promoting transcription 
essential for cell survival, growth and proliferation. According to recent reports, 
Akt may also promote survival by negatively regulating the Ras-Raf-MAPKinase 
pathway. At first sight this proposal may appear counter-intuitive as this 
pathway has traditionally been associated with promoting growth and 
proliferation (Zimmerman and Moelling, 1999). In the human breast cancer cell 
line, MCF-y, however, prolonged Raf activation has been shown to lead to 
growth arrest. Thus, by phosphorylating and inactivating Raf at Ser^^ ,^ Akt shifts 
the cellular response from growth arrest to proliferation.
3.1.2 Mechanisms of FcyRllb negative regulation
Following BCR-FcyRllb co-ligation in vitro, the phosphorylated ITIM of FcyRllb 
recruits the tyrosine phosphatases, SHP-1 and SHP-2 and an SH2 domain 
containing 5'-inositol phosphatase, SHIP-1 (section 1.4). Studies with dominant 
negative SHIP mutants and knockout models have confirmed that SHIP-1, 
rather than SHP-1, is preferentially recruited to FcyRllb following BCR-FcyRllb 
co-ligation in vivo (Gupta et a/., 1997; Liu et a/., 1998; Huber et a/., 1998). By 
hydrolysing lns(1 ,3 ,4 ,5 )P4 and Ptdlns(3 ,4 ,5 )P3 to lns(1 ,3 ,4 )P3 and Ptdlns(3 ,4 )P2 
respectively, SHIP is able to uncouple the BCR from a specific subset of 
pathways involving PLC-y and the Tec family kinases, such as phosphoinositide 
hydrolysis, extracellular calcium influx and cellular proliferation.
SHIP-1 mediated hydrolysis of Ptdlns(3 ,4 ,5 )p3 prevents the recruitment of PLC- 
y and Btk to the plasma membrane and thus abrogates the pathways 
downstream of their activation, in particular the sustained mobilisation of 
calcium. In addition, lns(1 ,3 ,4 ,5 )P4 has been proposed to participate in calcium 
signalling thus SHIP may inhibit calcium mobilisation not only by hydrolysing 
lns(1,3 ,4 ,5 )p 4 to produce a form of InsPs (!ns(1,3,4)Ps) unable to bind to 
receptors (InsPsR) in the endoplasmic reticulum (Bolland et ai., 1998;
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Scharenberg, 1998) but also by blocking entry of extracellular calcium (Luckhoff 
and Clapham, 1992).
The conversion of Ptdlns(3 ,4 ,5 )P3 to Ptdlns(3 ,4 )p2 by SHIP-1 has also been 
reported to result in the partial inhibition of the survival factor Akt/PKB (Jacob et 
al., 1999; Aman et al., 1998). However, since Ptdlns(3 ,4 )P2 has also been 
shown to be involved in the positive regulation of Akt activity, the observed 
inhibition of Akt may rather reflect upstream deregulation by the alternative 
inositol phosphatase, PTEN. Whilst SHIP has been shown to dephosphorylate 
the 5’ position of Ptdlns(3 ,4 ,5 )p 3 and lns(1,3,4,5)P4, PTEN is able to 
dephosphorylate the 3’ position. PTEN or MMAC (phosphatase and fensin 
homologue deleted on chromosome ten or mutated in multiple advanced 
cancer) (Li et al., 1997) was originally identified as a tumour suppressor gene 
implicated in the progression of a variety of human cancers. Further studies 
demonstrated that this 55-kDa protein contained a signature catalytic motif 
common to members of the protein tyrosine phosphatase (PTP) family. This 
was confirmed in vitro, where PTEN displayed enzymatic activity towards both 
protein and lipid substrates. Substantial evidence suggests that PTEN acts 
primarily to dephosphorylate the phosphoinositide Ptdlns(3 ,4 ,5 )P3 and possibly 
Ptdlns(3 ,4 )P2 and thus acts to directly antagonise the actions of PI-3-Kinase. 
Both lipid substrates are commonly associated with mediating positive cell 
signals resulting in cell proliferation and survival.
Consistent with this, several papers have now established a link between the 
PI-3-K/Akt pathway and PTEN. Indeed, a study by Stambolic ef a/., 1998 
confirmed that negative regulation of Akt/PKB by PTEN is critical for normal 
apoptotic signalling induced by a variety of apoptotic stimuli. Furthermore, 
PTEN deficiency leads to enhanced phosphorylation and activation of Akt/PKB 
confirming that PTEN can inhibit Akt-dependent survival signals induced in 
response to PI-3-kinase activation. These studies suggest that, like SHIP, 
PTEN may act in vivo as a negative regulator of cell proliferation and activation. 
Indeed, knockout models support a role for PTEN in maintaining lymphocyte 
homeostasis and immune tolerance, as PTEN insufficiency results in T cell
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lymphoma, hyperplasia and the development of lethal autoimmune disorders 
(Suzuki et al., 2001).
In addition to its phosphatase activity, SHIP has a number of putative tyrosine 
phosphorylation sites and a proline rich domain, which could enable protein 
adapter interactions. In particular, via its association with the adapter molecule. 
She, SHIP-1 is thought to abrogate normal recruitment and activation of the 
GTPase Ras. FcyRllb activated SHIP-1 is thought to mediate inhibition of the 
Ras/MAP kinase pathway by competing with the Grb2/S0S complex for She 
binding. The sequestration of She by SHIP-1 is believed to prevent the 
recruitment and activation of the GTPase, Ras. In addition, SHIP-1 may act to 
terminate Ras/MAPK activation via its interaction with p62Dok, a RasGAP 
binding protein (Tamir et al., 2000a). RasGAP acts to convert the active form of 
Ras-GTP into an inactive GDP form, thus preventing activation of the Raf- 
MAPK pathway.
However, the molecular mechanisms of SHIP-1 inhibition appear to alter 
depending on the activation status of the cells (Brauweiler et al., 2001). Unlike 
resting B cells, B cell blasts from SHIP-1 deficient mice are still able to inhibit 
calcium mobilisation, Akt and ErkMAPK activation following FcyRllb co-ligation. 
The discovery of an alternative SHIP isoform, SHIP-2 that is upregulated in 
activated B cells may provide an alternative inhibitory mechanism for FcyRllb on 
memory and plasma cells and explain why activated cells are able to convert 
Ptdlns(3 ,4 ,5 )P3 to Ptdlns(3 ,4 )P2 in a SHIP-1 independent manner.
Chimeric FcyRllb experiments and SHP-1 knockout models have demonstrated 
that SHP-1 is dispensable for FcyRIlb-mediated inhibition of B cells, since 
FcyRllb is still able to inhibit BCR-mediated proliferative events. However, a 
modulatory role for SHP-1 in FcyRI lb-mediated B cell inhibition has not been 
completely discounted. The strongest evidence in support of SHP-1 
involvement comes from the studies in the SHP-1 deficient motheaten (me) and 
motheaten viable (me'^ mice (previously described in section 1.4) as FcyRllb- 
mediated inhibition of BCR-induced proliferation in mature B cells is impaired in
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these mice (Nadler et aL, 1997). This suggests that SHP-1 is not (completely) 
redundant in all FcyRllb-mediated signalling events and that it is required for 
FcyRllb to be fully functional. Thus, it is possible that SHP-1 and SHIP 
differentially but synergistically target distinct signalling pathways in B cells.
Specific targets of SHP-1 in FcyRllb signalling have not been characterised but 
the number of potential targets is quite large and varied. A proposed substrate, 
however, is GDI 9, which is dephosphorylated during FcyR!lb-mediated negative 
signalling (Hippen et aL, 1997). One function of GDI9 is to promote BCR- 
mediated activation of PLC-y by the recruitment of PI-3-kinase. The 
dephosphorylation of GDI9 by SHP-1 could therefore result in an abrogation of 
decreased calcium influx. Other possible targets of SHP-1 include the Src- 
family PTKs, dephosphorylation of which would disrupt initiation of all signalling 
pathways. Indeed, studies in a BCR-expressing myeloma cell line demonstrated 
that SHP-1 mediates the negative regulatory effects of CD72 by 
dephosphorylating the BCR accessory molecules, Ig-a/lg-p, the PTK Syk and 
the recruitment of BLNK (Adachi etal., 2001).
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3.2 Aims and objectives of this study
Previous studies on FcyRllb signalling have concentrated on how BCR-FcyRllb 
co-ligation inhibits early B cell activation. However, recent studies have 
indicated that FcyRllb ligation can lead to distinct cellular responses of growth 
arrest and/or apoptosis in B cells, dependent on the levels and type of 
aggregation. This finding has important implications for the selection and 
modulation of B cell activity by immunocomplexes during B cell development.
Therefore, the aims of this study were to investigate the signalling mechanisms 
responsible for FcyRllb inhibition of B cell antigen receptor (BCR) mediated 
proliferative signalling in primary, mature B cells. In particular, it was planned to 
address,
• the differing signals involved in immune complex-induced growth arrest 
and/or commitment to apoptosis of resting B cells.
• the signals responsible for FcyRllb mediated uncoupling of BCR signalling 
resulting in growth arrest.
In particular, potential differences in early signalling relating to SHIP, SHP-1 and 
PTEN regulation of PI-3-Kinase, PLC-y and MAPK pathways in resting and 
activated cells were investigated in order to dissect differential effects of 
immune complexes on resting cells and those underlying negative feedback 
inhibition of BCR-driven proliferation and antibody production.
In addition, investigations into how such differential FcyRIlb-mediated signals 
result in sustained B cell growth arrest or lead to apoptosis have been limited. 
Therefore, part of this study was to examine whether FcyRllb signalling 
modulates the BCR-activated cell cycle machinery by examining the role and 
kinetics of BCR-driven nuclear signalling components in the presence and 
absence of inhibitory signalling via FcyRllb.
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3.3 Results
3.3.1 FcyRllb ligation abrogates antigen receptor mediated B cell 
proliferation
It is known that ligation of the BCR with F(ab’ )2 fragments of anti-mouse Ig 
antibodies leads to B cell proliferation whilst BCR-FcyRllb co-ligation using 
intact anti-lg antibodies inhibits BCR-mediated DMA synthesis (Klaus et al., 
1984 and 1985; section 1.4). Using DMA synthesis as a measure of 
proliferation, Figure 3.1A shows that stimulation of murine splenic B cells via 
the BCR (F(ab')2), results in a dose-dependent increase in DNA synthesis. 
However, no DNA synthesis was observed following ligation of FcyRllb with the 
intact form of the antibody alone, over a range of similar concentrations (Figure
3.1 B). BCR-FcyRllb co-ligation by a combination of both F(ab' )2  and intact anti- 
lg antibodies together results in a dose-dependent decrease in BCR-induced 
DNA synthesis (Figure 3.10) and provides an experimental model for negative 
feedback inhibition of ongoing B cell responses. Maximal inhibition of F(ab')2  
induced DNA synthesis was achieved using intact anti-lg antibodies at a 
concentration of 75 pg/ml i.e. at a concentration which is equimolar to that of the 
F(ab’) 2  concentration required for maximum DNA synthesis (Figure 3.1 and 
results not shown).
To confirm that co-ligation of BCR-FcyRllb is required for the inhibitory effect of 
FcyRllb on BCR-mediated proliferation, an anti- FcyRII/lll antibody (2.4G2) was 
used to block BCR-FcyRllb co-ligation (Figure 3.10). Consistent with published 
observations (Unkeless, 1979), co-stimulation of B cells via the BCR and 
FcyRllb, in the presence of 2.4G2, resulted in almost total restoration of BCR- 
induced levels of DNA synthesis. Together these results confirm that FcyRllb 
co-ligation can reduce or prevent BCR-mediated proliferation of murine B cells, 
supporting a role for this receptor in negative feedback regulation of B cells.
To confirm that FcyRllb-mediated inhibition of splenic B cells was independent 
of the activation status of the ceils the effect of FcyRllb ligation on populations 
of resting and activated mature B cells was investigated. Activated splenic B
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cells were separated from the resting population by differential density 
centrifugation using Percoll. The results shown in Figure 3.2A confirm that 
FcyRllb is able to induced growth arrest in B cells that are already actively 
proliferating, similar to that shown by resting splenic B cells Figure 3.2B.
3.3.2 Ligation of FcyRllb on splenic B cells induces apoptosis.
The above experiments confirmed that BCR-FcyRllb co-ligation was able to 
induce growth-arrest in splenic B cells, a process that could be prevented by an 
anti-FcyRII/lll blocking antibody. To investigate whether the FcyRllb-mediated 
growth-arrest observed in the DNA synthesis assay was truly due to growth 
arrest or actually a consequence of apoptosis, sub-diploid DNA content levels 
were determined by FACS analysis of propidium iodide incorporation. The 
results shown in Figure 3.3 confirm the ability of BCR stimulation to promote B 
cell entry into 8  and G2/M phases of the cell cycle, leading to increased levels of 
proliferation and DNA synthesis seen in Figure 3.1. In contrast, BCR-FcyRllb 
co-ligation resulted in an increased percentage of B cells undergoing cell cycle 
arrest (G0/G1) and apoptosis (sub-diploid) above control level. Indeed, sub­
diploid levels are enhanced in B cells stimulated with intact anti-lg antibody 
alone.
These results suggested that FcyRllb-ligation is indeed able to induce 
responses of cell cycle arrest and apoptosis in splenic B cells. The remainder of 
the study will therefore investigate the signalling mechanisms responsible for 
these differential responses and will begin with an examination of FcyRI lb- 
induced growth-arrest.
3.3.3 Differential tyrosine phosphorylation during positive and negative 
cell signalling.
As discussed in the introduction, one of the earliest events detected following 
BCR ligation is protein tyrosine phosphorylation and activation of key 
downstream effector proteins. FcyRllb-mediated inhibition of BCR-induced 
proliferation may act to modulate the phosphorylation of these proteins and thus 
prevent downstream signalling events. To investigate the possible target
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recruited proteins following FcyRllb ligation, splenic B cells were stimulated via 
the BCR with F(ab' )2  fragments of anti-lg antibody or via FcyRllb with the intact 
form of the antibody, or a combination of the two, for the times indicated The 
presence of phosphotyrosine containing proteins was detected by Western 
blotting, using the monoclonal anti-phosphotyrosine antibody (4G10).
In unstimulated B cells few proteins are tyrosine phosphorylated but following 
BCR stimulation several proteins become tyrosine phosphorylated (Figure 
3.4A). Phosphorylation peaks at 1 minute post stimulation and is reduced by 30 
minutes. Ligation of FcyRllb induces the phosphorylation of a distinct group of 
proteins. The approximate molecular weights of these target proteins were 145, 
70 and 65 kDa. Again, the strongest signals are transient, appearing 1 minute 
post stimulation and returning towards basal levels by 30 minutes post 
stimulation. Certain proteins are tyrosine phosphorylated during both positive 
and negative signalling. Indeed, the phosphorylation of these proteins seems to 
be stronger following FcyRllb co-ligation. Co-stimulation via the BCR and 
FcyRllb using F(ab’)2 and intact anti-lg antibodies together, leads to a similar 
profile of tyrosine phosphorylation to that seen following stimulation with intact 
antibodies alone. As the recruitment and phosphorylation of the phosphatases 
SHP-1 (65 kDa), SHP-2 (70 kDa) and the 5’-inositol-phosphatase SHIP (145 
kDa) by FcyRllb, is well documented in vitro, it was not surprising that the 
identity of these bands was confirmed by immunoprécipitation and Western Blot 
analysis using the anti-phosphotyrosine antibody, 4G10 (Figure 3.4B).
Interestingly, these results indicate that SHIP is also recruited and activated 
following stimulation via the BCR, disputing earlier studies that demonstrated an 
exclusive role for SHIP in FcyRllb-mediated negative signalling. Indeed, SHIP is 
transiently phosphorylated following BCR aggregation, with peak 
phosphorylation occurring after 1 minute. However, whilst following similar 
kinetics, the levels of SHIP phosphorylation induced by BCR ligation are lower 
than that observed following FcyRllb co-ligation (Figure 3.4B).
In agreement with the kinetics of SHIP tyrosine phosphorylation following BCR- 
FcyRllb co-ligation, measurement of in vitro SHIP inositol 5' phosphatase
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activity revealed a rapid enhancement of phosphatase activity, resulting in an 
increase of Ins(1,3,4)p3 levels (Figure 3.5). Maximal SHIP activity was shown 
to peak at 5 minutes post-FcyRllb co-ligation, returning towards basal levels by 
15 minutes. In contrast, stimulation via the BCR alone resulted in limited inositol 
phosphatase activity by anti-SHIP immune complexes. Thus, the level of 
tyrosine phosphorylation of SHIP seems to correlate with its inositol 
phosphatase activity in vitro.
3.3.4 FcyRllb co-ligation induces the formation of SHIP complexes with 
downstream signalling molecules.
The above results highlighted the possibility that SHIP is differentially activated 
in B cells following BCR and/or FcyRllb ligation. To investigate the possibility 
that SHIP may associate with different downstream regulatory proteins under 
the different stimulatory conditions, anti-SHIP immune precipitates were 
Western blotted for associated proteins (Figure 3.6). Following BCR or FcyRllb 
stimulation, SHIP was shown to transiently associate with the adaptor protein. 
She. The comparable time course of SHIP tyrosine phosphorylation (Figure 
3.4B) with She association suggests that this interaction is tyrosine 
phosphorylation dependent. These results are in agreement with recent 
published kinetic data for the recruitment and phosphorylation of SHIP by 
FcyRllb resulting in enhanced affinity of SHIP for She (Tridandapani et a!., 
1999). Consistent with the SHIP tyrosine phosphorylation profile following BCR 
ligation (Figure 3.4B), Shc-SHIP complexes are also detectable in BCR 
stimulated cells. Recent studies have confirmed that tyrosine phosphorylation of 
She, in response to BCR stimulation, is SHIP-dependent thus describing a 
novel role for SHIP in BCR signalling (Ingham et al., 1999).
In agreement with a recent study (Harmer and DeFranco, 1999), SHIP immune 
precipitates also revealed the presence of Grb2, another adaptor protein 
normally associated with She and SOS in a tri-molecular complex following 
BCR ligation. Grb2 was shown to be associated with SHIP, following B cell 
stimulation via the BCR and/or FcyRllb however levels of Grb2 association were
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reduced under conditions modelling negative feedback inhibition of BCR- 
signalling. Grb2 is thought to stabilise SHIP-Shc complexes, presumably by 
simultaneously binding via its SH3 domains to SHIP and via its SH2 domain to 
She. The demonstration by Harmer and DeFranco, 1999 that SHIP is unable to 
associate with She in Grb-2 deficient B cells highlighted the importance of this 
interaction.
The formation of SHIP complexes with the protein phosphatases SHP-1 and 
SHP-2 is intriguing and may indicate a possible modulatory role of SHIP on 
downstream pathways associated with these molecules. Indeed, a study of 
FcyRllb function using SHIP, SHP-1 and SHP-2 binding decoys demonstrated 
that although SHIP is the predominant intracellular ligand for the 
phosphorylated FcyRllb ITIM, the SHP-2 decoy exhibited some ability to bind to 
FcyRllb and block its function (Nakamura, K. etal., 2000). SHIP recruited SHP- 
2 may therefore act to switch off further FcyRllb signals.
3.3.5 Association of She with SHIP but not SHP-1 following FcyRllb co­
ligation
SHIP has been demonstrated to be essential for the inhibitory role of FcyRllb in 
B cells (Ono et a!., 1996; Chacko et a!., 1996; Liu et a!., 1998). The consensus 
that the sequestration of the adaptor protein She by SHIP is thought to lead to a 
reduction in Ras activation and subsequent inhibition of the Ras/MAP kinase 
pathway is still not fully established, however. SHIP-1'^' splenic B cells, display 
enhanced MAPK activation in response to BCR ligation or BCR-FcyRllb co­
ligation (Liu et a!., 1998). However, these results are not consistent with those 
of Ingham et a/.,1999, which demonstrate that BCR-mediated tyrosine 
phosphorylation of She and hence, activation of RasMAPK, is SHIP dependent. 
Similarly, the SHIP-Shc sequestration model is not consistent with the results 
reported here showing that mitogenic BCR signalling also promotes strong 
SHIP-Shc complex formation. These results imply that further modulation of 
SHIP activity is required to produce the differential responses following BCR or 
FcyRllb ligation.
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The formation of SHIP-Shc and SHIP-SHP-1 complexes (Figure 3.6) suggested 
that SHP-1 might modulate FcyRllb signalling by forming a SHP-1-SHIP-Shc 
complex. To investigate whether SHP-1 could associate with She, possibly via 
SH2 domain interactions, anti-SHP-1 immune precipitates were Western blotted 
with an anti-Shc antibody (Figure 3.7A). Despite the strong expression of SHP- 
1, no association between SHP-1 and She was demonstrated under any 
stimulation conditions. In addition, anti-Shc immune precipitates failed to 
demonstrate any associated SHP-1 phosphatase activity (Figure 3.7B). These 
results suggest that complexes containing SHP-1 and She are unlikely to be 
formed following FcyRllb ligation and that FcyRllb activated SHP-1 does not 
mediate its inhibitory effects via inhibition of the RasMAPK pathway by 
recruitment of She. However, it does not exclude the formation of SHIP-SHP-1 
complexes with the BCR and the potential for SHP-1 to contribute to Ras 
inhibition by dephosphorylating the ITAMs of the BCR accessory molecules, Ig- 
a/lg-p, or their associated PTKs.
3.3.6 SHP-1 is activated following BCR-FcyRllb co-ligation and 
dephosphorylates Lyn
SHP-1 is known to be associated with the BCR in resting B cells and is thought 
to maintain the resting status of the unstimulated BCR by dephosphorylating 
the ITAMs on the BCR-accessory molecules, Ig-a and Ig-p (section 1.2.2). In 
contrast, the PTK, Lyn is thought to initiate both BCR and FcyRllb activation by 
phosphorylating the cytoplasmic tails of their respective ITAMs or ITIMs. Thus, 
FcyRllb may inhibit BCR-coupling to PTK-dependent events by recruiting SHP- 
1 to counteract Lyn mediated phosphorylation.
To investigate this possibility, SHP-1 activity was assessed in both SHP-1 
(Figure 3.8A) and Lyn containing (Figure 3.8B) immune complexes over a 30 
minute time period of BCR or BCR-FcyRllb co-ligation. BCR stimulated SHP-1 
activity was maximal at 1 minute post-stimulation, possibly reflecting residual 
inhibition prior to activation and the transient requirement for phosphatase 
activity in reinitiation and perpetuation of PTK signals in activated B cells.
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Importantly, FcyRllb co-ligation induced a sustained increase in SHP-1 activity 
over the equivalent time period.
Analysis of the SHP-1 activity associated with Lyn demonstrated a reduced 
association following BCR stimulation that reverted to basal level by 5 minutes 
(Figure 3.8B). These results reflect the transient downregulation of SHP-1 
mediated inhibition of Lyn activity following BCR ligation, which is followed by 
the reinitiation of phosphatase activity to return the BCR signalling complex to 
a resting state. In contrast, Lyn-SHP-1 association was enhanced in FcyRllb 
stimulated B cells at 5 minutes returning to basal levels by 30 minutes. In 
agreement with this, SHP-1 was found to co-immunoprecipitate with Lyn in 
control unstimulated cells, supporting the proposal that SHP-1 acts to keep the 
BCR in a resting state (Figure 3.80). Interestingly, Lyn association with SHP-1 
was maximal in BCR stimulated cells at 1 minute post-stimulation and 
decreased steadily over the time period of BCR stimulation FcyRllb ligation 
also resulted in decreased association of Lyn with SHP-1 over time. Taken 
together, these results might suggest that Lyn-association is required for 
phosphorylation and activation of SHP-1, as dissociation correlates with a 
decrease in SHP-1 activity in BCR-stimulated cells. This latter point, however, 
suggests that in FcyRllb-stimulated cells, SHP-1 activity is somehow 
maintained in the absence of Lyn, perhaps by an, as yet, unidentified 
alternative PTK. Unlike SHIP and SHP-1, FcyRllb signalling was shown not to 
modulate SHP-2 phosphatase activity (results not shown) therefore 
questioning the role of this protein tyrosine phosphatase activity in the 
inhibitory SHIP-1 complexes in Figure 3.6.
3.3.7 FcyRllb inhibits Erk/MAPK phosphorylation
The BCR is coupled to the ErkMAPK pathway via PTK recruitment of the 
adaptor molecule She and subsequent activation of the GTPase, Ras 
(Campbell, 1999; Henning and Cantrell, 1998). As shown, FcyRllb-ligation 
results in the activation of the phosphatases SHIP-1 (Figure 3.5) and SHP-1 
(Figure 3.8) which are known to dephosphorylate and deactivate key BCR-
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coupled signalling molecules and thus interrupt normal proliferative signalling. In 
particular, SHIP, may act as a negative regulator of the ErkMAPK pathway by 
the sequestration of She and via its interaction with p62Dok, a RasGAP binding 
protein (Tamir et a/., 2000a). Both of these mechanisms are thought to lead to 
the inactivation of Ras and downstream MAPK effector molecules. FcyRllb 
ligation also leads to enhanced Lyn associated SHP-1 activity, which may lead 
to an inactivation of all B cell pathways downstream of this primary PTK (Figure 
3.8). However, it has been shown that tyrosine phosphorylation of the FcyRllb 
ITIM, following coligation with the BCR, is almost exclusively catalysed by Lyn 
in murine B cells (Nishizumi et al., 1998). Thus, FcyRllb may promote a 
negative feedback mechanism for its own activation to switch off further 
negative signalling.
To investigate the inhibitory role of FcyRllb ligation on BCR-induced MAPK 
activation, the effects of stimulation via the BCR and FcyRllb on ErkMAPK 
phosphorylation was investigated. Western blotting of whole cell lysates show 
that unstimulated splenic B cells exhibit little or no Erk phosphorylation, 
reflecting the resting state of the cells (Figure 3.9). Consistent with a BCR- 
mediated proliferative response, stimulation via the BCR results in a rapid 
phosphorylation of ErkMAPK, which is sustained for at least 30 minutes. In 
contrast, stimulation via FcyRllb results in a transient phosphorylation of 
ErkMAPK, which is rapidly terminated by 30 minutes. Furthermore, FcyRllb 
stimulation was able to abrogate the tyrosine phosphorylation of ErkMAPK 
induced by mitogenic signalling via the BCR. Thus, the induction of growth- 
arrest and apoptosis by FcyRllb ligation appears to correlate with the 
uncoupling of the BCR from early ErkMAPK phosphorylation.
3.3.8 Sustained FcyRllb inhibition of Erk/MAPK phosphorylation is 
independent of Ras activation.
The above data demonstrated that FcyRllb might act to prevent B cell activation 
through the termination of early ErkMAPK signals. However, the exact 
mechanism by which this is achieved is still unknown. Studies demonstrating 
that SHIP-Shc interactions are also important for normal BCR-mediated signals
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have questioned the initial theories that the sequestration of She by SHIP and 
inhibition of subsequent interactions with the GTPase, Ras, are essential for 
FcyRllb-mediated inhibition of RasMAPK. This reasoning suggests that the 
inhibition of ErkMAPK could be due to a negative regulatory effect on a 
mediator downstream of She.
Raf-1, a mitogen-activated protein kinase, is the main effector recruited by GTP- 
bound Ras in order to activate the MAPK pathway (Avruch et al., 1994). To 
determine if the FcyRllb-mediated inactivation of ErkMAPK was due to 
inactivation of Ras and an inability to recruit Raf-1, the kinetics of Ras activation 
were investigated under similar conditions of BCR and/or FcyRllb ligation. The 
study utilised the availability of a glutathione-coupled Ras-RBD substrate, which 
binds selectively to active-GTP-bound Ras and not inactive-GDP-bound Ras. 
Thus, the levels of activated Ras following FcyRllb-ligation can be assayed for 
by the selective pull-down of active-Ras from whole-cell lysates. Interestingly, 
unstimulated cells expressed a basal level of Ras activity, despite the lack of 
downstream ErkMAPK activation (Figure 3.1 OA). This suggests that B cells 
must initiate additional inhibitory mechanisms to prevent excessive 
ErkMAPKinase activation during normal, unstimulated, proliferation. However, 
as Ras has been shown to have several additional downstream effectors, such 
basal Ras activity could also represent a signalling requirement for the survival 
of resting B cells .
Ras activation was not shown to be consistent with the kinetics of BCR 
mediated ErkMAPK activation, confirming reports that BCR-mediated ErkMAPK 
activation is not exclusively Ras-dependent. For example, BCR-coupled Raf-1 
activation via DAG-sensitive PKC isoforms has been reported. Importantly, 
however, although co-stimulation via FcyRllb lead to a transient decrease in 
Ras activation, consistent with the kinetics of SHIP-Shc complex formation 
(Figure 3.6) and downstream inactivation of ErkMAPK (Figure 3.9), this period 
of downregulation was followed by a dramatic upregulation of Ras activation at 
30 minutes, which may reflect a downregulation in the formation of SHIP-Shc 
complexes, as shown in Figure 3.6 Despite the re-activation of Ras, a
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concomitant upregulation in ErkMAPK activity is not shown at 30 minutes 
(Figure 3.9). These results suggest that whilst SHIP sequestration of She may 
lead to short-term inactivation of the Ras/ErkMAPK pathway alternative 
inhibitory signals must be induced at later time points to uncouple the BCR from 
ErkMAPK under conditions in which Ras is hyper-activated.
Additional studies were carried out to determine whether long term 
downregulation of ErkMAPK activation was due to the sequestration of active 
Raf-1 by the alternative GTPases Rap-1 or Rai. Rap-1 activity has not been 
extensively studied in B cells, however, its role as a negative regulator of T cell 
mediated ErkMAPK activation has been studied (Henning and Cantrell, 1998). 
Results indicated that neither of these molecules was activated in either basal, 
BCR or FcyRllb stimulated splenic B cells (results not shown). In addition to the 
sequestration of She, SHIP is proposed to inhibit Ras activation via the 
recruitment of the RasGAP binding protein p62Dok (Tamir etal., 2000a). Thus, 
whilst Ras may be activated at later time points, p62Dok could promote its rapid 
inactivation. However, no expression of p62Dok in Ras immune complexes 
could be detected at these later time points (results not shown).
3.3.9 FcyRllb co-ligation modulates BCR-mediated MEK activation.
The MAPKinase kinases (MEKs), MEK1 and MEK2, are responsible for the 
regulation and activation of ErkMAPK by the dual phosphorylation of tyrosine 
and threonine residues within a characteristic threonine-X-tyrosine activation 
motif of ErkMAPK. Similarly, each family of the MAPKinase group is activated 
by specific MEKs allowing independent activation and regulation following cell 
stimulation (Figure 1.8). Ras activated Raf-1 is able to activate the dual­
specificity kinases MEK1 and MEK2. Thus to determine if the sustained 
FcyRllb-mediated inactivation of ErkMAPK was due to inactivation of MEK, the 
kinase activity in MEK immune precipitates following BCR and FcyRllb ligation 
was investigated.
Figure 3.1 OB shows that MEK activity is increased in BCR stimulated cells with 
kinetics that are consistent both with ErkMAPK activity and activation by Ras.
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Although BCR-FcyRllb co-stimulated B cells demonstrate MEK activity, the 
levels of activation are dramatically reduced in comparison with BCR-stimulated 
samples. Thus, sustained ErkMAPK inactivation following FcyRllb-ligation is 
occurring in a Ras independent manner but FcyRllb-mediated inhibitory 
mechanisms may operate downstream or at the level of MEK activation.
The inhibition of ErkMAPK activation can occur through a variety of negative 
feedback mechanisms, several of which rely on molecules that compete as 
substrates for the Ras/MAPK signalling kinases. Amongst these is the recently 
discovered Raf-kinase inhibitor protein (RKIP), which prevents MEK activation 
by Raf-1 (Yeung et al., 1999). In order to determine whether RKIP could be 
responsible for sustained FcyRllb-mediated suppression of ErkMAPK, Raf-1 
immunoprecipitates were Western blotted with RKIP antiserum (a kind gift from 
W. Kolch, Beatson Institute for Cancer Research, Glasgow). Unfortunately, no 
conclusive results could be obtained concerning the association of RKIP with 
Raf-1 following BCR or FcyRllb-ligation in splenic B cells (results not shown). 
However, as evidence is emerging that RKIP may not be expressed in 
lymphocytes (Walter Kolch, personal communication) these results do not 
exclude a role for a RKIP-homologue in the negative regulation of ErkMAPK by 
FcyRllb.
3.3,10 FcyRllb modulates Erk/MAPK activation by recruiting the Erk/MAPK 
phosphatase Pac-1.
A number of proteins such as Pac-1 and PP2A have recently been identified 
that act to terminate sustained MAPKinase activity (Robinson and Cobb, 1997). 
Furthermore, Pac-1 has been shown to be involved in the regulation of antigen- 
receptor directed ErkMAPK activation in lymphocytes (Ward et al., 1994). 
Therefore, these molecules may play essential roles in FcyRllb-mediated 
mechanisms of ErkMAPK down-regulation in splenic B cells, in addition to 
modulating other BCR-mediated responses.
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To investigate whether ErkMAPK associated protein tyrosine phosphatases 
play a role in FcyRllb-mediated suppression of ErkMAPK phosphorylation, 
phosphatase activity was studied in ErkMAPK immune precipitates following 
BCR and/or FcyRllb ligation. Figure 3.11 A demonstrates that phosphatase 
activity following BCR stimulation is reduced compared to basal levels, with 
minimal activity at 5 minutes post-stimulation. BCR stimulated phosphatase 
activity is also shown to be biphasic in nature, possibly reflecting the 
requirement to down modulate ErkMAPK activity following BCR ligation. In 
contrast, FcyRllb co-ligation results in a rapid and increase in ErkMAPK 
associated phosphatase activity, which peaks at 5 minutes and remains above 
basal level for the entire period of co-stimulation. Thus, FcyRllb-mediated 
inhibition of early and sustained BCR-induced ErkMAPK activation, may be due 
to the rapid recruitment of protein tyrosine phosphatases.
Pac-1 was originally identified as a nuclear product of an early-response gene 
in activated T-cells (Rohan etal., 1993). It is an inducible nuclear phosphatase 
that functions to terminate the activation of Erk, JNK and p38 MAPKinases 
through the targeting of specific tyrosine and threonine phosphorylation sites 
(Ward et al., 1994). Recombinant Pac-1 has also been shown to inhibit 
MAPKinase activity stimulated by epidermal growth factor, phorbol myristyl 
acetate, or TCR ligation (Ward et al., 1994). Studies have also indicated a role 
for Pac-1 in B cells, demonstrating that expression of Pac-1 mRNA is 
suppressed in resting mature B cells (Grumont et al., 1996). However, levels 
are upregulated following mitogenic stimulation with anti-lg, anti-CD40 
antibodies and LPS. These results suggest that Pac-1 may also be involved in 
the regulation of proliferative B cell responses.
To investigate a possible association between ErkMAPK and Pac-1 in splenic B 
cells, whole cell lysates from BCR and/or FcyRllb stimulated B cells were 
immuno-precipitated with an ErkMAPK antibody. Samples were then subjected 
to Western blot analysis with an antibody recognising Pac-1. Little or no 
detectable association between Pac-1 and ErkMAPK was found in unstimulated 
or BCR stimulated cells, indicating that the majority of the phosphatase activity
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employed to regulate ErkMAPK phosphorylation under these conditions in 
splenic B cells is not Pac-1 (Figure 3.11B). However, in agreement with 
published observations by our lab (Deehan et al., 2001) Western blot analysis 
revealed an association with ErkMAPK and Pac-1 under conditions of negative 
regulation. The association appears rapidly after just 1 minute co-stimulation via 
FcyRllb and the signal is sustained for at least 30 minutes. The kinetics of 
association were mirrored in western blots of total Pac-1 in whole cell lysates.
The serine/threonine protein phosphatase, PP2A, is present in most tissues and 
cell types, and has been implicated in the regulation of cell cycle progression, 
DNA replication, transcription, and translation. Importantly, PP2A has been 
shown to both negatively and positively regulate the Ras/MAPK cascade by 
dephosphorylating factors that function at different steps in the cascade 
(Wassarman et al., 1996). However, no association of PP2A could be 
demonstrated in ErkMAPK immune precipitates following stimulation via the 
BCR or FcyRllb. Consistent with this finding, no modulation of PP2A 
phosphatase activity could be found in either BCR and/or FcyRllb-stimulated B 
cells (results not shown).
Measurement of in vitro Pac-1 phosphatase activity in anti-Pac-1 immune 
complexes revealed a similar profile of activation to ErkMAPK associated 
phosphatase activity (results not shown). FcyRllb co-ligation resulted in an 
enhancement of Pac-1 activity at the earliest time points, which subsequently 
decreased and then remained above BCR induced levels for the remaining 
stimulation period. Moreover, analysis of these anti-Pac-1 immune precipitates 
showed association of ErkMAPK with Pac-1 (30 minutes) under conditions of 
negative but not BCR signalling (results not shown).
The rapid upregulation of ErkMAPK-associated Pac-1 expression and activity 
following BCR-FcyRllb co-ligation made it unlikely that this reflected de novo 
gene induction or even protein synthesis. This prompted an investigation into 
the localisation of Pac-1 protein expression within the cell, to determine whether 
existing Pac-1 was being recruited from the nucleus. However, Western blot
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analysis of nuclear and cytoskeleton fractions, failed to demonstrate re­
localisation of Pac-1 expression following co-stimulation via the BCR or FcyRllb 
(results not shown) suggesting that the observed upregulation reflects rapid 
translation of pre-existing mRNA.
3.3.11 FcyRllb inhibits BCR-induced activation of the PI-3-Kinase/Akt 
signalling pathway by recruitment of the inositol phosphatases, SHIP and 
PTEN, in vitro.
FcyRllb signalling Is also thought to contribute to B cell growth-arrest and 
apoptosis through SHIP-mediated reduction of BCR-induced Ptdlns(3,4,5)P3 
levels. Consistent with this hypothesis, recent findings have shown that a 
reduction in Ptdlns(3,4,5)P3 levels disrupts PH domain-phosphoinositol lipid 
interactions and prevents the association of Btk and PLC-y with the plasma 
membrane (Boliand ef a/., 1998).
BCR mediated generation of Ptdlns(3,4,5)P3 is also known to be essential for 
the activation of the survival-promoting factor, Akt/PKB. Akt promotes cell 
survival by phosphorylating and compromising multiple targets of the cell-death 
pathway, including the pro-apoptotic Bcl-2 family member BAD and the cell- 
death pathway enzyme, caspase-9. Thus, SHIP activity may contribute to the 
induction of apoptosis by converting Ptdlns(3,4,5)P3to Ptdins(3,4)p2 resulting in 
the inhibition of the activation/recruitment of the survival factor Akt/PKB. 
Western blot analysis for the expression and activation of Akt, following FcyRllb 
ligation on splenic B cells, proved unsuccessful. Thus, to determine Akt activity 
in splenic B cells, Akt-mediated phosphorylation of the pro-apoptotic 
serine/threonine kinase, glycogen synthase kinase-3 (GSK-3) was investigated. 
Measurement of Akt activity was determined in anti-Akt immune complexes 
from BCR and FcyRllb stimulated B cells, by an in vitro kinase assay using 
GSK-3 as a substrate. As Akt is known to phosphorylate GSK-3 at Ser21 of 
GSK-3a and Ser9 of GSK-3p, GSK-3 activation was determined by Western 
blot analysis using a phospho-GSK-3a/p (Ser21/9) antibody.
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BCR stimulation of mature splenic B cells results in the upregulation of Akt pro­
survival activity, as demonstrated by the phosphorylation of GSK-3 (Figure 
3.12). Activation of GSK-3 is biphasic and maximal activity is shown at 30 
minutes post-BCR stimulation. In agreement with others, (Jacob, etal., 1999; 
Aman, et al., 1998) BCR and FcyRllb co-stimulation results in the 
downregulation of Akt activity from 5 minutes, consistent with the kinetics of 
SHIP activation.
Interestingly, the product of SHIP activity, Ptdlns(3,4)P2, has also been shown 
to be involved in the positive regulation of Akt (Downward, 1998). Thus, the 
inhibition of Akt demonstrated may not reflect SHIP activity but rather be due to 
upstream deregulation by an alternative inositol phosphatase. PTEN has 
recently been identified as a protein and lipid phosphatase (reviewed by Cantley 
and Neel, 1999), which is able to negatively regulate Akt/PKB by 
dephosphorylating both Ptdlns(3,4,5)P3 (Stambolic, et al., 1998) and 
Ptdlns(3,4)P2 (Haas-Kogan, etal., 1998). Furthermore, the negative regulation 
of Akt/PKB by PTEN is known to be critical for normal apoptotic signalling 
induced by a variety of apoptotic stimuli. To investigate the involvement of 
PTEN in FcyRiib-induced B cell apoptosis, PTEN expression and protein/lipid 
phosphatase activity was investigated in splenic B cells, following BCR and/or 
FcyRllb ligation.
PTEN expression levels in whole cell lysates of BCR or FcyRllb co-stimulated 
splenic B cells were determined by Western blot analysis (Figure 3.13A). 
Surprisingly, PTEN levels in FcyRllb co-stimulated cells were reduced 
compared to resting B cells. However, PTEN expression was not shown to be 
modulated following BCR stimulation thus, the PTEN identified in resting and 
BCR stimulated cells may represent inactive PTEN. To investigate the 
activation status of PTEN under the same stimulation conditions, in vitro protein 
phosphatase activity was assessed in anti-PTEN immune complexes following 
stimulation of the BCR or co-ligation with FcyRllb. Consistent with the Western 
blot analysis, levels of PTEN protein phosphatase activity were similar in both 
resting and BCR stimulated cells (Figure 3.138). However, co-stimulation with
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FcyRllb resulted in enhanced levels of activity, which were maximal at ten 
minutes, suggesting that the PTEN protein identified in the Western blot 
analysis represents an inactive form of PTEN.
To determine whether the lipid phosphatase activity of PTEN was similarly 
activated following FcyRllb ligation, inositol 3’ phosphatase activity was 
assessed in anti-PTEN immune complexes. Figure 3.14 shows that at early 
time points, FcyRllb co-ligation results in similar levels of inositol phosphatase 
activity, compared with BCR ligation alone. However, enhanced levels of 
lns(1,4,5)P3 are produced at 30 minutes, following FcyRllb co-ligation. These 
results suggest that PTEN is activated in splenic B cells under conditions of 
negative regulation by FcyRllb. The kinetics of PTEN activation are slower than 
those demonstrated by SHIP and thus may act downstream of SHIP, to 
terminate ongoing BCR stimulation of the PI-3-kinase/Akt pathway. 
Furthermore, sustained PTEN activation may account for FcyRllb induction of 
an apoptotic response in splenic B cells by the negative regulation of Akt/PKB 
and the prevention of a cell survival signal. Indeed, the kinetics of PTEN activity 
are more consistent with the negative regulation of GSK-3 than those of SHIP 
activity.
Thus, to investigate whether PTEN activity was sustained in FcyRllb co­
stimulated B cells, inositol phosphatase activity was assessed in PTEN immune 
complexes over 24 hours. Figure 3.15A shows that PTEN inositol phosphatase 
activity is enhanced in BCR-FcyRllb co-stimulated B cells for up to four hours, 
compared to B cells stimulated via the BCR alone, and is maximal at 2 hours. 
The profile of activation correlated with the tyrosine phosphorylation and hence 
activation of PTEN, as indicated by Western blot analysis with 4G10 (Figure 
3.15B). However, tyrosine phosphorylation of PTEN was also observed 
following BCR stimulation from 8 hours and this was reflected in increased 
levels of PTEN activity after 24 hours. Thus, PTEN activation may also provide 
a regulatory mechanism for BCR proliferative signalling. Overall, these results 
support a potential role for PTEN in the sustained inhibition of the PI-3- 
kinase/Akt pathway by FcyRllb.
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3.3.12 FcyRllb induction of growth-arrest and apoptosis in splenic B cells 
is independent of JNK/p38 activation.
The results demonstrated in this study have supported a role for FcyRllb in the 
induction of B cell growth arrest and apoptosis via the inhibition of BCR- 
mediated proliferative signals, such as ErkMAPK. However, FcyRllb may also 
contribute to B cell apoptosis by promoting B cell neglect, via the prevention of 
BCR signalling, or by active apoptotic signalling mechanisms. Studies of BCR- 
mediated cell death in immature B cell lines Graves, et al., 1996 have 
implicated a role for the stress activated JNK and p38 MAPKinases in active 
apoptotic mechanisms. Indeed, studies have suggested that the balance of 
activities between ErkMAPKinase and the stress-activated MAPKinases may be 
an important factor in determining cell fate. Thus, whilst FcyRllb acts to 
down regulate the ErkMAPK proliferative pathway, upregulation and expression 
of the pro-apoptotic, stress-activated MAPKinases, JNK and p38 could also 
occur and result in the promotion of commitment of apoptosis.
Western blot analysis of dually phosphorylated activated and total JNK and p38 
MAPK in splenic B cell lysates and immune precipitates proved to be 
unsuccessful. The activation of JNK and p38 was thus examined indirectly by 
investigating the activation of the downstream targets of these kinases, c-Jun 
and ATF-2, respectively. Figure 3.18 demonstrates that basal levels of c-Jun 
activation are increased in cells stimulated via the BCR and/or FcyRllb. Indeed, 
phosphorylation of c-Jun is enhanced in B cells stimulated via the BCR for 10 
minutes, compared to the levels observed following co-ligation of the BCR and 
FcyRllb. Thus, JNK activation does not appear to be a pro-apoptotic mechanism 
induced exclusively by FcyRllb ligation. In contrast, as no p38/SAPK activation 
of ATF-2 could be detected in basal or BCR and/or FcyRllb stimulated splenic B 
cells, an active role for p38/SAPK in FcyRllb-mediated negative signalling can 
not as yet be ruled out. Additional studies were carried out to examine the 
activation of Rac and Cdc42, which have been proposed to be upstream 
activators of JNK. These results indicated that neither of these molecules were 
activated in either basal, BCR and/or FcyRllb stimulated splenic B cells (results 
not shown).
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3.3.13 FcyRllb modulates the expression of key cell-cycle 
regulator proteins
The tumour suppressor protein, retinoblastoma protein (Rb), controls 
progression through the late Gi restriction point of the cell cycle by binding to 
and sequestrating a family of transcription factors, called the E2-F family 
(section 1.2.4). When bound to E2-F, hypo-phosphorylated Rb represses 
transcription of E2-F response genes that are important for S-phase entry. 
Differential phosphorylation of Rb has been shown to modulate its function both 
in vitro and in vivo and in vitro hyper-phosphorylation and deactivation of Rb is 
mediated by Cdk4/6 and Cdk2-Cyciin complexes (Zarkowska and Mittnacht, 
1997). Importantly, both immature and mature B cells show BCR-induced 
increases in Cyclin D and Cdk4 levels, which are essential for early Gi phase 
progress and transition through the Gi restriction point. This may be due to 
ErkMAPK dependent activation of the Cyclin D gene via the transcription of 
MAPK responsive genes. However, in some systems high levels of Cdk activity 
have also been demonstrated to be sufficient for the induction of apoptosis 
(Harvey, 1998)
Since FcyRllb signalling has been demonstrated to inhibit B cell Gi-S 
progression following co-ligation with the BCR (reviewed by Anderson and 
Sinclair, 1998) the effect of FcyRllb recruitment on the expression of key cell- 
cycle regulator proteins was investigated. The relative expression levels of 
Cdk4 and Rb were investigated in whole cell lysates of BCR and BCR-FcyRllb 
stimulated splenic B cells. Figure 3.17A shows that BCR stimulation for 1 hour, 
results in a downregulation in Cdk4 expression levels followed by an increase 
over time. A similar pattern of Cdk4 suppression and upregulation is shown 
following FcyRllb co-ligation with the BCR. However, whilst longer BCR 
stimulation results in higher levels of Cdk4 expression, the levels induced are 
still below basal. The lack of significant modulation of Cdk4 levels following 
stimulation may be due to the short stimulation times chosen and an 
investigation of later times in the cell cycle may highlight differential expression 
or activation of Cdk4 by FcyRllb and the BCR. Indeed, recent studies in murine 
B cells over 48 hours, have shown that FcyRllb ligation does not inhibit the
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expression of Cdk4 but acts to block the assembly and stabilisation of Cyclin D- 
Cdk4/6 complexes (Tanguay et al., 1999).
Gi Cyclin dependent kinases (Gi-Cdks) have been implicated in the 
phosphorylation of Rb (Zarkowska and Mittnacht, 1997). Cyclin D-Cdk4/6 
complexes contribute only partially to the activation of Rb; Cyclin E-Cdk2 
complexes are also required. Whilst Cdk4 did not appear to be modulated 
following FcyRllb ligation, FcyRllb may act on the regulation of Rb via 
interaction with other cell-cycle regulatory proteins. Thus, to avoid such 
complications the phosphorylation status of Rb was investigated using a 
phospho-Rb specific antibody in cells stimulated for up to 72 hours. The 
existence of multiple forms of Rb observed during Western blotting is indicative 
of Rb phosphorylation; with hyper-phosphorylated Rb exhibiting a greater 
apparent molecular weight in comparison to hypo- or unphosphorylated Rb. 
Figure 3.17B shows that Rb is differentially phosphorylated in splenic B cells 
following BCR and/or FcyRllb stimulation. Correlating with entry into the S and 
G2/M phases of the cell cycle, BCR stimulation over 72 hours results in the 
hyper-phosphorylation of Rb, as indicated by the predominance of the higher 
molecular weight form. In contrast, co-ligation of FcyRllb results in a Rb 
phosphorylation profile similar to that of basal cells, with a large percentage of 
cells demonstrating hypo-phosphorylated Rb. Thus, FcyRllb actively inhibits 
entry in the proliferative phases of the cell cycle by preventing the hyper­
phosphorylation and deactivation of Rb.
Following mitogenic stimulation of cells, two events controlling the Gi/S 
transition are thought to occur, firstly Cyclin D levels are increased and 
secondly, the levels of p27, a Cyclin-dependent kinases inhibitor (CKI), are 
reduced (Sherr and Roberts, 1999). Together with another CKI, p21, p27 
inhibits Cyclin-E/Cdk2 complexes whilst acting as an assembly factor for Cyclin 
D and Cdk4/6 (Cheng, 1999). By binding to the Cyclin/Cdk complexes, these 
CKIs lead to the inhibition of Cdk activity and thus prevent the phosphorylation 
of Rb and cell cycle progression. Whilst p27 is constitutively expressed, p21 
levels are induced during periods of stress by p53.
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The tumour suppressor protein, p53, plays a major role in the cellular response 
to DNA damage and other genomic aberrations. Importantly, the activation of 
p53 by MAPK mediated phosphorylation on multiple residues, can either lead to 
cell cycle arrest and DNA repair or apoptosis (Meek, 1994; Levine, 1997). p53 
is normally held in an inactive complex with a negative regulator, MDM2. MDM2 
inhibits the accumulation of p53 by targeting it for ubiquination and proteasomal 
degradation (Chehab, 1999). DNA damage or apoptotic signals, induce the 
phosphorylation of p53 at residues serine 15 and serine 20. These 
phosphorylation events impair the MDM2-p53 interaction thus promoting both 
the accumulation and functional activation of p53.
To investigate whether p53 was functionally activated by FcyRllb ligation, whole 
cell lysates from BCR and/or FcyRllb co-stimulated splenic B cells were 
Western blotted for the expression of phospho-p53 Ser^ ®. Figure 3.170 clearly 
demonstrates that FcyRllb induces the phosphorylation of p53 on the critical 
serine residue over 72 hours, compared to control or BCR stimulated cells. 
Thus, the activation of p53 may represent an important pro-apoptotic 
mechanism initiated by FcyRllb following ligation on splenic B cells. Further 
attempts to investigate the role of these key cell-cycle regulator proteins in 
FcyRllb-mediated negative regulation, by intracellular staining, proved 
unsuccessful due to problems of cross-reactivity between the stimulating 
antibodies and primary fluorescence-conjugated FACS antibodies.
3.3.14 FcyRllb modulates the expression of nuclear transcriptional 
proteins
Nuclear factor kB (NF-kB) transcriptionally activates genes that promote 
immunity and cell survival (reviewed by Ghosh etal., 1998). Activation of NF-kB 
is induced by an IkB kinase (IKK) complex that phosphorylates and promotes 
dissociation of IkB from NF-kB, which then translocates to the nucleus. 
Conversely, NF-kB activation is inhibited by an iKBa complex. Interestingly, 
PTEN has been shown to inhibit cytokine induced NF-kB activation (Koul et al., 
2001). PTEN did not appear to interfere with the degradation of IkB or with the
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nuclear translocation of p65/Rel, normally obligatory for NF-kB activation. This 
suggests that additional PI-3-Kinase-mediated signals may be required for the 
ability of NF-kB to bind to DNA and to transactivate genes.
Given that BCR-FcyRllb co-ligation modulates PTEN activity it was decided to 
investigate whether FcyRllb-mediated B cell inhibition reflected modulation of 
NF-KB. The activation status of NF-kB was assessed following FcyRllb-ligation 
by electrophoretic mobility shift assay (EMSA). As shown in Figure 3.18, BCR 
stimulation of splenic B cells leads to an increase in nuclear NF-kB activity after 
4 hours which decreases by eight hours. Co-ligation of BCR and FcyRllb results 
in a marked increase in NF-kB activity over four hours that is rapidly 
downregulated. In contrast, under conditions of FcyRllb-mediated negative 
feedback inhibition of mitogenic BCR signalling, co-ligation of the BCR with 
FcyRllb results in minimal NF-kB activity. Importantly, the EMSA demonstrates 
the formation of distinct NF-kB/DNA complexes following BCR and/or FcyRllb 
ligation. Several groups have shown that the predominant form of NF-kB in B 
cells is the p50-c-Rel heterodimer (Buhl and Cambier, 1999); in particular c-Rel 
was shown to be essential for B cell proliferation after BCR engagement. 
Attempts to determine whether FcyRllb signalling modulates the relative 
expression levels of c-Rel and the p50 subunit in the nucleus of splenic B cells 
were hampered by poor protein recovery from stimulated cells.
E2-F responsive elements are present in the promoters of cell cycle-related 
genes (REF). Hypo-phosphorylated Rb protein binds to the E2-F gene product, 
inhibiting E2-F activity and inducing Gi growth arrest. Recent studies have also 
demonstrated that p53 is able to bind to E2-F and inhibit E2-F transcriptional 
activity, suggesting that transcription of the gene can also be independently 
repressed by p53 (Ookawa etal., 2001). Since FcyRllb ligation on splenic B 
cells is shown to modulate the phosphorylation profile of both Rb and p53 the 
binding activity of E2-F, following BCR and/or FcyRllb ligation, was assessed by 
EMSA. Unfortunately, conclusive results could not be obtained concerning the 
activation of E2-F following BCR or FcyRllb-ligation in splenic B cells (results
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not shown). However, since Rb phosphorylation is modulated by FcyRllb 
ligation, a role for E2-F in the inhibition of cell cycle progression by FcyRllb can 
not be excluded.
3.3.15 FcyRllb-mediated mechanisms of B cell inhibition result in a 
decrease in mitochondrial membrane potential.
Several studies have highlighted an important role for mitochondrial integrity in 
determining commitment to apoptosis (section 1.2.4). Association of apoptosis- 
regulatory proteins from the Bcl-2 and caspase families with the mitochondria 
largely determine the fate of the cell. Thus, in many cases of apoptotic cell 
death, the decision Is dependent upon mitochondrial events. Depolarisation of 
the mitochondrial membrane potential is one of the main internal mitochondrial 
changes that can occur during the early initiation stages of apoptosis. A 
decrease in mitochondrial membrane potential can be assayed for by the 
incorporation of the lipophilic dye DiOC6(3) (ZamZami et al., 1995). DiOCe(3) 
possesses a net negative charge, permitting its accumulation in the 
mitochondrial matrix along an electrochemical gradient. Cells with a high 
mitochondrial membrane potential retain the dye and possess high fluorescence 
intensity, as assessed by FACS analysis. The initiation of apoptotic 
mechanisms may lead to a loss of mitochondrial membrane potential and result 
in the subsequent loss of dye retention by the mitochondria. Thus, cells 
possessing a low DiOCe(3) fluorescence intensity are considered to be 
committed to apoptosis.
To determine whether mitochondrial membrane potential was perturbed 
following FcyRllb ligation, primary B cells stimulated via the BCR and/or FcyRllb 
were assessed for loss of DiOCe(3) fluorescence over 72 hours. In agreement 
with the analysis of DNA content, stimulation via co-ligation of the BCR and 
FcyRllb either on resting cells or cells mitogenically stimulated via the BCR, 
resulted in an increased percentage of B cells with a low DiOCe(3) fluorescence 
intensity (Figure 3.19). interestingly, co-ligation of FcyRllb in cells mitogenically 
stimulated via the BCR, conditions that have previously been reported to 
promote survival despite growth-arrest, demonstrated enhanced depolarisation
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of the mitochondrial membrane potential. These results therefore confirm that 
FcyRllb ligation on B cells can initiate mechanisms that lead to the disruption of 
mitochondrial stability.
3.3.16 Effects of BCR and FcyRilb co-ligation on the mRNA expression 
levels of FcTRIIbl and Fc7RIIb2 in splenic B cells.
FcyRllb is expressed on B cells as two differentially spliced isoforms, FcyRllbl 
and FcyRllb2. These isoforms appear to be identical except for an amino acid 
insert in the cytoplasmic domain of FcyRllbl, which abolishes the endocytic 
capacity of the receptor. Thus, FcyRllb2 could be the isoform predominantly 
utilised by B cells for antigen uptake and processing whilst modulation of 
FcyRllbl expression may dictate the threshold for BCR signalling, indeed, B cell 
expression levels of the two isoforms are thought to be modulated in response 
to activation by crosslinking of the BCR or culture with cytokines (Gergely, et al., 
1994). Therefore, it may be possible that differences in the relative expression 
levels of the two isoforms of FcyRllb, may influence T cell-mediated help and 
thus the regulation of B cell activation by immune-complexes.
Various attempts to determine the relative FcyRllb expression levels on splenic 
B cells by FACS analysis or immunoprécipitation with the pan-FcyRII 
monoclonal antibody, 2.4G2, proved unsuccessful. Due to the identical nature 
of the extracellular domains, antibodies raised against these FcyRllb structures 
are unable to discriminate between the two isoforms. Thus, to identify the two 
FcyRllb isoforms and quantify the relative expression levels, RT-PCR was 
performed to identify the isoforms at the level of mRNA message. Total RNA 
was extracted from BCR and/or FcyRllb stimulated splenic B cells, reversed 
transcribed and the relative expression levels of the isoform transcripts were 
determined by quantitative TaqMan analysis.
Figure 3.20 demonstrates that the levels of FcyRllbl mRNA detected were 
higher than that of FcyRllb2, throughout the period of stimulation and 
independent of the stimulus. Stimulation of the BCR alone resulted in an
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Increase in the levels of both FcyRllbl and FcyRllb2 mRNA. Similarly, co­
ligation of BCR and FcyRllb on resting cells increased the message levels of 
both isoforms. However, co-ligation of the receptors, under conditions of 
mitogenic BCR signalling, results in minimal enhancement above basal levels 
and predominantly a downregulation in expression over 30 minutes. By 
maintaining expression of both isoforms, a B cell can remain responsive to 
mitogenic stimulation by antigen and co-stimulatory T cell help, whilst still being 
able to undergo negative regulation following further interactions with immune 
complexes. In contrast a selective downregulation in FcyRllb2 expression on 
normal B cells following co-ligation of the receptors, under conditions of 
mitogenic BCR signalling, may result in the abrogation of antigen uptake, 
processing and presentation. A downregulation in antigen presentation will 
prevent T cell mediated help and promote B cell anergy and survival or 
commitment to apoptosis.
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3.4 Discussion
Signalling via the FcyRllb receptor subsequently decreases B cell 
responsiveness and provides a potent mechanism for the downregulation of 
humoral immunity. Indeed, it is thought that deregulation of FcyRllb receptor 
signalling may contribute to the pathology of certain autoimmune diseases (see 
Chapter 4; Nakamura, A. et al., 2000; Dijstelbloem eta}., 2001; Ravetch and 
Bolland, 2001). Unfortunately our understanding of the mechanisms underlying 
such Fcyllb-mediated suppression of BCR signalling are not well defined. 
Experimental models have developed, however, which potentially allow 
disection of the key regulatory events. For example, stimulation of the BCR with 
F(ab’)2 fragments of anti-lg antibodies results in B cell activation and 
proliferative responses. In contrast, by using intact anti-lg antibodies to mimic 
physiological cognate antibody-antigen complexes, it is possible to co-ligate the 
BCR with FcyRllb, conditions which do not induce DNA synthesis in murine B 
cells, Moreover, co-ligation of the BCR and FcyRllb inhibits the response to 
mitogenic F(ab’)2  antibodies. Indeed, by stimulating murine B cells with a 
combination of F(ab’) 2  fragments and intact antibody, the intact antibodies 
produce a dominant negative signal. Thus, using these different methods of 
antibody stimulation, we have investigated the functional uncoupling of the 
BCR by FcyRllb in primary, mature B cells.
As stated above, our understanding of the mechanisms underlying such Fcyllb- 
mediated suppression of BCR signalling are not well defined. However, it is well 
established that following FcyRllb co-ligation with the BCR the SH2-domain 
containing inositol 5’-phosphatase, SHIP is recruited to the phosphorylated ITIM 
of FcyRllb . SHIP is thought to act in part by preventing the activation of Btk and 
PLC-y by Ptdlns(3,4,5)Ps, resulting in the inhibition of sustained influx of 
extracellular calcium required for growth.
In addition, SHIP is proposed to prevent the induction of the BCR-coupled 
Ras/MAPKinase cascade via interactions with the adaptor molecule She and 
the RasGAP binding protein, p62Dok (Tamir et a!., 2000a). In addition to the
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involvement of SHIP, we now demonstrate that FcyRllb uncouples the BCR 
from the Ras/MAPKinase pathway through the inhibition of MEK and the rapid 
recruitment and activation of the dual-specific nuclear MAPK phosphatase, Pac- 
1 (Figure 3.21).
Furthermore, it was thought that SHIP activity may contribute to the FcyRIlb- 
mediated induction of apoptosis by inhibiting the BCR-coupled 
activation/recruitment of the survival factor Akt/PKB. However, we now 
demonstrate the activation of a second inositol phosphatase, PTEN, which is 
known to negatively regulate Akt/PKB. PTEN activation following BCR-FcyRllb 
co-ligation in B cells could potentially contribute to the inactivation of the PI-3- 
K/Akt pathway by FcyRllb (Figure 3.22) suggesting that, like SHIP, PTEN may 
act in vivo as a negative regulator of B cell survival and proliferation. Thus, this 
study effectively demonstrates that FcyRllb co-ligation acts to switch off both 
BCR-mediated proliferative and survival pathways resulting in the induction of B 
cell growth-arrest and/or commitment to apoptosis.
Recent studies have demonstrated that aggregation of FcyRllb alone, via non­
cognate antigen-antibody complexes, generates a pro-apoptotic signal that is 
mediated via Btk (Bolland and Ravetch, 1998). Rather surprisingly, this pro- 
apoptotic signal is blocked by the recruitment of SHIP to FcyRllb following BCR 
co-ligation. This novel FcyRllb-mediated mechanism has been proposed to act 
as a means of maintaining B cell peripheral tolerance in the germinal centre, by 
promoting apoptosis of B cells with low-affinity, potentially cross-reactive 
antigen-receptors. Antigen (in the form of immune complexes) that interacts 
with FcyRllb alone will result in commitment to apoptosis whilst BCR-FcyRllb 
co-ligation promotes survival yet growth-arrest. Interestingly, we demonstrate 
that BCR-FcyRllb co-ligation is also capable of inducing apoptosis in B cells. 
Thus, inactivation of B cells may represent the integration of signals generated 
by the interaction of immunocomplexes with the BCR and FcyRllb through 
pathways modulated by SHIP.
144
Chapter 3 -  Molecular mechanisms of FcyRllb signalling
The binding of antigen-antibody complexes by FcyRllb may also result in a 
feedback mechanism that regulates the production of the inhibitory receptor. An 
investigation of the relative mRNA expression levels of FcyRllbl and FcyRllb2 
following BCR stimulation demonstrated increased message levels of both 
isoforms consistent with the idea that activation primes the cell for cognate 
negative feedback regulation. However, FcyRllb co-ligation, resulting in 
negative feedback regulation of ongoing B cell responses, resulted in an overall 
downregulation of isoform expression. Importantly, this downregulation of 
FcyRllb production could result in the abrogation of antigen uptake, processing 
and presentation to helper T cells. Moreover, a downregulation in antigen 
presentation will prevent T cell mediated help which can overcome negative 
feedback inhibition and promote B cell anergy and survival or commitment to 
apoptosis.
We have confirmed that FcyRllb ligation modulates the recruitment and 
activation of three SH2-domain containing phosphatases, SHIP, SHP-1 and 
SHP-2, in vitro. Unlike SHP-1 and SHP-2, SHIP was previously thought to be 
phosphorylated and activated exclusively under negative signalling conditions. 
However, in agreement with recent studies by Ingham et ai., 1999 we now show 
that phosphotyrosine-dependent Shc-SHIP complexes are also detectable in 
BCR stimulated cells, questioning the role of SHIP-Shc complexes in regulating 
BCR-coupling to MAPK. For example, SHIP has been proposed to sequester 
She (Damen et ai., 1996; Tridandapani et ai., 1999) and hence result in an 
ability to inhibit MAPKinase activation. However, She has been shown to be 
dispensable for BCR coupling to the RasMAPK pathway in chicken DT40 B 
cells (Hashimoto et ai., 1998), although many other groups have demonstrated 
an essential role for She in coupling the BCR to ErkMAPK in mammalian B cells 
(Campbell, 1999; Kelly and Chan, 2000). In addition, further doubt about the 
role of SHIP-Shc complexes is provided by studies revealing the existence of 
Shc-independent pathways for Grb2-S0S recruitment by the BCR, involving 
BLNK (reviewed by Kelly and Chan, 2000). This has lead to the proposal that 
She may regulate the level of activation of Ras via Grb2-S0S complexes. 
Interestingly, Tridandapani et ai. 1999 have discovered that two separate pools
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of SHIP may exist: one bound to FcyRllb and one bound to She. Kinetic studies 
revealed a rapid association of SHIP with FcyRllb following ligation but a slower 
and more transient association with She. Subcellular localisation of these 
signaling molecules is regulated by the phosphotyrosine-SH2 domain 
interactions, thus dephosphorylation may result in the re-direction of She and 
SHIP within the cell, and consequently, in the modulation of their activity.
In addition to the p52/46 She isoforms recruited by SHIP, recent studies have 
identified a third She isoform, p66Shc, which may play a role in promoting 
apoptosis. Homozygous mutation of p66Shc in mice was shown both to prolong 
the life span and to prevent oxidative-stress induced apoptosis (Migliaccio et al.,
1996). Despite its tyrosine phosphorylation by active RTKs, p66Shc is not 
involved in Ras activation (Migliaccio et al., 1996). The ability of SHIP to recruit 
p66Shc is unknown but an association may implicate a novel mechanism by 
which SHIP might be linked mechanistically to growth arrest and apoptosis.
The formation of SHIP complexes with the protein phosphatases SHP-1 and 
SHP-2 indicates a further role for SHIP in assembling regulatory complexes. 
Indeed, recent studies have identified a Grb2-associated binder 1 docking 
protein (Gabi) which binds to the SH2 domains of SHP-2, SHIP and the p85 
subunit of PI-3-Kinase and may regulate their activity (Koncz et a!., 2001). For 
example activation of SHP-2, following binding to the FcyRllb-SHIP complex, 
results in partial dephosphorylation of Gabi, resulting in the release of 
Ptdlns(3,4,5)P3 and the inhibition of downstream activation pathways from the 
BCR.
Although following ligation of FcyRllb, She and SHP-1 containing SHIP 
complexes were formed, we found no evidence to support the disruption of 
Ras/MAPKinase signalling by SHP-1 via the recruitment of She. However, SHP- 
1 was shown to be activated following FcyRllb co-ligation and appeared to be 
modulated by association with the PTK, Lyn. Thus, SHIP and SHP-1 do not 
appear to have redundant functions in negative signalling with each targeting 
distinct signalling intermediates and pathways. So far, and in line with previous
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studies these results support a more dominant and central role for SHIP in 
FcyRllb-mediated inhibitory signalling than SHP-1. Investigation into the 
expression and activation of the newly identified isoforms of SHIP, which may 
reside in separate activation 'pools' may help to confirm the primary importance 
of this activity in FcyRllb signalling. Studies by March et al., 2000 have already 
demonstrated that a second isoform, SHIP-2 can substitute for SHIP in FcyRllb- 
mediated inhibitory signalling in B cells. However, Brauweiler et ai, 2000a and 
2000b have shown that the different SHIP isoforms mediate distinct molecular 
mechanisms depending on the activation status of the B cells. They revealed 
that whilst resting cells express only SHIP, LPS stimulated B cell blasts also 
express SHIP-2. Moreover, that both isoforms can mediate downstream 
biological consequences of FcyRllb signalling, including inhibition of the 
proliferative response. Thus, recruitment of a second isoform of SHIP by 
activated cells represents a novel mechanism by which FcyRllb can inhibit 
BCR-mediated proliferative responses. It would therefore be interesting to 
investigate whether this isoform is preferentially recruited following co-ligation of 
the BCR and FcyRllb in our experimental model for negative feedback inhibition 
of ongoing B cell responses
The demonstration that sustained FcyRllb inhibition of ErkMAPK 
phosphorylation is independent of Ras implies that much of the early ErkMAPK 
phosphorylation by the BCR in mature B cells may occur via cross-talk from 
other signalling pathways, such as PKC activation of Raf-1. Nevertheless, the 
modulation of ErkMAPK by Pac-1 represents an important direct signal induced 
by FcyRllb to terminate ongoing ErkMAPK activity. Since, Pac-1 is thought to be 
a nuclear phosphatase we were initially surprised at its rapid association with 
ErkMAPK following FcyRllb co-ligation. This apparent upregulation of Pac-1 
expression and activity following FcyRllb co-ligation was initially thought to 
represent an initial priming event further upstream, whereupon Pac-1 rapidly 
associates with ErkMAPK in the cytosol following an accumulation of 
cytoskeletal or nuclear Pac-1 that is lost in the preparation of whole cell lysates. 
However, analysis of sub-cellular fractions demonstrated this not to be the case 
and hence, its expression may represent pre-existing mRNA that is rapidly
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translated following FcyRllb co-ligation and investigations of Pac-1 mRNA 
expression levels using TaqMan quantitative RT-PCR analysis may confirm this 
theory. However, it may also reflect a simple enhancement of association above 
the levels of detection permitted by the commercially available antibodies. The 
finding that Pac-1 did not associate with ErkMAPK under conditions of BCR- 
mediated signalling may be consistent with this latter proposal as Pac-1 has 
been demonstrated to be rapidly upregulated in lymphocytes to regulate 
mitogen-driven MAPKinase signalling. Thus, lack of detection may simply reflect 
low levels of detection or alternatively that another phosphatase is preferentially 
recruited to terminate ErkMAPK signals following BCR-stimulation. We are 
currently investigating cellular fractions to identify where Pac-1 is located upon 
association with ErkMAPK, following FcyRllb ligation. Thus, co-ligation of 
FcyRllb under conditions of negative feedback inhibition of ongoing B cell 
responses may act to inhibit early BCR-mediated activation of ErkMAPK 
through the recruitment of SHIP whilst Pac-1 is activated to terminate any 
residual ongoing responses (Figure 3.21).
Whilst co-ligation of FcyRllb acts to down regulate BCR-mediated proliferative 
pathways, recent studies have confirmed the ability of FcyRllb to signal 
independently of BCR co-ligation and directly mediate an apoptotic response 
(Pearse et al., 1999). An investigation of the DNA content of B cells following 
FcyRllb ligation confirmed this observation over 72 hours. FcyRllb induction of 
apoptotic mechanisms has been proposed to be due to a failure to recruit SHIP, 
as demonstrated by a deletion of SHIP or mutation of FcyRllb (Pearse et al., 
1999). A lack of SHIP recruitment prevents the membrane association of Btk, 
resulting in an inhibition of calcium influx (Bolland et al., 1998). This novel 
FcyRllb-mediated mechanism has been proposed to act as a means of 
maintaining B cell peripheral tolerance in the germinal centre, by promoting 
apoptosis of B cells with low-affinity, potentially cross-reactive antigen- 
receptors. Antigen that interacts with FcyRllb alone will result in B cell apoptosis 
whilst antigen co-engagement of FcyRllb with the BCR will promote survival. 
Interestingly, SHP-1-mediated inhibitory signalling blocks this apoptotic 
mechanism, whilst SHIP recruitment attenuates it (Ono et al., 1997). These
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studies highlight the differential roles for SHIP in mediating FcyRllb induced B 
cell inhibition while implicating novel mechanisms for the newly identified SHIP 
isoforms.
Most recently, it has been shown that BCR ligation and CD19 activation induces 
activation of the pro-survival factor Akt and promotes B cells survival (Pogue et 
al., 2000; Otero eta!., 2001). Co-ligation of the BCR with FcyRllb has been 
proposed to result in the termination of this signal (Aman et al., 1998; Carver et 
al., 2000). Due to the requirement of SHIP, termination of Akt activity is more 
consistent with FcyRllb-mediated growth-arrest than apoptosis. However, these 
results are inconsistent with recent studies that demonstrate that the product of 
SHIP activity, Ptdlns(3,4)P2, may also be involved in the positive regulation of 
Akt (Downward, 1998). Thus, the inhibition of Akt demonstrated may not reflect 
SHIP activity but rather be due to upstream deregulation by an alternative 
inositol phosphatase. We now show that FcyRllb inhibition of BCR-activated Akt 
might be due to the recruitment of the inositol 3’-phosphatase, PTEN. Through 
the conversion of Ptdlns(3,4,5)p3 to Ptdlns(4,5)P2, PTEN could impair BCR 
mediated activation of Akt by counteracting the activities of PI-3-Kinase (Figure 
3.22). Interestingly, PTEN activity has been shown in T cells to induce an 
increased rate of apoptosis, whilst inhibiting basal and TCR-induced ErkMAPK 
phosphorylation (Wang et al., 2000). This could be explained following evidence 
indicating that Pl-3-Kinase signalling can upregulate the ErkMAPKinase 
pathway at the level of Raf-1. Thus, inhibition of PI-3-K activity by PTEN could 
lead to the suppression of ErkMAPK activation and cell proliferation. This 
mechanism may also explain the observation that PTEN appears to 
differentially suppress cell growth in different tumours. PTEN lipid phosphatase 
activity promotes Gi cell cycle arrest in glioblastoma cells (Furnari et al., 1998) 
but induces commitment to apoptosis in carcinomas (Myers et al., 1998). The 
kinetics of PTEN activation by FcyRllb are slower than that demonstrated by 
SHIP. Thus, PTEN may act sequentially to terminate any ongoing PI-3-Kinase 
activity following the downregulation of transient SHIP activity.
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interestingly, PTEN has also been demonstrated to inhibit TNF-mediated 
activation of NF-kB by preventing the activation of Akt and the IKK complex 
(Gustin et al., 2001). BCR-mediated activation of the transcription factor, NF-kB, 
has been shown to be important for B cell activation and development by 
promoting the expression of survival genes and regulating the expression of 
several anti-apoptotic molecules (Ghosh et al., 1998). Indeed, inhibition of NF- 
KB activity with protease inhibitors, which prevents BCR mediated Ik B 
degradation, has been shown to induce apoptosis in a number of B cell lines 
(Baichwal and Baeuerle, 1997). Indeed, FcyRllb co-ligation with the BCR 
resulted in the formation of differential NF-KB/protein complexes that were 
rapidly downregulated. Thus, FcyRllb ligation may alter the ability of NF- 
KB/protein complexes to bind to DNA and therefore modulate the expression of 
survival genes. One candidate NF-kB protein is c-Rel, which is vital for 
maintaining c-myc levels and preventing cell death (Baichwal and Baeuerle,
1997). Further investigation of the NF-KB/protein complexes using band-shift 
assays will help characterise the proteins involved and possibly determine 
whether FcyRllb-mediated abrogation of NF-k B activation is mediated via 
PTEN.
Recent studies in bone marrow derived mast cells (BMMCs) have shown that 
crosslinking of FcyRllb with the stem cell factor receptor (SCFR), Kit induces 
cell cycle arrest and SHIP-1 dependent inhibition of p38 and JNK (Malbec et al., 
2001). The demonstrated inhibition of the stress activated MAPKinases is likely 
to be due to the recruitment of SHIP-1 as the subsequent degradation of 
Ptdlns(3,4,5)P3 is thought to prevent the membrane recruitment of the 
exchange factor Vav and thus inhibit downstream SAPK activation. However, in 
the absence of SHIP recruitment, FcyRllb ligation mediates apoptosis via Btk- 
dependent activation of JNK (Kawakami et al., 1997; Bolland et al., 1998). In 
contrast, our studies revealed that FcyRllb induction of splenic B cell inhibition 
appears to be independent of JNK and p38. The differential triggering of JNK by 
FcyRllb may represent differences in the experimental systems utilised and
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warrants further investigation. A role for p38 in FcyRl lb-mediated B cell 
inhibition has yet to be determined.
Malbec et a/., 2001 and others have shown that FcyRllb-mediated growth-arrest 
leads to the modulation of cell-cycle regulatory proteins. In BMMCs, FcyRllb- 
mediated inhibition of Kit-dependent cell proliferation abrogated activation of 
Cyclins D2, D3 and A, thus preventing the BMMCs from entering the cell cycle 
(Malbec et al., 2001). In contrast, studies in mature B cells have shown that 
BCR-FcyRllb co-ligation does not affect BCR-induced Cyclin D expression 
(Tanguay et al., 1999). Since Cyclin D-Cdk4/6 complexes are essential for the 
Gi-S transition, we postulated that FcyRllb might abrogate Cdk4 expression and 
in this way achieve its inhibitory effects on cell progression. However, Cdk4 
expression was shown not to be modulated following FcyRllb stimulation. Thus, 
FcyRllb appears to mediate its effects on the cell cycle independently of Cdk4 
expression.
Both Cyclin D-Cdk4/6 complexes and Cyclin E-Cdk2 complexes contribute to 
the phosphorylation of Rb following BCR stimulation (Cheng et al., 1999). Thus 
to determine whether FcyRllb inhibited cell cycle progression at the level of Rb, 
the phosphorylation status of Rb was investigated following FcyRllb ligation. 
Indeed, FcyRllb ligation was shown to result in a Rb phosphorylation profile 
similar to that of quiescent cells. B cells stimulated to progress to S phase 
following signalling via the BCR exhibited an increase in Rb phosphorylation, 
whereas signals derived from FcyRllb partially suppressed BCR-induced Rb 
phosphorylation (Figure 3.23). Further investigations of whether modulation of 
Rb phosphorylation by FcyRllb impacts on downstream interactions with E2-F, 
will help elucidate the mechanisms by which FcyRllb induces cell-cycle arrest in 
B cells.
Interactions between the tumour suppressor protein, p53 and phospho-Rb have 
been suggested due to the ability of forced phospho-Rb expression to relieve 
MDM2-mediated repression and restore DNA binding of the transcription factor
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Sp-1 (Johnson-Pais et al., 2001). These results suggest a model in which the 
opposing activities of MDiVI2 and phospho-Rb regulate Spl DNA-binding and 
transcriptional activity. p53 plays a central role in cellular responses to stress 
and damage by inducing cell cycle arrest and DNA repair or apoptosis (Meek, 
1994; Levine et al., 1997). The mechanisms involved in the activation of p53 
responsive genes are still elusive but phosphorylation of Ser^^ on p53 is 
considered to be the minimal requirement for its transactivation as it impairs the 
ability of MDM2 to bind p53, promoting both the accumulation and functional 
activation of p53 (Meek, 1994). In this study, we show that co-ligation of BCR 
and FcyRllb, results in the rapid phosphorylation of p53 on Ser^ .^ Thus, FcyRllb- 
mediated B cell inhibition may promote conditions of growth arrest by 
modulating the phosphorylation and hence transactivation of p53. A reduction in 
the phosphorylation levels of Ser^ ®, observed from 24 hours, could be due to the 
partial reassociation of MDM2. However, attempts to demonstrate the 
reassociation of MDM2 with p53, following long term FcyRllb co-ligation, proved 
unsuccessful. Interestingly, the Cdk inhibitor, p19Arf, blocks the nucleo- 
cytoplasmic shuttling of MDM2, which normally degrades p53 (Tao and Levine, 
1999). Thus, inactivation of p19Arf would subsequently lead to reassociation of 
MDM2 with p53 and result in p53 inactivation. It would therefore be interesting 
to investigate whether the reduction in Ser^^phosphorylation levels was due to 
the inactivation of p19Arf following long term FcyRllb co-ligation or the 
downregulation of the ATM/ATR kinases which promote phosphorylation of p53 
on serine 15.
The loss of mitochondrial function and integrity is proposed to be an initial 
indication of commitment to apoptosis. Mitochondrial function may also be 
modulated by p53, which induces the expression of both Bcl-2 and Bax, leading 
to a rise in oxidative species and degradation of mitochondrial components 
(Miyashita, et al., 1994). By controlling levels of pro- and anti-apoptotic 
members of the Bcl-2 family, p53 may exert another level of control in 
determining cell fate. A role for mitochondria in FcyRllb-mediated B cell 
apoptosis has not previously been described. Therefore, the mitochondrial 
membrane potential of splenic B cells following FcyRllb ligation was
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investigated. Indeed, FcyRllb ligation was shown to induce a decrease in 
mitochondrial membrane potential, consistent with the commitment to 
apoptosis.
Overall, these results suggest that FcyRllb is capable of inducing a rapid and 
effective inhibition of BCR coupled signalling pathways, in particular the 
Ras/MAPKinase and PI-3-Kinase/Akt pathways. FcyRllb rapidly terminates 
early BCR-coupled signals whilst recruiting further downstream inhibitory 
mediators, such as PTEN and Pac-1, to terminate any residual BCR-induced 
activity. Synergistically these events result in the modulation of BCR-activated 
cell cycle machinery and nuclear signalling components resulting in B cell 
anergy, growth arrest and/or apoptosis.
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Figure 3.1 FcyRllb co-ligation inhibits BCR-mediated B cell proliferation, 
which can be restored in the presence of a blocking antl-FcyRII/lll 
antibody.
Purified splenic B cells from Balb/c mice (2 x 10® cells/well) were stimulated for 
48 hours in the presence of the indicated antibodies. Control cells were cultured 
in the presence of medium alone. Culture wells were pulsed with [®H]-Thymidine 
(0.5 jiCi/well) 4 hours prior to harvesting and [®H]-incorporation was assessed 
by scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from a single experiment, representative of at least two other 
independent experiments.
(A) Cells stimulated with increasing concentrations of P(ab’)2  fragments of goat 
anti-mouse IgM (p-chain specific).
(B) Cells stimulated with increasing concentrations of intact rabbit anti-mouse 
IgG/lgM.
(C) Cells stimulated with increasing concentrations of P(ab’)2  fragments of goat 
anti-mouse IgM (ja-chain specific) in combination with increasing concentrations 
of intact rabbit anti-mouse IgG/lgM.
(D) Cells stimulated with 50 {ig/ml P(ab’)2  fragments of goat anti-mouse IgG/lgM 
or 75 pg/ml intact rabbit anti-mouse IgG/lgM or 50 pg/ml anti-FcyRII/lll (2.4G2) 
antibody either alone, or in combination, as indicated.
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Figure 3.2 Effect of FcyRllb and BCR co-ligation on the BCR-mediated 
proliferative response of resting and activated splenic B ceiis.
Activated (A) and resting (B) purified splenic B cells from Balb/c mice were 
isolated by Percoll density centrifugation and stimulated (2x10^ cells/well) for 
48 hours in the presence of 50 pg/ml F(ab’)2  fragments of goat anti-mouse 
IgG/lgM or 75 pg/ml intact rabbit anti-mouse IgG/lgM either alone, or in 
combination, as indicated. Control cells were cultured in the presence of 
medium alone. Culture wells were pulsed with [^H]-Thymidine (0.5 pC i/we 11) 4 
hours prior to harvesting and [^H]-incorporation was assessed by scintillation 
counting. Data are the mean ± standard deviation of triplicate measurements, 
from a single experiment, representative of at least two other independent 
experiments.
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Figure 3.3 Effects of BCR and FcyRllb co-ligation on the DNA content of 
splenic B cells from Balb/c mice.
Purified splenic B cells from Balb/c mice (1 x 10® cells) were subjected to DNA 
content analysis post-sacrifice or were stimulated in the presence of 50 pg/ml 
F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml Intact 
rabbit anti-mouse IgG/lgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. DNA content was determined by propidium iodide (PI) staining and 
FACS analysis, as described in the Materials and Methods. Data represents 
each cell cycle stage expressed as a percentage of the total cells analysed from 
a single experiment, representative of at least two other independent 
experiments.
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Figure 3.4 Effect of BCR and FcyRllb co-ligation on tyrosine 
phosphorylation of splenic B cell proteins.
Purified splenic B cells from Balb/c mice (1 x 10  ^cells) were stimulated in the 
presence of 50 pg/ml F(ab’)2  fragments of goat anti-mouse IgG/lgM or 75 pg/ml 
intact rabbit anti-mouse IgG/lgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. Data are from a single experiment, representative of at least two other 
independent experiments.
(A) Tyrosine phosphorylation was assessed by Western blot analysis of whole 
cell lysates (50 pg/lane) with the anti-phosphotyrosine monoclonal antibody, 
4G10.
(B) Tyrosine phosphorylation in anti-SHIP, SHP-1 and SHP-2 immune 
complexes was assessed by Western blot analysis with the anti- 
phosphotyrosine monoclonal antibody, 4G10. To confirm equal loading of 
samples, blots were stripped and reprobed with the immune precipitating 
antibody.
157
F(ab'). Intact
F(ab’)2 + 
Intact
c8 1 5 30 1 5 30 1 5 30 Time (mins)
kDa
208
127
85
— p150
45 _
K — p70— p65
B F(ab’), Intact
F(ab'); + 
Intact
^ 1 5 30 1 5 30 1 5 30 Time (mins)
anti-SHIP
anti-SHP-1
anti-SHP-2
41
# # # »
1
__ 1
a. 4
11
------ 1
—  SHIP
—  pTyr
—  SHP-1
pTyr
Chapter 3 -  Molecular mechanisms of FcyRllb signalling
Figure 3.5 Effect of BCR and FcyRllb co-ligation on the 5 -inositol 
phosphatase activity of SHIP.
Purified splenic B cells from Balb/c mice (1.5 x 10  ^cells) were stimulated in the 
presence of 50 p.g/ml F(ab')z fragments of goat anti-mouse IgG/lgM or 75 pg/ml 
intact rabbit anti-mouse IgG/lgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
Inositol phosphatase activity in anti-SHIP immune precipitates was assessed by 
the hydrolysis of [®H]-lnsP4 and the subsequent production of [®H]-lnsP3 , as 
described in Materials and Methods. Data are the mean ± standard deviation of 
triplicate measurements from a single experiment, representative of at least 
three other independent experiments.
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Figure 3.6 Effect of BCR and FcyRllb co-ligation on the formation of SHIP- 
complexes.
Purified splenic B cells from Balb/c mice (1.5 x 10  ^cells) were stimulated in the 
presence of 50 j,ig/ml F(ab’)2  fragments of goat anti-mouse IgG/lgM or 75 pg/ml 
intact rabbit anti-mouse IgG/lgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. Anti-SHIP immune precipitates were subjected to Western blot analysis 
with anti-Shc, anti-SHP-1, anti-SHP-2, anti-Grb2 and anti-SHIP antibodies as 
indicated. Data are from a single experiment, representative of at least one 
other independent experiment.
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Figure 3.7 Effect of BCR and Fc^llb co-ligation on She associated SHP-1 
phosphatase activity.
Purified splenic B cells from Balb/c mice (1 x 10  ^ cells) were stimulated in the 
presence of 50 pg/ml F(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
(A) Anti-SHP-1 immune precipitates were subjected to Western blot analysis 
with anti-Shc antibody (upper panel), stripped and reprobed with anti-SHP-1 
antibody (lower panel).
(B) Anti-Shc immune precipitates were assayed for associated SHP-1 
phosphatase activity by the hydrolysis of a SHP-1 specific phosphopeptide, as 
detailed in Materials and Methods. Data are expressed from a single 
experiment, representative of at least two other independent experiments
160
F(ab’)2 Intact
F(ab')z +
Intacti ; 5 30 1 5 30 1 5 30 c8(D>+ Time (mins)
—  SHC
—  SHP-1
B 0.9
co
t )I?
-  ^  CO Q-sz ^CL(/)O
0.6 -
0.3
0
T
0
Time (mins)
□  Control
□  F(ab’)2
■  Intact
g  F(ab’)2 + 
Intact
Chapter 3 -  Molecular mechanisms of FcyRllb signalling
Figure 3.8 Effect of BCR and FcTRlIb co-ligation on Lyn associated SHP-1 
phosphatase activity.
Purified splenic B cells from Balb/c mice (1x10^ cells) were stimulated in the 
presence of 50 pg/ml F(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 [ig/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
(A) Anti-SHP-1 immune precipitates were assayed for associated SHP-1 
phosphatase activity by the hydrolysis of a SHP-1 specific phosphopeptide, as 
detailed in Materials and Methods. Data are expressed as the mean ± standard 
deviation from triplicate measurements of a single experiment and 
representative of at least one other independent experiment. *p<0.05, paired 
Student T-test.
(B) Anti-Lyn immune precipitates were assayed for associated SHP-1 
phosphatase activity by the hydrolysis of a SHP-1 specific phosphopeptide, as 
detailed in Materials and Methods. Data are expressed as the mean ± standard 
deviation from triplicate measurements of a single experiment and 
representative of at least one other independent experiment. *p<0.05, paired 
Student T-test.
(C) Anti-SHP-1 immune precipitates were subjected to Western blot analysis 
with anti-Lyn antibody (upper panel), stripped and reprobed with anti-SHP-1 
antibody (lower pane!).The numbers beneath the blots represent the relative 
band densities of Lyn as assessed by densitometry, adjusted with respect to 
SHP-1 loading and compared to the band densities obtained for the basal 
control and arbitrarily set as 1.
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Figure 3.9 Effect of BCR and FcyRllb co-ligation on the phosphorylation of 
ErkMAPK.
Purified splenic B cells from Balb/c mice (1 x 10  ^ cells) were stimulated in the 
presence of 50 |xg/ml F(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. Whole cell lysates were subjected to Western blot analysis with 
phospho-specific ErkMAPK antibody (upper panel), stripped and reprobed with 
total ErkMAPK antibody (lower panel).
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Figure 3.10 Effect of BCR and FcyRllb co-ligation on Ras and MEK 
activation.
Purified splenic B cells from Balb/c mice (3x10^ cells) were stimulated in the 
presence of 50 |Lig/ml P(ab’)2  fragments of goat anti-mouse IgG/IgM either 
alone, or in combination, with 75 pg/ml rabbit anti-mouse IgG/IgM intact 
antibody for the times indicated. Cells stimulated in the presence of medium 
alone were included as a control. Data are from a single experiment, 
representative of at least one other independent experiment.
(A) Ras activity was assayed for by the phosphorylation of a Raf-1-RBD- 
agarose conjugate, as described in Materials and Methods. Raf-1 -RBD-agarose 
conjugate pull-downs were subjected to Western blot analysis with an anti-Ras 
antibody (upper panel), stripped and reprobed with an anti-Raf-1 antibody 
(lower panel).
(B) MEK kinase activity was assayed for by the phosphorylation of a p42- 
MAPKinase GST-fusion protein, as described in Materials and Methods. 
MEKb42-MAPKinase GST-fusion protein pull-downs were subjected to 
Western blot analysis with an anti-phospho-ErkMAPKantibody (upper panel), 
stripped and reprobed with an anti-MEK antibody (lower panel).
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Figure 3.11 Effect of BCR and FcyRllb co-ligation on ErkMAPK-associated 
phosphatase activity.
Purified splenic B cells from Balb/c mice (1x10^ cells) were stimulated in the 
presence of 50 pg/ml F(ab')z fragments of goat anti-mouse IgG/IgM or 75 |ig/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
(A) Phosphatase activity was assayed for in anti-ErkMAPK immune precipitates 
by the hydrolysis of pNPP, as detailed in Materials and Methods. Data are 
expressed as the mean ± standard deviation from triplicate measurements of a 
single experiment and representative of at least one other independent 
experiment. Basal control level - 3.3 ± 0.2.
(B) Anti-ErkMAPK immune precipitates were subjected to Western blot analysis 
with Pac-1 antibody (upper panel), and PP2A antibody (middle panel). Whole 
cell lysates were subjected to Western blot analysis with Pac-1 antibody (lower 
panel).
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Figure 3.12 Effect of BCR and FcyRllb co-ligation on Akt kinase activity.
Purified splenic B cells from Balb/c mice (2 x 10  ^ cells) were stimulated in the 
presence of 50 |ig/ml P(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 pg/mt 
rabbit anti-mouse IgG/IgM intact antibody either alone, or in combination, for the 
times indicated. Cells stimulated in the presence of medium alone were 
included as a control. Data are from a single experiment, representative of at 
least one other independent experiment.
Akt kinase activity was assayed for by the phosphorylation of a GSK-3a/p fusion 
protein, as described in Materials and Methods. Akt/GSK-3a/p fusion protein 
pull-downs were subjected to Western blot analysis with anti-phospho-GSK- 
3cx/p antibody, stripped and reprobed with anti-Akt antibody.
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Figure 3.13 Effect of BCR and FcyRllb co-ligation on PTEN protein 
phosphatase activity.
Purified splenic B cells from Balb/c mice (1.5 x 10  ^cells) were stimulated in the 
presence of 50 pg/ml P(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
(A) Whole cell lysates (50 pg/lane) were subjected to Western blot analysis 
with an anti-PTEN antibody.
(B) Protein phosphatase activity was assayed for in anti-PTEN immune 
complexes by the hydrolysis of pNPP, as detailed in Materials and Methods. 
Data are expressed as the mean ± standard deviation from triplicate 
measurements of a single experiment and representative of at least two other 
independent experiments.
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Figure 3.14 Effect of BCR and FcyRllb co-ligation on PTEN 3’-inositol 
phosphatase activity.
Purified splenic B cells from Balb/c mice (1.5 x 10  ^cells) were stimulated in the 
presence of 50 pg/ml F(ab')2  fragments of goat anti-mouse IgG/IgM or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control.
Anti-PTEN immune precipitates was assayed for inositol phosphatase activity 
by the hydrolysis of [^H]-lnsp4 and the subsequent production of [^Hj-lnsPs, as 
described in Materials and Methods. Data are expressed as the mean ± 
standard deviation from triplicate measurements of a single experiment and 
representative of at least two other independent experiments. Basal control 
level 208 ± 6 .
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Figure 3.15 Effect of BCR and FcyRllb co-ligation on long-term PTEN 3 -  
inositol phosphatase activity.
Purified splenic B cells from Balb/c mice (1.5 x 10  ^cells) were stimulated in the 
presence of 50 pg/ml P(ab’) 2  fragments of goat anti-mouse IgG/IgM or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control,
(A) Anti-PTEN immune precipitates was assayed for inositol phosphatase 
activity by the hydrolysis of [^H]-lnsp4 and the subsequent production of [^H]- 
InsPa, as described in Materials and Methods. Data are expressed as the mean 
± standard deviation from triplicate measurements of a single experiment and 
representative of at least one other independent experiment.
(B) Anti-PTEN immune precipitates were subjected to Western blot analysis 
with the monoclonal anti-phosphotyrosine antibody, 4G10.
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Figure 3.16 Effects of FcyRllb and BCR co-ligation on JNK/SAPK activity
Purified splenic B cells from Balb/c mice (3 x 10^) were stimulated in the 
presence of 50 |ig/ml F(ab’) 2  fragments of goat anti-mouse IgG/IgM or 75 jig/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
basal level control, whilst cells stimulated for 30 minutes in the presence of 
PMA (100 ng/ml) and ionomycin (1 |ag/ml) were included as a positive control. 
Data are from a single experiment, representative of at least one other 
independent experiment. This study was done in collaboration with a fellow 
post-graduate student in the laboratory, Derek Blair.
JNK activity was assayed for by the phosphorylation of a c-Jun fusion protein, 
as described in Materials and Methods. c-Jun fusion protein pull-downs were 
subjected to Western blot analysis with an anti-phospho-c-Jun antibody, 
stripped and reprobed with anti-c-Jun antibody. The numbers beneath the blots 
represent the relative band densities as assessed by densitometry, compared to 
the band densities obtained for the basal control and arbitrarily set as 1.
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Figure 3.17 FcyRllb ligation modulates BCR-mediated phosphorylation of 
Rb and p53.
Purified splenic B cells from Balb/c mice (1x10^ cells) were stimulated in the 
presence of 50 fxg/ml P(ab’)2  fragments of goat anti-mouse IgG/IgM or 75 jig/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, for the times 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. Data are from a single experiment, representative of at least one other 
independent experiment. This study was done in collaboration with a fellow 
post-graduate student in the laboratory, Derek Blair.
(A) Whole cell lysates (50 p.g/lane) were subjected to Western blot analysis with 
a an anti-Cdk4 antibody.
(B) Whole cell lysates (50 p,g/lane) were subjected to Western blot analysis with 
a anti-phospho-Rb antibody.
(C) Anti-p53 immune precipitates were subjected to Western blot analysis with 
the monoclonal anti-phosphoserine-15 antibody, stripped and reprobed with 
anti-p53 antibody.
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Figure 3.18 Effects of FcyRllb and BCR co-ligation on NF-kB binding.
Purified splenic B cells from Balb/c mice (3 x 10  ^cells) were stimulated in the 
presence of 50 ng/ml P(ab’)2  fragments of goat anti-mouse IgM (p-chain 
specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, for the times indicated. Cells stimulated in the presence of medium 
alone were included as a control. Nuclear protein extracts were assayed by 
EMSA for binding to a ^^P-labelled oligonucleotide probe that represents a NF- 
KB binding site of the iNOS promoter. Arrows denote binding complexes. Data 
are from a single experiment, representative of at least two other independent 
experiments.
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Figure 3.19 FcyRllb-medlated mechanisms of B cell inhibition result in a 
decrease in mitochondrial membrane potential.
Purified splenic B cells from Balb/c mice (1 x 10® cells) were stimulated in the 
presence of 50 pg/ml P(ab’ ) 2  fragments of goat anti-mouse IgM (p-chain 
specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM alone, or in combination 
as indicated for 72 hours. Cells stimulated in the presence of medium alone 
were included as a control. The mitochondrial membrane potential was 
determined by DiOC6(3) staining and PACS analysis, as described in the 
Materials and Methods. Data represents the DiOC6(3)'"°'^ cell population, as 
determined on a logarithmic FL-1 axis, and expressed as a percentage of the 
total cells analysed of a single experiment and representative of at least two 
other independent experiments.
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Figure 3.20 Effect of BCR and FcyRlib co-ligation on the mRNA expression 
levels of FcTRIIbl and Fc7Rllb2 in splenic B cells.
Purified splenic B cells from Balb/c mice (5 x 10® cells) were stimulated in the 
presence of 50 {ig/ml P(ab’ ) 2  fragments of goat anti-mouse IgM (jii-chain 
specific) or 75 pg/ml intact rabbit anti-mouse IgG/lgM alone, or in combination 
for the times indicated. Cells stimulated in the presence of medium alone were 
included as a control. Total RNA was isolated and subjected to reverse 
transcription in the presence of 100 U of Superscript RT 11. FcyRllbl (upper 
panel) and FcyRllbZ (lower panel) isoform transcripts were assayed for by real­
time PGR (TaqMan). Levels are expressed as a percentage relative to HPRT 
mRNA level ± standard deviation from triplicate measurements of a single 
experiment.
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Figure 3.21 Effect of BCR and FcyRUb co-ligation on the ErkMAPKinase 
pathway
Co-ligation of the BCR with FcyRlib results in the phosphorylation of the FcyRlib 
cytoplasmic ITIM motif by the Src-family PTK, Lyn (1). Following recruitment to 
the phosphorylated ITIM the SH2-domain containing inositol 5’-phosphatase, 
SHIP, prevents the induction of the BCR-coupled Ras/MAPKinase cascade via 
interactions with the adaptor molecule She and the RasGAP binding protein, 
p62Dok (2). In addition to the activation of SHIP, FcyRlib appears to uncouple 
the BCR from the Ras/MAPKinase pathway through the rapid activation and 
recruitment of the dual-specific nuclear MAPK phosphatase, Pac-1 (3) and by 
promoting the BCR recruitment of Lyn-SHP-1 protein tyrosine phosphatase 
complexes (4).
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Figure 3.22 Effect of BCR and FcyRUb co-ligation on the Akt survival 
pathway
BCR ligation is known to induce the activation of the pro-survival factor Akt and 
promote B cells survival. Co-ligation of the BCR with FcyRlib results in the 
termination of this signal, through the conversion of Ptdlns(3,4,5)P3 to 
Ptdlns(3,4)P2 by the inositol 5’-phosphatase, SHIP. However, Ptdlns(3,4)P2 is 
also known to activate Akt, thus FcyRlib may inhibit BCR-activated Akt by the 
recruitment of the inositol 3’-phosphatase, PTEN. Through the conversion of 
Ptdlns(3,4,5)p3 and Ptdlns(3,4)P2, PTEN could impair BCR mediated activation 
of Akt by counteracting the activities of PI-3-Kinase.
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Figure 3.23 Effect of BCR and FcyRlib co-ligation on the regulation of the 
cell cycle.
FcyRIlb-mediated growth-arrest leads to the modulation of cell cycle regulatory 
proteins. BCR-mediated Gi-S phase progression results in an increase in Rb 
phosphorylation. However, FcyRlib co-ligation results in the partial suppression 
of BCR-induced Rb phosphorylation, potentially preventing the release of E2F 
and the transcription of S phase genes (1). FcyRlib ligation also disrupts BCR- 
mediated cell-cycle progression by the modulation of NF-kB activation and the 
rapid phosphorylation of p53 on serine 15 (2). The activation of p53 can lead to 
cell cycle arrest at the Gi-S and G2-M transition points (3) and DNA repair or 
apoptosis.
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Chapter 4 - FcyRlib and Murine Autoimmune Disease 
Models
4.1 Autoimmunity and autoimmune disease
As with any balanced system, inappropriate activation and a loss of 
homeostasis can result in detrimental effects. In the case of the immune 
response, deregulation may result in a variety of chronic inflammatory 
processes, and in some situations, may cause serious disease. Autoimmunity is 
the inappropriate response of the immune system to self-antigens, which can 
lead to autoimmune disease. Autoimmune disease-mediated tissue damage 
can be caused by a variety of mechanisms involving autoimmune T cells or the 
production of autoantibodies (antibodies against self-antigens) (reviewed by 
Ada et al., 1997).
Tissue damage may result from a number of aberrant responses including 
direct attack on cells bearing the self-antigen, from the formation of immune 
complexes or from local inflammation. For example, in autoimmune haemolytic 
anaemia, autoantibody recognition of self-antigens on the surface of red bloods 
cells, mediates their destruction. The autoantibody-coated cells are cleared by 
Fc receptor expressing phagocytic cells in the spleen or by complement 
receptor bearing macrophages. The binding of certain rare autoantibodies, with 
the ability to fix complement efficiently, can also cause haemolysis via the 
formation of a complement membrane attack complex. Systemic lupus 
erythematosus arises from the production of autoantibodies to common cellular 
constituents, such as dsDNA and ribonuclear proteins (section 5.1.1). Due to 
the large quantities of self-antigen available, large numbers of immune 
complexes are deposited in small blood vessels in the renal glomerulus, joints 
and other organs. This tissue-deposition leads to the release of inflammatory 
mediators, infiltration of inflammatory cells and complement fixation. The 
consequent tissue damage results in the release of more nuclear-protein 
complexes from the damaged cells. The increase in self-antigen concentrations 
results in the further production of immune complexes and a cyclical
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exacerbation of the disease. Finally, inflammatory injury in Goodpasture’s 
syndrome is caused by the production of autoantibodies to the basement 
membrane collagen of the renal glomeruli. Antibody binding results in 
complement activation and the influx of neutrophils causing inflammatory injury 
to the glomerulus and a rapidly fatal disease if untreated.
4.1.1 The role of B cells in the loss of tolerance and production of 
autoantibodies.
In order to determine how an autoimmune response is induced, an 
understanding of (i) how tolerance is maintained normally in the immune system 
and (ii) why responses occur in autoimmune disease, is required. Tolerance is 
the failure of the immune system to respond to a specific antigen and is 
required to prevent inflammatory responses to the many innocuous substances 
that are encountered on a daily basis. When the specific antigen is borne by 
self-tissues, then tolerance is described as self-tolerance. Tolerance to self­
antigens is important in preventing the mounting of an immune response 
against the tissues of the body.
The most important mechanisms of tolerance to self involve clonal deletion and 
inactivation (anergy) of lymphocytes by exposure to the antigen during the 
maturation stages of lymphocyte development (see section 1.2.1). Clonal 
deletion of B cells that express antigen-receptors to ubiquitous self-antigens 
occurs in the bone marrow and secondary lymphoid tissue follicles. Deletion is 
dependent on BCR signal strength or a lack of co-stimulatory T cell help in the 
form of CD40 and IL-4. Thus, immature B cells with low affinity or redundant 
antigen spécificités undergo receptor editing or apoptosis in the bone marrow 
whilst a lack of co-stimulatory T cell-derived cytokines will also promote 
apoptosis. These processes prevent the maturation of those B cells that would 
potentially recognise self-structures present during the maturation stages, 
resulting in the generation of autoantibodies (reviewed by Cushley and Harnett, 
1993).
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Despite the stringent selective processes of clonal deletion and receptor editing 
in the maturation stages, B cells expressing antigen-receptors for self are still 
present in the periphery. This is presumably because not all self-antigens can 
be sufficiently presented during the selection processes as many self-molecules 
are available only in the periphery. Therefore mechanisms exist to ensure that B 
cells reactive to these self molecules do not cause autoimmune disease. B cell 
recognition of self-antigen in the T cell zone of peripheral lymphoid organs, 
results in the arrest of their migration. Inactivation of B cells in the periphery is 
also achieved through the induction of B cell anergy by the downregulation of 
sIgM and/or partial inhibition of sIgM-mediated intracellular signalling pathways. 
Monomeric soluble antigens can induce this mechanism when presented in the 
absence of co-stimulatory signals from T cells in the periphery. A subsequent 
lack of self-antigen specific CD4^ T cell help, results in apoptosis of the trapped 
B cells.
Autoreactive B cells may also be forced to undergo apoptosis by activated 
autoreactive T cells that express Fas ligand (Fas-L) (reviewed by Sigel, et al.,
2000). Although negative selection in the thymus usually eliminates such T 
cells, when an auto reactive T cell is activated, it is able to kill autoreactive B 
cells through the binding of Fas-L to Fas (CD96) on the B cell surface. In the 
absence of normal co-stimulatory signals the autoreactive B cells show 
enhanced sensitivity to apoptosis following Fas-L/Fas interactions. Indeed, 
humans and mice that are deficient in Fas, or Fas-ligand, develop severe 
autoimmune disease associated with the overproduction of lymphocytes (Ada, 
et al., 1997; Sigel, et al., 2000). B cells bearing antigen receptors for self­
antigens, developed as a result of somatic hypermutation, may also undergo 
Fas-dependent apoptosis within a few hours if they encounter soluble antigen in 
the absence of T cell co-stimulatory signals (Alt, et al., 1997). Indeed, if there is 
no co-stimulatory help at the time of antigen encounter, the antigen is likely to 
be ignored by the immune system.
In addition, immune-complexes consisting of antigen and specific antibody can 
provide a feedback mechanism for the inhibition of B cells through co­
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engagement of the low affinity receptor for IgG, FcyRlib. In a normal immune 
response co-ligation of FcyRlib acts to uncouple antigen-receptor signalling and 
thus, acts to suppress B cell activation and the production of antibodies. Thus 
self-antigen immune complexes should act to inhibit autoreactive B cell 
activation via the BCR through the co-ligation of FcyRlib.
The mechanisms leading to the breakdown in immune tolerance and self­
recognition are many and varied. These can include genetic susceptibility 
factors which can predispose an individual to autoimmunity, such as the 
association of specific MHO class II alleles with insulin-dependent diabetes 
mellitus and rheumatoid arthritis. An autoimmune response may also be 
directed at a cross-reactive microbial antigen which mimics a self-antigen. For 
example, the initiation of Lyme arthritis is thought to be due to infection with the 
spirochete Borrelia burgdorferi which shares an antigenic determinant in its 
outer surface protein with the leukocyte function associated antigen 1 (LFA-1) 
(Regner and Lambert, 2001). Similarly, aberrant presentation of self-antigens 
may also result in activation of otherwise “silent” autoreactive lymphocytes. 
Thus, disease exacerbation of systemic lupus erythematosus occurs when 
tissue damage results in the release of cellular components not normally in 
immune circulation, thus promoting an immune response (section 5.1.1). 
Autoantibodies may also arise due to random mutations in the antigen-receptor 
genes of B cells during a normal immune response. The new self-reactive B cell 
clones may be selected for by mutant self-reactive T cells concomitantly binding 
to self-epitopes. The produced autoantibodies may then bind to surface 
receptors and stimulate or block normal cellular responses.
The propensity of B-1 cells to produce low-affinity autoreactive antibodies 
implicates a role for these cells in autoimmune disease, (reviewed by Hayakawa 
and Hardy, 2000). The restricted diversity of B-1 cell antigen-receptors helps 
provide a population of antibodies of degenerate specificity that are able to bind 
to common bacterial antigens and mimic self-structures. Indeed, B-1 cell 
populations that produce autoantibodies are expanded in autoimmune disease 
models such as NZB and motheaten, SHP-1 deficient, mice and elevated levels
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of B-1 a cells have been found in a proportion of patients with rheumatoid 
arthritis and systemic lupus erythematosus (Porakishvili et al., 2001). A final 
model for the breakdown of immune tolerance proposes that suppressive 
regulatory T cells, responsible for inhibiting self-reactive T or B cells, are 
somehow deleted thus permitting activation by self-antigens (Maloy and Powrie,
2001). However, the cellular mechanisms responsible for this model are, as yet, 
unclear.
4.1.2 Immune-complex formation and autoimmunity
Immune complexes are formed whenever there is an antibody response to 
antigen. Normally these complexes are cleared efficiently by Fc and 
complement receptor bearing cells of the phagocytic and red blood cell system, 
such that they cause little tissue damage. However, this system can fail in three 
circumstances (reviewed by Ada et al., 1997). If high levels of antigen are 
introduced into the system, this can lead to the formation of large amounts of 
immune complexes that can overwhelm the normal clearance response. This is 
exemplified in the case of serum protein injections, which can result in a 
hypersensitivity reaction known as serum sickness. The immune-complex- 
mediated reaction is initiated by the development of antibodies to the injected 
foreign protein. The antigen-antibody complexes are deposited in small blood 
vessels and subsequently bind and activate Fc and complement receptor 
bearing effector cells. Fever and symptoms of nephritis and arthritis are 
induced. However, these effects are transient and resolve when the foreign 
protein is cleared. Similarly, chronic bacterial infection, where there is a 
continual strong antibody response, results in the deposition of immune 
complexes in the small blood vessels of organs such as the kidney and the skin. 
Tissue injury occurs through the activation of complement and the recruitment 
of inflammatory cells. Finally, the immune system may suffer from an inherent 
inability to clear immune complexes, as seen in diseases such as systemic 
lupus erythematosus. This immune complex driven autoimmune disease, will be 
discussed in more detail in later sections and Chapter 5.
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4.1.3 The role of FctRs in autoimmune disease
The cellular responses to, and the effective clearance of, immune complexes 
not only depends on the immunoglobulin subtype(s) involved but also on the 
repertoire of immunoglobulin-binding receptors expressed. Studies in mice 
deficient in either Fc or complement receptors have revealed distinct functions 
for these two classes of molecules in the immune response to antigen 
(reviewed by Ravetch and Clynes, 1998; Heyman, 2000). Results have 
indicated that immune complex binding by complement is essential for innate 
immunity against microbial pathogens, whereas FcyRs have emerged as the 
essential component for coupling antigen specific IgG antibodies to effector 
cells to trigger inflammatory responses.
Murine models of inflammatory disease have supported the concept that a 
balance between stimulatory and inhibitory FcyRs, Is a determinant of the 
susceptibility to, and severity of disease (Clynes et aL, 1999; Heyman, 2000, 
Dijstelbloem et al., 2001). This is because the initiation and propagation of an 
inflammatory response results, in part, from the interaction of immune 
complexes and antibodies with ITAM containing IgG Fc receptors, such as 
FcyRlla. In general, activation and inhibitory FcyRs are co-expressed on the 
same cell. Their co-expression provides a physiologically important mechanism 
for setting the threshold for activating stimuli, because the IgG ligand will co­
engage both receptors. The ratio of expression of these two opposing signalling 
systems will directly influence the signalling pathways engaged and determine 
the cellular response of the expressing cell.
Support for the role of FcyRs in immune complex-mediated disease comes from 
mice with targeted gene deletion of the y-chain, such that they do not express 
the activating FcyRs, FcyRI and FcyRllla (Clynes etal., 1998). Deletion of these 
FcyRs protects the mice from spontaneous or induced antibody-mediated 
autoimmune disease without altering the production of autoantibodies. This 
absence of disease induction is thought to be due to a lack of FcyR-mediated 
phagocytosis resulting in the subsequent lack of initiation of type II and type III
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hypersensitivity antibody-mediated reactions. These include Arthus’ reactions, 
autoimmune glomerulonephritis and experimental antigen-induced arthritis 
(Sylvestre and Ravetch, 1994; Clynes and Ravetch, 1995, Ravetch and Clynes, 
1998; Clynes et al., 2000).
In contrast, disruption of the inhibitory FcyR, FcyRlib, by gene targeting has a 
pro-inflammatory effect. FcyRlib deficient mice have augmented humoral (type 
It and type III) hypersensitivity responses and anaphylactic (type I) responses 
(Takai et al., 1996). In studies of inflammatory disease, these mice display high 
levels of antigen specific serum IgG in response to thymus-dependent and 
thymus-independent antigens, with an increased incidence of autoimmune 
disease (Takai et al., 1996). Furthermore, studies have demonstrated that in 
specific strains, FcyRlib -/- mice are able to develop an autoimmune syndrome 
resulting in the production of autoantibodies, accelerated antibody-induced 
glomerulonephritis and immune complex mediated alveolitis (Suzuki et al., 
1998; Clynes et al., 1999; Nakamura et al., 2000).
Relevant to this, studies of the FcyRlib promoter region in strains of 
autoimmune-prone mice, have highlighted that deletions in this area are 
associated with reduced surface expression and function of FcyRlib on 
macrophages and B cells (Luan etal., 1996; Pritchard etal., 2000). Indeed, 
studies in disease-prone mice have shown a correlation between FcyRlib 
promoter polymorphisms and the subsequent down-regulation of surface 
expression with the promotion of autoimmune disease (Jiang, 2000). The same 
group also found that antigen stimulation of germinal-centre B cells resulted in 
reduced surface expression of FcyRlib and a concomitant up-regulation of IgG 
antibody responses (Jiang, 1999). Bone marrow transfer experiments have also 
suggested that the autoimmune phenotype displayed by certain strains of 
FcyRlib -I- mice, is dependent upon FcyRlib deficiency in B cells but not in 
macrophages (Bolland and Ravetch, 2000). This suggests that the absence of 
FcyRlib mediated inhibitory signals in B cells leads to a spontaneous induction
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of autoimmune disease in these mice. Indeed, FcyRlib may prevent 
autoimmune disease by immune complex-mediated induction of B cell 
tolerance.
Overall, these data appear to support a role for FcyRlib in maintaining immune 
tolerance and preventing autoimmune disease. Moreover, they imply that 
FcyRlib may function in vivo to suppress autoimmunity by regulating both B cell 
and effector cell activation. Hence, lesions in the expression or signalling of 
FcyRlib receptors may contribute to the development of B cell-mediated 
autoimmune disease. Preliminary studies into the modulation of FcyR signalling 
represent an exciting potential therapeutic strategy into the treatment of human 
autoimmune disease for which no effective treatment currently exists (see 
Chapter 5). Strategies based on the downregulation of activating FcyRs and the 
upregulation of inhibitory FcyRs, like FcyRlib, may represent a realistic 
approach to ameliorating immune complex driven autoimmune disease.
Therapeutic mechanisms involving the modulation of FcyRlib expression on B 
cells must also account for the two alternatively spliced isoforms, FcyRllbl and 
FcyRI I b2. Both isoforms possess an inhibitory ITIM motif in their cytoplasmic 
domains and are able to mediate negative feedback regulation of ITAM 
containing receptors. However, whilst FcyRI Ib2 is capable of mediating rapid 
IgG endocytosis, a sequence insertion in the cytoplasmic tail of FcyRllbl 
disrupts the cytoskeletai attachment domain responsible for modulating receptor 
internalisation. Therefore, differences in the relative expression levels of the two 
isoforms of FcyRlib may influence the regulation of B cell tolerance by immune- 
complexes and an individuals overall risk of developing autoimmune disease.
With a wealth of data supporting a potential role for FcyRlib in the prevention of 
autoimmune disease, we decided to investigate whether abnormal FcyRlib 
signalling or isoform expression in B cells contributes to the generation of 
disease in established autoimmune diseases models. In particular, we 
investigated its regulatory role in the collagen-induced arthritis (CIA) and the 
systemic lupus erythematosus (SLE, MRL-lpr/lpi) murine models.
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4.1.4 Collagen-induced arthritis (GiA)
Experimental models, which imitate human rheumatoid arthritis (RA) (section 
5.1.2), have been characterised as a means to understanding disease 
pathophysiology and identifying new strategies for treatment. The two animal 
models that have been studied in the greatest depth are the adjuvant arthritis 
(AA) model in rats and the collagen-induced arthritis (CIA) model in mice. The 
AA model relies on the induction of an immune response against a bacterial 
antigen whereas in CIA an autoimmune response is raised against a major 
component of articular cartilage. However, as CIA has histopathological 
features in common with rheumatoid arthritis (Durie, et al., 1994; Staines and 
Wooley, 1994) it is considered the preferred model of investigation and has 
been widely used for the evaluation of potential anti-rheumatic agents.
CIA is a chronic inflammatory polyarthritis, characterised by hyperplasia of the 
synovium, mononuclear infiltration of the synovial tissue, osteolysis and 
eventual destruction of joint cartilage (Stuart, et al., 1988). The development of 
the disease is highly influenced by MHC genes (Wooley, et al., 1981) with 
additional roles implicated for non-MHC genes (Watson and Townes, 1985). 
CIA can be induced in susceptible strains of mice which express the major 
histocompatibility complex (MHC) class II H-2^ or H-2^ haplotype, by the 
intradermal injection of native type II collagen (CM) in complete Freund’s 
adjuvant (CFA) (Trentham, et al., 1977). The H-2^ haplotype codes for a MHC 
class II molecule that binds the immunodominant CM peptide region, whilst the 
H-2'' haplotype confers susceptibility to CIA when bovine or porcine Cl I is used.
The essential role of this susceptibility factor is exemplified by the DBA mouse 
strains, where DBA/1 (H-2^) mice are susceptible to CIA whilst the DBA/2 (H-2^) 
are not. CM antigen presentation leads to activation of Cll-reactive CD4+ T cells 
and the generation of a Tnl-type immune response, which is crucial for the 
development of arthritis in this model (reviewed by Luross and Williams, 2001). 
In addition, a strong B cell response is activated in CIA, producing complement
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fixing IgG autoantibodies directed towards Cll-specific structures. B cells have 
been shown to be crucial for the development of CIA, as B cell deficient mice of 
a susceptible background do not develop disease (Svensson etal., 1998). 
Importantly, mice with MHC class II haplotypes, normally associated with 
resistance to CIA (H-2^), become susceptible to autoimmune arthritis when 
FcyRlib is deleted (Yuasa et a!., 1999).
4.1.5 MRL-/pr//pr
Several animal models have aided the investigation into the pathogenesis of 
systemic lupus erythematosus (SLE) (reviewed by Theofilopoulos and Dixon, 
1985; Cohen and Eisenberg, 1991 and section 5.1.1). Two well characterised 
models are the Fi hybrid of New Zealand black (NZB) (H-2^) and New Zealand 
white (NZW) (H-^) mice and the MRL mouse (reviewed by Vyse and Kotzin, 
1998). Independently, NZB mice develop autoantibodies and haemolytic 
anaemia and NZW a mild, late onset of autoimmune nephritis. However, the 
(NZW X NZB)Fi results in the development of lupus-like disease and a more 
severe autoimmune phenotype than that predicted by the additive effect of the 
parental phenotypes. A minimum of three genetic loci are required for full 
autoimmune glomerulonephritis in the (NZW x NZB)Fi, two from NZB and one 
from NZW mice. The heterozygosity is associated with enhanced production of 
pathogenic IgG autoantibodies to double-stranded (ds) DNA and chromatin.
MRL mice are a mixture of LG/J , AKR/J and C3H/Di strains with /-/-2^ 
backgrounds. The MRL mice most frequently studied also carry a single gene 
mutation that accelerates lupus-like disease, either homozygosity for the 
lymphoproliferatlon (Ipr) mutation in the Fas or the gid mutation in the Fas 
ligand genes. Although the mechanisms by which mutations in Fas lead to 
enhanced autoimmunity are unknown, the consensus is that self-reactive T and 
B cells arise when they fail to undergo normal apoptosis.
However, no counterparts to the Ipr and gId phenotypes exist in human SLE, 
and studies have not provided evidence of defects in the Fas or Fas-L 
homologous genes in human SLE patients. Indicating that there many factors 
involved in the initiation of lupus-like disease. Therefore, the (NZW x NZB)Fi
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and MRL-/pr//pr strains are primarily models for lupus-like glomerulonephritis 
associated with the production of IgG antibodies towards dsDNA. These 
autoantibodies mediate nephritis, probably as a result of in situ immune 
complex deposition in the glomerulus. However, genetic studies have 
demonstrated that these strains also produce autoantibodies against 
endogenous retroviral glycoproteins, which are implicated in the pathogenesis 
of murine nephritis (reviewed by Vyse and Kotzin, 1998).
In both human and murine SLE, one susceptibility allele for IgG 
hypergammaglobulinemia has been mapped to the interval linked to the FcyRI I 
gene on chromosome 1 (Vyse and Kotzin, 1998). Whilst the dysfunction of 
FcyRlib has not yet been determined in MRL-/pr//prmice, FcyRI lb-deficient mice 
produce high levels of anti-nuclear antibodies of a comparable titre to that found 
in sera from this well studied autoimmune model (Bolland and Ravetch, 2000). 
Furthermore, studies in (NZW x NZB)Fi mice deficient in the y-chain have 
demonstrated that the balance of activation and inhibitory FcyR expression on 
effector cells is important for immune-complex-mediate nephritis (Clynes et a!., 
1998). Consistent with this, one study on MRL-/pr//pr mice, has examined the 
effect of administering peptides that bind the constant region of IgG and thus 
inhibit the subsequent interactions with FcyRs (Marino et a!., 2000). These 
results demonstrated that whilst the peptides had little effect on the serum level 
of anti-DNA autoantibodies, they had a much more dramatic effect on reducing 
proteinuria and increasing survival in the mice. These results support the role of 
FcyRs in SLE pathogenesis whilst indicating a possible divergence in the roles 
of immune-complex binding receptors and their abilities to mediate autoimmune 
disease.
4.2 Aims and objectives of this study
The production of autoantibodies in the collagen-induced arthritis (CIA) model 
implies the involvement of aberrant B cell activation. FcyRlib is known to play an 
important role in maintaining normal B cell responses to antigen and thus may 
be involved in the pathogenesis of CIA. In addition, systemic lupus
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erythematosus (SLE) is a classic immune-complex mediated disease that is 
characterised by the production of autoantibodies against ubiquitous self­
antigens. FcyRlib is the only Fey receptor present on B cells that can interact 
with IgG containing immune-complexes. Therefore, the primary objectives of 
this study were to investigate whether FcyRllb-mediated negative regulation of 
B cell activation becomes defective during onset and progression of disease in 
CIA and MRL-/pr//pr models. The relative expression levels of the FcyRlib 
isoforms on B cells may represent a physiologically important mechanism for 
setting the threshold of BCR-mediated activation. Thus, the ratio of expression 
of FcyRllbl and FcyRllb2 may directly influence the modulation of B cell 
responses by immune-complexes. It was therefore also planned to determine 
whether B cells from CIA and MRL-/pr//pr mice develop aberrant FcyRlib 
isoform mRNA expression during the disease status transition and progression.
Finally, previous studies from this laboratory had shown that an anti­
inflammatory molecule, ES-62 could “anergise” B cells. It was therefore planned 
to investigate whether FcyRlib mediates, at least in part, the therapeutic effects 
of this inflammatory molecule, ES-62, in the CIA model.
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4.3 Results
4.3.1 The role of FcyRllb-mediated B cell inhibition in the progression of 
collagen-induced arthritis (d0-d47).
Genetic studies have suggested a potential role for FcyRlib in suppressing the 
induction of collagen-induced disease (CIA) in certain murine strains (Yuasa et 
al., 1999; Bolland and Ravetch, 2000). To investigate whether abnormal FcyRlib 
signalling or isoform expression contributes to the generation of disease in an 
established murine arthritis model, the integrity of FcyRlib signalling in ex vivo B 
cell responses during onset and progression of CIA was tested. Susceptible 
male DBA/1 mice (H-2^) were injected intradermally with type II collagen (Cll) in 
CFA and a gradual onset of arthritis was observed when challenged 
intraperitoneally with collagen 21 days later (see Figure 2.1). Mice were 
monitored for a further 5 weeks for signs of arthritis; disease incidence rates, 
mean clinical score, and paw swelling. Littermates, which had been injected and 
subsequently challenged with CFA alone, did not develop arthritis. Naïve or 
CFA alone DBA/1 mice were taken as baseline controls.
4.3.1.1 FcyRlib co-ligation results in the inhibition of BCR-mediated 
ErkMAPK phosphorylation in splenic B cells from both CFA control and 
CIA mice, ex vivo (dO-d47).
In order to investigate putative signalling lesions following FcyRlib ligation on B 
cells from CFA/Cll, CFA control and naïve DBA/1 mice, the effect of FcyRlib 
ligation on BCR-signalling was determined. Ligation of the BCR on splenic B 
cells is known to induce the phosphorylation and activation of the Ras/ErkMAPK 
pathway (reviewed by Campbell, 1999), which is inhibited by the co-ligation of 
FcyRlib (reviewed by Cambier, 1995). Previous DNA synthesis studies in 
primary B cells by our laboratory had indicated that 48 hours was the optimal 
timepoint to observe maximal BCR-mediated proliferative and FcyRllb-mediated 
inhibitory effects (Chapter 3). Thus, the negative regulation of BCR-mediated 
ErkMAPK signalling by FcyRlib was investigated in CFA/Cll, CFA control and 
naïve DBA/1 mice. Anti-ErkMAPK immunoprecipitates were prepared from
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whole cell lysates of splenic B cells treated with intact or F(ab’) 2  fragments of 
anti-mouse IgM/IgG antibody for 48 hours. Western blot analysis was carried 
out with an antibody specific to the dually phosphorylated (active) form of 
p44/p42 ErkMAPK, as an indication of ErkMAPK activation.
BCR stimulation of splenic B cells from CFA/Cll, CFA control and naïve DBA/1 
mice, results in the phosphorylation of ErkMAPK and this is sustained at 48 h 
(Figure 4.1). Interestingly, ErkMAPK phosphorylation, particularly that of p44 
Erk, is enhanced in the CFA/Cll mice following BCR stimulation. This increased 
level of ErkMAPK activation, however, could possibly also reflect the collagen- 
specific co-stimulatory effect of bystander inflammatory cells in vivo. However, 
although co-ligation of FcyRlib either alone or in combination with mitogenic 
signalling via the BCR, resulted in reduced levels of ErkMAPK phosphorylation, 
compared to BCR stimulation a reduction in ErkMAPK activation back to basal 
control levels is not demonstrated. Indeed, BCR-coupled p42 ErkMAPK is only 
partially inactivated (-40% inhibition) following intact antibody stimulation of 
CFA/Cll B cells. Furthermore, whilst BCR and FcyRlib co-ligation abrogated 
signalling by an average of 67% in CFA control B cells, only an average of 43% 
inhibition of the BCR-mediated ErkMAPK phosphorylation levels by FcyRlib, 
was achieved in CFA/Cll B cells. Interestingly, in contrast to the situation in 
naïve mice, stimulation with intact anti-lg alone induced a substantial amount of 
Erk activation at 48 hours, particularly in B cells derived from CFA-treated mice.
Thus, ErkMAPK phosphorylation is differentially inhibited by FcyRlib in CFA 
control and CFA/Cll mice, but with both types of mice exhibiting preferential 
inhibition of the p44 form of ErkMAPK. In agreement with published studies on 
the induction of inflammatory and autoimmune disease in FcyRlib deficient mice 
(Takai et al., 1996; Nakamura, A. etal., 2000) these results indicate that 
FcyRlib inhibition of BCR-activated ErkMAPK appears to be dysregulated in 
CF/VCII mice throughout the progression of disease.
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4.3.1.2 FcyRlib co-ligation inhibits the BCR-mediated proliferative
response of splenic B cells from both CFA control and CIA mice, ex vivo 
(d0-d47).
CIA is dependent on the dysregulation of both humoral and cell-mediated 
responses. To determine whether the putative dysregulation of FcyRlib 
functionality on B cells observed above reflected uncoupling of negative 
feedback inhibition of B cell responses in CIA mice through disease onset and 
progression, the proliferative response of splenic B cells derived from CFA/Cll, 
CFA control and naïve DBA/1 mice on days 0, 7, 23, 34 and 47, was 
investigated.
Antigenic stimulation of splenic B cells with F(ab’)2  fragments of anti-mouse Ig 
resulted in increased levels of B cell proliferation in naïve, CFA control and 
CFA/Cll primed DBA/1 mice (Figure 4.2).The levels of DNA synthesis observed 
were similar in both CFA primed groups of mice (but greater than those of B 
cells from naïve DBA/1 mice) throughout the disease onset and progression, 
until day 47, when particularly enhanced DNA synthesis levels were obtained 
(Figure 4.2). With the exception of day 47, stimulation of FcyRlib by means of 
intact antibody alone resulted in a lack of DNA synthesis in all three groups. The 
increased levels of DNA synthesis on day 47 following coligation of BCR and 
FcyRlib were presumably as a result of an increase in the percentage of 
activated cells and this might perhaps reflect signals generated by CFA-induced 
inflammation resulting in T cell-derived signals overcoming FcyRllb-mediated 
anergy and/or apoptosis.
Co-ligation of the BCR and FcyRlib in the presence of mitogenic BCR signalling, 
resulted in similar percentage levels of inhibition of BCR-mediated DNA 
synthesis in all mice. However, FcyRlib inhibition of BCR-induced DNA 
synthesis was slightly reduced in the CFA/Cll mice on day 23, 2 days post­
collagen (Cll) challenge (30% compared to 54% in the CFA control mice). In our 
laboratory, previous DNA synthesis studies in primary B cells have indicated 
that FcyRllb-mediated suppression of BCR-induced DNA synthesis, following 
co-ligation of the receptors, is approximately 50% (c.f. typical example in Figure 
3.1). Thus, it was possible that, in agreement with the ErkMAPK results, the
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reduction in FcyRllb-mediated suppression in the CFA/Cll mice on day 23 
indicated that FcyRllb-mediated inhibition of B cell proliferation may be 
dysregulated at the initial onset of acute inflammatory disease.
In light of studies suggesting that FcyRlib deficiency is a susceptibility factor for 
inflammatory and autoimmune disease in mice, the finding that FcyRlib 
appeared to be functional throughout the remaining disease progression was 
somewhat surprising. This result implies that a deregulation of the BCR- 
mediated B cell response by FcyRlib at the time of antigen re-challenge, could 
be sufficient to initiate an inflammatory and subsequent autoimmune response.
4.3.1.3 FcyRlib ligation results in growth-arrest and/or apoptosis of 
splenic B cells from both CFA control and CIA mice, ex vivo (d0-d47).
The above experiment confirmed that BCR-FcyRllb co-ligation in splenic B cells 
was unable to induce DNA synthesis in CFA/Cll, CFA control and naïve DBA/1 
mice and that co-ligation in the presence of mitogenic stimulation via the BCR 
resulted in the inhibition of BCR-mediated proliferation. However, DNA 
synthesis studies give no indication as to whether such FcyRllb-mediated 
inhibition of DNA synthesis is due to apoptosis, anergy or growth arrest. This is 
of importance since recent studies have indicated that FcyRlib ligation can lead 
to distinct cellular responses of growth arrest and/or apoptosis in B cell lines, 
dependent on the mechanism of receptor aggregation (Ashman et al., 1996; 
Ono etal., 1997). Thus, co-ligation of BCR and FcyRlib with intact anti-lg 
antibodies is known to result in lower levels of DNA synthesis than those of 
control unstimulated B cells reflecting induction of a pro-apoptotic signal. In 
contrast, co-ligation of FcyRlib with the BCR during mitogenic signalling via the 
BCR results in a survival signal and the induction of growth-arrest (Pearse et 
al., 1999). This finding has important implications for the selection and 
activation of B cells by immunocomplexes in the development of both normal 
and autoimmune responses. The mechanisms reflect the differential 
requirements of the immune system to both dispose of autoreactive naïve cells 
whilst only suppressing antibody production by activated cells during an 
ongoing infection. As such a B cell may require re-activation if the immune
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system re-encounters antigen. Therefore, to confirm the results obtained in the 
DNA synthesis experiment, suggesting that FcyRllb mediated negative 
feedback regulation is dysregulated in BCR-PcyRIIb co-ligated B cells at 
disease onset, the levels of FcyRIlb-induced apoptosis were measured.
The levels of apoptosis were determined by measuring the population of cells 
that expressed sub-diploid DNA, as measured by FACS analysis using 
propidium iodide (PI) staining. Figure 4.3 shows that post-sacrifice 70% of 
splenic B cells from CFA/CII, CFA control and naïve DBA/1 mice are in the 
G0/G1 phase of the cell cycle and the majority of which, if left unstimulated for 48 
hours, undergo apoptosis (sub-diploid population) (Figures 4.3 and 4.4). 
Stimulation of the BCR with F(ab')z fragments of anti-mouse Ig for 48 hours, 
resulted in increased cell numbers entering into the proliferative S and G2/M 
stages in all three groups of mice, whilst, FcyRllb-co-ligation resulted in 
enhanced levels of growth-arrest and apoptosis. Importantly, the percentage of 
cells committed to growth arrest or apoptosis following FcyRllb co-ligation was 
shown to be similar in CFA/CII and CFA control mice on day 23. Indeed, levels 
of apoptosis following co-ligation of BCR-FcyRllb in CFA/CII B cells were 
elevated compared to CFA control B cells. Thus, these results confirm the 
ability of B cells from ClA/CIl and CFA control mice to readily undergo apoptosis 
or growth arrest following FcyRllb-co-ligation throughout disease onset and 
progression. Interestingly, the responses of B cells derived from CFA/Cll and 
CFA control mice resulted in enhanced proliferative or apoptotic effects with 
respect to naïve B cells. Indicating, perhaps, that the exposure of B cells to CFA 
results in an increase of sensitivity of B cells to both stimulation and inhibition.
To further examine the growth-arrest effects induced by FcyRllb ligation, the 
DNA content of the living population of B cells was analysed in naïve (Figure 
4.5) CFA control and CFA/CII primed DBA/1 mice (Figure 4.6). These figures 
clearly demonstrate that there is no appreciable difference in the percentage of 
B cells in the distinct stages of the cell cycle, when comparing CFA/CII and CFA 
control mice. Moreover, that FcyRllb-mediated inhibition of cell cycle 
progression appears to be functioning in these cells. Indeed, the percentage of
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viable cells in the G0/G1 phase of the cell cycle increases from 50%, when 
stimulated via the BCR, to 75% when FcyRllb is co-ligated. When the two 
receptors are co-ligated in the presence of mitogenic signalling via the BCR the 
levels of growth-arrest are intermediate to these two values, suggesting an 
integration of signals from the positive and negative regulatory receptors. The 
discrepancy between the DNA synthesis and cell cycle data, may reflect the 
differential numbers of rounds of division at day 23 by cells within the 
population. Such that a small sub-group of cells, for example, collagen-specific 
B cells, may be responsible for the proliferative response observed in the DNA 
synthesis assay. Thus, analysis of cell division numbers following FcyRllb co­
ligation may help to explain the contradictory data. However, attempts to 
ascertain the number of rounds of cell division using the cell-permeable dye, 
CFSE, were prevented by a lack of dye reduction in actively proliferating cells.
4.3.2 The role of FcyRllb-mediated B cell inhibition in the secondary 
immune response to collagen and the onset of collagen-induced arthritis, 
ex vivo (d21-d25).
The regulation of B cell clonal expansion following re-exposure to antigen is 
important for the production of a rapid and augmented secondary immune 
response. Whilst contradictory, the results obtained above implicated a potential 
dysregulation of FcyRllb-mediated negative feedback regulation corresponding 
to the onset of a secondary immune response to collagen. To further investigate 
this putative deregulation of FcyRllb, the effect of FcyRIIb-ligation on the 
collagen specific B cell response in CFA/CII and CFA control mice was 
investigated, during the days immediately pre- and post-collagen challenge 
(d21-d25).
4.3.2.1 FcyRllb co-ligation modulates BCR-mediated ErkWlAPK 
phosphorylation in splenic B cells from CFA control and CIA mice, ex vivo 
(d21-d25).
To determine whether the negative regulation of BCR-mediated ErkMAPK
signalling by FcyRllb was functional in CFA/Cll and CFA control mice during the
period of collagen re-challenge, the phosphorylation status of ErkMAPK
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following FcyRllb ligation or co-ligation with the BCR was investigated. Western 
blot analysis of anti-ErkMAPK immunoprecipitates from ex vivo stimulated B 
cells demonstrated that stimulation of the BCR with F(ab’)2  fragments of anti- 
IgM or collagen resulted in enhanced phosphorylation of ErkMAPK in CFA/CII 
mice (Figure 4.7). Similar to the stimulation with F(ab’)2  fragments, exposure to 
collagen stimulated ErkMAPK with preferential activation of the p42 form of 
ErkMAPK. Similar to the ErkMAPK results previously shown in Figure 4.1, 
FcyRllb co-ligation with the BCR on CFA/CII B cells resulted in a small 
reduction of p44 ErkMAPK phosphorylation levels. Interestingly, stimulation with 
collagen or F(ab’) 2  fragments of anti-lg antibodies demonstrated differential 
ErkMAPK phosphorylation profiles during the period of investigation. Collagen 
stimulation promoted a strong ErkMAPK response in d21 cells, correlating with 
the time of collagen challenge, which returned to basal levels over time. In 
contrast, F(ab’)2 stimulation promoted a maximal ErkMAPK response on day 23 
which remained above basal levels for the remainder of the time period. 
Importantly, FcyRllb-mediated negative feedback regulation of ErkMAPK 
appeared to be functional on days 23-25, but inoperative on days 21-22. These 
data suggest that deregulation of FcyRllb-mediated abrogation of ErkMAPK 
signalling may occur at the time of collagen challenge and could promote 
aberrant B cell responses.
4.S.2.2 FcyRllb co-ligation inhibits the BCR-mediated proliferative 
secondary response of splenic B cells, ex vivo (d21-d25).
Similar to the results obtained in 4.3.1.2, stimulation of the BCR with F(ab’)2
fragments of anti-mouse IgM antibody resulted in proliferation of splenic B cells
from both CFA/CII and CFA mice (Figure 4.8). Moreover, this proliferative
response could be inhibited in both groups of mice following FcyRllb-co-ligation
with the intact form of the antibody. Interestingly, the B cells appeared to be
rather anergic to BCR-induced stimulation in the days corresponding to the
onset of acute disease in the CFA/CII mice. In particular, the B cells appeared
to be unresponsive to stimulation or inhibition on days 24 and 25. However,
since the unresponsiveness is also demonstrated, albeit to a lesser degree by
the CFA mice, it suggests an inherent problem with the experimental procedure,
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as opposed to a suppressed immunological response. Importantly, no 
differences in the levels of FcyRllb-mediated inhibition of BCR-induced 
proliferation were seen between the CFA/CII and CFA control mice, even on 
day 23 as previously observed in 4.3.1.2.
Interestingly, although a low level collagen-specific B cell response was 
expected in the CFA control mice, B cells from both CFA/CII and CFA mice 
proliferated poorly when cultured in the presence of collagen (Figure 4.9). 
However, in the pre-exposed CFA/CII mice the poor proliferative response may 
be reflective of the low percentage of collagen-specific B cells in the purified 
splenic population. Thus the in vitro environment may also lack the co­
stimulatory signals that would be necessary for a full immunological response to 
collagen in vivo. Whilst the lack of a collagen-induced response makes the 
determination of whether FcyRllb is actively inhibiting the collagen-specific B 
cell population difficult, the DNA synthesis results following collagen-FcyRllb co­
stimulation suggest that FcyRllb-mediated inhibition could be dysfunctional on 
days 21-23. However, the low percentage of inhibition is similar in both groups 
of mice, suggesting a lack of collagen-specificity and perhaps reflects the 
breaking of naïve B cell unresponsiveness by inflammatory stimuli discussed 
above.
4.3.2.3 FcyRllb ligation induces growth-arrest and/or apoptosis of
splenic B cells from CFA control and CIA mice, ex vivo (d21-d25).
The FcyRllb-mediated growth arrest observed in 4.3.2.2 was confirmed by DNA 
content analysis. However, whilst data showed that FcyRllb- co-ligation with the 
BCR results in the accumulation of cells in the Gq/Gi phase of the cell cycle, 
(Figure 4.10) enhanced G0/G1 levels were also demonstrated by BCR and 
collagen stimulated cells on days 24 and 25. This result is supported following 
re-examination of the viable population of cells in Figure 4.11 These results 
show a correlation between the poor proliferative response following antigen 
receptor ligation or collagen stimulation in 4.3.2.2, with a reduction in the 
number of cells entering S phase. Furthermore, these studies show no
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differences in the commitment to growth-arrest or apoptosis between the two 
groups of mice following FcyRllb- co-ligation with the BCR.
4.3.3 The role of FcyRllb-mediated inhibition of peripheral lymphoid 
tissue mononuclear cells in the progression of collagen-induced arthritis, 
ex vivo (d8-d34).
The peripheral lymphoid organs are organised tissues where lymphocytes 
engage in important interactions with non-lymphoid cells for the initiation of an 
adaptive immune response. Although there are structural and anatomical 
differences, induction of immune responses in lymph nodes and the spleen 
occur by essentially similar mechanisms. Phagocytic and antigen-presenting 
cells bearing antigens are carried to the draining lymph nodes by the lymphatic 
system. Trapped in the nodes, naive B cells are localised into follicles and 
undergo intense proliferation after encountering the displayed specific antigen 
and helper T cells. Once antigen-specific B cells have undergone proliferation 
and differentiation they leave the lymph nodes and enter into circulation as 
effector cells. Whilst the organisation of the spleen is similar to that of the lymph 
node, antigen enters the spleen from the blood rather than from the lymph. The 
spleen is a larger lymphoid organ that also engages in the destruction of 
damaged red blood cells and thus the majority of the structure is dedicated to 
disposal of these cells.
In the spleen and lymph nodes, the distinct populations of cells are carefully 
regulated. A balance is required between the continuous supply of cells from 
the primary lymphoid tissues and their proliferation, terminal differentiation and 
death, in response to antigen. One method by which this achieved is through 
the expression of negative regulatory receptors, such as FcyRllb, by B cells and 
effector cells. Co-ligation of this receptor with the B cell antigen receptor or with 
other ITAM-containing receptors can lead to inhibition of cellular responses. 
Thus, lesions in the expression or signalling of FcyRllb may contribute to 
dysregulation of lymphocyte and other non-lymphoid cell responses and the 
development of inflammatory autoimmune disease. Indeed, published studies 
appear to support a role for FcyRllb in vivo to suppress autoimmunity by
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regulating both B cell and non-lymphoid cell activation (Suzuki et al., 1998; 
Clynes et al., 1999; Pearse et a!., 1999; Heyman, 2000; Nakamura, A. et a!., 
2000).
In contrast, previous results in this study, from DNA synthesis and cell-cycle 
analysis, seem to indicate that FcyRllb-mediated regulation of splenic B cells in 
CIA mice is intact and functional. In order to investigate the role of FcyRllb- 
mediated inhibition of both non- and lymphoid cells in the peripheral lymphoid 
organs, throughout CIA disease onset and progression, the ex vivo cellular 
responses of whole spleen and nodal populations to FcyRllb ligation were 
investigated. This method allows us to rule out the possible selective nature of 
the B cell purification process relating to distinct B cell sub-populations in the 
previous studies and to determine whether co-stimulatory signals from 
accessory cells are necessary for full FcyRllb-mediated inhibition of a collagen- 
induced immunological response ex wVo. This method also permits an 
investigation of the effect of Fcyllb induced growth-arrest or apoptosis by 
ligation or co-ligation of the receptor in two distinct sites of antigen encounter 
where antigen regulation of B cells is of primary importance for their proliferation 
and differentiation.
Spleens and lymph nodes were obtained post-sacrifice from CFA/CII and CFA 
control mice at stages of pre-disease and during disease onset and 
progression. The following study first examines the effect of FcyRllb ligation on 
the antibody-mediated proliferative response of splenic populations before 
looking at the nodal population responses.
4.3.3.1 FcyRllb co-ligation inhibits the BCR-mediated proiiferative 
response of spienic mononuciear cells from CFA control and CIA mice, ex 
vivo (d8-d34).
Using DNA synthesis assays as an indication of proliferation. Figure 4.12 
shows that stimulation of splenic cells with F(ab' )2 fragments of anti-lgM results 
in enhanced DNA synthesis in both groups of mice. This proliferative response
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could be inhibited in both groups of mice following FcyRllb-co-ligation with the 
intact form of the antibody. Similar to the results shown in (Figures 4.8 and 
4.9), the splenic cells were less responsive to BCR-induced stimulation as the 
disease progressed. However, in contrast to that observed with purified B cells, 
these results indicate that intact antibody alone actually stimulates low levels of 
cell proliferation, possibly through the co-activation of effector cells bearing 
ITAM-containing Fc receptors.
4.3.5.2 FcyRllb co-ligation modulates the collagen-induced proliferative 
response of splenic mononuclear cells from CFA control and CIA mice, ex 
vivo (d8-d34).
Similar to the results obtained in Figure 4.9, stimulation with collagen produced 
very little proliferative response thus confirming the low percentage of collagen- 
specific cells in the splenic population (Figure 4.13). Due to the lack of a 
collagen-induced response it is difficult to determine whether the intact antibody 
and thus, FcyRllb, is actively inhibiting proliferation of the collagen-specific cell 
population. Indeed, due to the ability of intact antibody alone to slightly enhance 
proliferation of the splenic population, co-stimulation with collagen results in an 
enhancement of the collagen initiated response.
4.3.3.3 FcyRllb ligation induces growth-arrest and/or apoptosis in 
splenic mononuclear cells from CFA control and CIA mice, ex wVo (d8- 
d34).
To confirm the induction of FcyRllb-mediated growth-arrest of the splenic cells, 
DNA content was analysed. Figures 4.14 and 4.17 show that BCR stimulation 
of the splenic population from naïve DBA/1 mice results in increased levels of 
cells entering the proliferative S and G2/M phases of the cycle. In contrast, 
BCR-FcyRllb co-ligation results in the accumulation of cells in the G0/G1 phase 
of the cell cycle and blocks entry into the S phase. Ligation of FcyRllb did not 
appear to modulate the cell cycle of the naïve cells co-stimulated with collagen. 
FcyRllb co-ligation was shown to inhibit cell cycle progression and induce 
growth-arrest and/or apoptosis in both BCR (Figures 4.15 and 4.18) and
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collagen (Figures 4.16 and 4.19) stimulated splenic cells from both CFA control 
and CIA mice. Interestingly, in BCR stimulated cells FcyRllb co-ligation 
enhanced both growth-arrest and apoptosis levels whilst in collagen stimulated 
cells, FcyRllb co-stimulation appeared to modulate apoptosis levels only. The 
differential response to FcyRllb co-ligation in the two stimulations may be due to 
the fact F(ab’)2 anti-lg stimulation will provide a positive survival signal to all the 
cells, whereas collagen stimulation will promote survival in only a small 
percentage of the cells.
4.3.3.4 Effect of FcyRllb co-ligation on the mitochondrial membrane 
potential of splenic mononuclear cells from CFA control and CIA mice, ex 
vivo (d8-d34).
In many cells, one of the consequences of the commitment to apoptosis is the 
disruption of mitochondrial function and depolarisation of the mitochondrial 
membrane potential ( A \ j /m ) .  This effect can be investigated in cells by the 
incorporation of the cationic lipophilic dye, DiOC6(3), where uptake of the dye is 
directly proportional to the A\|/m. To investigate whether FcyRlib-induced 
apoptosis in splenic mononuclear cells correlated with a reduction in A ij/m , BCR, 
FcyRllb and collagen stimulated cells from CFA/CII and CFA control mice were 
loaded with DiOCe(3) and subjected to FACS analysis. Figures 4.20 and 4.21 
clearly demonstrate that stimulation of the BCR results in a stabilisation of the 
mitochondria and a high A\|/m in splenic mononuclear cells from all groups of 
mice. In contrast, co-ligation of FcyRllb on the splenic cells with intact anti- 
IgM/IgG antibodies induced a decrease in Av|/m. Indeed, this decrease was more 
profound in cells stimulated with intact alone, whereas co-ligation with the BCR 
(Figures 4.21 and 4.22) in the presence of a mitogenic stimulus via the BCR 
produced an intermediate A\j/m. In agreement with the DNA synthesis and cell 
cycle analysis results, collagen stimulation resulted in minimal stabilisation of 
the mitochondrial membrane potential which was partially modulated following 
FcyRllb ligation (Figure 4.22) Thus, the FcyRllb-mediated mitochondrial 
depolarisation in splenic mononuclear cells correlates with the commitment and 
induction of apoptosis. Importantly, in agreement with the DNA synthesis and
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content analysis data, no differences between CFA/CII and CFA control mice 
were observed.
4.3 3.5 FcyRllb co-ligation inhibits the BCR-mediated proliferative 
response of mononuclear cells from lymph nodes of CFA control and CIA 
mice, ex vivo (d8-d34).
Inguinal and popliteal draining lymph nodes from CFA/II and CFA control mice 
were obtained at stages of pre-disease and during CIA onset and progression 
(days 8, 23 and 34 after the primary immunisation). The overall proliferative 
response of the cells to stimulation with F(ab’)2  fragments of anti-mouse Ig was 
reduced in comparison to that of the splenocyte population (Figure 4.23). This 
difference can presumably be explained by the low percentage of B cells in the 
lymph node compared to in the spleen (nodes, 20%; spleen 45%, results not 
shown). During disease progression, the response to proliferative and inhibitory 
stimuli was also reduced in the nodal population. Despite the reduced 
proliferative response, FcyRllb-ligation resulted in the inhibition of the BCR- 
mediated proliferative response by nodal mononuclear cells from both CFA 
control and CIA mice.
4.3.3.G FcyRllb co-ligation modulates the collagen-induced proliferative 
response of mononuclear cells from lymph nodes of CFA control and CIA 
mice, ex vivo (d8-d34).
Similar to the results obtained for the splenic population, the collagen-induced 
proliferative response of the nodal population was minimal (Figure 4.24) and 
stimulation with intact antibody alone resulted in enhanced DNA synthesis. Co­
stimulation of the nodal populations from both groups of mice, with collagen and 
intact antibody, did not inhibit the collagen-induced proliferative response. This 
lack of inhibition is presumably not due to deregulation of FcyRllb-mediated 
inhibitory effects, but is simply a reflection of the stimulatory effect of intact 
antibody alone. Furthermore, the co-stimulation also resulted in enhanced DNA 
synthesis in the CFA mice on day 8.
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4.3.3.7 FcyRllb ligation induces growth-arrest and/or apoptosis in 
mononuclear cells from lymph nodes of CFA control and CIA mice, ex 
vivo (d8-d34).
FcyRllb-mediated growth-arrest and/or apoptosis of nodal B cells was confirmed 
by DNA content analysis of the cells after 48 hours stimulation, ex vivo. Figure 
4.26 demonstrates that pre-disease onset, FcyRllb co-stimulation prevents the 
BCR-mediated S phase transition of nodal mononuclear cells and promotes 
G0/G1 arrest (Figures 4.26) and the commitment to apoptosis. However, at later 
stages of disease progression, FcyRllb co-ligation does not modulate the BCR- 
mediated cell cycle progression. This is accounted for by the minimal S/G2/M 
phase progression observed following BCR stimulation, when compared to 
control basal levels. The discrepancy of the results with the DNA synthesis 
data, may, once again, reflect differential numbers of rounds of division by the 
population of cells.
4.3.3 8 Effects of FcyRllb co-ligation on the mitochondrial membrane 
potential of mononuclear cells from lymph nodes of CFA control and CIA 
mice, ex wVo (d8-d34).
In agreement with the DNA synthesis and content data. Figure 4.27 
demonstrates that BCR stimulation results in minimal stabilisation of A\|/m in the 
nodal mononuclear cells. Interestingly, whilst co-ligation of FcyRllb induces a 
substantial decrease in A\j/m in nodal mononuclear cells from CFA/CII mice, the 
FcyRllb induced decrease in A\|/m of nodal mononuclear cells from CFA control 
mice is less pronounced as BCR-stimulation does not appear to protect the 
cells. This differential mitochondrial response to FcyRllb ligation between the 
two groups perhaps Indicates that nodal cells from CIA mice are more 
responsive to apoptotic signals than mice primed with CFA alone.
4.3.3.9 FcyRllbl and FcyRllb2 mRNA expression levels in spienic B
cells from CFA control and CIA mice (d21-d25).
As discussed in section 3.2.16, FcyRllb is expressed on B cells as two 
differentially-spliced isoforms, FcyRllbl and FcyRllb2. These isoforms appear to
202
Chapter 4 -  FcyRllb and Murine Autoimmune Disease Models
be identical except for an amino acid insert in the cytoplasmic domain of 
FcyRllbl, which abolishes the endocytic capacity of the receptor. Importantly, B 
cell expression levels of the two isoforms are thought to be modulated in 
response to activation by crosslinking of the BCR or culture with cytokines 
(Gergely, et ai, 1994). Thus, the relative expression levels of the different 
isoforms may be involved in the regulation of B cell response to antigen as 
downregulation of the endocytosis-competent isoform would prevent the 
interaction between antigen-specific B and T cells and hence suppress T cell- 
mediated help. To quantify the relative expression levels of the two FcyRllb 
isoforms RT-PCR was performed. Total RNA was extracted from purified, 
unstimulated splenic B cells from CFA/CII and CFA control mice during the days 
immediately pre- and post-collagen challenge. The RNA was reversed 
transcribed and the relative expression levels of the isoform transcripts were 
determined by quantitative TaqMan analysis.
The levels of FcyRllbl mRNA detected were higher than that of FcyRIIb2 in 
both groups of mice throughout the period of study (Figure 4.28). Interestingly, 
Gergely et al., 1994 have shown that in human B cells the expression levels of 
FcyRI I b2 greatly exceed that of FcyRllbl but activation by antigen-receptor 
stimulation induces alternative splicing of FcyRllbl and simultaneous 
suppression of FcyRllb2 mRNA. However, in both groups of mice the FcyRllbl 
message levels remain relatively constant through the period of disease onset, 
whilst FcyR 11 b2 is enhanced in CFA/CII mice following the second collagen 
challenge. These preliminary results suggest that FcyRllbl may be constantly 
expressed by murine B cells and predominantly mediate the negative regulation 
of B cell activation, whilst FcyRIIb2 expression is modulated depending on the 
availability of antigen and possibly influences the presentation of antigen by B 
cells. However, since these results are preliminary, the fluctuations observed 
may represent variation inherent within the assay. Thus, only through repeat 
experiments and the examination of surface expression of the two isoforms 
could this hypothesis be confirmed.
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4.3.4 Modulation of the immune response by a filarial nematode 
excretory-secretory product (ES-62).
Filarial nematodes are a large group of arthropod-transmitted vertebrate 
parasites that mediate lifelong infection. Moreover, individual parasites are 
capable of surviving in the host for in excess of five years. They are known to 
cause a range of debilitating diseases known collectively as filariasis, which 
includes lymphatic filariasis and onchocerciasis (WHO, 1987). Clinical 
manifestations of the disease can include blindness, swollen limbs, genitals and 
severe damage to the kidneys and lymphatic system, much of this pathology 
resulting as a consequence of the host immune response. The general success 
of the parasites, however, reflects the fact that the majority of infected 
individuals exhibit much less severe symptoms as a consequence of their ability 
to modulate or suppress the host immune response. Indeed, filarial Infection 
has been demonstrated to modulate both parasite-specific and general immune 
cell mediated responses. (Nutman et a!., 1987; Ottesen, 1984; Kwa and Mak, 
1984; Haque and Capron, 1986; King and Nutman, 1991; Maizels and 
Lawrence, 1991).
Despite numerous investigative studies the mechanisms of modulation are, as 
yet, undetermined. However, molecules released by the adult nematode during 
infection have been implicated as a causative factor for lymphocyte 
hyporesponsiveness (Weiss, 1978; Soboslay, et al., 1991). Work by this 
laboratory has previously shown that ES-62, a homologue of phosphorylcholine 
(PC)-containing glycoproteins secreted by human parasites, is the active 
inhibitory molecule secreted by the rodent filarial parasite Acanthocheilonema 
vlteae. Infection by this parasite leads to the targeting and subversion of the 
responses of a number of cells of the immune system including T and B cells 
dendritic cells and macrophages. For example, exposure to ES-62 not only 
renders B and T cells anergic to subsequent stimulation via the antigen 
receptors but also polarises immune responses to a Th2 phenotype by inhibiting 
pro-inflammatory cytokine production and driving differentiation of DCs to a 
DC2, TH2-promoting phenotype (reviewed by Harnett and Harnett, 1999).
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Extensive studies in lymphocytes have shown that ES-62 mediates its anti­
proliferative effects by uncoupling the antigen receptors from key downstream 
proliferative signalling pathways. In particular, by selectively downregulating 
certain PKC isoforms and by desensitising protein tyrosine kinase-dependant 
coupling of the antigen receptors to PI-3-kinase and the Ras/ErkMAPKinase 
signalling cascades (Figure 4.29). Thus, this uncoupling results in a novel 
mechanism by which ES-62 can inhibit antigen receptor-mediated proliferative 
responses and subvert the normal immune response of the host.
Similarities between the inhibitory signalling mechanisms of ES-62 and FcyRllb 
on B cells suggested that they could share similar effector pathways. 
Specifically, ES-62 has been shown to desensitise the BCR-mediated activation 
of ErkMAPK by the recruitment of the tyrosine phosphatase SFIP-1 and the 
MAPKinase phosphatase, Pac-1 (Deehan etal., 2001) (Figure 4.30) Moreover, 
the ability of ES-62 to initiate a polarised Th2 response may represent a novel 
therapeutic strategy for the treatment of inflammatory-type autoimmune 
diseases, since the generation of a Tni-type immune response by collagen- 
specific CD4^ T cells, is crucial for the development of arthritis in the CIA model. 
Thus, the ability of ES-62 to suppress B cell activation and antibody production 
was of interest when investigating the role of FcyRllb in the regulation of CIA.
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4.3.4.1 Effect of in vivo exposure to ES-62 on the FcyRllb Inhibition of 
BCR-mediated proliferative responses of nodal mononuclear and splenic 
B cells, ex vivo.
To determine whether ES-62 subverts the negative regulation of B cells by 
FcyRllb, the antibody-mediated proliferative responses of nodal mononuclear 
and splenic B cells, pre-exposed to ES-62 in vivo, were investigated. Through 
the use of osmotic pumps to deliver ES-62, the constant release of the parasite 
product during infection is mimicked efficiently in vivo, whilst minimising animal 
handling and stress which may influence the overall immune response 
(Goodridge et a!., 2001). Figure 4.31 demonstrates that proliferation of 
mononuclear cells from the draining lymph nodes and B cells from the spleens 
of ES-62 treated mice, in response to anti-mouse Ig stimulation, is suppressed 
in comparison to the control mice treated with PBS. Furthermore, this 
suppression is shown to be dose-dependent. Importantly, FcyRllb mediated 
inhibition of B cell proliferation is shown to be functional at all concentrations of 
ES-62 treatment, resulting in enhanced suppression of the BCR-mediated 
proliferative response.
4.3.4.2 Collagen-induced Arthritls/ES-62 prophylactic model
The generation of a Tnl-type immune response by collagen-specific CD4+ T 
cells, is thought to be essential for the development of arthritis in the CIA model. 
The ability of ES-62 to bias the immune system in favour of an anti­
inflammatory Th2 response has prompted the investigation into the use of ES- 
62 as a possible therapeutic candidate for the treatment of arthritis. A 
prophylactic model for the prevention of disease onset by ES-62 is shown in 
Figure 4.32. Results of clinical measurements and histological assessments 
taken by Dr. Bernard Leung (Department of Immunology, University of 
Glasgow) are shown in Figure 4.33 The results clearly show that prophylactic 
use of ES-62, either in limited or multiple dosage, results in a reduction of the 
mean articular index, disease incidence rate and characteristic paw thickening 
throughout the onset and progression of CIA in DBA/1 mice. In vitro analysis 
also demonstrated that ES-62 modulates the anti-collagen response of nodal
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mononuclear cells by reducing the levels of pro-inflammatory mediators TNF-a, 
IFN-y and IL-6 whilst promoting the production of the anti-inflammatory cytokine, 
IL-10 (d33; results not shown). Continual in vivo exposure to ES-62 also 
suppressed the production of anti-collagen lgG2a antibodies whilst enhancing 
the levels of collagen-specific lgG1 (d50). This modulation was also shown to 
last beyond the time period of treatment, until the termination of the study at day 
50.
4.3.4.3 Effect of FcyRllb co-ligation on the BCR and collagen-mediated 
proliferative response of spienic B cells from CFA/Collagen primed DBA/1 
mice foliowing prophylactic ES-62 treatment, ex vivo.
Previous results from the CIA model demonstrated that FcyRllb-mediated 
negative regulation of B cell activation appeared to be intact throughout the 
onset and progression of arthritis. To determine whether the inhibitory role of 
FcyRllb is independent of the suppressive effects of ES-62 on the induction of 
CIA, the antibody-mediated proliferative responses of splenic B cells from 
CFA/Collagen primed DBA/1 mice following prophylactic ES-62 treatment were 
investigated. Figure 4.34 shows that on day 50 of the study, the proliferation of 
splenic B cells from ES-62 treated mice, in response to BCR and collagen 
stimulation, is suppressed in comparison to mice treated with PBS alone. In 
addition, this suppression is enhanced in mice treated with multiple doses of 
ES-62. Importantly, FcyRllb mediated inhibition of BCR and collagen-specific 
proliferation is shown to be functional and independent of ES-62 treatment.
4.3.5 The role of FcyRllb-mediated inhibition of B cells in a murine model 
of systemic lupus erythematosus.
Several studies have demonstrated that an essential component for the
development of lupus-like disease in mice is the presence of autoreactive B
cells. These are found at relatively higher numbers and are substantially
activated compared with non-autoimmune mice (reviewed by Schlomchik et ai.,
1994). These autoreactive B cells produce a variety of autoantibodies which are
virtually diagnostic of lupus, such that agents that interfere with autoantibody
production have been shown to attenuate disease (Tumlin, 1999). To
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investigate whether abnormal FcyRllb negative regulation or isoform expression 
in B cells contributes to the generation of disease in an established murine 
lupus model, the involvement of FcyRllb on ex vivo B cell immunological 
responses of MRI_/Mp-/pr//pr mice was tested.
Initial results from a preliminary experiment using an in-house, in-bred mouse 
colony seemed to indicate that FcyRllb might be dysregulated in this disease. 
Figure 4.35 shows that splenic B cells from a female MRL-ZprZ/pr mouse with 
chronic lupus-like disease, have enhanced levels of DNA synthesis when 
stimulated with F(ab’ ) 2  fragments of anti-mouse IgM/lgG. In contrast, no 
stimulation of DNA synthesis is observed following co-ligation of the BCR with 
FcyRllb with the intact form of the antibody alone. Importantly, BCR-FcyRllb co­
ligation, with a combination of both F(ab’)2  and intact anti-lg together, does not 
result in a significant inhibition of BCR-induced DNA synthesis.
This result was in direct contrast to the induction of growth-arrest normally 
observed when co-crosslinking FcyRllb and the BCR on splenic B ceils from 
Balb/c or DBA/1 (Fas^) mice. These initial observations suggested that Fas, or 
Fas related signalling pathways, could play a role in the regulation of FcyRllb- 
mediated inhibition of splenic B cell activation. Thus, Fas may be required for 
the successful inhibition of BCR-mediated activation by antigen-antibody 
complexes.
To investigate the potential involvement of dysfunction of Fcy-mediated 
regulation of B cell activation in murine lupus, the proliferative responses of 
splenic B cells from MRL/Mp-/pr//pr mice was investigated throughout the onset 
and progression of disease. The SLE model strain used in these secondary 
studies {NlRLMp-lpr/Oia/Hsd, H-2 )^ was developed in the Jackson Laboratory, 
Bay Harbor, USA, by backcrossing the congenic mutant gene ip r  
{iymphoproiiferation) by 5-cycles of cross-intercross matings from substrain 
MRL/1 to substrain MRL/n (now designated MRL/Mp-+/+). Male MRL/Mp-/pr//pr 
mice were monitored for the physiological signs of disease onset from 13 
weeks, in particular for the development of lymphadenopathy and diseased ear
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lobes. Male MRLMp-lpr/lpr lupus model mice normally have a mean survival 
age of 22 weeks, compared to 20 weeks in the females. This difference is 
presumably due to the presence of oestrogen in female mice which is thought to 
slightly accelerate the disease onset. However, mortality in both genders 
usually arises from renal failure, due to glomerulonephritis.
4.3.5.1 Effect of FcyRllb co-ligation on the BCR-mediated proliferative 
response of splenic B cells from MRL/MP-/pr//pr mice, ex vivo.
DNA synthesis experiments demonstrated that FcyRllb was capable of inducing 
B cell growth-arrest following co-ligation with the BCR in male MRL/MP-/pr//pr 
mice up to 21-26 weeks of age (Figure 4.36). This inhibition is also shown to be 
overcome by co-culturing the cells with IL-4, a B cell stimulatory cytokine 
produced by Th2 CD4+ T cells. Whilst FcyRllb co-ligation is shown to inhibit 
BCR-mediated proliferation during weeks 14-21, the inhibitory effect is reduced 
as the disease progresses. Thus, by week 26, FcyRllb co-ligation does not 
significantly inhibit BCR induced DNA synthesis. In agreement with previous 
results, no DNA synthesis is associated with intact antibody stimulation alone, 
throughout the period of study.
4.3.5.2 FcyRllb ligation induces growth-arrest and/or apoptosis splenic 
B cells from MRL/MP-/pr//pr mice, ex wVo.
DNA content analysis confirmed the induction of growth-arrest following BCR- 
FcyRllb co-ligation in the early weeks of disease, whilst also demonstrating that 
commitment to apoptosis by FcyRllb is Fas independent (Figures 4.37 and 
4.38). In contrast to the DNA synthesis results, stimulation with intact antibody 
alone, or in combination with F(ab’) 2  fragments, resulted in similar levels of 
growth-arrest and apoptosis in splenic B cells from mice aged 26 weeks. 
Furthermore, following stimulation with intact anti-lg antibodies fewer cells 
accumulated in G0/G1 than in the control, with an increase in the sub-diploid 
population. These results may indicate that only a small population of cells were 
responsible for the enhanced levels of proliferation seen in the DNA synthesis 
assay.
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4.3.5.3 Effects of BCR and FcyRllb co-ligation on the mitochondrial 
membrane potential of splenic B cells from MRL/MP-/pr//pr mice, ex vivo.
Cell death receptors such as Fas (CD95) initiate apoptotic pathways by directly 
recruiting pro-caspases, such as caspases 10 and 8 (see 1.2.4). Activation of 
the caspase-cascade can lead to a loss of mitochondrial function and integrity, 
resulting in enhanced production of reactive oxygen species, calcium cycling 
and disruption of the inner mitochondrial potential. FcyRllb ligation on splenic B 
cells has been shown in this study to result in a depolarisation of the 
mitochondrial membrane that is indicative of apoptosis. To investigate whether 
FcyRllb-mediated mitochondrial disruption is Fas-dependent, the mitochondrial 
membrane potential of intact antibody stimulated B cells from MRL-/pr//pr mice 
was assessed. Figure 4.39 demonstrates that FcyRllb stimulation of Fas 
deficient splenic B cells results in a loss of mitochondrial membrane potential, 
whilst stimulation via the BCR results in membrane potential stabilisation. Thus, 
the mechanism by which this is achieved is not dependent on the expression of 
Fas.
4.3.5.4 Effects of BCR ligation on the FcyRllbl and FcyRllb2 mRNA 
expression levels in splenic B ceils from MRL/l\/lP-/pr//pr mice, ex vivo.
To investigate whether the modulation of FcyRllb isoform expression by splenic 
B cells is involved in the initiation of lupus-like disease in MRL/Mp-/pr//pr mice, 
RT-PCR was performed to identify potential lesions in the expression of the 
isoforms at the mRNA. Throughout the progression of disease total RNA was 
extracted from splenic B cells of MRL/Mp-Zpr/Zprmice, following BCR stimulation 
for 48 hours. The RNA was reversed transcribed, in the presence of Superscript 
RT™ II and the relative expression levels of the isoform transcripts were 
determined by quantitative TaqMan analysis. Figure 4.40 shows preliminary 
results from these investigations. Interestingly, the data implies that during the 
progression of disease in MRL/Mp-lpr/lpr mice the relative expression levels of 
both FcyRllb isoforms decreases. Thus, these results correlate with the 
dysregulation of FcyRllb-mediated B cell inhibition found in the later stages of 
lupus-like disease in the MRL-Zpr/Zpr mice suggesting that FcyRllb may be a
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susceptibility factor, contributing to the genetic and environmental background 
that is required for the emergence of lupus-like disease in these mice.
4.4 Discussion
4.4.1 FcyRllb and collagen-induced arthritis.
The role of inhibitory receptors and molecules in the regulation of lymphocyte 
homeostasis and tolerance to self-antigens has been demonstrated in 
numerous knockout and deletion studies. Studies that have investigated the 
involvement of FcRs in the onset of disease in CIA have highlighted their 
importance. In particular, mice deficient in the low affinity receptor for IgE 
(FceRII), and FcyRlla developed CIA with delayed onset and reduced severity 
compared with wild-type mice (Kleineau etal., 1999). In contrast, mice deficient 
in the inhibitory receptor for IgG, FcyRllb, have augmented immune responses, 
high levels of antigen specific serum IgG and an increased incidence of 
autoimmune disease (Takai etal., 1996). Furthermore, mice with genotypes 
normally associated with resistance to collagen-induced arthritis, become 
susceptible to autoimmune arthritis when FcyRllb is deleted (Yuasa et al.,
1999).
In this study, we have demonstrated that in an established murine model of 
inflammatory arthritis, CIA, FcyRllb-mediated negative regulation of splenic B 
cell proliferation is functional throughout disease onset and progression, 
however there was a suggestion that FcyRllb-mediated negative regulation of 
the BCR-mediated response may be deregulated in CIA mice at the time of 
collagen re-challenge. Furthermore, BCR-mediated ErkMAPK phosphorylation 
in CIA mice did not appear to be uncoupled following BCR-FcyRllb co-ligation. 
However, these results were not reflected in the percentage of cells undergoing 
growth-arrest or commitment to apoptosis by cell cycle analysis of DNA content, 
following FcyRllb co-ligation. Indeed, similar levels of growth-arrest and/or 
apoptosis were shown in both CIA and control CFA mice. To clarify this 
discrepancy and to determine whether FcyRllb deregulation in CIA mice was 
potentially limited to collagen-specific B cells, the regulatory role of FcyRllb-
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ligation on the collagen-specific B cell response, during the days immediately 
pre- and post-collagen challenge, was investigated. Similarly, BCR-mediated 
ErkMAPK phosphorylation did not appear to be uncoupled in CIA mice following 
FcyRllb co-ligation. In contrast, DNA synthesis and content analysis 
demonstrated that FcyRllb-mediated negative regulation was functional in both 
general and collagen-specific B cells. This suggest that ErkMAPK may be 
coupled to mechanisms that lead to both proliferation and growth arrest in CIA 
mice or that FcyRllb mediated disruption of ErkMAPK is not required to induce 
growth-arrest in splenic B cells from CIA mice. It also implicates the requirement 
for further positive signals, in addition to ErkMAPK, to promote a proliferative 
response. Thus, examination of alternative signalling components, in addition to 
ErkMAPK phosphorylation, is required to understand the mechanisms leading 
to proliferation, growth-arrest and/or commitment to apoptosis in these cells.
These results are in direct contrast to studies in FcyRllb deficient mice which 
implicate FcyRllb as a susceptibility factor for the onset and progression of 
spontaneous autoimmune disease and collagen-induced arthritis (Takai et al., 
1996; Yuasa etal., 1999; Bolland and Ravetch, 2000). Interestingly, the 
incidence of arthritic disease in FcyRllb deficient mice was lower than in the 
established DBA/1 CIA model (42% versus 95%) (Yuasa etal., 1999), 
confirming that multiple defects are required for the full initiation of disease. 
Similar to our studies, the proliferative responses of mononuclear lymphoid cells 
to antigenic stimulation in CIA and FcyRllb deficient mice with collagen (CM) 
were limited. Indeed, demonstrable differences in the collagen-specific 
responses were only observed by Yuasa et al. following priming and stimulation 
with twice the amount of Cll used in our study. Furthermore, the CM specific 
responses were identical in FcyRllb deficient, wild type and DBA/1 CIA mice at 
the normal levels of CM immunisation required for CIA induction. These results 
therefore suggest that the level of circulating antigen-antibody complexes 
dictate whether FcyRllb is important for mediating negative feedback regulation 
of antigenic stimulation.
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However, in the present study, the collagen-specific proliferative response in the 
CFA/CII mice was very low and implied that the percentage of collagen-specific 
B cells in the purified splenic population was minimal. Poor collagen-specific 
responses may also be due to the lack of lymphoid organ structure in vitro, 
resulting in the absence of co-stimulatory signals necessary for a full 
immunological response to collagen in vivo.
Thus, to examine the requirement for bystander lymphoid cells in the collagen- 
specific proliferative response, the ex wVo cellular responses of whole spleen 
and nodal populations to FcyRllb ligation were investigated. DNA synthesis and 
content analysis confirmed that FcyRllb-mediated negative regulation was 
functional in mononuclear cells from spleen and nodal populations. This finding 
was also supported by a demonstrable disruption of the mitochondrial 
membrane potential following FcyRllb-ligation, an early indication of 
commitment to apoptosis.
Interestingly, in our study discrepancies were found in FcyRllb-mediated 
inhibition of ErkMAPK phosphorylation in CIA and ClA-control mice. In 
particular, phosphorylation of the p44 (Erk1) form of ErkMAPK was differentially 
inhibited by FcyRllb in CFA control and CIA mice. Studies in p44 (Erk1) 
MAPKinase knockout mice (Pages et a!., 1999) have demonstrated that whilst 
lymphocyte maturation is normal in Erki deficient mice, proliferation in response 
to antigenic stimulation is reduced. Thus, whilst p42 (Erk 2) MAPKinase can 
compensate for the loss of p44 (Erki) in lymphocyte development, their findings 
indicate that there may be physiological distinctions between the two isoforms in 
the regulation of lymphocyte proliferation. This suggests that there may be a 
potential requirement for ErkMAPK activity, in particular Erki, in the basal 
proliferation of splenic B cells from DBA/1 mice and that the removal of this 
signal, due to FcyRllb co-ligation, may be sufficient to induce growth arrest 
and/or apoptosis. However, the finding that FcyRllb-mediated growth arrest and 
commitment to apoptosis are accompanied by the activation of ErkMAPK in B 
cells from CIA mice is of interest (see above). These data suggest that rather 
than being essential for proliferation, ErkMAPK may represent a permissive
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signal for B cell proliferation in these mice and that further positive signals are 
required for the full proliferative effect. Thus, these results may indicate the 
downregulation or inhibition of a further component of a BCR-mediated 
signalling pathway that modulates ErkMAPK derived proliferative signals.
A central role for phosphatases in the development of autoimmunity has been 
implicated in other murine models displaying deficiency in an inhibitory receptor, 
such as CD22 (O’Keefe et al., 1996) or PD-1 (Nishimura et al., 1999). B cells 
from CD22-deficient mice exhibit the cell surface phenotype and augmented 
intracellular calcium responses characteristic of hyper-responsive B cells, 
similar to that of SHP-1 deficient mice (Sato et al., 1996). CD22 may control 
basal BCR signal transduction thresholds in resting B cells through the binding 
of SHP-1. Thus, in the absence of CD22 a lack of SHP-1 recruitment permits 
chronic tyrosine phosphorylation of the BCR in resting B cells and 
hyperactivation. Therefore, alterations in CD22 function or expression could 
contribute to autoimmunity or other disease in which B cell function is 
dysregulated. Indeed, reduced up-reguiation of CD22 on activated B cells and 
aberrant expression of the CD22 allele, CD22a, is implicated in autoantibody 
production in NZW murine models of lupus-like disease (Mary et al., 2000) 
providing support for CD22a as a possible candidate allele contributing to lupus 
susceptibility. Furthermore, genetic variations of human CD22 and the possible 
association with rheumatic diseases has been investigated in patients with 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Whilst no 
significant association was observed between any of the CD22 variations and 
RA, the data indicated that a number of genetic variants are present in CD22, 
and the authors suggest that CD22 could be considered as a candidate 
susceptibility gene for autoimmune diseases (Hatta et al., 1999).
PD-1 is an ITIM-containing, transmembrane Ig Super-Family (IgSF) receptor 
(reviewed by Nishimura and Honjo, 2001). It is expressed on thymocytes and 
mature macrophages and lymphocytes following activation. Engagement of PD- 
1 with PD-1 ligand (PD-L) expressing antigen-presenting cells results in 
negative signalling. Similar to FcyRllb, co-ligation of the BCR with the PD-1 
cytoplasmic region in vitro, results in the recruitment of the tyrosine
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phosphatase, SHP-2, and the inhibition of BCR mediated calcium influx and 
tyrosine phosphorylation of downstream signalling activation molecules, such as 
Syk, PI-3-Kinase, PLC-y and Vav. The inhibitory effect also leads to the 
inhibition of the MAPKinase pathway, resulting in inhibition of B cell 
proliferation. Importantly, PD-1 deficiency causes lupus and arthritis like disease 
in a C57BL/6 mouse background (Nishimura etal., 1999). Thus, similar to 
FcyRllb, PD-1 could be involved in the onset and progression of autoimmune 
disease. Unfortunately, primary splenic B cells and mononuclear cells 
stimulated with LPS, F(ab’)2  fragments of anti-lg antibodies or IL-4 failed to 
demonstrate upregulation of PD-1 expression, as determined by FACS analysis 
with a PD-1 specific monoclonal antibody. Thus, investigation of its potential 
role in autoimmune disease murine models proved impossible.
Examination of the relative message levels of the two isoforms of FcyRllb during 
the period of collagen re-challenge indicated that differential isoform expression 
might play a role in the initiation of disease. Indeed, FcyRllbl mRNA levels 
remained relatively constant throughout the period of disease onset in both 
groups of mice, whilst FcyRIIb2 was enhanced in CFA/CII mice following the 
second collagen challenge. Alterations in FcyRllb isoform expression may 
contribute to the disease initiation process by modulating antigen-presentation 
by autoreactive B cells. Thus in healthy strains of mice a balance of FcyRllb 
isoform expression levels on B cells will prevent aberrant activation by immune- 
complexes and regulate IgG antibody responses through a negative feedback 
mechanism. In contrast, selective down-regulation of FcyRllbl in B cells might 
promote T cell mediated help and hence permit inappropriate activation of B 
cells by immune-complexes. An upregulation of FcyRIIb2 may also promote 
antigen uptake and presentation by the B cells and thus could break normally 
tolerant B cells. Moreover, co-stimulatory T cell help will also overcome the 
negative feedback regulation mediated by FcyRllbl. Thus in CIA, an 
upregulation of FcyRIIb2 on B cells may promote the presentation of self­
antigen to autoreactive T cells and initiate an autoimmune response.
As a low affinity receptor, FcyRllb acts most successfully in areas with high 
concentrations of immunocomplex such as the germinal centre. The down-
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regulation of FcyRllbl expression on germinal centre B cells in autoimmune 
disease prone mice is, however, unlikely to be an effect of disease, since a 
downregulation in the expression of FcyRllbl was found in mice at an age 
before the onset of disease (Jiang et al., 1999). These results are in agreement 
with our proposal that downregulation of FcyRllbl expression may promote 
disease initiation.
B cells studies from CIA mice carried out in vitro are usually naive cells derived 
from spleens primed with high doses of antigen in vivo. Activated B cells have 
Fc receptors with a higher affinity for passively administered IgG than naïve B 
cells. However, disruption of FcyRllb has been shown not to appreciably modify 
the antigen-specific T cell response in non-permissive animals and thus is not 
likely to account for the susceptibility of these animals to CIA (Bolland and 
Ravetch, 2000). However, the fact that FcyRllb is thought to prevent the 
activation of low-affinity autoreactive cells in the periphery and that auto­
antibody production is enhanced in FcyRllb knockout mice, may support a role 
for this receptor in some experimental disease systems. Thus, further 
investigation of FcyRllb function in B-1 cells, which display a propensity to 
produce low-affinity autoreactive antibodies, may provide further insight into 
how dysregulation of B cell activation promotes the initiation and progression of 
disease. Hyper-antibody production may also be attributed to a decrease in 
FcyRIIb2 expression on macrophages, as reported in NOD mice (Luan et al., 
1996), the result being a reduction in the clearance of IgG immune complexes 
leading to the accumulation of immune complexes in the circulation.
The finding that deletion of the FcyRllb gene renders mice susceptible to CIA 
does not confirm the role of the receptor in the initiation of disease. Indeed, the 
development of autoimmune disease in FcyRllb deficient mice has since been 
shown to be strain dependent (Bolland and Ravetch, 2000), such that the 
mechanisms by which B cell FcyRllb deficiency result in autoimmunity may be 
dependent on the C57/BL6 (H-2^) or 129/SvJ (H-2^) backgrounds. Thus, 
FcyRI lb-deficient Balb/c (H-2^) mice, remain non-susceptible to the
development of CIA. Interestingly, deletion of the FcyRllb gene backcrossed
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into the DBA/1 (/-/-2^) mouse, the strain used in these studies, leads to a 
dramatically enhanced development of CIA and also contributes to increased 
susceptibility to other autoimmune diseases, such as gastritis (Kleinau et a!., 
2000). The causes for strains differences are still unknown but one candidate is 
the bias towards a T r I  response in susceptible animals (Afonso et al., 1994).
These results suggest that in conjunction with certain HLA haplotypes, that 
selectively bind and present self-peptides to autoreactive T cells, FcyRllb plays 
an important role in regulating antigen-presentation in the pathogenesis of CIA 
and that the ability of the FcyRllb2 isoform to mediate antigen-endocytosis, may 
dictate the involvement of the receptor in the onset and progression of disease 
The initiation of CIA may therefore rely on both enhanced humoral responses to 
type II collagen and augmented proinflammatory mediator release (TNF-a) by 
effector cells, such as macrophages. Further investigation of these disease 
susceptibility genes will help to characterise the pathogenesis of autoimmune 
disease and provide new prophylactic and therapeutic approaches. One such 
approach currently being investigated is the use of an immunomodulatory 
molecule, ES-62, secreted by filarial nematodes.
4.4.2 Role of FcyRllb in ES-62 treatment of collagen-induced arthritis.
The generation of collagen-specific antibodies by B cells and the promotion of a 
Tnl-type immune response by collagen-specific CD4+ T cells are crucial for the 
development of arthritis in the CIA model. Thus, the inhibition of lymphocyte 
activation and the initiation of a Tr2 immune response by ES-62 may represent 
a novel therapeutic treatment strategy. In vivo exposure of B cells to ES-62 in 
this animal model confirmed the ability of the parasite product to inhibit BCR- 
mediated DNA synthesis. In contrast, FcyRllb-mediated inhibition of B cell 
proliferation was shown to be functional at all concentrations of ES-62 
treatment, resulting in enhanced suppression of the BCR-mediated proliferative 
response.
Prophylactic or therapeutic use of ES-62 in the treatment of CIA clearly 
demonstrated a reduction in the mean articular index, disease incidence rate
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and characteristic paw thickening throughout the onset and progression of CIA. 
Initial observations by our laboratory had suggested that FcyRllb and ES-62 
might mediate their suppressive effects by similar routes of inhibition or that ES- 
62 might mediate its effects through binding or upregulation of FcyRllb. 
However, ES-62 pre-treatment did not affect the ability of FcyRllb to Inhibit 
BCR-mediated DMA synthesis nor did it result in a synergistic inhibition of B cell 
activation, implying that ES-62 did not mediate its effects directly via FcyRllb 
signalling. It would be interesting to speculate, however, that, in addition to its 
direct anti-proliferative effects on B cells, ES-62 may inhibit antigenic stimulation 
of the BCR by upregulating the expression of FcyRllbl. This may prove 
important in the perpetuation of disease, where expansion of autoreactive B 
cells requires T cell help. However, preliminary investigations of FcyRllb isoform 
expression on B cells following pre-exposure to ES-62 were inconclusive and 
were unable to support this theory.
Interestingly, ES-62 was shown to skew the anti-collagen antibody response 
from lgG2a to lgG1 phenotype. This modulation of IgG subclass may play an 
important role in the regulation of the immune response to collagen as it 
dictates which FcyRs are ligated and therefore determines the effector 
mechanism elicited. For example, lgG2a will only ligate the low affinity FcyR, 
FcyRlla, on inflammatory effector cells. A switch to lgG1 permits binding to all 
FcyR members . Thus, ES-62 may mediate its anti-inflammatory effects through 
the upregulation of IgG immune complex binding receptors and FcyR-bearing 
phagocytic cells whilst switching off the generation of inflammatory mediators by 
antigen-presenting cells and autoantibody production by B cells
4.4.3 Role of FcyRllb In a murine model of systemic lupus erythematosus 
(SLE).
As discussed above, mice deficient in FcyRllb have been shown to develop 
lupus-like disease spontaneously (Bolland and Ravetch, 2000; Nakamura et al.,
2000) whilst some autoimmune disease prone mouse strains have a promoter 
that is associated with reduced surface expression and function of this receptor
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(Pritchard et al., 2000). These results indicate that FcyRllb may have a 
preventative influence on the initiation of autoimmunity. Importantly, lupus-like 
disease is accelerated in mice deficient in Fas or Fas-ligand. Since B cell Fas 
expression is considered to most important in preventing inappropriate Th 
dependent expansion of autoreactive B cells in the peripheral lymphoid tissues 
this could suggest that FcyRllb-mediated commitment to apoptosis may occur 
via a Fas dependent mechanism. However, the exact mechanisms of FcyRIlb- 
induced apoptosis have not been elucidated and a requirement for Fas has not 
been investigated.
Initial studies in a female MRL-lpr/lpr mouse, in which lupus-like disease was 
well established, indicated that FcyRllb-mediated inhibition was indeed 
dysregulated in Fas deficient mice. These data suggested that FcyRllb may be 
involved in the initiation of lupus-like disease and that Fas may play a role in 
FcyRllb killing. Analysis of FcyRllb-mediated negative regulation in male MRL- 
Ipr/lpr mice before disease onset and during onset and progression 
demonstrated that prior to disease onset FcyRllb-mediated negative regulation 
was functional. However, FcyRllb inhibition of BCR-induced DNA synthesis was 
lost during disease progression. Interestingly, this loss of FcyRllb-mediated 
negative regulation correlated with an increase of disease severity in the mice, 
thus the animals analysed at 26 weeks displayed chronic physiological signs of 
inflammatory disease. Analysis of apoptosis levels demonstrated that FcyRIlb- 
induced apoptosis was functional throughout the disease progression and 
contradicted the DNA synthesis data. However, the data also indicated that 
FcyRllb-mediated growth arrest was functional. It is difficult to explain these 
obvious differences in DNA synthesis and content but these results suggest that 
FcyRllb mediated growth-arrest is Fas-independent but that disease 
progression in these mice could induce this additional lesion. Furthermore, 
disruption of the mitochondrial membrane potential, suggests that apoptosis is 
Fas-independent. However, studies of Fas-mediated death have indicated that 
Fas can initiate apoptotic mechanisms that are independent of mitochondrial
219
Chapter 4 -  FcyRllb and Murine Autoimmune Disease Models
disruption (reviewed by Krammer, 2000) and thus supports a Fas-independent 
mechanism for FcyRllb induced cell death.
The strongest hypothesis for the initiation of lupus-like disease in these mice is 
that self-reactive T and B cells arise when they fail to undergo normal apoptosis 
therefore it is of interest that FcyRllb-mediated apoptosis appears to be 
functional and this requires further investigation. Others, who suggest that B cell 
tolerance may be relatively independent of Fas, may support the theory that 
FcyRllb mediated effects are perhaps more important for inducing self-tolerance 
at other stages of B cell development. Consistent with this, our preliminary data 
from MRL-/pr//pr mice investigating the relative B cell expression levels of 
FcyRllb isoforms following BCR-stimulation, suggest that FcyRllb expression 
may be modulated in these mice. Disease progression was accompanied by a 
downregulation in mRNA levels of both isoforms of FcyRllb. Suggesting that 
aberrant expression of FcyRllb could promote perpetuation of lupus-like disease 
in these mice.
Discrepancies in the results obtained from the female and male MRL//pr//pr 
mice may be accounted for by differences in supply and disease onset. The 
females were supplied in house from an in-bred colony, whereas the males 
were bred commercially. The females displayed advanced physiological stages 
of disease by 18 weeks. In contrast, the males only demonstrated chronic 
physiological signs of disease by 26 weeks. It is therefore of interest that the 
male mice demonstrated aberration in FcyRllb-mediated B cell inhibition at 
week 26, at a similar stage of disease progression as the females. Furthermore, 
there are marked age- and sex related variations in the isotype of anti-DNA 
antibodies seen in murine models of SLE. Importantly, there is an antibody 
isotype switch from IgM to lgG2a as the mice mature. This switch is seen earlier 
in females than males, coinciding with the onset of renal disease. This 
observation highlights the importance of antibody isotype in immune complex 
deposition and that FcyR-bearing antigen-presenting cells will only be able to 
bind the anti-DNA antibodies and promote an inflammatory response following 
the isotype switch.
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In MRL“/pr//pr no evidence for linkage of H-2 haplotype with nephritis is 
apparent, however, IgG autoantibody production was reduced by breeding H-2*^  
onto B6-/pr//pr mice suggesting that the disease is related to HLA and antigen 
presentation. However, the full expression of lupus-like disease is dependent on 
complex genetic contributions from other non-MHC genes. Indeed, a minimum 
of three distinct genetic loci is required for the development of disease in the Fi 
cross of NZB/NZW. Spontaneous SLE models of NZB and (NZW x NZB) Fi 
mice also demonstrate downregulation of FcyRllb in germinal centre B cells 
associated with IgG hypergammaglobulinemia and IgG autoantibody production 
(Jiang, et al., 1999) indicating a possible lack of negative feedback. Genetic 
linkage studies have associated Fas-L (gid) on chromosome 1 with FcyRllb but 
Fas (Ipr) is on chromosome 19 and not linked to FcyRllb. In addition, nephritis in 
New Zealand hybrid mice (NBA2/S/e1) mice map to a region that is linked to 
FcyRllb. Thus it would be of interest to repeat this study and investigate the role 
of FcyRllb function and expression in these other murine models of lupus-like 
disease, such as female MRL/g/d/g/d mice, to confirm whether FcyRllb does 
indeed play a role in the initiation of disease.
No counterparts to Ipr or gId phenotypes exist in human SLE, indicating that 
there are multiple different factors involved in the initiation of lupus-like disease 
in humans and mice. However, a skewing of FcyRlla allotype expression has 
been reported in SLE patients and linked with nephritis in African-Americans 
and Caucasians (Duits et al., 1995). The differential expression results in the 
downregulation of the H I31 allele of FcyRlla, the only human FcyR that 
recognises lgG2a efficiently, implying that the skewing may lead to the 
downregulation of endocytic capability of phagocytes and insufficient clearance 
of immune complexes (Vyse and Kotzin, 1998).
Except for the complete deficiencies of classical pathway complement proteins 
the association of SLE with non-MHC genes or loci remains for the most work in 
progress. However, FcyRIIb-deficiency appears to be a susceptibility factor, 
contributing to the genetic and environmental background that is required for 
the emergence of disease.
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Figure 4.1 Effect of FcyRllb co-ligation on BCR-mediated ErkMAPK 
phosphorylation in splenic B cells from naïve, CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (dO-d47).
Purified splenic B cells from naïve, CFA control or CFA/Collagen primed DBA/1 
mice (1 X 10  ^ cells) were stimulated for 48 hours in the presence of 50 |Lig/ml 
F(ab’)2 fragments of goat anti-mouse IgM (p-chain specific) or 75 |ig/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Whole 
cell lysates were immunoprecipitated with anti-ErkMARK antibody (Erk23) and 
Western blotted for phospho-ErkMAPK. The numbers beneath the blots 
represent the relative band density as assessed by densitometry from a single 
experiment, compared to the band density obtained for the naïve control and 
arbitrarily set as 1. (-) represents bands that were too faint for accurate 
quantitation.
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Figure 4.2 Effect of Fc^llb co-ligation on the BCR-mediated proiiferative 
response of splenic B cells from naïve, CFA control and CFA/Collagen 
primed DBA/1 mice, ex vivo (d0-d47).
Purified splenic B cells from naïve, CFA control or CFA/Collagen primed DBA/1 
mice (2 x 10  ^cells) v/ere stimulated for 48 hours in the presence of 50 jig/ml 
P(ab’}2  fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Culture 
wells were pulsed with [^H]-Thymidine (0.5 pC i/we 11) 4 hours prior to harvesting 
and pH]-incorporation was assessed by scintillation counting. Data are 
expressed as the mean ± standard deviation from triplicate measurements of a 
single experiment.
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Figure 4.3 DNA content of splenic B cells from naïve, CFA control or 
CFA/Collagen primed DBA/1 mice post-sacrifice and following BCR and 
FcyRllb stimulation of naïve splenic B cells, ex vivo (d0-d47).
Purified splenic B cells from naïve, CFA control and CFA/Collagen DBA/1 mice 
(1 X 10® cells) were subjected to DNA content analysis post-sacrifice. In 
addition, splenic B cells from naïve DBA/1 mice (1x10® cells) were stimulated 
for 48 hours in the presence of 50 pg/ml F(ab')z fragments of goat anti-mouse 
IgM (p-chain specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, 
or in combination, as indicated. Cells stimulated in the presence of medium 
alone were included as a control. DNA content was determined by propidium 
iodide (PI) staining and FACS analysis, as described in the Materials and 
Methods. Data represents each cell cycle stage expressed as a percentage of 
the total number of cells analysed from a single experiment.
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Figure 4.4 Effects of BCR and FcyRllb co-ligation on the DNA content of 
splenic B cells from CFA control and CFA/Collagen primed DBA/1 mice, 
ex wVo (dO-d47).
Purified splenic B cells from CFA control or CFA/Collagen primed DBA/1 mice 
(1x10® cells) were stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total number of cells analysed from a 
single experiment.
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Figure 4.5 DNA content of the living population of splenic B cells from 
naïve, CFA control or CFA/Collagen primed DBA/1 mice post-sacrifice and 
following BCR and FcyRllb stimulation of naïve splenic B cells, ex wVo 
(dO-d47).
Purified splenic B cells from naïve, CFA control and CFA/Collagen DBA/1 mice 
(1 X 10® cells) were subjected to DNA content analysis post-sacrifice. In 
addition, purified splenic B cells from naïve DBA/1 mice (1 x 10® cells) were 
stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  fragments of goat 
anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM 
either alone, or in combination, as indicated. Cells stimulated in the presence of 
medium alone were included as a control. DNA content was determined by 
propidium iodide (PI) staining and FACS analysis, as described in the Materials 
and Methods. Data represents each cell cycle stage expressed as a percentage 
of the total living population of cells analysed from a single experiment.
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Figure 4.6 Effects of BCR and FcyRllb co-ligatlon on the DNA content of 
the living population of splenic B cells from CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (d0-d47).
Purified splenic B cells from CFA control or CFA/Collagen primed DBA/1 mice 
(1 X 10® cells) were stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total living population of cells analysed 
from a single experiment.
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Figure 4.7 Effect of FcyRllb co-ligation on BCR-mediated ErkMAPK 
phosphorylation in splenic B cells from CFA/Collagen primed DBA/1 mice, 
ex vivo (d21-d25).
Purified splenic B cells from CFA/Collagen primed DBA/1 mice (1.5 x 10^  cells) 
were stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 pg/ml 
F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Whole 
cell lysates were immunoprecipitated with anti-ErkMAPK antibody (Erk23) and 
Western blotted for phospho-ErkMAPK. The numbers beneath the blots 
represent the relative band density as assessed by densitometry from a single 
experiment, compared to the band density obtained for the individual control at 
48 hours and arbitrarily set as 1. (-) represents bands that were too faint for 
accurate quantitation.
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Figure 4.8 Effect of FcyRllb co-ligation on the BCR-mediated proliferative 
response of splenic B cells from CFA control and CFA/Collagen primed 
DBA/1 mice, ex vivo (d21-d25).
Purified splenic B cells from CFA control or CFA/Collagen primed DBA/1 mice 
(2x10® cells) were stimulated for 48 hours in the presence of 50 pg/ml F(ab')z 
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Culture 
wells were pulsed with [®H]-Thymidine (0.5 pCi/well) 4 hours prior to harvesting 
and [®H]-incorporation was assessed by scintillation counting. Data are the 
mean ± standard deviation of triplicate measurements from a single experiment.
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Figure 4.9 Effects of FcyRllb ligation on the collagen-specific proliferative 
response of splenic B cells from CFA control and CFA/Collagen primed 
DBA/1 mice, ex vivo (d21-d25).
Purified splenic B cells from CFA control or CFA/Collagen primed DBA/1 mice 
(2x10® cells) were stimulated for 48 hours in the presence of 50 pg/ml collagen 
or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in combination, as 
indicated. Cells stimulated in the presence of medium alone were included as a 
control. Culture wells were pulsed with [®H]-Thymidine (0.5 pCi/well) 4 hours 
prior to harvesting and [®H]-incorporation was assessed by scintillation counting. 
Data are the mean ± standard deviation of triplicate measurements from a 
single experiment.
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Figure 4.10 DNA content of splenic B cells from CFA control and 
CFA/Collagen primed DBA/1 mice post-sacrifice or following BCR and 
FcyRllb co-ligation, ex vivo (d21-d25).
Purified splenic B cells from CFA control and CFA/Collagen primed DBA/1 mice 
(1 X 10® cells) were subjected to DNA content analysis post-sacrifice or were 
stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total number of cells analysed from a 
single experiment.
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Figure 4.11 DNA content of the living population of splenic B cells from 
CFA control and CFA/Collagen primed DBA/1 mice post-sacrifice or 
following BCR and FcyRllb co-ligation, ex vivo (d21-d25).
Purified splenic B cells from CFA control and CFA/Collagen primed DB/V1 mice 
(1x10® cells) were subjected to DNA content analysis post-sacrifice or were 
stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total living population of cells analysed 
from a single experiment.
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Figure 4.12 Effect of FcTRIIb co-ligation on the BCR-mediated proliferative 
response of splenic mononuclear cells from CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control and CFA/Collagen primed DBA/1 
mice (5 x 10® cells) were stimulated for 48 hours in the presence of 50 |xg/ml 
F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Culture 
wells were pulsed with f  H]-Thymidine (0.5 pC i/we 11) 4 hours prior to harvesting 
and [®H]-incorporation was assessed by scintillation counting. Data are the 
mean ± standard deviation of triplicate measurements.
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Figure 4.13 Effect of FcyRHb ligation on the collagen-specific proliferative 
response of splenic mononuclear cells from CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control or CFA/Collagen primed DBA/1 
mice (5 x 10® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
collagen or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Cells stimulated in the presence of medium alone 
were included as a control. Culture wells were pulsed with [®H]-Thymidine (0.5 
pC i/we 11) 4 hours prior to harvesting and [®H]-incorporation was assessed by 
scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from a single experiment.[®H]-incorporation data from 
stimulation of splenic mononuclear cells from naïve DBA/1 mice: Collagen 
3681 ±394, Intact + Collagen 16181 ± 1731.
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Figure 4.14 DNA content of splenic mononuclear cells from naïve, CFA 
control or CFA/Collagen primed DBA/1 mice post-sacrifice and following 
BCR, collagen or FcyRHb stimulation of naïve splenic B cells, ex vivo (d8- 
d34).
Splenic mononuclear cells from naïve, CFA control and CFA/Collagen DBA/1 
mice (1 X 10® cells) were subjected to DNA content analysis post-sacrifice. In 
addition, splenic mononuclear cells from naive DBA/1 mice (1 x 10® cells) were 
stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml Intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total number of cells analysed from a 
single experiment.
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Figure 4.15 Effects of BCR and FcyRHb co-ligation on the DNA content of 
splenic mononuclear cells from CFA control or CFA/Collagen primed 
DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control and CFA/Collagen DBA/1 mice (1 x 
10® cells) were stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total number of cells analysed from a 
single experiment.
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Figure 4.16 Effect of FcyRHb co-ligation on the DNA content of collagen- 
specific splenic mononuclear cells from CFA control and CIA mice, ex 
vivo (d8-d34).
Splenic mononuclear cells from CFA control or CFA/Collagen primed DBA/1 
mice (1x10® cells) were stimulated for 48 hours in the presence 50 pg/ml 
collagen or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Cells stimulated in the presence of medium alone 
were included as a control. DNA content was determined by propidium iodide 
(PI) staining and FACS analysis, as described in the Materials and Methods. 
Data represents each cell cycle stage expressed as a percentage of the total 
number of cells analysed from a single experiment.
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Figure 4.17 DNA content of the living population of splenic mononuclear 
cells from naïve, CFA control or CFA/Collagen primed DBA/1 mice post­
sacrifice and following BCR, collagen or FcyRHb stimulation of naïve 
splenic mononuclear cells, ex vivo (d8-d34).
Splenic mononuclear cells from naïve, CFA control and CFA/Collagen DBA/1 
mice (1 X 10® cells) were subjected to DNA content analysis post-sacrifice. In 
addition, splenic mononuclear cells from naive DBA/1 mice (1x10® cells) were 
stimulated for 48 hours in the presence 50 pg/ml collagen or 50 pg/ml F(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total living population of cells analysed 
from a single experiment.
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Figure 4.18 Effects of BCR and FcyRHb co-ligation on the DNA content of 
the living population of splenic mononuclear cells from CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control or CFA/Collagen primed DBA/1 
mice (1x10® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. DNA 
content was determined by propidium iodide (PI) staining and FACS analysis, 
as described in the Materials and Methods. Data represents each cell cycle 
stage expressed as a percentage of the total living population of cells analysed 
from a single experiment.
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Figure 4.19 Effect of FcyRHb co-Hgatlon on the DNA content of the living 
population of collagen-specific splenic mononuclear cells from CFA 
control and CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control or CFA/Collagen primed DBA/1 
mice (1x10® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
collagen or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. DNA content was determined by propidium iodide 
(PI) staining and FACS analysis, as described in the Materials and Methods. 
Data represents each cell cycle stage expressed as a percentage of the total 
living population of cells analysed from a single experiment.
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Figure 4.20 Mitochondrial membrane potential of splenic mononuclear 
cells from naïve, CFA control or CFA/Collagen primed DBA/1 mice post­
sacrifice and following BCR, collagen or FcyRHb stimulation of naïve 
splenic mononuclear cells, ex vivo (d8-d34).
The mitochondrial membrane potential of splenic mononuclear cells from naïve, 
CFA control and CFA/Collagen DBA/1 mice (1 x 10® cells) was analysed post- 
sacrifice. In addition, splenic mononuclear cells from naive DBA/1 mice (1x10® 
cells) were stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 
pg/ml F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. 
Cells stimulated in the presence of medium alone were included as a control. 
The mitochondrial membrane potential was determined by DiOC6(3) staining 
and FACS analysis, as described in the Materials and Methods. Data 
represents DiOCe (3)^°^ and DiOCe (3)^'°^ cell populations, as determined on a 
logarithmic FL-1 axis, and expressed as a percentage of the total number of 
cells analysed from a single experiment.
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Figure 4.21 Effects of BCR and FcyRHb co-ligation on the mitochondrial 
membrane potential of splenic mononuclear cells from CFA control and 
CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CFA control or CFA/Collagen primed DBA/1 
mice (1 X 10® ceils) were stimulated for 48 hours in the presence of 50 pg/ml 
F(ab')z fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. The 
mitochondrial membrane potential was determined by DiOC6(3) staining and 
FACS analysis, as described in the Materials and Methods. Data represents 
DiOC6(3)‘'°'^ and DiOCe(3) cell populations, as determined on a logarithmic 
FL-1 axis, and expressed as a percentage of the total number of cells analysed 
from a single experiment.
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Figure 4.22 Effects of FcyRHb ligation on the mitochondrial membrane 
potential of collagen-specific splenic mononuclear cells from CFA control 
and CFA/Collagen primed DBA/1 mice, ex vivo (d8-d34).
Splenic mononuclear cells from CPA control or CFA/Collagen primed DBA/1 
mice (1 X 10® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
collagen or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. The mitochondrial membrane potential was 
determined by DiOC6(3) staining and FACS analysis, as described in the 
Materials and Methods. Data represents DiOC6(3)"-°^ and DiOC6(3)"^"^^ cell 
populations, as determined on a logarithmic FL-1 axis, and expressed as a 
percentage of the total number of cells analysed from a single experiment.
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Figure 4.23 Effect of FcyRHb co-ligation on the BCR-mediated proliferative 
response of mononuclear cells from lymph nodes of CFA control and CIA 
mice, ex vivo, (d8-d34).
Mononuclear cells from lymph nodes of CFA or CFA/Collagen primed DBA/1 
mice (5 x 10® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75pg/ml intact 
rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. Culture 
wells were pulsed with [®H]-Thymidine (0.5 pCi/well) 4 hours prior to harvesting 
and [®H]-incorporation was assessed by scintillation counting. Data are the 
mean ± standard deviation of triplicate measurements from a single experiment. 
[®H]-incorporation data from stimulation of mononuclear cells from lymph nodes 
of naïve DBA/1 mice was unavailable.
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Figure 4.24 Effects of FcyRllb co-ligation on the collagen-specific 
proliferative response of mononuclear cells from lymph nodes of CFA 
control and CIA mice, ex vivo, (d8-d34).
Mononuclear cells from lymph nodes of CFA or GFA/Collagen primed DBA/1 
mice (5 xIO® cells) were stimulated for 48 hours in the presence of 50 pg/ml 
Collagen or 75pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Culture wells were pulsed with [^H]-Thymidine (0.5 
pCi/well) 4 hours prior to harvesting and [^H]-incorporation was assessed by 
scintillation counting. Data are the mean ± standard deviation of triplicate 
measurements from a single experiment. pH]-incorporation data from 
stimulation of mononuclear cells from lymph nodes of naïve DBA/1 mice was 
unavailable.
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Figure 4.25 Effects of BCR and FcyRllb co-ligation on the DNA content of 
mononuclear cells from lymph nodes of CFA control and CIA mice, ex 
vivo (d8-d34).
Mononuclear cells from lymph nodes of CFA control or CFA/Coliagen primed 
DBA/1 mice (1x10® cells) were analysed for DNA content post-sacrifice or 
were stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  fragments of 
goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit anti-mouse 
IgG/IgM either alone, or in combination, as indicated. Cells stimulated in the 
presence of medium alone were included as a control. DNA content was 
determined by propidium iodide (PI) staining and FACS analysis, as described 
in the Materials and Methods. Data represents each cell cycle stage expressed 
as a percentage of the total number of cells analysed from a single experiment, 
n.d. = not done.
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Figure 4.26 Effects of BCR and FcyRllb co-ligation on the DNA content of 
the living population of mononuclear cells from lymph nodes of CFA 
control and CIA mice, ex vivo (d8-d34).
Mononuclear cells from lymph nodes of CFA control or CFA/Collagen primed 
DBA/1 mice (1x10® cells) were analysed for DNA content post-sacrifice or 
were stimulated for 48 hours in the presence of 50 pg/ml F(ab’)2  fragments of 
goat anti-mouse IgM (p-chain specific) or 75pg/ml intact rabbit anti-mouse 
IgG/IgM either alone, or in combination, as indicated. Cells stimulated in the 
presence of medium alone were included as a control. DNA content was 
determined by propidium iodide (PI) staining and FACS analysis, as described 
in the Materials and Methods. Data represents each cell cycle stage expressed 
as a percentage of the total living population of cells analysed from a single 
experiment, n.d. = not done.
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Figure 4.27 Effects of BCR and FcyRllb co-ligation on the mitochondrial 
membrane potential of mononuclear cells from lymph nodes of CFA 
control and CIA mice, ex vivo (d8-d34).
The mitochondrial membrane potential of mononuclear cells from lymph nodes 
of CFA control or CFA/Collagen primed DBA/1 mice (1 x 10® cells) was 
analysed post-sacrifice of following stimulation for 48 hours in the presence of 
50 pg/ml F(ab’)2  fragments of goat anti-mouse IgM (p-chain specific) or 75pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. 
Cells stimulated in the presence of medium alone were included as a control. 
The mitochondrial membrane potential was determined by DiOC6(3) staining 
and FACS analysis, as described in the Materials and Methods. Data 
represents DiOCe(3)^^'^ and DiOC6(3)^‘®'^  cell populations, as determined on a 
logarithmic FL-1 axis, and expressed as a percentage of the total number of 
cells analysed from a single experiment.
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Figure 4.28 FcyRllbl and FcyRilb2 mRNA expression levels in splenic B 
cells from CFA control and CFA/Collagen mice (d21-d25).
Total RNA was extracted from unstimulated, purified splenic B cells (5 x 10® 
cells) of CFA control or CFA/Collagen primed DBA/1 mice and was subjected to 
reverse transcription in the presence of 100 U Superscript II RT, as described in 
the Materials and Methods. FcyRllbl (upper panel) and FcyRllb2 (lower panel) 
isoform transcripts were assayed for by real-time PCR (TaqMan). mRNA levels 
are expressed as a percentage relative to HPRT mRNA levels ± standard 
deviation of triplicate measurements from a single experiment.
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Figure 4.29 ES-62 desensitises coupling of the BCR to key proliferative 
signalling cascades.
Exposure of murine B cells to ES-62 selectively desensitises BCR-mediated 
proliferation by targeting key proliferative signalling pathways. Whilst, early slg- 
coupled mediators such as the PTKs Lyn, Syk and BIk are relatively unaffected 
the subsequent PTK-mediated activation of downstream PI3-K and Ras-MAPK 
pathways is targeted. The nematode product also modulates the activity of 
certain PKG isoforms. The BCR is uncoupled from those pathways represented 
to the right of the arrow. (Adapted from Harnett and Harnett, 1999).
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Figure 4.30 ES-62 uncouples the BCR from ErkMAPK activation by 
priming B cells for BCR-mediated recruitment of SHP-1 and Pac-1.
ES-62 uncouples the BCR from ErkMAPK by (1) promoting the BCR 
recruitment of Lyn-SHP-1 protein tyrosine phosphatase complexes. (2) the 
dephosphorylation of Ig-p, preventing the recruitment of Shc-SOS complexes. 
(3) the formation of ErkMAPK/Pac-1 complexes (adapted from Deehan et a!., 
2001).
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Figure 4.31 Effect of in vivo exposure to ES-62 on the FcyRllb inhibition of 
BCR-mediated proliferative responses of spienic B cells and mononuclear 
cells from lymph nodes of Balb/c mice, ex vivo.
Balb/c mice were exposed to PBS or different concentrations of ES-62 in vivo 
by release from osmotic pumps for two weeks. Mononuclear cells from lymph 
nodes (upper panel) (5 x 10® cells) and purified splenic B cells (lower panel) (2 x 
10® cells) were stimulated for 48 hours in vitro in the presence of 50 pg/ml 
F(ab’)2 fragments of goat anti-mouse IgM (p-chain specific) alone or 75 pg/ml 
intact rabbit anti-mouse IgG/IgM either alone, or in combination, as indicated. 
Cells cultured in the presence of medium alone were included as a control. 
Culture wells were pulsed with [®H]-Thymidine (0.5 pCi/well) 4 hours prior to 
harvesting and [®H]-incorporation was assessed by scintillation counting. Data 
are the mean ± standard deviation of triplicate measurements from a single 
experiment.
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Figure 4.32 Collagen-induced Arthritis/ES-62 prophylactic protocol.
Î  = Induction of CIA. Î  = ES-62 treatment. Male DBA/1 mice (PBS 13 per 
group: ES-62 14 per group) were immunised intradermally at the tail base with a 
total of lOOpI CFA emulsified bovine type II collagen (CM; 200pg) or CFA alone 
on day 0. An intraperitoneal Cll challenge (CM, 200pg in PBS) was carried out 
on day 21. ES-62 (2 pg/animal, s.c.) was administered prior to induction of CIA 
at d-2, and concurrently with collagen challenges at dO and d21. *ES-62: 
additional ES-62 treatments were administered d22-24 plus 1 treatment every 
three days until the end of the study (ES-62 Multi). PBS was used as the 
control. Animals were observed for up to 5 weeks for the development of 
arthritis.
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Figure 4.33 Clinical measurements and histological assessments of 
collagen-induced arthritis mice following prophylactic treatment with ES- 
62.
Dr. Bernard Leung undertook all clinical measurements and histological 
assessments of the collagen-induced Arthritis/ES-62 prophylactic model. Data 
of individual measurements from the PBS, ES-62 and ES-62 Multi groups (PBS 
n=13 /group; ES-62 n=14/group) were collected from the time of the 
Intraperitoneal Cll challenge on day 21 until the termination of the study on day 
50. Graphs represent the mean articular index and disease incidence rates of 
the arthritic groups only and the paw pad thickness of the entire study group. 
Data are the mean ± S.E.M from a single experiment.
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Figure 4.34 Effect of FcyRllb co-ligation on the BCR-mediated proliferative 
response of splenic B cells from collagen-induced arthritis model mice 
following prophylactic treatment with PBS or ES-62, ex vivo (d50).
On day 50 of the study, purified splenic B cells (2 x10® cells) from PBS, single­
dose ES-62 or multiple dose ES-62 prophylactic treated CIA mice, were 
stimulated for 48 hours in the presence of 50 pg/ml collagen or 50 pg/ml P(ab’)2  
fragments of goat anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit 
anti-mouse IgG/IgM either alone, or in combination, as indicated. Cells cultured 
in the presence of medium alone were included as a control. Culture wells were 
pulsed with [^H]-Thymidine (0.5 pCi/well) 4 hours prior to harvesting and [^H]- 
incorporation was assessed by scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from a single experiment.
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Figure 4.35 Effect of FcyRllb co-ligation on the BCR-mediated proliferative 
response of splenic B cells from a female MRL-/pr//pr mouse, ex vivo.
Purified splenic B cells (2 x 10® cells) from a female MRL-/pr/7pr mouse, aged 18 
weeks, were stimulated for 48 hours in the presence of 50 |ig/ml F(ab’)2  
fragments of goat anti-mouse IgG/IgM or 75pg/ml intact rabbit anti-mouse 
IgG/IgM either alone, or in combination, as indicated. Cells stimulated in the 
presence of medium alone were included as a control. Culture wells were 
pulsed with [®H]-Thymidine (0.5 jxCi/well) 4 hours prior to harvesting and [®H]- 
incorporation was assessed by scintillation counting. Data are the mean ± 
standard deviation of triplicate measurements from a single experiment. 
*p<0.05, Mann-Whitney test.
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Figure 4.36 Effect of FcyRllb co-ligation on the BCR-mediated proliferative 
response of splenic B cells from MRL-/pr//pr mice, ex vivo (w14-w26).
Purified splenic B cells from male MRL-/pr//pr mice (2 x10® cells) were 
stimulated for 48 hours in the presence of 50 p,g/ml P(ab’) 2  fragments of goat 
anti-mouse IgM (p-chain specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM 
or 10 U/ml murine IL-4 either alone, or in combination, as indicated. Cells 
stimulated in the presence of medium alone were included as a control. Culture 
wells were pulsed with [®H]-Thymidine (0.5 pC i/we 11) 4 hours prior to harvesting 
and [®H]-incorporation was assessed by scintillation counting. Data are the 
mean ± standard deviation of triplicate measurements from a single 
experiment.*p<0.05, Mann-Whitney test.
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Figure 4.37 Effects of BCR and FcyRllb co-ligation on the DNA content of 
splenic B cells from WlRL-/pr//pr mice, ex vivo (w14-w26).
Purified splenic B cells from male MRL-/pr//pr mice (1 x 10® cells) were 
subjected to DNA content analysis post-sacrifice or were stimulated for 48 
hours in the presence of 50 p,g/ml P(ab’)2 fragments of goat anti-mouse IgM (ju- 
chain specific) or 75 ng/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Cells stimulated in the presence of medium alone 
were included as a control. DNA content was determined by propidium iodide 
(PI) staining and FACS analysis, as described in the Materials and Methods. 
Data represents each cell cycle stage expressed as a percentage of the total 
number of cells analysed from a single experiment.
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Figure 4.38 Effects of BCR and FcTRIIb co-iigation on the DNA content of 
the living population of splenic B cells from MRL-/pr//pr mice, ex vivo 
(w14-w26).
Purified splenic B cells from male MRL-/pr//pr mice (1x10® cells) were 
subjected to DNA content analysis post-sacrifice or were stimulated for 48 
hours in the presence of 50 jig/ml F(ab’)2  fragments of goat anti-mouse IgM (|i- 
chain specific) or 75 |ig/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Cells stimulated in the presence of medium alone 
were included as a control. DNA content was determined by propidium iodide 
(PI) staining and FACS analysis, as described in the Materials and Methods. 
Data represents each cell cycle stage expressed as a percentage of the total 
living population of cells analysed from a single experiment.
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Figure 4.39 Effects of BCR and FcyRllb co-ligation on the mitochondrial 
membrane potential of splenic B cells from MRL-/pr//prmice, ex vivo (w14- 
w26).
Purified splenic B cells from male MRL-lpr/lpr mice (1x10® cells) were 
assessed for mitochondrial membrane potential post-sacrifice or were 
stimulated for 48 hours in the presence of 50 jiig/ml F(ab' )2  fragments of goat 
anti-mouse IgM (ji-chain specific) or 75 |ig/ml intact rabbit anti-mouse IgG/IgM 
either alone, or in combination, as indicated. Cells stimulated in the presence of 
medium alone were included as a control. The mitochondrial membrane 
potential was determined by DiOC6(3) staining and FACS analysis, as 
described in the Materials and Methods. Data represents DiOC6(3)^°^ and 
DiOC6(3)^’°^ cell populations, as determined on a logarithmic FL-1 axis, and 
expressed as a percentage of the total number of cells analysed from a single 
experiment, (n.d. = not done).
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Figure 4.40 Effects of BCR and FcyRllb co-ligation on the FcyRllbl and 
FcyRllbZ mRNA expression levels in splenic B cells from MRL-/pr//pr mice, 
ex vivo (w14-w26).
Total cellular RNA was extracted from purified splenic B cells from male MRL- 
/pr//pr mice (5 x 10® cells) post-sacrifice or following stimulation for 48 hours in 
the presence of 50 pg/ml P(ab’)2 fragments of goat anti-mouse IgM (ja-chain 
specific) or 75 pg/ml intact rabbit anti-mouse IgG/IgM either alone, or in 
combination, as indicated. Cells stimulated in the presence of medium alone 
were included as a control. Total RNA was subjected to reverse transcription in 
the presence of 100 U Superscript RT II. FcyRllbl (upper panel) and FcyRllb2 
(lower panel) isoform transcripts were assayed for by real-time PCR (TaqMan). 
Levels are expressed as a percentage relative to HPRT mRNA levels ± 
standard deviation of triplicate measurements from a single experiment.
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Chapter 5 -  Role of FcyRllb in Human Autoimmune 
Disease
5.1 Human Autoimmune Disease
As discussed in the previous chapter autoimmunity is the inappropriate 
response of the immune system to self-antigens. Autoimmunity can lead to 
autoimmune diseases such as systemic lupus erythematosus (SLE) and 
Goodpasture’s syndrome which are characterised by tissue damage, caused as 
a result of the formation of immune complexes and local inflammation (Ada, et 
al., 1997). Clinical disease generally manifests as a result of damage induced 
in one or more organs via the inappropriate activation of immune-mediated 
inflammation. Collectively, autoimmune disease is estimated to affect 4-5% of 
the total human population, with females generally having a higher disease 
incidence than males (Vyse and Todd, 1996). Five of the most common 
autoimmune diseases are rheumatoid arthritis (RA), Graves’ disease, insulin- 
dependent diabetes mellitus (IDDM), SLE and multiple sclerosis (MS). Together 
they represent almost 50% of all autoimmune diseases.
Despite numerous studies, the pathogenic mechanisms leading to a breakdown 
of self-tolerance and the initiation of autoimmunity remain poorly characterised. 
Many studies have attempted to associate autoimmunity with abnormal 
lymphocyte homeostasis (Theofilopoulos, eta!., 2001), focusing on abnormal T 
cell responses, production of T cell cytokines and/or defective control by 
regulatory T cells (Maloy and Powrie, 2000). Early investigations into the role of 
B cells focused on their ability to produce pathogenic autoantibodies and the 
formation of antigen-antibody complexes. However, recent studies of B cells 
have demonstrated that they display a variety of characteristics that could 
contribute towards the initiation and perpetuation of an autoimmune disease 
(Edwards, at a!., 1999). Whilst acting as the precursors for antibody-secretion, 
B cells play an essential role in the development of lymphoid architecture by 
influencing the differentiation of follicular dendritic cells in the secondary 
lymphoid organs. In addition, by acting as antigen-presenting cells, B cells can
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co-ordinate T cell migration and differentiation. B cell-derived cytokine 
production may also upregulate the functions of a variety of other cells involved 
in immune responses, such as antigen-presenting ceils (reviewed by 
Porakishvili, et al., 2001). Together, these results indicate that B cells play an 
essential role in the initiation and regulation of both T and B cell responses. 
Thus, excessive or upregulated B cell activity may increase the likelihood of 
developing autoimmunity. Importantly B cells have been shown to play a crucial 
role in the initiation of autoimmune disease in a murine model of SLE 
(Schlomchik, et al., 1994) and in patient studies of rheumatoid arthritis 
(Edwards and Cambridge, 2001).
5.1.1 Systemic lupus erythematosus
Systemic lupus erythematosus is considered to be the prototypic immune 
complex disease (reviewed by Kotzin, 1996). It is a chronic autoimmune 
disease characterised by the development of IgG hypergammaglobulinemia and 
antibody production directed at the nuclear components of cells. Principal 
targets include certain protein-DNA complexes and ribonucleic proteins. Since 
large quantities of self-antigen are available, large numbers of immune 
complexes are deposited in the walls of the small blood vessels in the renal 
glomerulus, joints and other organs. The tissue-deposition of these antigen- 
antibody complexes ultimately leads to the release of inflammatory mediators 
and infiltration of inflammatory cells. These factors cause further tissue damage 
and the release of cellular contents. The increase in concentration of available 
self-antigen results in the further production of nuclear-protein complexes and a 
cyclical exacerbation of the disease.
The clinical manifestations of SLE are extremely diverse with patients displaying 
a multitude of different disease phenotypes (reviewed by Kotzin and O’Dell, 
1995). For example, whilst some patients demonstrate a skin rash and joint pain 
but undergo spontaneous remission and hence require little medication, others 
may suffer from severe and progressive glomerulonephritis that require high 
dose steroid therapy and cytotoxic drugs. As such, it remains unclear whether
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SLE is a single disease with variable severity levels or a group of related 
conditions.
The exact causative factor of SLE is unknown but the emergence of disease 
appears to depend on environmental factors that initiate or contribute to 
autoimmunity in genetically prone individuals (reviewed by Vyse and Kotzin, 
1998). Candidate factors include female sex hormones (the disease is 
predominantly found in females of childbearing age) and viral/bacterial infection. 
The mechanism by which most autoantibodies in SLE may cause disease is 
also uncertain as the formation of circulating immune complexes, resulting in 
the deposition of anti-nuclear autoantibodies, does not appear to mediate the 
renal damage commonly observed. It is thought that either the glomerulus binds 
DNA, which is subsequently recognised by anti-DNA antibodies leading to in 
situ complex formation or there is cross reaction between a subset of anti-DNA 
antibodies with glomerular structures that are not DNA in origin.
The main immunological characteristics of SLE are a number of profound B cell 
abnormalities that permit the generation, differentiation and positive selection of 
B cells that secrete pathogenic autoantibodies (reviewed by Lipsky, 2001). SLE 
patients may possess B cells that display abnormal antigen-receptor repertoires 
or undergo mechanisms contributing to somatic hypermutation. Intrinsic B cell 
hyperactivity to normal antigenic stimulation may also provide the drive for 
autoantibody production.
5.1.2 Rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory joint disease, resulting from a 
dysregulation of the immune response (reviewed by Sturrock, 1987; Feldmann 
et a/., 1996). The disease is characterised by the infiltration of the synovial 
membrane by activated lymphocytes, neutrophils and macrophages and 
hyperplasia of the resident synoviocytes. Often the initial damage occurs in the 
small joints of the hands and the feet, although any joint can be affected. 
Articular damage arises due to deregulated cellular processes and the 
overproduction of inflammatory cytokines (IL-1p and TNF-a) and other soluble 
mediators. These cytokines mediate the further production of inflammatory
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molecules and the secretion of metalioproteinases (MMP) to degrade type II 
collagen in cartilage. The synovium thus becomes progressively thickened and 
inflamed with further infiltration by lymphocytes and plasma cells. The cellular 
aggregates present in rheumatoid synovium histologically resemble an active 
lymphoid tissue, thus implying immunological processes are a causative factor.
Despite numerous investigative studies the aetiological agent of rheumatoid 
arthritis is, as yet, unknown (reviewed by Feldmann et al., 1996). It Is not known 
whether the disease is initiated by an unrestrained inflammatory response to a 
microbial antigen or by a loss of self-antigen tolerance resulting in the 
production of autoantibodies, or a combination of the two. Investigations In a 
variety of animal arthritis models have highlighted important roles for 
autoreactive T cells, presentation of self-antigens by dendritic cells, pro- 
inflammatory cytokine secretion by macrophages and fibroblast mediated- 
cartilage damage. All of these mechanisms are thought to contribute to the 
synovial hyperplasia via the hyper-activation of effector cells and the increased 
levels of soluble inflammatory mediators.
Despite being present in the inflamed synovium, the role of B cells in 
rheumatoid arthritis is less well established (reviewed by Edwards et a!., 1999). 
It is thought that the local production of autoantibodies by B cells leads to 
complement fixation and the deposition of immune complexes within the 
synovial membrane. Combined with a heavy infiltration of plasma cells, 
autoantibody production results in remitting, relapsing inflammation and the 
progressive, erosive destruction of the adjacent cartilage and bone. Importantly, 
approximately 80% of subjects with rheumatoid arthritis develop circulating 
autoantibodies to IgG Fc, referred to as rheumatoid factor (RF). Interestingly, 
rheumatoid factor producing B cell clones are present in a few normal 
individuals. The rheumatoid factor produced by these normal individuals is 
mostly IgM and low affinity, with very little evidence of gene mutation. Thus, a 
block in class switching to IgG and affinity maturation of rheumatoid factor may 
be occurring in these individuals or a protective mechanism may operate in the 
follicle centre, preventing the initiation of disease.
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Normally B cells are activated upon interaction with their specific antigen in 
conjunction with co-stimulatory signals from Th cells. In theory, autoreactive B 
cells should be unable to survive because of T cell anergy to self resulting in a 
lack of positive co-stimulatory signals. However, reactive B cell clones 
expressing RF-BCRs may be able to circumvent this activation route by binding 
IgG attached to a non-self antigen, that can subsequently be presented to a 
responsive cognate T cell (Roosnek and Lanzavecchia, 1991). At the sites of 
rheumatoid factor synthesis, as in rheumatoid synovium, higher concentrations 
of IgG rheumatoid factor leads to the formation of dimers. These multimers fix 
complement poorly and thus have the potential to escape clearance by platelet 
complement receptors. Once in circulation these complexes may be able to 
access tissue macrophages and rheumatoid factor-specific B cells, providing a 
positive survival signal whilst disturbing the regulation by Th cells (section 5.2) 
(Edwards et ai, 1999).
Treatment of rheumatoid arthritis currently relies on a combinatorial approach of 
disease-modifying anti-rheumatic drugs (DMARD) and non-steroidal anti­
inflammatory drugs (NSAID). DMARDs (also referred to as second-line agents) 
partially suppress the chronic inflammation and may slow down the rate of joint 
destruction and loss of function, whilst NSAIDs control the initial inflammation 
and the patient’s appreciation of pain (Sturrock, 1987; Dinarello and Moldawer, 
2000). New arthritis therapies are being designed to target specific pathways 
known to be involved in disease pathogenesis, such as the p38/MAPKinase 
pathway. The stress-activated p38/MAPKinase plays a major role in the 
synthesis and activity of several pro-inflammatory cytokines, particularly IL-1 
and TNF-a (Lee, et ai, 1994), and inhibitors of p38-MAPKinase are non-specific 
anti-inflammatory agents. Rheumatoid arthritis is a “Tnl-type” inflammatory 
disease therefore new therapies aim to target the production of cytokines 
associated with ThI development, such as IL-12 and IL-18. Therapeutic studies 
have also included the targeting of pro-inflammatory cytokine production (TNF-a 
and IL-1) (Feige, et ai, 2000), macrophage cytokine networks (IL-15 and IL-18) 
and promoting the production of anti-inflammatory cytokines (IL-4 and IL-10) 
(Keystone, et ai, 1998). Non-cytokine approaches aim to address the synovial
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hyperplasia and bone destruction by modulating the cell-cycle or inducing 
apoptosis of the proliferating synovium (Dinarello and Moldawer, 2000). Overall, 
any effective treatment of arthritis will require the elimination of disease- 
perpetuating lymphocytes as well as the induction of tissue repair. Indeed, a 
recent study has shown a sustained improvement in rheumatoid arthritis 
patients that have undergone B cell depletion (Edwards and Cambridge, 2001). 
Supporting the hypothesis that B cells play a major role in the perpetuation of 
disease.
5.2 Role of FcyRs in human autoimmune disease
Since the formation of autoantibodies and immune-complexes is central to 
many of the described autoimmune diseases, recent studies have focused on 
the role of antibody binding receptors in the immune response. Results obtained 
in mice deficient in ether FcR or complement have revealed distinct functions 
for these two classes of molecules (reviewed by Ravetch and Clynes, 1998; 
Heyman, 2000). Complement and its receptors was found to be essential for the 
interaction with natural antibodies (IgM) to mediate protection against 
pathogens. In addition, FcyRs couple the interaction of IgG antibodies to 
effector cells to trigger inflammatory responses. Interestingly, B cells express a 
Fc receptor for immunoglobulin, which is known to play an important role in the 
maintenance of B cell homeostasis and tolerance to self-antigen. Indeed, 
FcyRllb directly influences the signalling threshold of B cells and, in conjunction 
with other B cell co-receptors, is essential for maintaining the balance between 
immunity and autoimmunity (Bolland and Ravetch, 2000).
To date, there have been no reports of a deficiency in FcyRllb function in 
antibody-mediated human disease. A total absence of specific isoforms of FcyR 
is extremely rare in humans but individuals lacking stimulatory receptors (FcyRI 
or FcyRlllb) have been reported to be generally healthy (Ceupeens, 1988). 
Therefore, it may be possible that differences in the relative expression levels of 
activation (ITAM) and inhibition (ITIM) FcyR influence the overall risk of 
developing autoimmune disease. Studies in activatory FcyR-deficient mice
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seem to indicate this, as they demonstrate significantly reduced autoimmune- 
mediated tissue damage in disease models of systemic lupus erythematosus 
and rheumatoid arthritis (Clynes, etal., 1998).
Inflammatory cytokines elicited during an immune response may also alter the 
expression and functional capacity of FcyRs, thereby modulating the signalling 
threshold of the FcyR bearing cell. For example, IFN-y, a Th1-type cytokine, has 
been shown to decrease FcyRllb2 expression on circulating human monocytes 
whilst IL-4, a TH2-type cytokine increases levels resulting in the enhancement of 
phagocytic capacity and the rapid clearance of immune complexes (Pricop et 
al., 2001). Thus, FcyRllb may function to establish the threshold for activation of 
macrophages by immune complexes in an inflammatory response. Interestingly, 
the production of the anti-inflammatory cytokine, IL-4, is known to overcome 
FcyR I lb-mediated inhibition of B cell activation by providing a positive, survival 
and proliferative signal (O’Garra etal., 1987).
Fc expressing effector cells also play an important role in rheumatoid arthritis, 
with the binding of IgG dimers by macrophages preceding the accumulation of T 
cells in the synovium. Expression levels of FcyRlla on macrophages are also 
upregulated in the presence of the inflammatory cytokine, IFN-y, enhancing the 
positive signal. Moreover, supporting evidence for a role of FcyRs in 
autoimmune diseases is demonstrated by the finding that negative signalling is 
blocked in neutrophils of rheumatoid arthritis patients by an anti-FcyRII antibody 
(Robinson, et al., 1994). In addition, rheumatoid factor may compete with 
FcyRllb for large antigen-antibody complexes, thus blocking FcyRI lb-mediated 
negative signalling in B cells (Edwards etal., 1999).
Recently two groups have shown in gene linkage studies an association 
between the two alleles of the FcyRI IA gene and a susceptibility gene for SLE 
(reviewed by Vyse and Kotzin, 1998). The FcyRlla-H131 allele is the only 
human FcyR that can recognises lgG2 efficiently and a decrease in the 
prevalence of this allele has been reported in patients with systemic lupus
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erythematosus. This implies that modulation of the expression of individual 
FcyRlla alleles is linked to abnormal downregulation of endocytic capacity of 
FcyRlla bearing cells, which may lead to insufficient immune-complex 
clearance. In addition, the nephritis loci in NZ hybrid mice maps to a region that 
contains FcyRllb, implicating a possible genetic linkage between disease and a 
FcyR (reviewed by Vyse and Kotzin, 1998). Overall, ample evidence exists to 
suggest that antibody-binding receptors in humans contribute to autoimmune 
disease (reviewed by Guarnotta, et al., 2000). Whether the results reflect a 
defect in the clearance of immune complexes or in the regulation of the 
antibody response is unclear.
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5.3 Aims and objectives of this study
Human B cells encode two isoforms of the low affinity IgG receptor, FcyRllb, 
FcyRllbl and FcyRIIb2. Both isoforms of FcyRllb possess an inhibitory ITIM 
motif in their cytoplasmic domains. In vitro and in vivo studies have shown that 
FcyRllb acts as a negative regulator of immune complex-triggered activation of 
B cells and, by directly influencing the signalling threshold of B cells, is essential 
for maintaining B cell homeostasis.
FcyRllb2 is capable of mediating rapid IgG endocytosis whilst an insertion of 19 
amino acids in the cytoplasmic tail of FcyRllbl disrupts the cytoskeletal 
attachment domain responsible for modulating receptor internalisation. 
Therefore, it may be possible that differences in the relative expression levels of 
the two isoforms of FcyRllb, may influence T cell-mediated help and thus the 
regulation of B cell tolerance by immune-complexes and hence an individual's 
overall risk of developing autoimmune disease.
The objectives of this study were therefore to investigate the expression levels 
of the specific FcyRllb isoforms using RT-PCR methods, to:
• define whether peripheral blood mononuclear cells from rheumatoid arthritis 
and systemic lupus erythematosus patients show aberrant FcyRllb isoform 
expression levels relative to controls.
• examine whether FcyRllb isoform expression levels are related to, or 
indicative of, disease status and progression in these rheumatoid arthritis 
and systemic lupus erythematosus patients.
In addition, the nuclear phosphatase, Pac-1 has been shown to be recruited 
during FcyRllb mediated negative signalling in murine B cells. Thus, a further 
objective was to examine whether peripheral blood mononuclear cells from 
autoimmune patients display aberrant FcyRI lb-mediated recruitment of Pac-1, 
by investigating the relative expression levels in the same patient samples.
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5.4 Results
5.4.1 RT-PCR analysis of FcyRllbl and FcyRllb2 mRNA expression levels 
In human cell lines.
Due to the high percentage of identity between the extracellular domains of 
FcyRllbl and FcyRllb2, commercial antibodies are unable to discriminate 
between the two isoforms on the cell surface due to cross-reaction. Thus, RT- 
PCR analysis was used to determine the mRNA message expression levels of 
the two FcyRllb isoforms. To optimise the PGR conditions and cycle number for 
the primer sets, prior to the analysis of primary human samples, RT-PCR was 
performed on total RNA from human monocytic and B cell lines (Figure 5.1A). 
For PCR a single primer pair, cross-reactive for both FcyRllbl and FcyRI I b2 
was used. The primers were designed to flank the splice region which gives rise 
to the two splice variants. Thus, the PCR product for FcyRllbl would be 365 
base pairs in length and FcyRllb2 would be 308 base pairs In length, FcyRllb2 
possessing a shorter C-terminal domain. A second primer pair was designed to 
amplify the internal insert present exclusively in the cytoplasmic domain of 
FcyRllbl, producing a product of 54 base pairs.
Products for both FcyRllbl and FcyRllb2 were detectable in the human 
monocytic cell line, U937 and the human mature B cell line, Daudi. Interestingly, 
whilst FcyRllbl is thought to be preferentially expressed by B cells, the level of 
FcyRllbl message is higher in U937 cells compared to the level in Daudi B 
cells. These data indicate that both cells types express mRNA for both isoforms 
whilst highlighting the potential differences between monocytic and B cell 
expression of FcyRllb. Furthermore, the monocytic cell line, THP1 and the B cell 
line, Ramos were shown not to express the full length message, despite 
possessing sequences for the insert region of FcyRllbl Thus the relevance of 
the constant level of the internal FcyRllbl insert in all four samples is unclear as 
an absence of product would be expected in THP1 and Ramos samples whilst 
U937 and Daudi samples should demonstrate enhanced expression. Therefore, 
the presence of insert in the THP1 and Ramos samples may indicate aberrant 
splicing of FcyRllb transcripts.
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Following positive expression with the primer pairs in human cell lines, RT-PCR 
was used to determine the expression of the differentially spliced isoforms of 
FcyRllb in human peripheral blood mononuclear cells (PBMCs). Details of the 
normal subjects assessed are shown in Table 5.1. Figure 5.1 B demonstrates 
detectable levels of both isoforms in primary PBMCs from normal individuals. 
With the exception of increased expression of FcyRllbl in subject 0834, the 
levels of both isoforms detected were approximately constant in all samples 
relative to p-actin control levels.
5.4.2 Patient subject data
Peripheral blood samples were obtained from rheumatoid arthritis patients 
attending the Centre for Rheumatic Diseases, Glasgow Royal Infirmary, 
Glasgow, who satisfied the 1987 American College of Rheumatology diagnostic 
criteria, (Arnett, et ai, 1988). Details of the subjects assessed are shown in 
Table 5.2. Disease status of arthritis patients was assessed by disease 
duration, full blood count, rheumatoid factor (positive or negative), extra- 
articular conditions and drug therapy, including non-steroidal anti-inflammatory 
drugs (NSAID), disease-modifying anti-rheumatic drugs (DMARD) and other 
non-related drugs. All clinical data was discussed in consultation with Dr lain 
Mclnnes, a rheumatology clinician.
5.4.2.1 RT-PCR analysis of FcyRllbl and FcyRllb2 mRNA expression 
levels in peripheral blood mononuclear cells from rheumatoid arthritis 
subjects.
To determine the mRNA expression levels of the two FcyRllb isoforms in 
PBMCs from arthritis subjects, a random selection of PBMC total RNA was 
subjected to RT-PCR analysis using the primer pairs described above. Figure
5.2 demonstrates minor differences in FcyRllb isoform mRNA expression 
between individual patients. However, quantitation of isoform expression levels 
was prevented by non-linearity between the amount of PCR product and the 
obtained gel-image. Absolute values for the amount of PCR product could be 
determined by semi-quantitative PCR, however this method is not a realistic 
approach for the analysis of a large cohort of patient samples. Thus,
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quantitative real-time PCR technology was utilised to quantify levels of isoform 
message in comparison to the message levels of Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT).
5.4.2.2 Quantitative TaqMan® analysis of FcyRllbl and FcyRllb2 mRNA 
expression levels in peripheral blood mononuclear cells from control and 
rheumatoid arthritis subjects.
TaqMan® primer and probe pairs were designed with the help of Dr. Carol 
Campbell (Dept, of Immunology, University of Glasgow) to amplify the individual 
FcyRllb isoforms. Primers were based on the published sequences for human 
CD32 isoforms (Brooks, et al., 1989). The FcyRllbl-specific primers were 
designed to amplify the sequences specific for the cytoplasmic insert encoded 
for by the cytoplasmic exon 1, whilst primers for the FcyRllb2 isoform were 
specific for areas across the splice site. Product sequences from the primer and 
probe pairs (Table 2.3 and Table 2.4 and Figure 2.7) were tested against 
Genebank sequences to ensure specificity and exclude cross-hybridisation with 
CD16 (FcyRllla or b), CD32 (FcyRllal and FcyRIIc) and CD64 (FcyRlal, b1 and 
b2).
All statistical analysis was performed with the help of Dr. Charlie McSharry 
(Dept, of Immunology, University of Glasgow) on Minitab software (State 
College, Pennsylvania, USA) using Pearson correlation and Mann-Whitney 
analysis as appropriate. A total of 47 arthritis and 13 control subjects were 
assessed for the relative expression of FcyRllb isoforms and the statistical 
analysis is shown in Table 6.3. In the control group, no significant difference 
was demonstrated between the genders in their median ages, or in the 
expression levels of FcyRllbl or FcyRllb2. Furthermore, the relative expression 
levels of FcyRllbl were found not to correlate with the expression levels 
FcyRI I b2 (Figure 5.3).
The arthritis subjects were significantly older than the control subjects, however 
no relation was found between FcyRllb expression levels and age or gender. In
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the arthritis group, FcyRllb expression was not related to disease duration, the 
presence of rheumatoid factor or the individual levels of white blood cells. No 
significant difference was demonstrated between the genders in the expression 
levels of FcyRllbl or FcyRllb2. Furthermore, no correlation was found between 
the relative expression levels of FcyRllbl or FcyRIIb2 (Figure 5.4). Interestingly, 
arthritis subject 908 demonstrated high levels of FcyRllb2 however, the 
standard error was also high for this patient. Due to the lack of a suitable cohort 
of arthritis subjects with single drug therapy treatments or extra-articular 
conditions, no statistical conclusions can be drawn concerning the expression of 
FcyRllb isoforms in relation to drug therapy and extra-articular disease. 
Importantly, expression levels of FcyRIIb2 were similar in both groups however, 
the expression levels of FcyRllbl were significantly lower in arthritis subjects 
(arthritis 4.9% vs. control 17.2%, p < 0.003) (Figure 5.5). These data clearly 
indicate that a downregulation of FcyRllbl mRNA levels is found in arthritis 
subjects and could represent a mechanism that predisposes an individual to 
disease onset and/or progression.
5.4.2.S Quantitative TaqMan® analysis of Pac-1 mRNA expression levels 
in peripheral blood mononuclear cells from control and arthritis subjects.
The nuclear phosphatase, Pac-1 has been shown in this study (Chapter 3) to be 
recruited during FcyRI lb-mediated negative signalling in murine B cells. To 
examine whether peripheral blood mononuclear cells from the same 
autoimmune patients displayed aberrant expression of Pac-1, the relative 
expression levels of Pac-1 were determined. A primer and probe pair was 
designed with the help of Dr. Carol Campbell (Dept, of Immunology, University 
of Glasgow) to amplify Pac-1 specific sequences in the samples (Table 2.3 and 
Table 2.4). To prevent the possible amplification of contaminating genomic 
DNA, TaqMan® probes are normally designed to bind directly over intron/exon 
junctions. A lack of binding to genomic DNA during the amplification process 
prevents probe cleavage and production of a positive signal. Due to the strict 
design requirements of the TaqMan® system it was not possible to design a 
probe and primer set that spanned an intron/exon boundary for Pac-1.
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Therefore to exclude the possibility of a false-positive, due to the amplification 
of genomic sequences, matching RNA samples that had not been reverse 
transcribed were run in parallel to the cDNA samples. Values from control 
samples, which amplified genomic sequences, were taken as base line controls 
and values subtracted from the Pac-1 expression levels to obtain a normalised 
Pac-1 expression value.
Statistical analysis of Pac-1 expression levels in control and arthritis subjects is 
shown in Table 5.3. Perhaps, surprisingly, given the downregulation of FcyRllbl 
expression in RA patients, no relationship was found between Pac-1 expression 
levels and any selected criteria in control or arthritis subjects. Thus, it is unlikely 
that modulation of Pac-1 message levels in peripheral blood mononuclear cells 
predisposes an individual to arthritis.
5.4.2.4 Quantitative TaqMan® analysis of FcyRllbl and FcyRllb2 mRNA 
expression levels in peripheral blood mononuclear cells from control and 
systemic lupus erythematosus subjects.
Total RNA from peripheral blood mononuclear cells of systemic lupus 
erythematosus patients and age matched controls was kindly provided by Dr. H. 
Slew (Dept, of Rheumatology, Allergy and Immunology, Tan Tock Seng 
Hospital, Singapore). A total of 15 SLE and 10 control subjects (Tables 5.4 and 
5.5) were assessed for the relative expression of FcyRllb isoforms. All the 
subjects were ethnically matched and female, as the disease is predominantly 
displayed in females of childbearing age. The same TaqMan® primer and probe 
pairs, as described above, were used to amplify up the individual FcyRllb 
isoforms and the statistical analysis is shown in Table 5.3. Graphical 
representations of the data are shown in Figures 5.6 and 5.7. In contrast to the 
arthritis patients, no relationship was found between the expression levels of the 
individual FcyRllb isoforms and any selected criteria in control or SLE subjects. 
Whilst not significant at a level of p<0.05, FcyRllbl expression levels in SLE 
patients were reduced in comparison to control subjects and a larger cohort of 
subjects may provide a statistically relevant significance between the two 
groups (see above).
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5.4 2.5 Quantitative TaqMan analysis of Pac-1 mRNA expression levels 
in peripheral blood mononuclear cells from control and systemic lupus 
erythematosus subjects.
To examine whether peripheral blood mononuclear cells from the same cohort 
of SLE patients and controls displayed aberrant expression of Pac-1, the 
relative expression levels of Pac-1 were determined. The same Pac-1 primer 
and probe pair, as described above, was used to amplify up a Pac-1 specific 
sequence in the samples. Matching RNA samples that had not been reverse 
transcribed were also run in parallel to the cDNA samples, to exclude the 
possibility of amplification of genomic sequences.
Statistical analysis of Pac-1 expression levels in control and SLE subjects is 
shown in Table 5.6. Graphical representations of the data are shown in Figures 
5.6 and 5.7. Similar to the arthritis subjects and controls, no relationship was 
found between Pac-1 expression levels and any selected criteria in control or 
SLE subjects. Thus, it is unlikely that modulation of Pac-1 message levels in 
peripheral blood mononuclear cells predisposes an individual to SLE.
5.5 Discussion
Differences in the relative expression levels of the two isoforms of FcyRllb, 
FcyRllbl and FcyRllb2, may influence the regulation of B cell responses by 
immune-complexes and thus may represent a mechanism that initiates 
autoimmunity. An investigation of the mRNA message levels of the two FcyRllb 
isoforms in peripheral blood cells from autoimmune patients, demonstrated that 
FcyRllbl expression levels were lower in rheumatoid arthritis patients compared 
to normal controls. In contrast, mRNA levels of the two isoforms were similar in 
patients with systemic lupus erythematosus. These preliminary results indicate 
that progression of rheumatoid arthritis in humans may be perpetuated by a 
downregulation of FcyRllb expression, which may remove the negative 
feedback regulation of autoreactive B cells, by IgG-containing immune 
complexes.
276
Chapter 5 -  Role of FcTRIIb in human autoimmune disease
5.5.1 FcyRllb and rheumatoid arthritis
Rheumatoid arthritis is a complex autoimmune disease and, similar to other 
autoimmune diseases, displays a polygenic phenotype. Disease susceptibility 
factors have been proposed to include MHC class II antigen HLA-DR4 and 
related haplotypes and a variety of non-MHC genes. Whilst FcyRllb has been 
implicated as a risk factor for the initiation and propagation of disease in murine 
models of arthritis, a similar role has not been attributed to this receptor in 
human rheumatoid arthritis. An investigation of FcyRllb isoform expression In 
PBMCs from 47 arthritis patients demonstrated a significant reduction in the 
mRNA expression levels of FcyRllbl in arthritis patients compared to controls. 
However, no differences in the expression of FcyRllb2 or Pac-1 were 
demonstrated.
Rheumatoid factor (RF) antibodies recognise the Fc portion of IgG and occur 
commonly in rheumatoid arthritis. High affinity rheumatoid factors accumulate in 
the synovium and contribute to the disease pathogenesis by forming immune 
complexes and inducing activation of complement. Moreover, B cells that 
express RF-BCRs can obtain help without requiring IgG-responsive T cells as, 
by taking up IgG attached to a non-self antigen, they can present that antigen to 
responsive T cells. Of interest to this study, RF-BCRs may compete with 
FcyRllb for large complexes, reducing the negative signals from this receptor.
Interestingly, only the expression of FcyRllbl appeared to be modulated in 
arthritis patients whilst expression of the endocytosis competent isoform, 
FcyRI Ib2, remained constant. Thus FcyRI Ib2 may be the isoform predominantly 
utilised by B cells for antigen uptake and processing whilst modulation of 
FcyRllbl expression dictates the threshold for BCR signalling. By 
down regulating expression of FcyRllbl, whilst keeping FcyRI Ib2 levels constant, 
an autoreactive B cell might remain responsive to stimulation by immune 
complexes and co-stimulatory T cell help. CD40 ligand (CD40-L) expressing, 
activated T cells, in conjunction with T cell derived IL-4, will induce proliferation, 
antibody production and isotype switching by the RF specific B cells in addition 
to overcoming the inhibitory effects of FcyRllb2. Furthermore, the cytokine
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profile present in inflammatory disease will affect not just B cells but also 
FcyRIlb-bearing phagocytic cells (see below) thus promoting the initiation and 
propagation of disease.
Sarmay et a/., 1991 have observed in their studies that whilst both isoforms are 
present, the mRNA levels of FcyRllb2 exceed that of FcyRllbl in resting and 
activated normal human tonsil B cells. In contrast, results from this study 
demonstrated higher levels of FcyRllbl expression in control subjects, in 
comparison to FcyRllb2. Indeed, this relationship was similar in all groups 
studied. It would therefore be of interest to examine the relative isoform 
expression in purified peripheral blood lymphocytes to examine whether the 
expression levels are similar when compared to the whole blood population.
However, peripheral blood contains only 1 x 10® lymphocytes/ml and, not 
accounting for losses during purification, at least 20 ml of blood would be 
required to purify enough B cells for a TaqMan® study. Peripheral blood 
samples from patients are uniformly only 10 mis, thus further studies may have 
to rely on FACS analysis with whole blood samples and specific antibodies to 
the intracellular domains of the two isoforms (currently not available 
commercially) in combination with 2.4G2 staining of FcyRllb on the cell surface.
Indeed, this further study would also exclude the contribution made to the 
expression levels by other FcyRIlb-bearing cells, since differential isoform 
expression by B cells may be masked by FcyRIlb-expressing myeloid cells 
and/or inappropriate tissue samples. The role of other FcyRllb-expressing cells 
is important to consider since the disease phenotype may not be solely 
attributable to the effect of FcyRllb on the production of autoantibodies but may 
well reflect aberrant non-inflammatory immune complex clearance by the 
phagocytic system. Indeed, studies in FcyRI lb-deficient mice indicate that 
FcyRllb has a dual function in the spontaneous development of lupus-like 
disease (see below) involving both the production of autoantibodies and the 
clearance of immune complexes (Bolland and Ravetch, 2000), thus implying 
that both of these events may be required for the initiation of autoimmune
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disease. However, in agreement with murine FcyRI!b-deficiency models the 
patient results suggest that downregulation or deficiency of the negative 
receptor may result in the exacerbation of disease. Similar to the study of 
FcyRllb promoter polymorphisms in germinal B cells of SLE mice (Jiang et al., 
1999, 2000) abnormal downregulation of FcyRllbl expression upon autoantigen 
stimulation might enable auto reactive B cells to escape suppressive signalling.
Future studies should also examine FcyRllb isoform expression in samples of 
synovial membrane from arthritis subjects, since it is uncertain whether PBMCs 
are reflective of the overall immune status. Indeed, preliminary studies in 
synovial membrane digests from six arthritic subjects correlate with the low 
levels of FcyRllbl expression observed in PBMCs (average expression level of 
17.2% in PBMCs of control subjects versus 6.2% in synovial membrane of 
patients, relative to HPRT levels; results not shown). However, FcyRllb2 
expression in the same digests was found to be enhanced (expression level of 
40% relative to HPRT levels; results not shown) and may reflect the high 
percentage of FcyRIIb2-expressing myeloid cells in the synovial population.
Interestingly, FcyRllb expression was found to be independent of age, gender, 
presence of rheumatoid factor, disease duration and white blood cell levels 
(results not shown). Due to the small cohort of patients analysed for this pilot 
study, no correlation could be drawn between individual drug therapies and 
FcyRllb expression. Since the majority of arthritis therapies modulate the 
synthesis of pro-inflammatory cytokines and signal transduction by inflammatory 
cell, it is likely that their therapeutic actions will modulate the expression of 
FcyRllb. Indeed, studies by Sarmay et a!., 1991 found that activation of human 
B cells, by IgM crosslinking or the presence of IL-4, induces alternative splicing 
of FcyRllbl mRNA with simultaneous suppression of FcyRllb2 mRNA. Their 
data clearly indicates that B cell activation promotes differential FcyRllb isoform 
expression and in RA patients this may modulate activation of auto re active B 
cells.
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Corticosteroids suppress gene expression and synthesis of pro-inflammatory 
cytokines whilst levels of anti-inflammatory cytokines are relatively unaffected 
(reviewed by Dinarello and Moldawer, 2000). Other observed effects include 
modulation of immunoglobulin synthesis and programmed cell death of 
lymphocytes, contributing to an overall suppression of the immune system. In 
contrast, non-steroidal anti-inflammatory drugs (NSAIDs) exert their primary 
influence on inflammatory disease by inhibiting prostaglandin synthesis. 
Disease-modifying anti-rheumatic drugs (DMARDs), such as methotrexate, 
inhibit the inflammatory response on many levels acting as anti-inflammatory 
agents, immunosuppressive therapies and anti-proliferative drugs. Whilst 
DMARDs non-specifically target the production of pro-inflammatory cytokines, 
recent therapeutic studies have specifically targeted the production of TNF-a, 
with the use of anti-TNF-a antibodies (Infliximab) or soluble TNF-a receptor 
fusion proteins (sTNF-RII:Fc; Etanercept). Neither of these drugs were currently 
being administered to any of the patients studied however, it would be of 
interest in future studies to investigate the role of these suppressive agents on 
the functionality and expression levels of FcyRllb in patients.
Many of these therapeutic drugs act, in part, to reduce the Th1 inflammatory 
disease phenotype thus patients on DMARD or NSAID therapy may express 
higher levels of FcyRllbl. Unfortunately, due to the complexity of involvement of 
co-morbid conditions and the fact that most patients are on combination 
therapy, it proved impossible to generate statistically meaningful comparative 
groupings. However, a small cohort of patients on single drug therapy appeared 
to demonstrate reduced or similar levels of FcyRllbl message when compared 
to the group as a whole (average expression level of 4.2% in PBMCs of single 
drug therapy patients versus 4.9% in PBMCs of total patient cohort; results not 
shown). These preliminary results implicate a potential role for pro-inflammatory 
cytokines in the differential expression of FcyRllbl and FcyRI Ib2 in arthritis.
5.5.2 FcyRllb and systemic lupus erythematosus
The main immunological characteristics of systemic lupus erythematosus (SLE) 
are a number of profound B cell abnormalities that permit the generation,
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differentiation and positive selection of B cells that secrete pathogenic 
autoantibodies (reviewed by Lipsky, 2001). Thus, it is possible that a loss of 
FcyRllb negative regulation, results in the production of B cells that are 
hyperactive to normal antigenic stimulation and provides the drive for 
autoantibody production. However, neither functional defects in FcyRllb nor 
polymorphic variants of this receptor have been described in patients with SLE 
thus far.
An investigation of FcyRllb expression in PBMCs from 15 SLE patients 
demonstrated no significant difference in the mRNA expression levels of 
FcyRllbl and FcyRllb2, compared to the expression levels of 10 matched 
controls. Furthermore, no correlation was found between the relative expression 
levels of FcyRllbl or FcyRllb2. Whilst not statistically significant, FcyRllbl 
expression levels in SLE patients were reduced in comparison to control 
subjects (SLE 10.1 vs. Control 16.3) and this may be of relevance in a clinical 
environment. A larger cohort of subjects may therefore provide a statistically 
relevant significance between the two groups. In addition, no significant 
difference in the mRNA expression levels of Pac-1 were found when comparing 
the two groups. Thus, it is unlikely that aberrant Pac-1 expression or function is 
a risk factor associated with susceptibility to SLE in humans.
These results were somewhat surprising in light of the results from the MRL- 
/pr/fpr mice, which suggested that FcyRI lb-mediated negative regulation might 
be dysregulated in this model. However, since functional expression of the 
receptor was not examined in this human study it is difficult to draw 
comparisons between the two studies. Furthermore, whilst a central role for 
hyperactive B cells and autoantibodies has been implicated in SLE, the role for 
autoantibodies in the development of disease has been challenged by a 
genetically manipulated MRL-/pr//pr model in which the mice are able to develop 
nephritis despite being unable to secrete autoantibodies (Chan et al., 1999). 
However, as B cell deficient MRL-/pr//pr mice do not develop nephritis 
(Schlomchik et a/., 1994), these latter results may suggest a more important
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role for B cells in the activation of T cells but not necessarily for the production 
of autoantibodies in this murine model of lupus-like disease.
The diversity of clinical manifestations and disease phenotypes in humans, 
together with a lack of a human counterpart to the murine Ipr phenotype, has 
made the study of FcyRs in human SLE very difficult. However, a skewing of 
FcyRlla allotype expression has been reported in SLE patients and linked with 
nephritis in African-Americans (Duits et al., 1995). The differential expression 
results in the downregulation of the high responder allele of FcyRlla, implying 
that the skewing may lead to the downregulation of endocytic capability of 
phagocytes and insufficient clearance of immune complexes. Polymorphisms in 
these FcyR genes may be important susceptibility factors for SLE nephritis. 
Thus, the diversity of disease phenotypes may be as a result of the genetically 
determined ability of FcyR to bind and clear the immune complexes.
In view of the ability of B cells to regulate many aspects of immune reactivity it 
is likely that dysregulated B cell functions contribute significantly to the initiation 
and progression of human SLE. Thus, whilst a role for FcyRllb in SLE is, as yet, 
undetermined future studies may reveal that aberrant expression or function of 
this receptor may predispose an individual to SLE.
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Figure 5.1 RT-PCR analysis of FcyRllbl and FcyRllb2 mRNA expression 
levels in human cell lines and peripheral blood mononuclear cells from 
normal individuals.
Total RNA was extracted from (A) human monocytic (U937 and THP-1) and B 
cell lines (Daudi and Ramos) or (B) human peripheral blood mononuclear cells 
from normal individuals (5 x 10® cells) and was reverse transcribed in the 
presence of 100 U Superscript II RT, as described in the Materials and 
Methods. PCR was performed using a single primer pair, cross-reactive for both 
FcyRllbl and FcyRllb2, producing PCR products of 365 and 308 base pairs in 
length, respectively. A second primer pair was designed to amplify the internal 
insert present exclusively in the cytoplasmic domain of FcyRllbl, producing a 
product of 54 base pairs. Human g-actin primers were used to assess the 
relative quantity of mRNA.
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Figure 5.2 RT-PCR analysis of FcyRllbl and FcyRllb2 mRNA expression 
levels in peripheral blood mononuclear cells from arthritis subjects.
Total RNA was extracted from human peripheral blood mononuclear cells (5 x 
10® cells) from arthritis subjects and was reverse transcribed in the presence of 
100 U Superscript II RT, as described in the Materials and Methods. PCR was 
performed using a single primer pair, cross-reactive for both FcyRllbl and 
FcyRllb2, producing PCR products of 365 and 308 base pairs in length, 
respectively. A second primer pair was designed to amplify the internal insert 
present exclusively in the cytoplasmic domain of FcyRllbl, producing a product 
of 54 base pairs. Human P-actin primers were used to assess the relative 
quantity of mRNA.
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Table 5.1 Details of control subjects at time of study
Peripheral blood samples were obtained from 13 normal individuals. FcyRllbl, 
FcyRIIb2 and Pac-1 transcripts were assayed for by real-time PCR (TaqMan®). 
mRNA levels are expressed as a percentage relative to HPRT mRNA levels ± 
S.E for three experiments.
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Table 6.2 Details of arthritis subjects at time of study
Peripheral blood samples were obtained from 47 arthritis patients attending the 
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, who 
satisfied the 1987 American College of Rheumatology diagnostic criteria, 
(Arnett, etal., 1988).
Disease duration is determined in years from the first clinical confirmation of 
arthritis. The drug profile is segregated into non-steroidal anti-inflammatory 
drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs) and other 
non-related drugs.
NSAID; Nap, Naproxen. Para, Paracetamol. Co-pro, Co-proxamol. Asp, 
Aspirin. Nab, Nabumetone. Indo, Indomethacin. Dicio, Diclofenac. Etod, 
Etodolac. Voi, Voltarol.
DMARD; Pen, Penicillamine. Sulph, Sulphasalazine. Metho, Methotrexate. 
Hydroxy, Hydroxychloroquine. Pred, Prednisolone. Aza, Azathioprine.
OTHER; Frus, Frusemide. Omer, Omerprazole. Giu, Gluclazide.
Full blood count; WBC, white blood cells. LYMPH, lymphocytes. NEUTRO, 
neutrophils. MONO, monocytes. EOSIN, eosinophils. BASO, basophils.
RF; rheumatoid factor assessed as either positive (+) or negative (-).
Total RNA was extracted from human peripheral blood mononuclear cells (5 x 
10® cells) from the 47 arthritis subjects and was reverse transcribed in the 
presence of 100 U Superscript II RT, as described in the Materials and 
Methods. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PCR (TaqMan®). mRNA levels are expressed as a percentage relative to 
HPRT mRNA levels ± S.E for three experiments.
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Table 6.3 Statistical analysis of FcyRllbl, FcyRllb2 and Pac-1 expression 
levels in peripheral blood mononuclear cells from control and arthritis 
subjects
All statistical analyses were performed on Minitab software (State College, 
Pennsylvania, USA) using Pearson correlation and Mann-Whitney analyses as 
appropriate. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PCR (TaqMan®). mRNA levels are expressed as a percentage relative to 
HPRT mRNA levels ± S.E for three experiments.
287
Arthritis subjects Control subjects Mann-Whitney
(n " 47) (n = 13) Significance
Male 17(35%) 8 (62 %) -
Female 30 (65 %) 5 (38 %) -
Age range (yr) 34-85 23-58 -
Age median (yr) 60 32 p = 0
Disease duration range (yr) 1-50 - -
Median disease duration (yr) 15 - -
B1 expression range 0.6-30 1.8-36 -
Median B1 expression 4.9 17.2 p = 0.0003
B2 expression range 0.4-209 0.1-54 -
Median B2 expression 4.7 5 n/s
PAC-1 expression range 0-290* 0-26.3 -
Median PAC-1 expression 0.5 0.2 n/s
Arthritis subjects (n = 47)
Mann-Whitney
MALE (n = 17) FEMALE (n = :30) Significance
Age range (yr) 34-72 39-85 -
Age median (yr) 58 65 p = 0.03
Disease duration range (yr) 1-34 1-50 -
Median disease duration (yr) 13 15 n/s
B1 expression range 0.7-30 0.6-23 -
Median B1 expression 4.2 4.9 n/s
B2 expression range 0.4-18.50 1.6-209 -
Median B2 expression 4.2 6.1 n/s
PAC-1 expression range 0-172.9 0-290 -
Median PAC-1 expression 0.1 0.6 n/s
Control subjects (n = 13)
Mann-Whitney
MALE (n = 8) FEMALE (n = 6) Significance
Age range (yr) 24-58 23-43 -
Age median (yr) 34 24 n/s
B1 expression range 4.6-36 1.8-33 -
Median B1 expression 17.3 10.4 n/s
B2 expression range 0.1-54 3.4-25.5 -
Median B2 expression 4.55 7 n/s
PAC-1 expression range 0.02-26.7 0-17.8 -
Median PAC-1 expression 1.99 0.01 n/s
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Figure 5.3 TaqMan®quantitative RT-PCR of FcyRllbl, FcyRllb2 and Pac-1 
mRNA expression levels in peripheral blood mononuclear cells from 
control subjects.
Total RNA was extracted from peripheral blood mononuclear cells (5x10® 
cells) from normal individuals and was subjected to reverse transcription in the 
presence of 100 U Superscript II RT, as described in the Materials and 
Methods. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PCR (TaqMan® ). Individual mRNA levels are expressed as a percentage 
relative to HPRT mRNA levels with the median indicated by the horizontal bar.
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Figure 5.4 TaqMan® quantitative RT-PCR of FcyRilbl, FcyRilbZ and Pac-1 
mRNA expression levels in peripharai blood mononuclear cells from 
arthritis subjects.
Total RNA was extracted from peripheral blood mononuclear cells (5 x 10® 
cells) from arthritis subjects and was subjected to reverse transcription in the 
presence of 100 U Superscript II RT, as described in the Materials and 
Methods. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PCR (TaqMan®). Individual mRNA levels are expressed as a percentage 
relative to HPRT mRNA levels with the median indicated by the horizontal bar.
A) Individual mRNA levels of FcyRllbl, FcyRilb2 and Pac-1 as determined by 
real-time PCR (TaqMan®) for the total arthritis group (n = 47).
B) Individual mRNA levels of FcyRllbl, FcyRIIb2 and Pac-1 as determined by 
real-time PCR (TaqMan®) for the total arthritis group minus the three highest 
expressing individuals (n = 44).
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Figure 5.5 Comparison of FcyRllbl, FcyRllb2 and Pac-1 mRNA expression 
levels in peripheral blood mononuclear cells from control and arthritis 
subjects.
A comparison of the mRNA expression levels of FcyRllbl, FcyRllb2 and Pac-1 
transcripts in peripheral blood mononuclear cells from control and arthritis 
subjects, as determined by real-time PCR (TaqMan®). Individual mRNA levels 
are expressed as a percentage relative to HPRT mRNA levels with the median 
indicated by the horizontal bar.
A) Comparison of the individual mRNA levels of FcyRllbl, FcyR!lb2 and Pac-1 
as determined by real-time PCR (TaqMan®) for the control versus the total 
arthritis group (n = 47).
B) Comparison of the individual mRNA levels of FcyRllbl, FcyRllb2 and Pac-1 
as determined by real-time PCR (TaqMan®) for the control versus the total 
arthritis group minus the three highest expressing individuals (n = 44).
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Table 5.4 Details of SLE control subjects at time of study
Total RNA from peripheral blood samples was obtained from 10 normal 
individuals. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PCR (TaqMan®). mRNA levels are expressed as a percentage relative to 
HPRT mRNA levels ± S.E for three experiments.
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Table 5.5 Details of SLE subjects at time of study
Total RNA from peripheral blood samples was obtained from 15 SLE subjects. 
FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real-time PCR 
(TaqMan®). mRNA levels are expressed as a percentage relative to HPRT 
mRNA levels ± S.E for three experiments.
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Table 5.6 Statistical analysis of FcyRllbl, Fc7Rllb2 and Pac-1 expression 
levels in peripheral blood mononuclear cells from control and SLE
subjects.
All statistical analysis was performed on Minitab software (State College, 
Pennsylvania, USA) using Pearson correlation and Mann-Whitney analyses as 
appropriate. FoyRllbl, FcyRllb2 and Pac-1 transcripts were assayed for by real­
time PGR (TaqMan®). mRNA levels are expressed as a percentage relative to 
HPRT mRNA levels ± S.E for three experiments.
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SLE subjects SLE Control subjects Mann-Whitney 
(n = 15)________ (n = 10) Significance
Male 0 (0 %) 0 (0 %) -
Female 1 5 (1 0 0 % ) 1 0 (1 0 0 % ) *•
Age range (yr) 19-52 22-45 -
Age median (yr) 38 36.5 n/s
B1 expression range 5.2-41 4.7-30.9 -
Median B1 expression 10.3 16.1 n/s
B2 expression range 3.1-23.2 2.3-12.2 -
Median B2 expression 6.5 4.8 n/s
Pac-1 expression range 0-3.5 0-2.7 -
Median Pac-1 expression 0.18 0.2 n/s
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Figure 5.6 TaqMan quantitative RT-PCR of FcyRllbl, FcyRllbZ and Pac-1 
mRNA expression levels in peripheral blood mononuclear cells from 
control subjects and SLE subjects.
Total RNA was extracted from peripheral blood mononuclear cells (5x10® cells) 
from (A) control and (B) SLE subjects and was subjected to reverse 
transcription in the presence of 100 U Superscript II RT, as described in the 
Materials and Methods. FcyRllbl, FcyRllb2 and Pac-1 transcripts were assayed 
for by real-time PCR (TaqMan®). Individual mRNA levels are expressed as a 
percentage relative to HPRT mRNA levels with the median indicated by the 
horizontal bar.
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Figure 5.7 Comparison of FcTRIIbl, Fc7Rllb2 and Pac-1 mRNA expression 
levels in peripheral blood mononuclear cells from control and SLE 
subjects.
A comparison of the mRNA expression levels of FcyRlibl, FcyRllb2 and Pac-1 
transcripts in peripheral blood mononuclear cells from control and SLE subjects, 
as determined by real-time PCR (TaqMan®). Individual mRNA levels are 
expressed as a percentage relative to HPRT mRNA levels with the median 
indicated by the horizontal bar.
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Chapter 6 - General Discussion
The work presented in this thesis has focused on identifying the important 
signalling mechanisms underlying the negative regulation of B cells by FcyRllb 
(Figure 6.1) and how dysregulation of FcyRlIb expression or signalling may 
provide a mechanism for the initiation of autoimmune disease in predisposed 
individuals. Co-ligation of the BCR and FcyRllb by cognate antigen-antibody 
complexes leads to the inhibition of BCR-triggered B cell activation and the 
arrest of cellular proliferation. In contrast, aggregation of FcyRllb alone, via non­
cognate antigen-antibody complexes, generates a pro-apoptotic signal. This 
study has not addressed the signalling mechanisms initiated following non­
cognate aggregation of FcyRllb but instead has focused on FcyRIlb-induced 
anergy of resting B cells and the switching off of activated B cells by cognate 
antigen-antibody complexes.
In Chapter 3, investigations centred on the molecular mechanisms initiated 
following BCR-FcyRllb co-ligation which might lead to the induction of growth- 
arrest and/or the commitment to apoptosis in primary B cells. Chapter 4 set out 
to ascertain whether aberrant FcyRI lb-mediated negative regulation of B cells is 
important for the onset and progression of autoimmunity in established murine 
models of autoimmune disease. This was accomplished by investigating the 
expression and function of FcyRllb in B cells from collagen-induced arthritis 
(CIA) and murine systemic lupus erythematosus {MRL-lpr/lpr) murine models. 
Finally, in Chapter 5, studies focused on determining whether the findings 
established in the in vitro signalling studies and/or the murine models of 
autoimmune disease translated to explaining the lesions underlying human 
autoimmune diseases. In particular, this chapter focused on analysis of whether 
differential expression of the two isoforms of FcyRllb, FcyRlibl and FcyRllb2, is 
related to, or indicative of, disease susceptibility and progression in patients 
with autoimmune disease, such as rheumatoid arthritis or systemic lupus 
erythematosus.
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6.1 Molecular mechanisms of FcyRllb signalling
Previous published studies had highlighted an important role for the inositol 5’- 
phosphatase, SHIP-1, in the inhibition of BCR-mediated activation by FcyRllb 
and the induction of growth-arrest mechanisms in B cells. An investigation of 
the downstream signalling mechanisms activated by this phosphatase therefore 
represented a starting point for the determination of FcyRI lb-induced signalling 
events in primary B cells.
Initial studies investigated the expression and activation kinetics of SHIP 
following BCR and/or FcyRllb ligation, in order to confirm that SHIP is 
exclusively and transiently activated under conditions of negative regulation. 
Interestingly, in agreement with recent studies by Ingham et al., 1999 our data 
suggests that both BCR and FcyRI lb-mediated signalling events are capable of 
inducing the phosphorylation of SHIP. However, SHIP-mediated inositol 
phosphatase activity was only active under conditions of FcyRllb co-ligation. 
Furthermore, phosphorylation under these conditions results in the formation of 
SHIP-Shc complexes. Whilst She has been shown to be dispensable for BCR 
coupling to the RasMAPK pathway in DT40 cells (Hashimoto et al., 1998), many 
other groups have demonstrated an essential role for She in the regulation of 
BCR-coupled ErkMAPKinase in mammalian B cells (Campbell, 1999; Ingham et 
al., 1999; Kelly and Chan, 2000) Thus, low affinity SHIP-Shc complexes may 
occur in BCR stimulated cells that promote activation of the RasMAPK pathway. 
Following FcyRllb co-ligation these complexes may undergo dissociation, 
following SHIP recruitment to FcyRllb, and reform under conditions that promote 
inactivation of the RasMAPK pathway. The recent identification of new isoforms 
of SHIP suggests that the differential roles previously described for SHIP may 
actually be due to the action of alternative forms, which are differentially 
regulated within the cell.
Examination of Ras activity indicated that whilst FcyRIIb-ligation resulted in the 
formation of SHIP-Shc complexes and the abrogation of ErkMAPKinase activity, 
Ras activity was unaffected. This finding is in contrast to recently published
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studies that have shown that SHIP-dependent recruitment of p62Dok is 
important for the down regulation of Ras activity following FcyRI Ib-ligation (Tamir 
et al., 2000a). Moreover, this novel finding questions the proposed mechanism 
of SHIP-mediated sequestration of She in FcyRI lb-mediated uncoupling of the 
BCR from ErkMAPKinase and suggests that inhibitory mechanism may act at or 
downstream of Ras recruitment of the Raf-MEK-ErkMAPKinase cascade. To 
investigate this proposal, we examined the mechanisms that inhibit 
ErkMAPKinase activity at the level of, or below Raf. Initial studies ruled out the 
involvement of Rap-1, RKIP and PP2A, so we examined whether the nuclear 
phosphatase, Pac-1, was involved in the suppression of ErkMAPKinase 
following co-ligation of FcyRllb with the BCR. Our results suggested that 
FcyRllb ligation increased the association of Pac-1 with ErkMAPKinase. 
Further studies to confirm co-localisation of these molecules would confirm a 
role for Pac-1 in FcyRI lb-mediated responses. It would also be interesting to 
examine which transcription factors are inhibited following FcyRlib-inhibition of 
B cell proliferation, with the previously described ErkMAPKinase targets of c- 
Myc and Elk-1 (Kolch, 2000) as possible candidates.
Whilst FcyRllb co-ligation Induced the abrogation of ErkMAPKinase activity, 
investigation of the other members of the MAPKinase family, JNK and p38, 
showed that JNK activity was also reduced following FcyRllb co-ligation so that 
surprisingly, JNK was more activated in BCR stimulated cells. These results are 
in contrast to other studies which implicate a possible role for JNK in the 
induction of FcyRI lb-induced apoptosis via Btk (Kawakami et al., 1997; Bolland 
et al., 1998) and thus warrants further investigation. However, activation of JNK 
may only occur under conditions of apoptosis and therefore may not be required 
for FcyRI lb-mediated growth-arrest, as demonstrated in our studies.
In addition to inhibiting BCR-proliferative signals, we have also shown that 
following co-ligation, FcyRllb mediates pro-apoptotic signals by inhibiting the 
activation of the pro-survival molecule Akt. Our results confirm a potential role 
for this protein in FcyRllb-induced apoptosis (Pearse et al., 1999). Although 
published results suggest that SHIP inhibits the activation of Akt by hydrolysing
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Ptdlns(3,4,5)P3, to Ptdlns(3,4)p2, Akt is now known to bind with higher affinity to 
this hydrolysis product, than to Ptdlns(3,4,5)P3 (Downward, 1998) suggesting 
that SHIP activation is not responsible for the FcyRllb-mediated inhibition of Akt. 
Therefore, we examined whether the inositol 3' phosphatase, PTEN, was 
activated following co-ligation of FcyRllb with the BCR. Our results 
demonstrated that FcyRllb co-ligation increased the phosphatase activity of 
PTEN, with kinetics to suggest that it acts downstream of SHIP, to generate 
Ptdlns(3,4)P2 and Ptdlns(3)P which do not recruit Akt and hence terminate 
ongoing BCR signalling.
In conclusion, our studies suggest that B cell unresponsiveness following 
FcyRllb ligation may result from the inhibition of proliferative signalling cascades 
and the promotion of apoptotic signals. This was further confirmed by studies on 
the activation of cell-cycle regulators and nuclear transcriptional proteins. For 
example, in agreement with studies by Malbec et al. and others we have shown 
that FcyRllb-mediated growth-arrest leads to the modulation of cell-cycle 
regulatory proteins. In particular, signals derived from FcyRllb partially 
suppressed BCR-induced Rb phosphorylation and thus potentially prevent the 
dissociation of E2F and transcription of S-phase genes resulting in cell cycle 
arrest in G0/G1 phase. Further studies, utilising RNA protection assays may 
enable us to identify the gene targets of E2F modulated by FcyRllb. Similarly, 
we have shown that FcyRllb ligation results in the disruption of BCR-mediated 
NF-kB activation which is required both for the induction of immunoregulatory 
genes and for the regulation of cell fate (Ghosh et al., 1998). Recent reports 
have implicated a role for PTEN in the regulation of such NF-kB activation and 
hence it would be interesting to determine whether FcyRllb signalling employed 
PTEN in a dual pronged mechanism (switch off of Akt-mediated survival signals 
and switch on of NF-KB-mediated apoptotic signals) to effect B cell tolerance. 
Finally, FcyRllb ligation also results in the rapid phosphorylation of the tumour 
suppressor protein, p53, on serine 15: a modulation, which correlates with 
disruption of the mitochondrial membrane potential and commitment to 
apoptosis. Furthermore, as, in addition to its role in promoting apoptosis, p53 
has been reported to influence regulation of cell cycle progression by promoting
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the upregulation of cyclin-dependent kinase inhibitors, such as p27, it will be 
interesting to determine whether FcyRllb ligation utilises such signals in driving 
B cell growth arrest. It would therefore be interesting to examine whether p53 
regulation promotes the disruption of NF-kB DNA binding complexes.
This study has therefore identified a number of novel features in the regulation 
of B cell activation by FcyRllb. In particular, this study is this first to describe the 
coupling of FcyRllb to PTEN and Pac-1 activation, highlighting a novel role for 
these signalling pathway regulators in the modulation of B cell fate by FcyRllb. 
Additionally it has highlighted the differential mechanisms of FcyRllb-mediated 
growth arrest versus commitment to apoptosis during negative regulation of B 
cells by immune complexes. A working model of how these inhibitory signals 
are integrated is shown in Figure 6.2.
6.2 FcyRllb and Murine Autoimmune Disease Models
Disruption of the inhibitory FcyR, FcyRllb, by gene targeting is known to disrupt 
the homeostasis of the immune system and have a pro-inflammatory effect. 
Thus FcyRllb deficient mice display augmented hypersensitivity and 
anaphylactic responses (Takai et al., 1996) whilst certain strains of FcyRllb' '^ 
mice are able to develop an autoimmune syndrome resulting in the production 
of autoantibodies, accelerated antibody-induced glomerulonephritis and 
immune complex mediated alveolitis (Suzuki et al., 1998; Clynes et al., 1999; 
Nakamura, A. et al., 2000). An investigation of the role of FcyRllb in the 
regulation of the development of collagen induced arthritis (CIA) in susceptible 
(DBA/1, H-2^) strains and in the spontaneous murine systemic lupus 
erythematosus model, MRL-/pr//pr demonstrated differential requirements for 
FcyRllb expression and function.
In contrast to the FcyRllb knockout studies, the demonstration that FcyRllb- 
mediated B cell inhibition appears to be intact throughout development of CIA 
disease in a naturally susceptible strain of the CIA murine model was somewhat 
surprising. However, in light of recent studies proposing that aberrant FcyRllb
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expression only pre-disposes certain strains of mice to autoimmune disease, 
these findings might suggest that this regulatory pathway is not important in the 
induction or progression of CIA in H-2^ susceptible strains of mice. Furthermore, 
these findings suggest that FcyRllb is not a uniform risk factor for this disease.
In contrast to the CIA data, FcyRllb-mediated B cell inhibition was found to be 
dysregulated in the later stages of lupus-like disease in MRL-/pr//pr mice. 
Furthermore, this progression was accompanied by a downregulation in FcyRllb 
isoform expression. Whilst FcyRllb deficiency may not generally predispose the 
immune system to mediate an autoimmune response, it suggests that FcyRllb 
may be a susceptibility factor which contributes to the genetic and 
environmental background that is required for the emergence of lupus-like 
disease in mice. Indeed, investigations of the FcyRllb promoter region in strains 
of autoimmune-prone mice, have highlighted that deletions in this area are 
associated with reduced surface expression and function of FcyRllb on 
macrophages and B cells (Luan et al., 1996; Pritchard et a!., 2000). 
Furthermore, studies in autoimmune disease-prone mice have shown a 
correlation between FcyRllb promoter polymorphisms and the subsequent 
down-regulation of surface expression and a concomitant up-regulation of IgG 
antibody responses and promotion of lupus-like disease (Jiang et al., 1999,
2000). Suggesting that FcyRllb plays an essential role in the regulation of B cell 
mediated immune responses in the initiation of disease in these models.
Since FcyRllb is known to play an important role in the maintenance of B cell 
homeostasis and tolerance to self-antigen, by directly influencing the BCR 
signalling threshold, it is interesting that a recent study has highlighted a role for 
different B cell receptor signaling thresholds in the spontaneous development of 
lupus-like disease in hybrid NZB/NZW Fi (NZB/W) mice (Wellmann et al.,
2001). This study demonstrated that whilst central tolerance to dsDNA was 
intact in these autoimmune disease-prone mice, the NZBAA/ B cells underwent 
an altered selection process. A lack of receptor editing and deletion of DNA 
reactive B cells, presumably due to an aberrantly high threshold for the 
induction of apoptosis, produced a higher frequency of anti-DNA B cells
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amongst the follicular B cell population, compared to the control strain. In 
conjunction with aberrant FcyRllb expression, these results could explain the 
qualitative differences in the B cell repertoire of NZB/W mice as well as the 
hyperactivity of the B cells in such a repertoire.
6.3 Role of FcyRllb in Human Autoimmune Disease
B cells are known to play an essential role in the initiation and regulation of both 
T and B cell responses. Thus, excessive or upregulated B cell activity may 
increase the likelihood of developing autoimmunity and subsequent 
autoimmune disease. Since the formation of autoantibodies and immune- 
complexes is central to many autoimmune diseases, such as rheumatoid 
arthritis and systemic lupus erythematosus, recent studies have focused on the 
role of antibody binding receptors in the initiation and progression of disease.
Since B cells are known to express two different isoforms of FcyRllb, that 
engage in differential responses to immune-complexes, an investigation of the 
expression of these isoforms in relation to human disease was undertaken. 
Using TaqMan® quantitative RT-PCR technology we examined the relative 
expression levels of the two FcyRllb isoforms in peripheral blood mononuclear 
cells from rheumatoid arthritis and systemic lupus erythematosus patients. 
Furthermore, having demonstrated in Chapter 3 the FcyRllb-mediated 
recruitment of the inducible dual (Thr/Tyr) phosphatase, Pac-1 played a key role 
in the uncoupling of the BCR from ErkMAPKinase and hence B cell 
proliferation, we also investigated whether the same patients demonstrated 
aberrant expression of this molecule. This dual approach allowed the 
assessment of whether aberrant FcR expression and/or functionality correlated 
with induction and/or progression of autoimmune disease in humans.
Consistent with the theory that FcyRllb expression is important for maintenance 
of self-tolerance, the most important finding of this study was that the 
expression of FcyRlibl mRNA was down-regulated in PBMCs of rheumatoid 
arthritis patients compared to controls. In contrast, expression levels of the
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endocytosis competent isoform FcyRI!b2 and Pac-1 mRNA were unaffected. 
Thus, this display of differential isoform expression provides a potential 
mechanism by which aberrant FcyRllb expression by autoreactive B cells may 
promote autoimmunity (Figure 6.3). Further studies need to investigate whether 
FcyRIIb2 is the isoform predominantly utilised by B cells for antigen uptake and 
processing whilst modulation of FcyRlibl expression dictates the threshold for 
BCR signalling. Furthermore, whether differential FcyRllb expression is 
promoted by the inflammatory cytokine profile and thus modulated by 
administration of anti-inflammatory drugs in rheumatoid arthritis patients.
Interestingly, systemic lupus erythematosus patients demonstrated similar 
mRNA expression levels of both FcyRllb isoforms and Pac-1 compared to 
controls. These results were somewhat surprising with respect to the essential 
role of immune-complex deposition in the initiation of lupus disease and 
following the study of FcyRllb function in MRL-/pr//pr mice in Chapter 4. The 
differences in results may simply reflect the requirement of further genetic 
susceptibility factors for the initiation of disease in the separate systems or the 
masking of B cell FcyRllb expression by other FcyR I lb-expressing cells in the 
PBMC samples. In addition, only a small cohort of patients of uniform ethnicity 
were studied, thus investigations of FcyRllb expression in B cells from a larger 
cohorts of SLE patients, potentially from varying ethnic backgrounds, may 
provide statistically significant data to support a similar role for aberrant FcyRllb 
expression in the initiation of SLE in certain populations.
Alternatively, although FcyRllb and Pac-1 expression were found to be similar in 
control and patient samples, it was possible that rather than FcyRI Ib- 
MAPKinase signalling being dysfunctional that another of the FcyRllb-mediated 
inhibitory signals was deregulated. Interestingly, a deficiency in the PTK, Lyn, 
has been identified in patients with systemic lupus erythematosus (Liossis et al.,
2001). Semi-quantitative PCR analysis of Lyn mRNA expression levels revealed 
a significant decrease in the levels of Lyn in peripheral B cell of lupus patients 
that were reflected in a decrease of Lyn protein. Due to the essential role of Lyn
303
Chapter 6 -  General Discussion
in the phosphorylation of FcyRllb, down-regulation of Lyn expression may result 
in a lack of FcyRllb activation following co-ligation with immune-complexes and 
thus prevent negative feedback regulation of potentially autoreactive B cells. 
Furthermore, Lyn deficiency may also prevent FcyRllb-mediated recruitment of 
negative regulators, such as PTEN, thus enabling aberrant activation of pro- 
survival signals by Akt.
Overall, this study is this first to describe the deregulation of differential 
expression of FcyRllb isoforms in relation to rheumatoid arthritis. Moreover, this 
study provides a potential mechanism for the modulation of B cell homeostasis 
whilst supporting the theory that an imbalance in FcyR interactions might 
underlie the severity of inflammation in autoimmune diseases such as 
rheumatoid arthritis and systemic lupus erythematosus.
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Figure 6.1 Regulation of the humoral immune response by FcyRllb.
FcyRllb plays an important role in the regulation of the humoral immune 
response by immune-complexes. Following co-ligation with the BCR, FcyRllb 
suppresses the activation of B cells and controls antibody production by 
inducing growth-arrest. In contrast, self-ligated FcyRllb results in the 
commitment of B cells to apoptosis and thus provides a mechanism for the 
maintenance of peripheral tolerance to self-antigen.
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Figure 6.2 A working model for the integration of FcyRllb-mediated 
inhibitory signals in B cells.
Co-ligation of the BCR and FcyRllb by cognate antigen-antibody complexes 
leads to tyrosine phosphorylation of the FcyRllb cytoplasmic ITIM motif by the 
Src-family kinase Lyn, recruitment of SHIP and the inhibition of BCR-triggered 
calcium mobilisation and arrest of cellular proliferation. FcyRllb uncouples the 
BCR from ErkMAPK by (1) the sequestration of She by SHIP, preventing the 
recruitment of Shc-Grb2-SoS complexes (2) recruiting a Ras GTPase activating 
protein (RasGAP) via p62Dok, in a SHIP-dependent manner (3) the 
dephosphorylation of MEK and (4) the formation of ErkMAPK/Pac-1 complexes.
SHIP is also able to inhibit calcium mobilisation by hydrolysing the membrane 
inositol phosphate, Ptdlns(3,4,5)Ps preventing the recruitment of Btk and PLC-y, 
thus blocking a sustained calcium signal by inhibiting the influx of extracellular 
calcium. Co-ligation of the BCR with FcyRllb also results in the termination of 
the pro-survival Akt signal, through the conversion of PI(3,4,5)P3 to PI(3,4)P2 by 
the inositol 5’-phosphatase, SHIP and the conversion of PI(3,4,5)P3 and 
PI(3,4)P2, by PTEN, thus counteracting the activities of PI-3-Kinase. Inhibition of 
these signals may also modulate the DNA binding activity of NF-kB.
FcyRllb co-ligation inhibits BCR-mediated Gi-S phase progression by the partial 
suppression of BCR-induced Rb phosphorylation, potentially preventing the 
release of E2F and the transcription of S phase genes. FcyRllb ligation also 
disrupts BCR-mediated cell-cycle progression by the rapid phosphorylation of 
p53 on Ser^  ^which can lead to cell cycle arrest at the Gi-S and G2-M transition 
points and DNA repair or apoptosis. p53 transactivation also correlates with 
FcyRllb-mediated disruption of the mitochondrial membrane potential.
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Figure 6.3 A potential mechanism for the initiation of autoimmunity by 
the differential expression of FcyRllb isoforms.
B cell homeostasis is dependent on the balance between the activities of 
activation and inhibitory receptors. Indeed, loss of suitable inhibitory signalling is 
frequently associated with the development of inflammatory responses and, in 
some cases, autoimmunity. Normally, FcyRllb ligation by immune-complexes on 
B cells will induce growth-arrest and/or commitment to apoptosis. However, 
differential expression of the two isoforms of FcyRllb, FcyRlibl and FcyRllb2, 
may modulate the ability of immune-complexes to promote B cell inactivation. 
Normal expression levels of FcyRllb isoforms will promote down-regulation of B 
cell function and prevent T cell mediated help. However, down-regulation of 
FcyRlibl expression may permit endocytosis of complexed antigen by FcyRllb2 
and presentation via MHC II to cognate helper T cells, thus breaking normally 
tolerant B cells. T cell derived CD40-L and IL-4 will promote B cell activation 
and further suppress any negative regulatory effects by FcyRllb2. Thus, down- 
regulation of FcyRlibl expression provides a potential mechanism for the 
initiation of autoimmunity by autoreactive B cells that may lead to inflammation 
and tissue damage.
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